text,title,id,project_number,terms,administration,organization,mechanism,year,award_amount,cong_dist,score
"Genetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancer    DESCRIPTION (provided by applicant): Prostate is the most common site of cancer in men in the United States. Most prostate cancers progress relatively slowly and stay confined within the prostate. However, some cases grow aggressively and metastasize to other parts of the body. The most important clinical challenge in the treatment of the disease is the not knowing which of these two clinical forms a patient is presenting with. This is critically important information given the significant morbidity associated with treatment interventions and could eventually help distinguish men who need intensive treatment from those who may be better served by watchful waiting. Currently, the level of serum PSA, clinical stage and Gleason score are used to estimate prognosis and inform treatment modalities. Although they are very useful, additional biomarkers may help to better predict the outcome of prostate cancer. Carefully designed molecular epidemiologic studies can contribute in this arena. Although the significance of angiogenesis in prostate cancer is demonstrated by its correlation with clinical features, such as clinical stage, Gleason scores, progression, metastasis and survival, relatively few studies have assessed the role of genes involved in the angiogenesis pathway with recurrence of prostate cancer. Research to identify the specific genes and genetic variants relevant to angiogenesis risk remain largely unexplored. Part of the reason why candidate gene studies have been inconclusive may be that a major source of genetic regulation has been ignored: gene silencing through DNA methylation. Our hypothesis is that genetic and epigenetic individual variation in genes involved in the angiogenesis pathway is associated with recurrence of prostate cancer. The ultimate goal of this study is to identify biomarkers that can be used at the time of diagnosis to predict prognosis and improve clinical treatment decision making. The proposed study involves (1) construction of a historical cohort of prostate cancer cases (n=~1300) treated with radical prostatectomy at the H. Lee Moffitt Cancer Center between 1987 and 2003, (2) evaluating the association between 802 SNPs in 52 genes involved in angiogenesis with risk of recurrent prostate cancer, (3) evaluating the association between DNA methylation in the promoter regions of angiogenesis genes and risk for recurrence of prostate cancer and (4) testing the combined effects of inherited and acquired genetic changes in the candidate genes on disease aggressiveness. PUBLIC HEALTH RELEVANCE: These studies will provide key information regarding the potential effect of epigenetic genetic variations on prostate cancer recurrence. The combination of the individual's epigenetic and genetic profile and a current prediction model can possibly estimate a more accurate recurrence risk of the prostate cancer patients. This model can be extremely useful for a strategy of prostate cancer treatment.                               ",Genetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancer,7849641,R01CA128813,"['Decision Making ', ' Bioinformatics ', ' Bio-Informatics ', ' Diagnosis ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Length ', ' Nomograms ', ' Angiogenesis Pathway ', ' VEGF, Hypoxia, and Angiogenesis ', ' Data ', ' TNM ', ' TNM staging system ', ' Cancer Center ', ' Cancer Etiology ', ' Cancer Cause ', ' Cancer Patient ', ' Clinical Treatment ', ' trial treatment ', ' trial regimen ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Molecular ', ' follow-up ', ' followed up ', ' follow up ', ' Active Follow-up ', ' Pathway interactions ', ' pathway ', ' Genes ', ' Genotype ', ' Age ', ' base ', ' Goals ', ' improved ', ' Haplotypes ', ' Hazard Models ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' Algorithms ', ' Clinical ', ' Phase ', ' Variant ', ' Variation ', ' Biological ', ' Logistic Regressions ', ' Evaluation ', ' Serum ', ' Blood Serum ', ' Body part ', ' Individual ', ' Linkage Disequilibrium ', ' Lymphatic System ', ' Lymphatic system (all sites) ', ' Lymphatic System Reticuloendothelial System ', ' Medical Records ', ' men ', "" men's "", ' Methylation ', ' Protein Methylation ', ' Morbidity - disease rate ', ' Morbidity ', ' Mortality Vital Statistics ', ' Mortality ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Neoplasm Metastasis ', ' tumor cell metastasis ', ' cancer metastasis ', ' Tumor Cell Migration ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastasize ', ' Metastasis ', ' Epidemiologic Studies ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' angiogenesis ', ' Pathology ', ' Patients ', ' Genetic ', ' Play ', ' Staging ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' outcome forecast ', ' Prognosis ', ' Promoter Regions (Genetics) ', ' genetic promoter element ', ' Promotor Regions (Genetics) ', ' Promotor Regions ', ' Promoter Regions ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostatic Neoplasms ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Race ', ' Racial Stocks ', ' Racial Group ', ' Receiver Operating Characteristics ', ' Recurrence ', ' Recurrent ', ' Research ', ' Research Institute ', ' Risk ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' DNA Methylation ', ' Area Under Curve ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Trees ', ' United States ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Caucasians ', ' Inherited ', ' Hereditary ', ' Source ', ' Techniques ', ' Tumor Tissue ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Biopsy ', ' Blood Circulation ', ' Circulation ', ' Bloodstream ', ' bone ', ' Gene Silencing ', ' Gene Inactivation ', ' cohort ', ' Modality ', ' Patient observation ', ' Watchful Waiting ', ' Caucasoid Race ', ' white race ', ' Occidental ', ' Caucasoid ', ' Caucasian Race ', ' Caucasian ', ' neoplasm registry ', ' cancer registry ', ' Regulation ', ' Paraffin Embedding ', ' abstracting ', ' Modeling ', ' case control ', ' cancer site ', ' cancer location ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Classification ', ' Systematics ', ' cancer recurrence ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Formalin ', ' genetic profiling ', ' genetic variant ', ' design ', ' designing ', ' Outcome ', ' tumor ', ' public health relevance ', ' biomarker ', ' ']",NCI,H. LEE MOFFITT CANCER CTR & RES INST,R01,2010,1,FL-14,0.3326285294846753
"Integrating Quantitative Histological Image and Vascular Density Patterns for Pro    DESCRIPTION (provided by applicant):       With increasing detection of early CaP with improved diagnostic methodologies, it has become important to predict biologic behaviors and ""aggressivity"" to identify patients who might benefit from a ""wait and watch policy"" as opposed to those who need more aggressive strategies. Traditionally, T-stage, amount of cancer in the core biopsy, the Gleason grade, and PSA at diagnosis has been used to evaluate the prognosis in localized CaP. While the Gleason score is currently assumed to be the strongest prognostic marker for CaP, there is often considerably high inter-, intra-observer variability associated with Gleason grade determination by pathologists. While some newer markers have recently shown promise, none of these methods have individually proven to be accurate enough to serve routinely as a prognostic marker for CaP.  Recently, there has been a call to combine multiple prognostic markers to create an integrated meta-marker, with potentially greater accuracy in predicting CaP recurrence compared to any individual marker. While it is apparent that prognostic information resides in histopathology imagery in terms of the arrangement of nuclei and glands, sophisticated graph, and computerized image analysis algorithms are required to quantitatively model and characterize the architectural appearance of prostate cancer histopathology and thus provide a marker that is accurate and reproducible (unlike Gleason grade). In addition, while tumor micro-vascular density has been correlated to CaP outcome, prognostic information may also potentially reside in the specific spatial architectural arrangement of the micro-vascular network. The objective of the proposed work is to develop an integrated quantitative prognostic marker that combines information based on architectural arrangement of nuclear, glandular, and micro-vasculature network patterns on whole mount histology sections (WMHS) obtained via radical prostatectomy (RP) to predict prostate cancer recurrence.  The proposed work comprises a total of 3 specific aims. For this project we will digitize approximately 100 annonymized WMHS obtained via RP that have been matched for Gleason score, stage, PSA, but with different clinical outcomes (half the patients having undergone cancer recurrence and the other not, following RP). Under Aim 1, segmentation algorithms will be developed to automatically identify cancerous nuclei, glands and tumor microvasculature (MV), stained immuno-histochemically via CD31. Under Aim 2 we will apply graph based image analysis algorithms to quantitatively characterize the architectural arrangement of CaP nuclei, glands and the MV network. These graph-based features will be integrated via a computerized machine learning algorithm to yield a numerical image based risk score (IbRiS) reflecting the CaP prognosis (disease recurrence or non-recurrence) of the patient. IbRiS will be evaluated in terms of its ability to distinguish between CaP progressors and non-progressors (matched for stage, Gleason grade, PSA), in a cohort of 50 independent studies (test set) for which survival and outcome data is available.  This project will be a collaboration between investigators at Rutgers University (RU) and the University of Pennsylvania (UPENN). Data accrual will be done at UPENN while algorithmic development for computerized image analysis and classification will be carried out at RU.             The broad long term goal of this project is to develop an integrated image based histological biomarker for  predicting  prostate  cancer  (CaP)  survival  and  outcome  by  integrating  quantitative  image  signatures  that  define  tissue  architecture  and  vascular  density  patterns.  Sophisticated  image  analysis  and  graph  based  algorithms will be developed to yield an image based risk score (IbRis) to predict whether or not a CaP patient  will  have  disease  recurrence  following  treatment.  Our  hypothesis  is  that  IbRis  will  prove  to  be  a  better  prognostic marker compared to such traditional markers as Gleason score and PSA.   ",Integrating Quantitative Histological Image and Vascular Density Patterns for Pro,7941833,R03CA143991,"['Metric ', ' Appearance ', ' Cell Nucleus ', ' Nucleus ', ' TP53 gene ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' Modeling ', ' repository ', ' Classification ', ' Systematics ', ' cancer recurrence ', ' vector ', ' digital ', ' computerized ', ' Outcome ', ' imaging Segmentation ', ' Cancerous ', ' tumor ', ' novel marker ', ' new marker ', ' biomarker ', ' Computers ', ' Diagnosis ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Gland ', ' Tumor stage ', ' T-Stage ', ' Core Biopsy ', ' Core Needle Biopsy ', ' PECAM1 gene ', ' PECAM1 ', ' CD31 ', ' Data ', ' Detection ', ' Prognostic Marker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Randomized ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Resolution ', ' Scheme ', ' Validation ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' Output ', ' Imagery ', ' Visualization ', ' base ', ' density ', ' Goals ', ' improved ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' Histocytochemistry ', ' histochemistry/cytochemistry ', ' histochemistry ', ' Histology ', ' Hospitals ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Clinical ', ' Intraobserver Variability ', ' Intraobserver Variations ', ' Intra-Observer Variation ', ' Intra-Observer Variability ', ' prognostic ', ' Training ', ' Learning ', ' Individual ', ' Policies ', ' Methods ', ' Methodology ', ' Method LOINC Axis 6 ', ' Collaborations ', ' Patients ', ' Pennsylvania ', ' Staging ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' outcome forecast ', ' Prognosis ', ' Pathologist ', ' Diagnostic ', ' Recurrence ', ' Recurrent ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Risk ', ' Specimen ', ' Research Specimen ', ' Architecture ', ' Engineering / Architecture ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' Stains ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Universities ', ' E-Cadherin ', ' Uvomorulin ', ' Epithelial-Cadherin ', ' Epithelial Calcium-Dependent Adhesion Protein ', ' Cadherin-1 ', ' CAM 120/80 ', ' Work ', ' Protocols documentation ', ' Protocol ', ' Slide ', ' Pattern ', ' Staining method ', ' Stainings ', ' Behavior ', ' Nuclear ', ' Blood Vessels ', ' vascular ', ' Early Diagnosis ', ' early detection ', ' cohort ', ' Histopathology ', ' Structure ', ' Graph ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' ']",NCI,"RUTGERS, THE STATE UNIV OF N.J.",R03,2010,81236,NJ-06,0.087246725565373
"""Statistical Methods for Genetic Epidemiology""    DESCRIPTION (provided by applicant):  The availability of high-dimensional single-nucleotide (SNP) data for large samples of individuals with and without disease presents unprecedented opportunities for genetic epidemiologists, but also many statistical challenges. Our ability to bring these opportunities to fruition depends on the development and application of sound and innovative statistical methods. Areas of particularly great need include methods for dealing with multiple hypothesis-testing problems (multiple comparison issues), and methods for combining data from multiple sources to achieve sharper inferences (data synthesis issues). The goals of this research are to develop new or improved methods for addressing these issues, and to apply them to data on cancers of the breast, ovary and prostate. To accomplish these goals, the investigators will build on more than 15 years of previous work. Specifically, in 1988 the National Cancer Institute (NCI) awarded an Outstanding Investigator Grant (OIG) to the Principle Investigator for the development and application of new and improved statistical methods for use in epidemiological research. In 1995 this grant was renewed until NCI terminated the program in 2001. The research was then funded by R01 CA94069 for the period January 2002 to December 2006. This competing renewal application requests funds to continue this work and to apply it to new areas of emerging importance. The specific aims are fourfold: 1) to evaluate new and existing methods for controlling confounding and tail count variability in case-control genome-wide association (GWA) studies; 2) to evaluate risks associated with missense mutations of unknown significance in genes of established disease relevance; 3) to combine multiple independent sources of data in assessing the joint carcinogenic effects of groups of genes; and 4) to integrate data on tumor and patient characteristics for improved assessment of phenotype-specific etiology. We will evaluate the new methods by simulations, and we will illustrate them by application to existing data on cancers of the breast, ovary and prostate, and emerging data from GWA studies of breast and prostate cancer. The existing data have been collected either by the investigators and the consultants to this project, or as part of three collaborations in which the investigators participate: the Breast Cancer Family Registry (Breast-CFR), the Ovarian Cancer Association Consortium (OCAC), and the International Consortium for Prostate Cancer Genetics (ICPCG). In summary, we need sound, reliable methods for analyzing the vast amounts of emerging genetic data from individuals with and without a given type of cancer. The goals of this research are to develop such methods, and thereby to help generate new knowledge useful for cancer prevention and treatment.                                         ","""Statistical Methods for Genetic Epidemiology""",7936896,R01CA094069,"['breast cancer family registry ', ' Critiques ', ' Data Sources ', ' Malignant neoplasm of ovary ', ' ovarian cancer ', ' Ovary Cancer ', ' Malignant Tumor of the Ovary ', ' Malignant Ovarian Tumor ', ' Malignant Ovarian Neoplasm ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Address ', ' Epidemiology ', ' epidemiological ', ' epidemiologic ', ' Data Set ', ' Dataset ', ' Admixture ', ' Data ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' International ', ' National Cancer Institute ', ' NCI Organization ', ' Request for Applications ', ' NIH RFA ', ' Stratification ', ' Study Section ', ' Epidemiologist ', ' transmission process ', ' Transmission ', ' Principal Investigator ', ' Characteristics ', ' Molecular ', ' Development ', ' developmental ', ' Family ', ' Output ', ' Genes ', ' Genotype ', ' base ', ' Goals ', ' Grant ', ' improved ', ' acronyms ', ' Site ', ' Area ', ' Variant ', ' Variation ', ' Incidence ', ' Predisposition ', ' Susceptibility ', ' Training ', ' Joints ', ' Articulation ', ' Life Style ', ' Lifestyle ', ' Individual ', ' Linkage Disequilibrium ', ' Funding ', ' Methods ', ' cancer prevention ', ' Collaborations ', ' Nucleotides ', ' Odds Ratio ', ' Risk Ratio ', ' Relative Odds ', ' Cross-Product Ratio ', ' Ovary ', ' Patients ', ' Phenotype ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' tool ', ' Registries ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Risk ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' BRCA1 gene ', ' brca 1 gene ', ' RNF53 ', ' Hereditary Breast Cancer 1 ', ' Early Onset Gene Breast Cancer 1 ', ' Breast Cancer Type 1 Susceptibility Gene ', ' Breast Cancer 1 Gene ', ' BRCA1 ', ' programs ', ' sound ', ' Suggestion ', ' Tail ', ' Testing ', ' Time ', ' Universities ', ' Work ', ' Award ', ' Source ', ' Techniques ', ' Penetrance ', ' BRCA2 gene ', ' brca 2 gene ', ' Hereditary Breast Cancer 2 ', ' FANCD1 ', ' FANCB ', ' Early Onset Gene Breast Cancer 2 ', ' Breast Cancer Type 2 Susceptibility Gene ', ' Breast Cancer 2 Gene ', ' BRCA2 ', ' Missense Mutation ', ' Breast ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' simulation ', ' Glossary ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' cancer genetics ', ' Case-Control Studies ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' response ', ' case control ', ' genetic epidemiology ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' conditioning ', ' Population ', ' cancer type ', ' innovation ', ' innovative ', ' innovate ', ' post-doctoral training ', ' postdoctoral training ', ' user-friendly ', ' tumor ', ' Computer Programs and Programming ', ' computer programming ', ' computer program ', ' ']",NCI,STANFORD UNIVERSITY,R01,2010,580133,CA-18,0.055282653734402554
"Software to facilitate multimode, multiscale fused data for Pathology and Radiolo    DESCRIPTION (provided by applicant): Medical informatics from the macro- to micro-scale is increasingly available for a range of detection/diagnosis/theragnostic applications tailored to each patient's history and current condition. Prostatic adenocarcinoma (CAP) is the second most common malignancy among men with an estimated 220,000 new cases in the USA in 2008. With the advent of multi-parametric high resolution (3 Tesla (T)) prostate MRI, providing anatomic, biochemical, and physiologic information, it has become increasingly important to identify the potential value of this information in pre-operative or pre-therapeutic CAP screening. However, in vivo prostate MRI lacks the resolution and ground truth diagnostic accuracy histopathological examination of biopsy cores provides. A first step toward getting prostate MRI for CAP into the clinic would be validating the information provided from MR at the cellular level. However, validating MRI against histological ground truth currently lacks the means to link the information provided by radiological imaging and pathology seamlessly. This is primarily due to a lack of interoperability between informatics representations and tools. One missing element, for instance, is robust and accurate image registration tools to align the multi-modal volumetric data sets. The overarching goal of this collaborative project between the University of Pennsylvania, Rutgers University, and Siemens Corporate Research is to develop and evaluate multi-modal image analysis and machine learning techniques within a software framework that will enable efficient analysis, correlation, and interpretation of multi-functional, multi-resolution patient data. The availability of these multi-modal, multi- scale analysis tools will enable alignment of radiology and pathological data which in turn will (a) enable building and validation of supervised computerized decision support systems for detection and grading of CAP from radiology and pathology data and (b) building meta-classifiers for CAP by integrating multi- modal, multi-scale disease signatures. Such a set of prostate-specific informatics tools promises clinical benefits including improved patient prognoses, more accurate disease diagnoses, and therapeutic recommendations. More generally, the tools developed as part of this project will also enable radiologic/pathologic studies in other disease entities. The specific goals of this project are 1) to develop cross-platform, open source, grid-enabled annotation, image analysis and image registration tools that will enable cross modality validation of radiology data (multi-functional 3 T prostate MRI) with expert histopathological annotation of prostatectomy specimens and provide independent computer-aided predictions of cancer extent and grade on radiology and histopathology, 2) curate an open source caGRID- connected database of prostate MRI and histopathological specimens that will enable development of quantitative signatures for detection and grading of CAP across multiple scales and imaging modalities.  PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a software tool kit (based on the XIP application from Siemens corporation) that will allow scientists to study prostate cancer by combining data from multiple imaging modalities (radiology and pathology) with molecular methodologies (including proteins, genes, epigenetic data). The results of this fused and combined data sets will allow scientists to create a more robust system based view of prostate cancer which allow prediction of diagnosis, follow outcomes of therapeutic treatment and facilitate discovery of new treatment options            The goal of this project is to develop a software tool kit (based on the XIP application from Siemens corporation) that will allow scientists to study prostate cancer by combining data from multiple imaging modalities (radiology and pathology) with molecular methodologies (including proteins, genes, epigenetic data). The results of this fused and combined data sets will allow scientists to create a more robust system based view of prostate cancer which allow prediction of diagnosis, follow outcomes of therapeutic treatment and facilitate discovery of new treatment options","Software to facilitate multimode, multiscale fused data for Pathology and Radiolo",7894897,R01CA136535,"['Diagnosis ', ' Computer-Assisted Diagnosis ', ' Computer aided diagnosis ', ' Diffusion ', ' Disease ', ' disease/disorder ', ' Disorder ', ' imaging modality ', ' imaging method ', ' Core Biopsy ', ' Core Needle Biopsy ', ' Elements ', ' Data Set ', ' Dataset ', ' Data ', ' Detection ', ' Premalignant ', ' precancerous ', ' Pre-Malignant ', ' Reader ', ' Research Infrastructure ', ' Infrastructure ', ' Resolution ', ' in vivo ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Validation ', ' Pathologic ', ' Molecular ', ' Development ', ' developmental ', ' Explosion ', ' Image ', ' imaging ', ' pre-clinical ', ' preclinical ', ' Imagery ', ' Visualization ', ' base ', ' Goals ', ' Label ', ' improved ', ' Procedures ', ' caGrid ', ' caGRID [{C1883657}] ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' Histology ', ' Recording of previous events ', ' History ', ' Hospitals ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Algorithms ', ' Clinical ', ' Physiological ', ' Physiologic ', ' Biochemical ', ' Medical ', ' Link ', ' Evaluation ', ' Screening procedure ', ' screenings ', ' screening ', ' System ', ' LOINC Axis 4 System ', ' Location ', ' Nuclear ', ' diagnostic accuracy ', ' Accuracy of Diagnosis ', ' Informatics ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Histopathology ', ' novel ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Modality ', ' Prostate Adenocarcinoma ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Gene Proteins ', ' Protein Gene Products ', ' Healthcare ', ' health care ', ' Schedule ', ' Decision Support Systems ', ' repository ', ' MRI Scans ', ' Communities ', ' anticancer research ', ' cancer research ', ' computerized ', ' image registration ', ' Computer Assisted ', ' computer aided ', ' spectroscopic imaging ', ' Outcome ', ' cancer imaging ', ' Population ', ' interoperability ', ' cancer Biomedical Informatics Grid ', ' caBIG ', ' open source ', ' public health relevance ', ' disease diagnosis ', ' Training ', ' Lesion ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Active Learning ', ' Experiential Learning ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' American Cancer Society ', ' Medical Informatics ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Method LOINC Axis 6 ', ' radiologist ', ' RDST ', ' Anatomy ', ' Anatomical Sciences ', ' Anatomic ', ' Therapeutic ', ' Pathology ', ' Patients ', ' Pennsylvania ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' outcome forecast ', ' Prognosis ', ' Pathologist ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostatectomy ', ' tool ', ' Radiology Specialty ', ' Radiology ', ' General Radiology ', ' Diagnostic ', ' Recommendation ', ' Research ', ' Sensitivity and Specificity ', ' Specimen ', ' Research Specimen ', ' Architecture ', ' Engineering / Architecture ', ' Computer software ', ' computer program/software ', ' Software ', ' Software Tools ', ' Computer Software Tools ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' Scientist ', ' Tissues ', ' Body Tissues ', ' United States ', ' Universities ', ' Weight ', ' Work ', ' Stream ', ' Clinic ', ' Source ', ' Techniques ', ' ']",NCI,UNIVERSITY OF PENNSYLVANIA,R01,2010,663749,PA-03,0.25911917171807936
"Genetics Variants in the Genome Predisposing to Aggressive PCa    DESCRIPTION (provided by applicant): Fortunately, most men diagnosed with prostate cancer (PCa) will not die from their disease, and some men diagnosed may not even require treatment for their cancers. However, on the other end of the spectrum, ~30,000 men annually die from PCa in the US alone. For these latter men, the concept of PCa as an indolent disease obviously does not apply. Understanding the molecular basis of aggressive PCa (aPCa) vs. indolent PCa (non-aPCa) is perhaps the most important basic, yet translational question in PCa biology. We hypothesize that multiple sequence variants in the genome confer risk to aPCa but not to non-aPCa. Taking advantage of the publicly available CGEMS genome wide association data, as well as the large and unique PCa patient population at Johns Hopkins Hospital (JHH), we propose a systematic genetic association study to confirm, fine map, and better characterize genetic risk variants for aPCa. We propose three specific aims: 1)Test the genetic variants implicated in the CGEMS study that distinguish aPCa from non-aPCa among ~3,000 aPCa and ~5,000 non-aPCa patients of European ancestry from the JHH, 2) Fine map the genomic regions for the SNPs implicated in Aim 1 among 3,000 aPCa and 5,000 non-aPCa patients of European ancestry from the JHH, and 3) Assess the association of the most significant SNPs found in Aim 2 with disease characteristics in all 8,000 patients, and with disease progression in a subset of patients that have follow-up data at JHH. In addition, we have two exploratory aims: 1) fine mapping of regions containing SNPs significant in European Americans in aPCa and non-aPCa in African Americans, and 2) testing for gene-gene interaction. Besides the obvious clues that the proposed research may provide in terms of etiologic mechanisms, this study may also lead to identification of new target genes and proteins for therapy and possible preventive strategies. Furthermore, the identification of multiple variants can lead to the development of a test panel that may improve prediction of aPCa risk.                                                 Project Narrative  Prostate cancer is a common cancer that varies widely in its aggressiveness. The ability to predict which men are at risk for the development of aggressive prostate cancer is urgently needed. This proposal addresses the possibility that genetic variants may differentiate risk for aggressive from non-aggressive prostate cancer and the results can be used to predict men at higher risk for aggressive prostate cancer.",Genetics Variants in the Genome Predisposing to Aggressive PCa,7788795,R01CA133009,"['Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Tissue Sample ', ' Core Needle Biopsy ', ' Core Biopsy ', ' datamining ', ' data mining ', ' genetic association ', ' Address ', ' Data ', ' 8q24 ', ' Cancer Biology ', ' Cancer Patient ', ' Genetic Risk ', ' Chromosome 17 Long Arm ', ' Chromosome 17 Distal Arm ', ' 17q ', ' 17q12 ', ' 17q24.3 ', ' Pathologic ', ' Characteristics ', ' Molecular ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' Family ', ' pathway ', ' Pathway interactions ', ' Affect ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' genetic biomarker ', ' Genetic Markers ', ' Genome ', ' Genotype ', ' Age ', ' analytical method ', ' base ', ' Organ ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' Goals ', ' improved ', ' Procedures ', ' Hand ', ' Haplotypes ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' Hospitals ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Logistic Regressions ', ' Allelomorphs ', ' Alleles ', ' Investments ', ' Evaluation ', ' Susceptibility ', ' Predisposition ', ' Articulation ', ' Joints ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Indolent ', ' Linear Regressions ', ' Individual ', ' Linkage (Genetics) ', ' genetic linkage ', ' European ', ' Family Medical History Epidemiology ', ' Family Medical History ', ' Family history of ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Policies ', ' Sample Size ', ' Disease Progression ', ' Maps ', "" men's "", ' men ', ' Methods ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Collaborations ', ' Patients ', ' Phenotype ', ' Genetic ', ' Physicians ', ' Staging ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Gleason Grade for Prostate Cancer ', ' Productivity ', ' Pathologist ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' QOL ', ' Quality of life ', ' recruit ', ' Recruitment Activity ', ' Statistical Regression ', ' Regression Diagnostics ', ' Regression Analyses ', ' Regression Analysis ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Risk ', ' social role ', ' Role ', ' Sampling Errors ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Testing ', ' Time ', ' Twins ', ' Twin Multiple Birth ', ' Universities ', ' Frequency ', ' Frequencies (time pattern) ', ' Pathological Staging ', ' Pattern ', ' disease severity ', ' Severity of illness ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' interest ', ' Biology ', ' American ', ' cancer risk ', ' experience ', ' gene interaction ', ' success ', ' cohort ', ' disease characteristic ', ' disease natural history ', ' Adjuvant Therapy ', ' Disease Outcome ', ' novel ', ' Preventive strategy ', ' Prevention strategy ', ' Population Study ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cancer genetics ', ' Protein Gene Products ', ' Gene Proteins ', ' linkage analyses ', ' genetic linkage analyses ', ' family based linkage study ', ' Linkage Analysis ', ' genetic linkage analysis ', ' ray (radiation) ', ' Radiation ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' forest ', ' Modeling ', ' LOINC Axis 2 Property ', ' Property ', ' Genomics ', ' cancer diagnosis ', ' Concurrent Studies ', ' Cohort Studies ', ' clinical phenotype ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' genetic variant ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' men at high risk ', ' high risk men ', ' therapeutic target ', ' tumor ', ' genome-wide analysis ', ' genomewide linkage ', ' genome-wide linkage ', ' high risk ', ' public health relevance ', ' patient population ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' genomewide ', ' genome-wide ', ' sharing data ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2010,620255,MD-07,0.16547876887647994
"Virtual Conversations for Prostate Cancer Decisions    DESCRIPTION (provided by applicant): The broad, long-term objective of this program is to improve the knowledge and awareness of patients with critical illnesses, empowering them to more actively participate in meaningful conversations with health care providers and in the decisions that must be made to remedy their current problem and improve their overall health. The specific aim of this Phase II project is to field test and refine a virtual dialogue prostate cancer patient education model involving a multidisciplinary team of experts. This unique patient education model will be accessible over the Internet. When this work is complete, patients and their families will be able to obtain accurate, reliable, comprehensive knowledge about this disease and current treatment modalities through independent virtual conversations with each of the prostate cancer experts. This project is in full support of the NIH mission of improving the health of the nation. If virtual dialogue technology were fully implemented as a unique patient education paradigm over the Internet, it could elevate the understanding patients have about health matters, and empower them with knowledge and the confidence to participate, with their health care provider, in decisions about their illness and general health. Also, this project is in full support of a primary aspect of the NCI mission regarding research in health information dissemination. Virtual dialogue technology offers the opportunity for patients to individually engage cancer experts in a systematic, reliable, multidisciplinary approach to learning about their illness. The dissemination of prostate cancer information to patients through direct, ""face-to-face"" dialogues with each practitioner in a multidisciplinary cancer clinic on a nationwide basis is unprecedented. The development and research that would lead to this phenomenon is being proposed. In Phase II, the researchers will partner with the Center for Prostate Disease Research (CPDR) clinical staff at the Walter Reed Army Medical Center (WRAMC). A series of virtual dialogue programs will be developed to embody the comprehensive knowledge of six essential prostate cancer experts from the CPDR multidisciplinary clinic (i.e., surgeon, radiation oncologist, urologic andrologist, etc). The series will be evaluated with regard to the feasibility of delivering this series of virtual dialogue programs over the Internet, and the patients' acceptance of this new method will be measured. Also, a usual-treatment Control group will be employed in a pre-post testing environment to assess the comparative knowledge gained by these newly diagnosed prostate cancer patients and to determine if this virtual dialogue model efficaciously delivers the knowledge of these multidisciplinary prostate cancer experts. PUBLIC HEALTH RELEVANCE:  An Internet-based virtual dialogue patient education model will make the most trustworthy health practitioners available to everyone for individual ""face-to-face"" dialogues about their area of expertise. Patients will be more knowledgeable about their illnesses because of the reliable, comprehensive information they obtain directly from the mouth of the expert. The researchers believe that virtual dialogue represents a new paradigm in patient education; one in which any patient can independently engage medical experts in one-on-one, face-to-face dialogues. The patient is the active participant in the dialogue, rather than a passive, compliant listener. The key technology objective of this Phase II project is to enhance the Virtual Conversations(R) patient education system to include the ability to distribute virtual dialogue programs over the Internet. Achieving this objective will open the door to quick and easy access to the proposed multidisciplinary, prostate cancer virtual dialogue series by all cancer institutions and prostate cancer patients with access to the Internet.           PROJECT NARRATIVE - RELEVANCE An Internet-based virtual dialogue patient education model will make the most trustworthy health practitioners available to everyone for individual ""face-to-face"" dialogues about their area of expertise. Patients will be more knowledgeable about their illnesses because of the reliable, comprehensive information they obtain directly from the mouth of the expert. The researchers believe that virtual dialogue represents a new paradigm in patient education; one in which any patient can independently engage medical experts in one-on-one, face-to-face dialogues. The patient is the active participant in the dialogue, rather than a passive, compliant listener. The key technology objective of this Phase II project is to enhance the Virtual Conversations(R) patient education system to include the ability to distribute virtual dialogue programs over the Internet. Achieving this objective will open the door to quick and easy access to the proposed multidisciplinary, prostate cancer virtual dialogue series by all cancer institutions and prostate cancer patients with access to the Internet.",Virtual Conversations for Prostate Cancer Decisions,7928093,R44CA103435,"['Critical Illness ', ' Critically Ill ', ' Diagnosis ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Institution ', ' District of Columbia ', ' DC Washington ', ' D.C. Washington ', ' Environment ', ' Radiation Oncologist ', ' Cancer Patient ', ' Newly Diagnosed ', ' Urologic Surgeon ', ' Development ', ' developmental ', ' Family ', ' Health Professional ', ' Healthcare professional ', ' Health Care Professional ', ' Image ', ' imaging ', ' base ', ' improved ', ' Health ', ' Health Personnel ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Left ', ' Area ', ' Clinical ', ' Phase ', ' Medical ', ' urologic ', ' urological ', ' Series ', ' Information Dissemination ', ' Oral cavity ', ' Mouth ', ' Cavitas Oris ', ' Buccal Cavity Head and Neck ', ' Buccal Cavity ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Individual ', ' Interdisciplinary Study ', ' Multidisciplinary Research ', ' Multidisciplinary Collaboration ', ' Interdisciplinary Research ', ' Wife ', ' men ', "" men's "", ' Methods ', ' Mission ', ' Persons ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Discipline of Nursing ', ' Nursing Profession ', ' Nursing Field ', ' Nursing ', ' Patient Education ', ' Patient Training ', ' Patient Instruction ', ' Patients ', ' Pre-Post Tests ', ' Prostatic Diseases ', ' prostate disorder ', ' Prostate Disease ', ' Psychologist ', ' Publishing ', ' Research ', ' research and development ', ' R&D ', ' R & D ', ' Development and Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Esthesia ', ' Sensation ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' programs ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Technology ', ' Testing ', ' Work ', ' Hour ', ' Clinic ', ' Awareness ', ' System ', ' LOINC Axis 4 System ', ' empowered ', ' Medical center ', ' Surgeon ', ' speech recognition ', ' success ', ' Participant ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Modality ', ' Reporting ', ' Measures ', ' Family member ', ' Modeling ', ' cancer education ', ' virtual ', ' digital ', ' multidisciplinary ', ' comparative ', ' interdisciplinary approach ', ' multidisciplinary approach ', ' public health relevance ', ' phase 1 study ', ' Phase I Study ', ' Computers ', ' Control Groups ', ' ']",NCI,"INTERACTIVE DRAMA, INC.",R44,2010,342158,MD-08,0.18681281881592318
"Genetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancer    DESCRIPTION (provided by applicant): Prostate is the most common site of cancer in men in the United States. Most prostate cancers progress relatively slowly and stay confined within the prostate. However, some cases grow aggressively and metastasize to other parts of the body. The most important clinical challenge in the treatment of the disease is the not knowing which of these two clinical forms a patient is presenting with. This is critically important information given the significant morbidity associated with treatment interventions and could eventually help distinguish men who need intensive treatment from those who may be better served by watchful waiting. Currently, the level of serum PSA, clinical stage and Gleason score are used to estimate prognosis and inform treatment modalities. Although they are very useful, additional biomarkers may help to better predict the outcome of prostate cancer. Carefully designed molecular epidemiologic studies can contribute in this arena. Although the significance of angiogenesis in prostate cancer is demonstrated by its correlation with clinical features, such as clinical stage, Gleason scores, progression, metastasis and survival, relatively few studies have assessed the role of genes involved in the angiogenesis pathway with recurrence of prostate cancer. Research to identify the specific genes and genetic variants relevant to angiogenesis risk remain largely unexplored. Part of the reason why candidate gene studies have been inconclusive may be that a major source of genetic regulation has been ignored: gene silencing through DNA methylation. Our hypothesis is that genetic and epigenetic individual variation in genes involved in the angiogenesis pathway is associated with recurrence of prostate cancer. The ultimate goal of this study is to identify biomarkers that can be used at the time of diagnosis to predict prognosis and improve clinical treatment decision making. The proposed study involves (1) construction of a historical cohort of prostate cancer cases (n=~1300) treated with radical prostatectomy at the H. Lee Moffitt Cancer Center between 1987 and 2003, (2) evaluating the association between 802 SNPs in 52 genes involved in angiogenesis with risk of recurrent prostate cancer, (3) evaluating the association between DNA methylation in the promoter regions of angiogenesis genes and risk for recurrence of prostate cancer and (4) testing the combined effects of inherited and acquired genetic changes in the candidate genes on disease aggressiveness. PUBLIC HEALTH RELEVANCE: These studies will provide key information regarding the potential effect of epigenetic genetic variations on prostate cancer recurrence. The combination of the individual's epigenetic and genetic profile and a current prediction model can possibly estimate a more accurate recurrence risk of the prostate cancer patients. This model can be extremely useful for a strategy of prostate cancer treatment.                               ",Genetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancer,8098046,R01CA128813,"['cancer site ', ' cancer location ', ' Medical Records ', ' Caucasoid Race ', ' white race ', ' Occidental ', ' Caucasoid ', ' Caucasian Race ', ' Caucasian ', ' Race ', ' Racial Stocks ', ' Racial Group ', ' Modality ', ' Epidemiologic Studies ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' case control ', ' Classification ', ' Systematics ', ' Recurrence ', ' Recurrent ', ' Decision Making ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' genetic variant ', ' Gene Silencing ', ' Gene Inactivation ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' Caucasians ', ' Trees ', ' DNA Methylation ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Haplotypes ', ' Methylation ', ' Protein Methylation ', ' Cancer Center ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Prostatic Neoplasms ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Promoter Regions (Genetics) ', ' genetic promoter element ', ' Promotor Regions (Genetics) ', ' Promotor Regions ', ' Promoter Regions ', ' Logistic Regressions ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Linkage Disequilibrium ', ' Paraffin Embedding ', ' Clinical Treatment ', ' trial treatment ', ' trial regimen ', ' Formalin ', ' Variant ', ' Variation ', ' Molecular ', ' Time ', ' biomarker ', ' Bio-Informatics ', ' Source ', ' 5 year old ', ' five year old ', ' age 5 years ', ' Risk ', ' Techniques ', ' tumor ', ' Disease ', ' disease/disorder ', ' Disorder ', ' design ', ' designing ', ' Goals ', ' Blood Circulation ', ' Circulation ', ' Bloodstream ', ' DNA ', ' Deoxyribonucleic Acid ', ' Serum ', ' Blood Serum ', ' Pathology ', ' Individual ', ' Health ', ' Pathway interactions ', ' pathway ', ' TNM ', ' TNM staging system ', ' Biopsy ', ' bone ', ' Phase ', ' Clinical ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Data ', ' follow-up ', ' followed up ', ' follow up ', ' Active Follow-up ', ' men ', "" men's "", ' Inherited ', ' Hereditary ', ' outcome forecast ', ' Prognosis ', ' Tumor Tissue ', ' Modeling ', ' Algorithms ', ' Genotype ', ' angiogenesis ', ' Genetic ', ' Testing ', ' Diagnosis ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Role ', ' social role ', ' Evaluation ', ' Regulation ', ' United States ', ' Biological ', ' Length ', ' abstracting ', ' Neoplasm Metastasis ', ' tumor cell metastasis ', ' cancer metastasis ', ' Tumor Cell Migration ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastasize ', ' Metastasis ', ' Patients ', ' Cancer Patient ', ' Research Institute ', ' Staging ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Cancer Etiology ', ' Cancer Cause ', ' Mortality Vital Statistics ', ' Mortality ', ' improved ', ' Morbidity - disease rate ', ' Morbidity ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Tissues ', ' Body Tissues ', ' Outcome ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' base ', ' Play ', ' cohort ', ' Research ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Genes ', ' cancer recurrence ', ' Bioinformatics ', ' Body part ', ' neoplasm registry ', ' cancer registry ', ' Nomograms ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' Angiogenesis Pathway ', ' VEGF, Hypoxia, and Angiogenesis ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' genetic profiling ', ' Lymphatic System ', ' Lymphatic system (all sites) ', ' Lymphatic System Reticuloendothelial System ', ' Hazard Models ', ' Receiver Operating Characteristics ', ' Area Under Curve ', ' Patient observation ', ' Watchful Waiting ', ' ']",NCI,H. LEE MOFFITT CANCER CTR & RES INST,R01,2011,463861,FL-14,0.3326285294846753
"""Statistical Methods for Genetic Epidemiology""    DESCRIPTION (provided by applicant):  The availability of high-dimensional single-nucleotide (SNP) data for large samples of individuals with and without disease presents unprecedented opportunities for genetic epidemiologists, but also many statistical challenges. Our ability to bring these opportunities to fruition depends on the development and application of sound and innovative statistical methods. Areas of particularly great need include methods for dealing with multiple hypothesis-testing problems (multiple comparison issues), and methods for combining data from multiple sources to achieve sharper inferences (data synthesis issues). The goals of this research are to develop new or improved methods for addressing these issues, and to apply them to data on cancers of the breast, ovary and prostate. To accomplish these goals, the investigators will build on more than 15 years of previous work. Specifically, in 1988 the National Cancer Institute (NCI) awarded an Outstanding Investigator Grant (OIG) to the Principle Investigator for the development and application of new and improved statistical methods for use in epidemiological research. In 1995 this grant was renewed until NCI terminated the program in 2001. The research was then funded by R01 CA94069 for the period January 2002 to December 2006. This competing renewal application requests funds to continue this work and to apply it to new areas of emerging importance. The specific aims are fourfold: 1) to evaluate new and existing methods for controlling confounding and tail count variability in case-control genome-wide association (GWA) studies; 2) to evaluate risks associated with missense mutations of unknown significance in genes of established disease relevance; 3) to combine multiple independent sources of data in assessing the joint carcinogenic effects of groups of genes; and 4) to integrate data on tumor and patient characteristics for improved assessment of phenotype-specific etiology. We will evaluate the new methods by simulations, and we will illustrate them by application to existing data on cancers of the breast, ovary and prostate, and emerging data from GWA studies of breast and prostate cancer. The existing data have been collected either by the investigators and the consultants to this project, or as part of three collaborations in which the investigators participate: the Breast Cancer Family Registry (Breast-CFR), the Ovarian Cancer Association Consortium (OCAC), and the International Consortium for Prostate Cancer Genetics (ICPCG). In summary, we need sound, reliable methods for analyzing the vast amounts of emerging genetic data from individuals with and without a given type of cancer. The goals of this research are to develop such methods, and thereby to help generate new knowledge useful for cancer prevention and treatment.                                         ","""Statistical Methods for Genetic Epidemiology""",8120480,R01CA094069,"['Suggestion ', ' Ovary ', ' cancer genetics ', ' National Cancer Institute ', ' NCI Organization ', ' conditioning ', ' Epidemiologist ', ' Stratification ', ' Penetrance ', ' genetic epidemiology ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' breast cancer family registry ', ' Study Section ', ' Request for Applications ', ' NIH RFA ', ' post-doctoral training ', ' postdoctoral training ', ' Linkage Disequilibrium ', ' Registries ', ' Nucleotides ', ' Malignant neoplasm of ovary ', ' ovarian cancer ', ' Ovary Cancer ', ' Malignant Tumor of the Ovary ', ' Malignant Ovarian Tumor ', ' Malignant Ovarian Neoplasm ', ' Tail ', ' Statistical Methods ', ' cancer prevention ', ' Breast ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Case-Control Studies ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' case control ', ' Incidence ', ' user-friendly ', ' Missense Mutation ', ' Award ', ' Odds Ratio ', ' Risk Ratio ', ' Relative Odds ', ' Cross-Product Ratio ', ' Data Sources ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Epidemiology ', ' epidemiological ', ' epidemiologic ', ' Grant ', ' Source ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' Genotype ', ' Testing ', ' cancer type ', ' simulation ', ' Area ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' tumor ', ' Molecular ', ' sound ', ' Joints ', ' Articulation ', ' Development ', ' developmental ', ' response ', ' improved ', ' Characteristics ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Goals ', ' Genes ', ' innovation ', ' innovative ', ' innovate ', ' Individual ', ' Methods ', ' Risk ', ' Time ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' tool ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Population ', ' Data ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Training ', ' International ', ' Principal Investigator ', ' Address ', ' Research ', ' Life Style ', ' Lifestyle ', ' Collaborations ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Modeling ', ' Knowledge ', ' programs ', ' Computer Programs and Programming ', ' computer programming ', ' computer program ', ' Family ', ' Predisposition ', ' Susceptibility ', ' Output ', ' Sampling ', ' Patients ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' Disease ', ' disease/disorder ', ' Disorder ', ' base ', ' Phenotype ', ' Genetic ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Funding ', ' Site ', ' Data Set ', ' Dataset ', ' Variant ', ' Variation ', ' Work ', ' Universities ', ' transmission process ', ' Transmission ', ' BRCA2 gene ', ' brca 2 gene ', ' Hereditary Breast Cancer 2 ', ' FANCD1 ', ' FANCB ', ' Early Onset Gene Breast Cancer 2 ', ' Breast Cancer Type 2 Susceptibility Gene ', ' Breast Cancer 2 Gene ', ' BRCA2 ', ' BRCA1 gene ', ' brca 1 gene ', ' RNF53 ', ' Hereditary Breast Cancer 1 ', ' Early Onset Gene Breast Cancer 1 ', ' Breast Cancer Type 1 Susceptibility Gene ', ' Breast Cancer 1 Gene ', ' BRCA1 ', ' Glossary ', ' Admixture ', ' Critiques ', ' acronyms ', ' ']",NCI,STANFORD UNIVERSITY,R01,2011,558584,CA-18,0.055282653734402554
"Software to facilitate multimode, multiscale fused data for Pathology and Radiolo    DESCRIPTION (provided by applicant): Medical informatics from the macro- to micro-scale is increasingly available for a range of detection/diagnosis/theragnostic applications tailored to each patient's history and current condition. Prostatic adenocarcinoma (CAP) is the second most common malignancy among men with an estimated 220,000 new cases in the USA in 2008. With the advent of multi-parametric high resolution (3 Tesla (T)) prostate MRI, providing anatomic, biochemical, and physiologic information, it has become increasingly important to identify the potential value of this information in pre-operative or pre-therapeutic CAP screening. However, in vivo prostate MRI lacks the resolution and ground truth diagnostic accuracy histopathological examination of biopsy cores provides. A first step toward getting prostate MRI for CAP into the clinic would be validating the information provided from MR at the cellular level. However, validating MRI against histological ground truth currently lacks the means to link the information provided by radiological imaging and pathology seamlessly. This is primarily due to a lack of interoperability between informatics representations and tools. One missing element, for instance, is robust and accurate image registration tools to align the multi-modal volumetric data sets. The overarching goal of this collaborative project between the University of Pennsylvania, Rutgers University, and Siemens Corporate Research is to develop and evaluate multi-modal image analysis and machine learning techniques within a software framework that will enable efficient analysis, correlation, and interpretation of multi-functional, multi-resolution patient data. The availability of these multi-modal, multi- scale analysis tools will enable alignment of radiology and pathological data which in turn will (a) enable building and validation of supervised computerized decision support systems for detection and grading of CAP from radiology and pathology data and (b) building meta-classifiers for CAP by integrating multi- modal, multi-scale disease signatures. Such a set of prostate-specific informatics tools promises clinical benefits including improved patient prognoses, more accurate disease diagnoses, and therapeutic recommendations. More generally, the tools developed as part of this project will also enable radiologic/pathologic studies in other disease entities. The specific goals of this project are 1) to develop cross-platform, open source, grid-enabled annotation, image analysis and image registration tools that will enable cross modality validation of radiology data (multi-functional 3 T prostate MRI) with expert histopathological annotation of prostatectomy specimens and provide independent computer-aided predictions of cancer extent and grade on radiology and histopathology, 2) curate an open source caGRID- connected database of prostate MRI and histopathological specimens that will enable development of quantitative signatures for detection and grading of CAP across multiple scales and imaging modalities.  PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a software tool kit (based on the XIP application from Siemens corporation) that will allow scientists to study prostate cancer by combining data from multiple imaging modalities (radiology and pathology) with molecular methodologies (including proteins, genes, epigenetic data). The results of this fused and combined data sets will allow scientists to create a more robust system based view of prostate cancer which allow prediction of diagnosis, follow outcomes of therapeutic treatment and facilitate discovery of new treatment options            The goal of this project is to develop a software tool kit (based on the XIP application from Siemens corporation) that will allow scientists to study prostate cancer by combining data from multiple imaging modalities (radiology and pathology) with molecular methodologies (including proteins, genes, epigenetic data). The results of this fused and combined data sets will allow scientists to create a more robust system based view of prostate cancer which allow prediction of diagnosis, follow outcomes of therapeutic treatment and facilitate discovery of new treatment options","Software to facilitate multimode, multiscale fused data for Pathology and Radiolo",8192918,R01CA136535,"['American Cancer Society ', ' Core Needle Biopsy ', ' Core Biopsy ', ' Reader ', ' disease diagnosis ', ' Computer Software Tools ', ' Software Tools ', ' open source ', ' Histopathology ', ' Accuracy of Diagnosis ', ' diagnostic accuracy ', ' computer aided ', ' Computer Assisted ', ' precancerous ', ' Pre-Malignant ', ' Premalignant ', ' Explosion ', ' Diffusion ', ' Visualization ', ' Imagery ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' malignant breast tumor ', ' Breast Cancer ', ' malignant breast neoplasm ', ' computer program/software ', ' Software ', ' Computer software ', ' Engineering / Architecture ', ' Architecture ', ' Schedule ', ' cancer research ', ' anticancer research ', ' Pathologist ', ' cancer imaging ', ' Informatics ', ' repository ', ' computerized ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Pathologic ', ' Pennsylvania ', ' Protein Gene Products ', ' Gene Proteins ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Prognosis ', ' outcome forecast ', ' imaging ', ' Image ', ' Diagnostic ', ' History ', ' Recording of previous events ', ' preclinical ', ' pre-clinical ', "" men's "", ' men ', ' Stream ', ' Location ', ' Histology ', ' Label ', ' Medical ', ' Validation ', ' Algorithms ', ' Link ', ' Lesion ', ' Patients ', ' Infrastructure ', ' Research Infrastructure ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Research Specimen ', ' Specimen ', ' Learning ', ' Sensitivity and Specificity ', ' Screening procedure ', ' Dataset ', ' Data Set ', ' Recommendation ', ' Method LOINC Axis 6 ', ' Methodology ', ' Hospitals ', ' Nuclear ', ' Modality ', ' Universities ', ' Source ', ' Scientist ', ' Training ', ' Research ', ' Resolution ', ' novel ', ' Weight ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' health care ', ' Healthcare ', ' Computer aided diagnosis ', ' Computer-Assisted Diagnosis ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' in vivo ', ' Clinic ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Work ', ' Clinical ', ' Evaluation ', ' Outcome ', ' imaging method ', ' imaging modality ', ' Elements ', ' Communities ', ' Detection ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Anatomical Sciences ', ' Anatomic ', ' Anatomy ', ' Health ', ' United States ', ' Body Tissues ', ' Tissues ', ' Biochemical ', ' Goals ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Procedures ', ' Molecular ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Gleason Grade for Prostate Cancer ', ' Therapeutic ', ' Techniques ', ' Methods ', ' tool ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Population ', ' Physiologic ', ' Physiological ', ' improved ', ' base ', ' developmental ', ' Development ', ' LOINC Axis 4 System ', ' System ', ' Pathology ', ' Diagnosis ', ' Data ', ' interoperability ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Prostate Adenocarcinoma ', ' spectroscopic imaging ', ' Experiential Learning ', ' Active Learning ', ' image registration ', ' caBIG ', ' cancer Biomedical Informatics Grid ', ' Medical Informatics ', ' Prostatectomy ', ' Decision Support Systems ', ' MRI Scans ', ' RDST ', ' radiologist ', ' ']",NCI,UNIVERSITY OF PENNSYLVANIA,R01,2011,636342,PA-03,0.25911917171807936
"Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies    DESCRIPTION (provided by applicant): In the PCPT and REDUCE trials, finasteride and dutasteride significantly reduced the detection of prostate cancer (PCa) by 23 and 25% respectively, and thus established that 51-reductase inhibitors (5ARI) are the first class of drugs proven as chemopreventive agents for PCa. The actual efficacy of these drugs varies among individuals, even after considering compliance with the prescribed dosage. Better understanding of the basis for sensitivity to 5ARI chemoprevention will: 1) pave the way for development of better-tolerated and more effective agents that exploit this established mechanism, 2) allow clinicians to target responsive men, thus reducing the cost and morbidity of life-long dosage, and 3) validate specific tissue biomarkers as surrogate endpoints for Phase II trials. Our preliminary data based on direct DNA staining suggest that nuclear morphometric features that characterize 5ARI response may also define a field effect that predicts PCa in untreated men with negative biopsies. REDUCE, which was completed in 2009, provides a unique opportunity to address these questions because intermediate, on-study biopsy samples (mandatory at Years 2 and 4) were collected. Previous research indicated that 5ARIs (at higher doses for short periods) produce changes in benign prostate that resemble incomplete atrophy. Our overall goal is to apply cutting- edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5ARI chemoprevention as well as the risk of PCa among men with negative biopsies. We will obtain Year 2 slides and tissue blocks from a random sample of REDUCE participants with various outcomes. Aim 1: To determine the effects of dutasteride (vs. placebo) on both nuclear and architectural features in benign tissue. Aim 2: To determine whether a multivariable treatment-response score differs between subjects who develop PCa while on dutasteride and those who do not, and, Aim 3: To determine the magnitude of association between nuclear phenotype in benign biopsies, and subsequent risk of PCa in untreated men at elevated risk. Altogether, we will use 3 techniques to assess cytomorphology: a) a morphometric score based on nuclear size, shape and texture, b) expression -via quantum dot imaging - of p300 and nucleolin (two proteins with major effects on chromatin pattern and nuclear morphology) and c) mapping of architectural features (e.g., epithelial area and height) via trainable software. This will be the first work to relate the cytomorphological effects of a 5ARI, given at a chemopreventive dose level for a lengthy period, to subsequent cancer occurrence. The results will have implications for chemoprevention research and clinical practice, including the large number of U.S. men who remain at risk following a negative prostate biopsy.      PUBLIC HEALTH RELEVANCE: Prostate cancer is the most commonly diagnosed form of cancer in men and strategies to prevent or inhibit its development are critically needed. The goal of the proposed research is to validate new tissue imaging methods for determining risk of prostate cancer among men who have a negative prostate biopsy and for identifying those who are most likely to benefit from life-long chemopreventive drugs.                    Prostate cancer is the most commonly diagnosed form of cancer in men and strategies to prevent or inhibit its development are critically needed. The goal of the proposed research is to validate new tissue imaging methods for determining risk of prostate cancer among men who have a negative prostate biopsy and for identifying those who are most likely to benefit from life-long chemopreventive drugs.                  ",Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies,8024885,R01CA155301,"['active treatment ', ' active technique ', ' active method ', ' morphometry ', ' Nuclear Proteins ', ' Texture ', ' Metric ', ' Surrogate End Points ', ' Surrogate Endpoint ', ' 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- ', ' Finasteride ', ' Intention ', ' Nuclear Structure ', ' anticarcinogenic ', ' Chemopreventive ', ' Chemopreventive Agent ', ' 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one ', ' Dutasteride ', ' Atrophy ', ' Atrophic ', ' p300 ', ' EP300 ', ' EP300 gene ', ' Deoxyribonucleic Acid ', ' DNA ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Randomized ', ' Individual ', ' Population ', ' Sampling ', ' developmental ', ' Development ', "" men's "", ' men ', ' Detection ', ' Work ', ' Measures ', ' Biopsy Sample ', ' Biopsy Specimen ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' Body Tissues ', ' Tissues ', ' preventing ', ' prevent ', ' resistant ', ' Resistance ', ' clinical practice ', ' Malignant Cell ', ' cancer cell ', ' Maps ', ' Dose ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Stainings ', ' Staining method ', ' Blood Serum ', ' Serum ', ' cost ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Normal Cell ', ' Biopsy ', ' response ', ' Nature ', ' Therapeutic Androgen ', ' Androgenic Compounds ', ' Androgenic Agents ', ' Androgens ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' social role ', ' Role ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' sham therapy ', ' Sham Treatment ', ' Placebos ', ' Morphology ', ' Phase ', ' computer program/software ', ' Software ', ' Computer software ', ' Participant ', ' Data ', ' Risk ', ' Validation ', ' Diagnosis ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Area ', ' gene product ', ' Proteins ', ' treatment response ', ' indexing ', ' member ', ' Morbidity ', ' Morbidity - disease rate ', ' Nuclear ', ' base ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Stains ', ' Pattern ', ' Life ', ' Address ', ' Research ', ' Phenotype ', ' Goals ', ' Microscopy ', ' Chromatin ', ' inhibitor ', ' inhibitor/antagonist ', ' Play ', ' Gene Expression ', ' cancer risk ', ' Phase III study ', ' phase 3 study ', ' Variation ', ' Variant ', ' imaging ', ' Image ', ' Techniques ', ' Outcome ', ' Pattern Recognition ', ' Epithelial ', ' Benign ', ' protein expression ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' digital ', ' Placebo Control ', ' Gland ', ' Shapes ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' phase II trial ', ' phase II protocol ', ' phase 2 trial ', ' Phase 2 Clinical Trials ', ' Phase II Clinical Trials ', ' deprivation ', ' Height ', ' Reductases ', ' Dehydrogenases ', ' Oxidoreductase ', ' dosage ', ' nucleolin ', ' drug efficacy ', ' Chemoprevention ', ' imaging method ', ' imaging modality ', ' Slide ', ' Q-Dot ', ' Quantum Dots ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT CHICAGO,R01,2011,343953,IL-07,0.2800451501047862
"Genetics Variants in the Genome Predisposing to Aggressive PCa DESCRIPTION (provided by applicant): Fortunately, most men diagnosed with prostate cancer (PCa) will not die from their disease, and some men diagnosed may not even require treatment for their cancers. However, on the other end of the spectrum, ~30,000 men annually die from PCa in the US alone. For these latter men, the concept of PCa as an indolent disease obviously does not apply. Understanding the molecular basis of aggressive PCa (aPCa) vs. indolent PCa (non-aPCa) is perhaps the most important basic, yet translational question in PCa biology. We hypothesize that multiple sequence variants in the genome confer risk to aPCa but not to non-aPCa. Taking advantage of the publicly available CGEMS genome wide association data, as well as the large and unique PCa patient population at Johns Hopkins Hospital (JHH), we propose a systematic genetic association study to confirm, fine map, and better characterize genetic risk variants for aPCa. We propose three specific aims: 1)Test the genetic variants implicated in the CGEMS study that distinguish aPCa from non-aPCa among ~3,000 aPCa and ~5,000 non-aPCa patients of European ancestry from the JHH, 2) Fine map the genomic regions for the SNPs implicated in Aim 1 among 3,000 aPCa and 5,000 non-aPCa patients of European ancestry from the JHH, and 3) Assess the association of the most significant SNPs found in Aim 2 with disease characteristics in all 8,000 patients, and with disease progression in a subset of patients that have follow-up data at JHH. In addition, we have two exploratory aims: 1) fine mapping of regions containing SNPs significant in European Americans in aPCa and non-aPCa in African Americans, and 2) testing for gene-gene interaction. Besides the obvious clues that the proposed research may provide in terms of etiologic mechanisms, this study may also lead to identification of new target genes and proteins for therapy and possible preventive strategies. Furthermore, the identification of multiple variants can lead to the development of a test panel that may improve prediction of aPCa risk. Project Narrative  Prostate cancer is a common cancer that varies widely in its aggressiveness. The ability to predict which men  are at risk for the development of aggressive prostate cancer is urgently needed. This proposal addresses the  possibility that genetic variants may differentiate risk for aggressive from non-aggressive prostate cancer and  the results can be used to predict men at higher risk for aggressive prostate cancer.",Genetics Variants in the Genome Predisposing to Aggressive PCa,8037735,R01CA133009,"['forest ', ' sharing data ', ' genetic association ', ' Disease Outcome ', ' 17q24.3 ', ' Investments ', ' disease characteristic ', ' Logistic Regressions ', ' Core Biopsy ', ' Core Needle Biopsy ', ' genome-wide analysis ', ' Family history of ', ' Family Medical History Epidemiology ', ' Family Medical History ', ' analytical method ', ' European ', ' Sampling Errors ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' Adjuvant Therapy ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Indolent ', ' data mining ', ' datamining ', ' 8q24 ', ' 17q ', ' Chromosome 17 Long Arm ', ' Chromosome 17 Distal Arm ', ' 17q12 ', ' cancer genetics ', ' high risk men ', ' men at high risk ', ' design ', ' designing ', ' cohort ', ' Role ', ' social role ', ' high risk ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Methods ', ' Procedures ', ' Testing ', ' Genes ', ' Affect ', ' Time ', ' novel ', ' Modeling ', ' Age ', ' Genetic ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Address ', ' Organ ', ' Family ', ' Population ', ' Goals ', ' Recruitment Activity ', ' recruit ', ' experience ', ' American ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Molecular ', ' Data ', ' biomarker ', ' Pathway interactions ', ' pathway ', ' Cancer Patient ', ' Biology ', ' Variant ', ' Variation ', ' success ', ' Phenotype ', ' therapeutic target ', ' Characteristics ', ' Research ', ' Pattern ', ' Diagnosis ', ' Predisposition ', ' Susceptibility ', ' Pathologic ', ' Area ', ' Risk ', ' innovation ', ' innovative ', ' innovate ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Joints ', ' Articulation ', ' Life ', ' improved ', ' Individual ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Universities ', ' Publications ', ' Scientific Publication ', ' tumor ', ' interest ', ' Evaluation ', ' Development ', ' developmental ', ' Publishing ', ' Property ', ' LOINC Axis 2 Property ', ' Collaborations ', ' Haplotypes ', ' base ', ' Staging ', ' Clinical ', ' Patients ', ' Frequencies (time pattern) ', ' Frequency ', ' Linear Regressions ', ' Gene Frequency ', ' allelic frequency ', ' Allele Frequency ', ' Pathologist ', ' Tissue Sample ', ' Regression Analysis ', ' Statistical Regression ', ' Regression Diagnostics ', ' Regression Analyses ', ' Pathological Staging ', ' genome-wide linkage ', ' genomewide linkage ', ' clinical phenotype ', ' genetic linkage analysis ', ' linkage analyses ', ' genetic linkage analyses ', ' family based linkage study ', ' Linkage Analysis ', ' genetic linkage ', ' Linkage (Genetics) ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Cancer Biology ', ' Population Study ', ' Radiation ', ' ray (radiation) ', ' Alleles ', ' Allelomorphs ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' Malignant neoplasm of prostate ', ' Malignant prostatic tumor ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant Tumor of the Prostate ', ' Policies ', ' men ', "" men's "", ' Sample Size ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Genotype ', ' Gene Proteins ', ' Protein Gene Products ', ' Cohort Studies ', ' Concurrent Studies ', ' Quality of life ', ' QOL ', ' follow-up ', ' followed up ', ' follow up ', ' Active Follow-up ', ' Genomics ', ' Hospitals ', ' genome-wide ', ' genomewide ', ' cancer diagnosis ', ' disease natural history ', ' Physicians ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Research Design ', ' study design ', ' Study Type ', ' Genetic Risk ', ' genetic variant ', ' cancer risk ', ' Disease Progression ', ' Productivity ', ' Genome ', ' African American ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Severity of illness ', ' disease severity ', ' Prevention strategy ', ' Preventive strategy ', ' gene interaction ', ' Recording of previous events ', ' History ', ' tumor progression ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' Twin Multiple Birth ', ' Twins ', ' patient population ', ' Maps ', ' Genetic Markers ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2011,585183,MD-07,0.16547876887647994
"Software to facilitate multimode, multiscale fused data for Pathology and Radiolo    DESCRIPTION (provided by applicant): Medical informatics from the macro- to micro-scale is increasingly available for a range of detection/diagnosis/theragnostic applications tailored to each patient's history and current condition. Prostatic adenocarcinoma (CAP) is the second most common malignancy among men with an estimated 220,000 new cases in the USA in 2008. With the advent of multi-parametric high resolution (3 Tesla (T)) prostate MRI, providing anatomic, biochemical, and physiologic information, it has become increasingly important to identify the potential value of this information in pre-operative or pre-therapeutic CAP screening. However, in vivo prostate MRI lacks the resolution and ground truth diagnostic accuracy histopathological examination of biopsy cores provides. A first step toward getting prostate MRI for CAP into the clinic would be validating the information provided from MR at the cellular level. However, validating MRI against histological ground truth currently lacks the means to link the information provided by radiological imaging and pathology seamlessly. This is primarily due to a lack of interoperability between informatics representations and tools. One missing element, for instance, is robust and accurate image registration tools to align the multi-modal volumetric data sets. The overarching goal of this collaborative project between the University of Pennsylvania, Rutgers University, and Siemens Corporate Research is to develop and evaluate multi-modal image analysis and machine learning techniques within a software framework that will enable efficient analysis, correlation, and interpretation of multi-functional, multi-resolution patient data. The availability of these multi-modal, multi- scale analysis tools will enable alignment of radiology and pathological data which in turn will (a) enable building and validation of supervised computerized decision support systems for detection and grading of CAP from radiology and pathology data and (b) building meta-classifiers for CAP by integrating multi- modal, multi-scale disease signatures. Such a set of prostate-specific informatics tools promises clinical benefits including improved patient prognoses, more accurate disease diagnoses, and therapeutic recommendations. More generally, the tools developed as part of this project will also enable radiologic/pathologic studies in other disease entities. The specific goals of this project are 1) to develop cross-platform, open source, grid-enabled annotation, image analysis and image registration tools that will enable cross modality validation of radiology data (multi-functional 3 T prostate MRI) with expert histopathological annotation of prostatectomy specimens and provide independent computer-aided predictions of cancer extent and grade on radiology and histopathology, 2) curate an open source caGRID- connected database of prostate MRI and histopathological specimens that will enable development of quantitative signatures for detection and grading of CAP across multiple scales and imaging modalities.  PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a software tool kit (based on the XIP application from Siemens corporation) that will allow scientists to study prostate cancer by combining data from multiple imaging modalities (radiology and pathology) with molecular methodologies (including proteins, genes, epigenetic data). The results of this fused and combined data sets will allow scientists to create a more robust system based view of prostate cancer which allow prediction of diagnosis, follow outcomes of therapeutic treatment and facilitate discovery of new treatment options            The goal of this project is to develop a software tool kit (based on the XIP application from Siemens corporation) that will allow scientists to study prostate cancer by combining data from multiple imaging modalities (radiology and pathology) with molecular methodologies (including proteins, genes, epigenetic data). The results of this fused and combined data sets will allow scientists to create a more robust system based view of prostate cancer which allow prediction of diagnosis, follow outcomes of therapeutic treatment and facilitate discovery of new treatment options","Software to facilitate multimode, multiscale fused data for Pathology and Radiolo",8305155,R01CA136535,"['Algorithms ', ' American Cancer Society ', ' Anatomical Sciences ', ' Anatomic ', ' Anatomy ', ' Engineering / Architecture ', ' Architecture ', ' malignant breast tumor ', ' Breast Cancer ', ' malignant breast neoplasm ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Prostate Adenocarcinoma ', ' Communities ', ' Diagnosis ', ' Computer aided diagnosis ', ' Computer-Assisted Diagnosis ', ' Diffusion ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Elements ', ' Explosion ', ' Goals ', ' Health ', ' Histology ', ' History ', ' Recording of previous events ', ' Hospitals ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Medical Informatics ', "" men's "", ' men ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Pathology ', ' Patients ', ' Pennsylvania ', ' Prognosis ', ' outcome forecast ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Prostatectomy ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Recommendation ', ' Research ', ' Sensitivity and Specificity ', ' computer program/software ', ' Software ', ' Computer software ', ' Computer Software Tools ', ' Software Tools ', ' Body Tissues ', ' Tissues ', ' United States ', ' Universities ', ' Weight ', ' Work ', ' health care ', ' Healthcare ', ' Schedule ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' base ', ' Label ', ' improved ', ' Procedures ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Biochemical ', ' Medical ', ' Link ', ' Evaluation ', ' screenings ', ' screening ', ' Screening procedure ', ' Training ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Experiential Learning ', ' Active Learning ', ' RDST ', ' radiologist ', ' Therapeutic ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Gleason Grade for Prostate Cancer ', ' Pathologist ', ' tool ', ' Diagnostic ', ' Research Specimen ', ' Specimen ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Scientist ', ' Stream ', ' Clinic ', ' Source ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' Location ', ' Nuclear ', ' Accuracy of Diagnosis ', ' diagnostic accuracy ', ' Informatics ', ' Histopathology ', ' novel ', ' Modality ', ' Protein Gene Products ', ' Gene Proteins ', ' Decision Support Systems ', ' repository ', ' MRI Scans ', ' imaging method ', ' imaging modality ', ' Core Needle Biopsy ', ' Core Biopsy ', ' Data ', ' Detection ', ' precancerous ', ' Pre-Malignant ', ' Premalignant ', ' Reader ', ' Infrastructure ', ' Research Infrastructure ', ' Resolution ', ' in vivo ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Validation ', ' Pathologic ', ' Molecular ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' preclinical ', ' pre-clinical ', ' cancer research ', ' anticancer research ', ' computerized ', ' image registration ', ' computer aided ', ' Computer Assisted ', ' spectroscopic imaging ', ' Outcome ', ' cancer imaging ', ' Population ', ' interoperability ', ' caBIG ', ' cancer Biomedical Informatics Grid ', ' open source ', ' disease diagnosis ', ' ']",NCI,UNIVERSITY OF PENNSYLVANIA,R01,2012,619383,PA-03,0.25911917171807936
"Decision support with MRI for targeting, evaluating laser ablation for prostate c     DESCRIPTION (provided by applicant): For a growing population of low- and intermediate-risk prostate cancer (CaP) patients, active surveillance may be biologically or psychologically undesirable. Yet the short- and long-term complications and co-morbidities associated with radical whole-organ therapies (e.g. intensity modulated radiation therapy) are still associated with a risk of treatment-related morbidity. With radical whole gland therapies, in certain patients who are more sensitive to radiation treatment, high dosage spots in the rectum and in the bladder can lead to complications including chronic rectal bleeding, diarrhea, and urinary symptoms such as cystitis. Laser induced interstitial thermal therapy (LITT) is a novel form of controlled, targeted thermal ablation that may offer measurable advantages over other ablative therapies for focal prostate therapy. Because LITT is MRI compatible, it enables an imaging advantage over other surgical or ablation techniques that utilize transrectal ultrasound to target and monitor treatment. However successful adoption of focal therapy for the treatment of CaP will hinge on several critical issues: 1) Can we accurately identify index lesions and cancers within the prostate? 2) Appropriate follow-up of patients treated with focal therapy and 3) How to detect recurrent/persistent disease? The introduction of multi-parametric (MP) MRI (T2w, dynamic contrast enhanced (DCE), Diffusion (DWI)) has allowed for (1) improved detection sensitivity and specificity for CaP localization, and (2) evaluating treatment response in the prostate. However there exists a need for (1) novel computational image analysis tools to quantitatively integrate MP-MRI parameters for improved CaP classification in vivo and (2) non-rigid registration tools for enabling targeted therapy and evaluation of post-treatment changes.  In this study we will employ sophisticated computer vision, image analysis, computer assisted diagnostic (CAD) and deformable registration tools in conjunction with MP-MRI to be used in conjunction with a small clinical trial involving 40 patients with documented CaP for (a) automated delineation of tumor regions on pre-treatment MP-MRI to thereby identify the specific regions for ablation via LITT, and (b) identify and delineate locally recurrent disease within and outside the ablation zone for post-LITT evaluation. Regions identified via CAD on pre-LITT MRI will be targeted for therapy, while on post-LITT MP-MRI, regions identified as being suspicious for CaP recurrence (on account of large changes in MR imaging markers) will be evaluated via needle core biopsy. The tools developed in this project will be integrated into a practical and feasible treatment paradigm for focal treatment of low-risk localized CaP which will allow patients to avoid the complications associated with radical whole-gland therapy. This inter-disciplinary, translational project combines engineering expertise in terms of CAD on MP-MRI, multimodal image registration and machine learning and clinical expertise in interventional radiology, prostate MRI, and MRI guided focal therapy.          In this study we will leverage sophisticated computer vision, image analysis, computer assisted diagnostic and deformable registration tools in conjunction with multi-parametric (MP) MRI in prostate cancer (CaP) patients for (a) automated delineation of tumor regions on pre-treatment MP-MRI and thereby identify the specific regions for ablation via laser induced interstitial thermal therapy (LITT), and (b) identify and delineate locally recurrent disease within and outside the ablation zone for post-LITT evaluation. The tools developed in this project will be integrated into a feasible treatment paradigm for focal treatment of low-risk localized CaP which will allow patients to avoid the complications associated with radical whole-gland therapy.            ","Decision support with MRI for targeting, evaluating laser ablation for prostate c",8574771,R21CA167811,"['Laser Radiation ', ' Laser Electromagnetic ', ' Lasers ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Prostate Ablation ', ' ']",NCI,CASE WESTERN RESERVE UNIVERSITY,R21,2012,269117,OH-11,0.2129907836938968
"Genetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancer    DESCRIPTION (provided by applicant): Prostate is the most common site of cancer in men in the United States. Most prostate cancers progress relatively slowly and stay confined within the prostate. However, some cases grow aggressively and metastasize to other parts of the body. The most important clinical challenge in the treatment of the disease is the not knowing which of these two clinical forms a patient is presenting with. This is critically important information given the significant morbidity associated with treatment interventions and could eventually help distinguish men who need intensive treatment from those who may be better served by watchful waiting. Currently, the level of serum PSA, clinical stage and Gleason score are used to estimate prognosis and inform treatment modalities. Although they are very useful, additional biomarkers may help to better predict the outcome of prostate cancer. Carefully designed molecular epidemiologic studies can contribute in this arena. Although the significance of angiogenesis in prostate cancer is demonstrated by its correlation with clinical features, such as clinical stage, Gleason scores, progression, metastasis and survival, relatively few studies have assessed the role of genes involved in the angiogenesis pathway with recurrence of prostate cancer. Research to identify the specific genes and genetic variants relevant to angiogenesis risk remain largely unexplored. Part of the reason why candidate gene studies have been inconclusive may be that a major source of genetic regulation has been ignored: gene silencing through DNA methylation. Our hypothesis is that genetic and epigenetic individual variation in genes involved in the angiogenesis pathway is associated with recurrence of prostate cancer. The ultimate goal of this study is to identify biomarkers that can be used at the time of diagnosis to predict prognosis and improve clinical treatment decision making. The proposed study involves (1) construction of a historical cohort of prostate cancer cases (n=~1300) treated with radical prostatectomy at the H. Lee Moffitt Cancer Center between 1987 and 2003, (2) evaluating the association between 802 SNPs in 52 genes involved in angiogenesis with risk of recurrent prostate cancer, (3) evaluating the association between DNA methylation in the promoter regions of angiogenesis genes and risk for recurrence of prostate cancer and (4) testing the combined effects of inherited and acquired genetic changes in the candidate genes on disease aggressiveness. PUBLIC HEALTH RELEVANCE: These studies will provide key information regarding the potential effect of epigenetic genetic variations on prostate cancer recurrence. The combination of the individual's epigenetic and genetic profile and a current prediction model can possibly estimate a more accurate recurrence risk of the prostate cancer patients. This model can be extremely useful for a strategy of prostate cancer treatment.                               ",Genetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancer,8260568,R01CA128813,"['abstracting ', ' Algorithms ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Biopsy ', ' Circulation ', ' Bloodstream ', ' Blood Circulation ', ' bone ', ' white race ', ' Occidental ', ' Caucasoid ', ' Caucasian Race ', ' Caucasian ', ' Caucasoid Race ', ' Systematics ', ' Classification ', ' Decision Making ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Genes ', ' Genotype ', ' Goals ', ' Haplotypes ', ' Hazard Models ', ' Health ', ' Linkage Disequilibrium ', ' Lymphatic system (all sites) ', ' Lymphatic System Reticuloendothelial System ', ' Lymphatic System ', ' Medical Records ', "" men's "", ' men ', ' Protein Methylation ', ' Methylation ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' tumor cell metastasis ', ' cancer metastasis ', ' Tumor Cell Migration ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastasize ', ' Metastasis ', ' Neoplasm Metastasis ', ' Pathology ', ' Patients ', ' Play ', ' Prognosis ', ' outcome forecast ', ' genetic promoter element ', ' Promotor Regions (Genetics) ', ' Promotor Regions ', ' Promoter Regions ', ' Promoter Regions (Genetics) ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' Racial Stocks ', ' Racial Group ', ' Race ', ' Receiver Operating Characteristics ', ' Recurrent ', ' Recurrence ', ' Research ', ' Research Institute ', ' Risk ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' social role ', ' Role ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Trees ', ' United States ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Caucasians ', ' Paraffin Embedding ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' base ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Biological ', ' Logistic Regressions ', ' Evaluation ', ' Blood Serum ', ' Serum ', ' Body part ', ' Individual ', ' angiogenesis ', ' Genetic ', ' Staging ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Gleason Grade for Prostate Cancer ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' DNA Methylation ', ' Area Under Curve ', ' Hereditary ', ' Inherited ', ' Source ', ' Techniques ', ' Tumor Tissue ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Gene Inactivation ', ' Gene Silencing ', ' cohort ', ' Modality ', ' Watchful Waiting ', ' Patient observation ', ' cancer registry ', ' neoplasm registry ', ' Regulation ', ' Modeling ', ' case control ', ' cancer location ', ' cancer site ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' cancer recurrence ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Formalin ', ' Bio-Informatics ', ' Bioinformatics ', ' Candidate Gene ', ' Candidate Disease Gene ', ' Length ', ' Nomograms ', ' VEGF, Hypoxia, and Angiogenesis ', ' Angiogenesis Pathway ', ' Data ', ' TNM staging system ', ' TNM ', ' Cancer Center ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' trial treatment ', ' trial regimen ', ' Clinical Treatment ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Molecular ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' pathway ', ' Pathway interactions ', ' genetic profiling ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' five year old ', ' age 5 years ', ' 5 year old ', ' tumor ', ' biomarker ', ' ']",NCI,H. LEE MOFFITT CANCER CTR & RES INST,R01,2012,327253,FL-14,0.3326285294846753
"Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies    DESCRIPTION (provided by applicant): In the PCPT and REDUCE trials, finasteride and dutasteride significantly reduced the detection of prostate cancer (PCa) by 23 and 25% respectively, and thus established that 51-reductase inhibitors (5ARI) are the first class of drugs proven as chemopreventive agents for PCa. The actual efficacy of these drugs varies among individuals, even after considering compliance with the prescribed dosage. Better understanding of the basis for sensitivity to 5ARI chemoprevention will: 1) pave the way for development of better-tolerated and more effective agents that exploit this established mechanism, 2) allow clinicians to target responsive men, thus reducing the cost and morbidity of life-long dosage, and 3) validate specific tissue biomarkers as surrogate endpoints for Phase II trials. Our preliminary data based on direct DNA staining suggest that nuclear morphometric features that characterize 5ARI response may also define a field effect that predicts PCa in untreated men with negative biopsies. REDUCE, which was completed in 2009, provides a unique opportunity to address these questions because intermediate, on-study biopsy samples (mandatory at Years 2 and 4) were collected. Previous research indicated that 5ARIs (at higher doses for short periods) produce changes in benign prostate that resemble incomplete atrophy. Our overall goal is to apply cutting- edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5ARI chemoprevention as well as the risk of PCa among men with negative biopsies. We will obtain Year 2 slides and tissue blocks from a random sample of REDUCE participants with various outcomes. Aim 1: To determine the effects of dutasteride (vs. placebo) on both nuclear and architectural features in benign tissue. Aim 2: To determine whether a multivariable treatment-response score differs between subjects who develop PCa while on dutasteride and those who do not, and, Aim 3: To determine the magnitude of association between nuclear phenotype in benign biopsies, and subsequent risk of PCa in untreated men at elevated risk. Altogether, we will use 3 techniques to assess cytomorphology: a) a morphometric score based on nuclear size, shape and texture, b) expression -via quantum dot imaging - of p300 and nucleolin (two proteins with major effects on chromatin pattern and nuclear morphology) and c) mapping of architectural features (e.g., epithelial area and height) via trainable software. This will be the first work to relate the cytomorphological effects of a 5ARI, given at a chemopreventive dose level for a lengthy period, to subsequent cancer occurrence. The results will have implications for chemoprevention research and clinical practice, including the large number of U.S. men who remain at risk following a negative prostate biopsy.        Prostate cancer is the most commonly diagnosed form of cancer in men and strategies to prevent or inhibit its development are critically needed. The goal of the proposed research is to validate new tissue imaging methods for determining risk of prostate cancer among men who have a negative prostate biopsy and for identifying those who are most likely to benefit from life-long chemopreventive drugs.                  ",Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies,8331466,R01CA155301,"['Therapeutic Androgen ', ' Androgenic Compounds ', ' Androgenic Agents ', ' Androgens ', ' inhibitor ', ' inhibitor/antagonist ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Chromatin ', ' Diagnosis ', ' Deoxyribonucleic Acid ', ' DNA ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Expression ', ' Goals ', ' indexing ', ' Maps ', "" men's "", ' men ', ' Microscopy ', ' Morbidity ', ' Morbidity - disease rate ', ' Nuclear Proteins ', ' Reductases ', ' Dehydrogenases ', ' Oxidoreductase ', ' Phenotype ', ' sham therapy ', ' Sham Treatment ', ' Placebos ', ' Play ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' gene product ', ' Proteins ', ' Research ', ' Risk ', ' social role ', ' Role ', ' computer program/software ', ' Software ', ' Computer software ', ' Stains ', ' Body Tissues ', ' Tissues ', ' Work ', ' 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- ', ' Finasteride ', ' nucleolin ', ' Measures ', ' Intention ', ' Surrogate End Points ', ' Surrogate Endpoint ', ' base ', ' dosage ', ' morphometry ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Area ', ' Benign ', ' Phase ', ' Variation ', ' Variant ', ' Epithelial ', ' Blood Serum ', ' Serum ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' phase II trial ', ' phase II protocol ', ' phase 2 trial ', ' Phase 2 Clinical Trials ', ' Phase II Clinical Trials ', ' Chemoprevention ', ' Morphology ', ' Shapes ', ' Atrophy ', ' Atrophic ', ' Malignant Cell ', ' cancer cell ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Slide ', ' Texture ', ' Pattern ', ' Techniques ', ' Stainings ', ' Staining method ', ' Height ', ' Nuclear ', ' cancer risk ', ' drug efficacy ', ' Biopsy Sample ', ' Biopsy Specimen ', ' Participant ', ' member ', ' Metric ', ' 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one ', ' Dutasteride ', ' Sampling ', ' response ', ' deprivation ', ' protein expression ', ' Q-Dot ', ' Quantum Dots ', ' Normal Cell ', ' imaging method ', ' imaging modality ', ' Gland ', ' preventing ', ' prevent ', ' p300 ', ' EP300 ', ' EP300 gene ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Randomized ', ' anticarcinogenic ', ' Chemopreventive ', ' Chemopreventive Agent ', ' Nuclear Structure ', ' Pattern Recognition ', ' Validation ', ' developmental ', ' Development ', ' active treatment ', ' active technique ', ' active method ', ' imaging ', ' Image ', ' Placebo Control ', ' cost ', ' digital ', ' Outcome ', ' Population ', ' resistant ', ' Resistance ', ' treatment response ', ' biomarker ', ' clinical practice ', ' Phase III study ', ' phase 3 study ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT CHICAGO,R01,2012,345183,IL-07,0.25455700287436306
"Decision support with MRI for targeting, evaluating laser ablation for prostate c     DESCRIPTION (provided by applicant): For a growing population of low- and intermediate-risk prostate cancer (CaP) patients, active surveillance may be biologically or psychologically undesirable. Yet the short- and long-term complications and co-morbidities associated with radical whole-organ therapies (e.g. intensity modulated radiation therapy) are still associated with a risk of treatment-related morbidity. With radical whole gland therapies, in certain patients who are more sensitive to radiation treatment, high dosage spots in the rectum and in the bladder can lead to complications including chronic rectal bleeding, diarrhea, and urinary symptoms such as cystitis. Laser induced interstitial thermal therapy (LITT) is a novel form of controlled, targeted thermal ablation that may offer measurable advantages over other ablative therapies for focal prostate therapy. Because LITT is MRI compatible, it enables an imaging advantage over other surgical or ablation techniques that utilize transrectal ultrasound to target and monitor treatment. However successful adoption of focal therapy for the treatment of CaP will hinge on several critical issues: 1) Can we accurately identify index lesions and cancers within the prostate? 2) Appropriate follow-up of patients treated with focal therapy and 3) How to detect recurrent/persistent disease? The introduction of multi-parametric (MP) MRI (T2w, dynamic contrast enhanced (DCE), Diffusion (DWI)) has allowed for (1) improved detection sensitivity and specificity for CaP localization, and (2) evaluating treatment response in the prostate. However there exists a need for (1) novel computational image analysis tools to quantitatively integrate MP-MRI parameters for improved CaP classification in vivo and (2) non-rigid registration tools for enabling targeted therapy and evaluation of post-treatment changes.  In this study we will employ sophisticated computer vision, image analysis, computer assisted diagnostic (CAD) and deformable registration tools in conjunction with MP-MRI to be used in conjunction with a small clinical trial involving 40 patients with documented CaP for (a) automated delineation of tumor regions on pre-treatment MP-MRI to thereby identify the specific regions for ablation via LITT, and (b) identify and delineate locally recurrent disease within and outside the ablation zone for post-LITT evaluation. Regions identified via CAD on pre-LITT MRI will be targeted for therapy, while on post-LITT MP-MRI, regions identified as being suspicious for CaP recurrence (on account of large changes in MR imaging markers) will be evaluated via needle core biopsy. The tools developed in this project will be integrated into a practical and feasible treatment paradigm for focal treatment of low-risk localized CaP which will allow patients to avoid the complications associated with radical whole-gland therapy. This inter-disciplinary, translational project combines engineering expertise in terms of CAD on MP-MRI, multimodal image registration and machine learning and clinical expertise in interventional radiology, prostate MRI, and MRI guided focal therapy.        PUBLIC HEALTH RELEVANCE: In this study we will leverage sophisticated computer vision, image analysis, computer assisted diagnostic and deformable registration tools in conjunction with multi-parametric (MP) MRI in prostate cancer (CaP) patients for (a) automated delineation of tumor regions on pre-treatment MP-MRI and thereby identify the specific regions for ablation via laser induced interstitial thermal therapy (LITT), and (b) identify and delineate locally recurrent disease within and outside the ablation zone for post-LITT evaluation. The tools developed in this project will be integrated into a feasible treatment paradigm for focal treatment of low-risk localized CaP which will allow patients to avoid the complications associated with radical whole-gland therapy.              In this study we will leverage sophisticated computer vision, image analysis, computer assisted diagnostic and deformable registration tools in conjunction with multi-parametric (MP) MRI in prostate cancer (CaP) patients for (a) automated delineation of tumor regions on pre-treatment MP-MRI and thereby identify the specific regions for ablation via laser induced interstitial thermal therapy (LITT), and (b) identify and delineate locally recurrent disease within and outside the ablation zone for post-LITT evaluation. The tools developed in this project will be integrated into a feasible treatment paradigm for focal treatment of low-risk localized CaP which will allow patients to avoid the complications associated with radical whole-gland therapy.            ","Decision support with MRI for targeting, evaluating laser ablation for prostate c",8308194,R21CA167811,"['neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Biopsy ', ' urinary bladder ', ' Bladder Urinary System ', ' Bladder ', ' Adoption ', ' post treatment ', ' After-Treatment ', ' After Care ', ' Aftercare ', ' Accounting ', ' Engineering ', ' Forms Controls ', ' Hemorrhage ', ' blood loss ', ' Bleeding ', ' Diagnostic Imaging ', ' clinical investigation ', ' Clinical Trials ', ' computer vision ', ' Computer Vision Systems ', ' feature recognition ', ' feature detection ', ' content based retrieval ', ' Computer-Assisted Image Analyses ', ' Computer-Assisted Image Analysis ', ' Diarrhea ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Systematics ', ' Classification ', ' co-morbidity ', ' Comorbidity ', ' Diffusion ', ' Cystitis ', ' Methods ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', ' Morbidity ', ' Morbidity - disease rate ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' indexing ', ' Laser Radiation ', ' Laser Electromagnetic ', ' Lasers ', ' Risk ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Rectum ', ' Pharmacokinetics ', ' Drug Kinetics ', ' Recurrent ', ' Recurrence ', ' Probability ', ' Patients ', ' Interventional radiology ', ' dosage ', ' Clinical ', ' Organ ', ' improved ', ' Chronic ', ' base ', ' Work ', ' Time ', ' Sensitivity and Specificity ', ' Computer-Assisted Protocol-Directed Therapy ', ' Computer Assisted Protocol Therapy ', ' Computer-Assisted Therapy ', ' laser therapy ', ' Low-Power Laser Therapy ', ' Low-Power Laser Irradiation ', ' Laser Biostimulation ', ' LLLT ', ' Low-Level Laser Therapy ', ' Diagnostic ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Techniques ', ' Transrectal Ultrasound ', ' Relapsed Disease ', ' Recurrent disease ', ' Lesion ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Site ', ' Spottings ', ' rectal ', ' ray (radiation) ', ' Radiation ', ' Gland ', ' thermal ablation ', ' Thermal Ablation Therapy ', ' Performance ', ' novel ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Ablation ', ' treatment planning ', ' interstitial ', ' cohort ', ' Histopathology ', ' image registration ', ' Cancer Detection ', ' Therapy Evaluation ', ' computer aided ', ' Computer Assisted ', ' in vivo ', ' Cancer Patient ', ' cancer research ', ' anticancer research ', ' enroll ', ' Enrollment ', ' Monitor ', ' urinary ', ' imaging ', ' Image ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' cancer classification ', ' cancer recurrence ', ' Symptoms ', ' Core Needle Biopsy ', ' Core Biopsy ', ' Multimodal Imaging ', ' Detection ', ' Intensity Modulated Radiation Therapy ', ' Intensity Modulated RT ', ' IMRT ', ' Intensity-Modulated Radiotherapy ', ' Measurable ', ' Prostate CA therapy ', ' Prostate Cancer therapy ', ' Population ', ' treatment response ', ' Prostate Ablation ', ' tumor ', ' ']",NCI,"RUTGERS, THE STATE UNIV OF N.J.",R21,2012,5883,NJ-06,0.2133561696533838
"An integrated approach to dissect the functional network of large non-coding RNA     DESCRIPTION (provided by applicant): Recent studies revealed that the human genome encodes thousands of lncRNAs with little protein-coding capacity. LncRNAs were shown to play important roles in cancer and are potentially a new class of therapeutic targets for cancer. However, the function of the vast majority of lncRNAs in cancer remains unknown. LncRNA function often depends on its physical interactions with protein complexes. They can also influence the abundance of other mRNAs that are targeted by the same microRNAs by competing for microRNA binding, i.e., serving as competing endogenous RNA (ceRNA). Advances in genomic technologies, especially those based on next generation sequencing (NGS), provide unparalleled opportunities to characterize the functional networks of lncRNA in cancer. However, analysis and integration of different types of genomic datasets to generate testable hypotheses is challenging, and systematic approaches to characterize lncRNA function in cancer are lacking. This application describes the development of computational methods and integrative genomic strategies for systematically dissecting the functional network of lncRNA in cancer, and a combination of computational and experimental approaches to unravel several important functional networks of lncRNA in prostate cancer. Specifically, it will (1) develop a computational method for repurposing the publically available array-based data to interrogate lncRNA expression in tumor samples and utilize an integrative genomic strategy to predict lncRNAs that may be important for tumorigenesis/tumor suppression in prostate cancer via analysis of lncRNA expression profiles, clinical information and somatic genomic alteration profiles of tumor samples, (2) identify the lncRNAs that are associated with EZH2 or direct transcriptional targets of EZH2 repression that are important for prostate tumorigenesis or tumor suppression, and (3) identify the ceRNAs of AR and PTEN that mediate prostate tumorigenesis or tumor suppression. In addition to its scientific proposal, this application proposes a comprehensive training program for preparing an independent investigator in the fields of computational genomics, non-coding RNA and cancer, who develops cutting-edge computational methods, and uses a combination of computational and experimental approaches to understand structure- function relationship of non-coding RNA and the function of non-coding RNA and RNA-protein interaction in cancer. While the candidate of this application has received extensive training in biophysics, statistics, machine learning and computational genomics, this career development award will allow him to develop his experimental skills, especially those next-generation sequencing-based techniques and molecular biology experiments in human cell lines. Dr. Liu, Professor of Biostatistics and Computational Biology and Dr. Brown, Professor of Medicine will mentor the candidate in the excellent training environment of Dana-Farber Cancer Institute, a part of Harvard Medical School community. A committee of experienced computational and cancer biologists will also advise him on both scientific research and career development.              PUBLIC HEALTH RELEVANCE: The proposed study is to decipher lncRNA function in cancer using a combination of novel computational methods and high-throughput experimental technologies. The proposed research will result in publically available bioinformatic resources for studying lncRNA function in cancer, a greater understanding of lncRNA function in prostate cancer, and will help to discover novel therapeutic target of lncRNA for treating prostate cancer.               The written critiques and criteria scores of individual reviewers are provided in essentially unedited form in the ""Critique"" section below. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The ""Resume and Summary of Discussion"" section above summarizes the final opinions of the committee.                ",An integrated approach to dissect the functional network of large non-coding RNA,8488044,K99CA175290,"['Algorithms ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Communities ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Critiques ', ' Data Analysis ', ' Data Analyses ', ' Environment ', ' Exons ', ' human whole genome ', ' Human Genome ', ' Immune Precipitation ', ' Immunoprecipitation ', ' Medicine ', ' Mentors ', ' Methods ', ' Play ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' gene product ', ' Proteins ', ' Androgen Receptor ', ' Repression ', ' Research ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleoproteins ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' school of medicine ', ' medical college ', ' medical schools ', ' statistics ', ' structure function relationship ', ' chemical structure function ', ' Structure-Activity Relationship ', ' Technology ', ' Training Programs ', ' Writing ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Training ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Computational Biology ', ' meetings ', ' experience ', ' professor ', ' Base Pairing ', ' skills ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Human Cell Line ', ' Categories ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN ', ' MMAC1 ', ' BZS ', ' PTEN gene ', ' Coding System ', ' Code ', ' Modeling ', ' Sampling ', ' career development ', ' Genomics ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' enhancer of zeste homolog 2 (Drosophila) protein, human ', ' Enhancer of Zeste Homolog 2 ', ' human EZH2 protein ', ' protein complex ', ' Oncogenesis ', ' tumorigenesis ', ' ChIP (chromatin immunoprecipitation) ', ' CHIP assay ', ' chromatin immunoprecipitation ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' DF/HCC ', ' Dana-Farber Cancer Institute ', ' Data ', ' Molecular Biology Techniques ', ' molecular signature ', ' molecuar profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' RNA-Protein Interaction ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' mRNA Expression ', ' Molecular Tumor Suppression ', ' Tumor Suppression ', ' developmental ', ' Development ', ' therapeutic target ', ' tumor ', ' novel therapeutic target ', ' new therapeutic target ', ' public health relevance ', ' prostate tumorigenesis ', ' prostate carcinogenesis ', ' RNA-seq ', ' transcriptome sequencing ', ' next generation sequencing ', ' ']",NCI,DANA-FARBER CANCER INST,K99,2013,112476,MA-07,0.19480020846285154
"Software to facilitate multimode, multiscale fused data for Pathology and Radiolo    DESCRIPTION (provided by applicant): Medical informatics from the macro- to micro-scale is increasingly available for a range of detection/diagnosis/theragnostic applications tailored to each patient's history and current condition. Prostatic adenocarcinoma (CAP) is the second most common malignancy among men with an estimated 220,000 new cases in the USA in 2008. With the advent of multi-parametric high resolution (3 Tesla (T)) prostate MRI, providing anatomic, biochemical, and physiologic information, it has become increasingly important to identify the potential value of this information in pre-operative or pre-therapeutic CAP screening. However, in vivo prostate MRI lacks the resolution and ground truth diagnostic accuracy histopathological examination of biopsy cores provides. A first step toward getting prostate MRI for CAP into the clinic would be validating the information provided from MR at the cellular level. However, validating MRI against histological ground truth currently lacks the means to link the information provided by radiological imaging and pathology seamlessly. This is primarily due to a lack of interoperability between informatics representations and tools. One missing element, for instance, is robust and accurate image registration tools to align the multi-modal volumetric data sets. The overarching goal of this collaborative project between the University of Pennsylvania, Rutgers University, and Siemens Corporate Research is to develop and evaluate multi-modal image analysis and machine learning techniques within a software framework that will enable efficient analysis, correlation, and interpretation of multi-functional, multi-resolution patient data. The availability of these multi-modal, multi- scale analysis tools will enable alignment of radiology and pathological data which in turn will (a) enable building and validation of supervised computerized decision support systems for detection and grading of CAP from radiology and pathology data and (b) building meta-classifiers for CAP by integrating multi- modal, multi-scale disease signatures. Such a set of prostate-specific informatics tools promises clinical benefits including improved patient prognoses, more accurate disease diagnoses, and therapeutic recommendations. More generally, the tools developed as part of this project will also enable radiologic/pathologic studies in other disease entities. The specific goals of this project are 1) to develop cross-platform, open source, grid-enabled annotation, image analysis and image registration tools that will enable cross modality validation of radiology data (multi-functional 3 T prostate MRI) with expert histopathological annotation of prostatectomy specimens and provide independent computer-aided predictions of cancer extent and grade on radiology and histopathology, 2) curate an open source caGRID- connected database of prostate MRI and histopathological specimens that will enable development of quantitative signatures for detection and grading of CAP across multiple scales and imaging modalities.   PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a software tool kit (based on the XIP application from Siemens corporation) that will allow scientists to study prostate cancer by combining data from multiple imaging modalities (radiology and pathology) with molecular methodologies (including proteins, genes, epigenetic data). The results of this fused and combined data sets will allow scientists to create a more robust system based view of prostate cancer which allow prediction of diagnosis, follow outcomes of therapeutic treatment and facilitate discovery of new treatment options         ","Software to facilitate multimode, multiscale fused data for Pathology and Radiolo",8512667,R01CA136535,"['Algorithms ', ' American Cancer Society ', ' Anatomical Sciences ', ' Anatomic ', ' Anatomy ', ' Engineering / Architecture ', ' Architecture ', ' malignant breast tumor ', ' Breast Cancer ', ' malignant breast neoplasm ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Prostate Adenocarcinoma ', ' Communities ', ' Diagnosis ', ' Computer aided diagnosis ', ' Computer-Assisted Diagnosis ', ' Diffusion ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Elements ', ' Explosion ', ' Goals ', ' Health ', ' Histology ', ' History ', ' Recording of previous events ', ' Hospitals ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Medical Informatics ', "" men's "", ' men ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Pathology ', ' Patients ', ' Pennsylvania ', ' Prognosis ', ' outcome forecast ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Prostatectomy ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Recommendation ', ' Research ', ' Sensitivity and Specificity ', ' computer program/software ', ' Software ', ' Computer software ', ' Computer Software Tools ', ' Software Tools ', ' Body Tissues ', ' Tissues ', ' United States ', ' Universities ', ' Weight ', ' Work ', ' health care ', ' Healthcare ', ' Schedule ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' base ', ' Label ', ' improved ', ' Procedures ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Biochemical ', ' Medical ', ' Link ', ' Evaluation ', ' Training ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Experiential Learning ', ' Active Learning ', ' RDST ', ' radiologist ', ' Therapeutic ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Gleason Grade for Prostate Cancer ', ' Pathologist ', ' tool ', ' Diagnostic ', ' Research Specimen ', ' Specimen ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Scientist ', ' Stream ', ' Clinic ', ' Source ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' Location ', ' Nuclear ', ' Accuracy of Diagnosis ', ' diagnostic accuracy ', ' Informatics ', ' Histopathology ', ' novel ', ' Modality ', ' Protein Gene Products ', ' Gene Proteins ', ' Decision Support Systems ', ' repository ', ' MRI Scans ', ' imaging method ', ' imaging modality ', ' Core Needle Biopsy ', ' Core Biopsy ', ' Data ', ' Detection ', ' precancerous ', ' Pre-Malignant ', ' Premalignant ', ' Reader ', ' Infrastructure ', ' Research Infrastructure ', ' Resolution ', ' in vivo ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Validation ', ' Pathologic ', ' Molecular ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' preclinical ', ' pre-clinical ', ' cancer research ', ' anticancer research ', ' computerized ', ' image registration ', ' computer aided ', ' Computer Assisted ', ' spectroscopic imaging ', ' Outcome ', ' cancer imaging ', ' Population ', ' interoperability ', ' caBIG ', ' cancer Biomedical Informatics Grid ', ' open source ', ' disease diagnosis ', ' screening ', ' ']",NCI,UNIVERSITY OF PENNSYLVANIA,R01,2013,569321,PA-03,0.23105352986994457
"Decision support with MRI for targeting, evaluating laser ablation for prostate c     DESCRIPTION (provided by applicant): For a growing population of low- and intermediate-risk prostate cancer (CaP) patients, active surveillance may be biologically or psychologically undesirable. Yet the short- and long-term complications and co-morbidities associated with radical whole-organ therapies (e.g. intensity modulated radiation therapy) are still associated with a risk of treatment-related morbidity. With radical whole gland therapies, in certain patients who are more sensitive to radiation treatment, high dosage spots in the rectum and in the bladder can lead to complications including chronic rectal bleeding, diarrhea, and urinary symptoms such as cystitis. Laser induced interstitial thermal therapy (LITT) is a novel form of controlled, targeted thermal ablation that may offer measurable advantages over other ablative therapies for focal prostate therapy. Because LITT is MRI compatible, it enables an imaging advantage over other surgical or ablation techniques that utilize transrectal ultrasound to target and monitor treatment. However successful adoption of focal therapy for the treatment of CaP will hinge on several critical issues: 1) Can we accurately identify index lesions and cancers within the prostate? 2) Appropriate follow-up of patients treated with focal therapy and 3) How to detect recurrent/persistent disease? The introduction of multi-parametric (MP) MRI (T2w, dynamic contrast enhanced (DCE), Diffusion (DWI)) has allowed for (1) improved detection sensitivity and specificity for CaP localization, and (2) evaluating treatment response in the prostate. However there exists a need for (1) novel computational image analysis tools to quantitatively integrate MP-MRI parameters for improved CaP classification in vivo and (2) non-rigid registration tools for enabling targeted therapy and evaluation of post-treatment changes.  In this study we will employ sophisticated computer vision, image analysis, computer assisted diagnostic (CAD) and deformable registration tools in conjunction with MP-MRI to be used in conjunction with a small clinical trial involving 40 patients with documented CaP for (a) automated delineation of tumor regions on pre-treatment MP-MRI to thereby identify the specific regions for ablation via LITT, and (b) identify and delineate locally recurrent disease within and outside the ablation zone for post-LITT evaluation. Regions identified via CAD on pre-LITT MRI will be targeted for therapy, while on post-LITT MP-MRI, regions identified as being suspicious for CaP recurrence (on account of large changes in MR imaging markers) will be evaluated via needle core biopsy. The tools developed in this project will be integrated into a practical and feasible treatment paradigm for focal treatment of low-risk localized CaP which will allow patients to avoid the complications associated with radical whole-gland therapy. This inter-disciplinary, translational project combines engineering expertise in terms of CAD on MP-MRI, multimodal image registration and machine learning and clinical expertise in interventional radiology, prostate MRI, and MRI guided focal therapy.          In this study we will leverage sophisticated computer vision, image analysis, computer assisted diagnostic and deformable registration tools in conjunction with multi-parametric (MP) MRI in prostate cancer (CaP) patients for (a) automated delineation of tumor regions on pre-treatment MP-MRI and thereby identify the specific regions for ablation via laser induced interstitial thermal therapy (LITT), and (b) identify and delineate locally recurrent disease within and outside the ablation zone for post-LITT evaluation. The tools developed in this project will be integrated into a feasible treatment paradigm for focal treatment of low-risk localized CaP which will allow patients to avoid the complications associated with radical whole-gland therapy.            ","Decision support with MRI for targeting, evaluating laser ablation for prostate c",8544441,R21CA167811,"['Accounting ', ' Adoption ', ' post treatment ', ' After-Treatment ', ' After Care ', ' Aftercare ', ' Biopsy ', ' urinary bladder ', ' Bladder Urinary System ', ' Bladder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' clinical investigation ', ' Clinical Trials ', ' co-morbidity ', ' Comorbidity ', ' computer vision ', ' Computer Vision Systems ', ' feature recognition ', ' feature detection ', ' content based retrieval ', ' Computer-Assisted Image Analyses ', ' Computer-Assisted Image Analysis ', ' Cystitis ', ' Diagnostic Imaging ', ' Diarrhea ', ' Diffusion ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Forms Controls ', ' blood loss ', ' Bleeding ', ' Hemorrhage ', ' indexing ', ' Laser Radiation ', ' Laser Electromagnetic ', ' Lasers ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' Patients ', ' Pharmacokinetics ', ' Drug Kinetics ', ' Probability ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Interventional radiology ', ' Rectum ', ' Recurrent ', ' Recurrence ', ' Risk ', ' Sensitivity and Specificity ', ' Computer-Assisted Protocol-Directed Therapy ', ' Computer Assisted Protocol Therapy ', ' Computer-Assisted Therapy ', ' Time ', ' Work ', ' base ', ' dosage ', ' Organ ', ' improved ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' rectal ', ' Site ', ' Chronic ', ' Clinical ', ' Lesion ', ' Relapsed Disease ', ' Recurrent disease ', ' laser therapy ', ' Low-Power Laser Therapy ', ' Low-Power Laser Irradiation ', ' Laser Biostimulation ', ' LLLT ', ' Low-Level Laser Therapy ', ' Spottings ', ' tool ', ' Diagnostic ', ' Transrectal Ultrasound ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Techniques ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Ablation ', ' interstitial ', ' Performance ', ' cohort ', ' treatment planning ', ' Histopathology ', ' thermal ablation ', ' Thermal Ablation Therapy ', ' novel ', ' ray (radiation) ', ' Radiation ', ' cancer classification ', ' cancer recurrence ', ' Gland ', ' Core Needle Biopsy ', ' Core Biopsy ', ' Symptoms ', ' Detection ', ' Intensity Modulated Radiation Therapy ', ' Intensity Modulated RT ', ' IMRT ', ' Intensity-Modulated Radiotherapy ', ' Measurable ', ' Multimodal Imaging ', ' Therapy Evaluation ', ' in vivo ', ' Cancer Detection ', ' Cancer Patient ', ' enroll ', ' Enrollment ', ' Monitor ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' urinary ', ' imaging ', ' Image ', ' cancer research ', ' anticancer research ', ' image registration ', ' computer aided ', ' Computer Assisted ', ' Prostate Ablation ', ' Population ', ' Prostate CA therapy ', ' Prostate Cancer therapy ', ' tumor ', ' treatment response ', ' ']",NCI,CASE WESTERN RESERVE UNIVERSITY,R21,2013,241056,OH-11,0.2129907836938968
"Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies    DESCRIPTION (provided by applicant): In the PCPT and REDUCE trials, finasteride and dutasteride significantly reduced the detection of prostate cancer (PCa) by 23 and 25% respectively, and thus established that 51-reductase inhibitors (5ARI) are the first class of drugs proven as chemopreventive agents for PCa. The actual efficacy of these drugs varies among individuals, even after considering compliance with the prescribed dosage. Better understanding of the basis for sensitivity to 5ARI chemoprevention will: 1) pave the way for development of better-tolerated and more effective agents that exploit this established mechanism, 2) allow clinicians to target responsive men, thus reducing the cost and morbidity of life-long dosage, and 3) validate specific tissue biomarkers as surrogate endpoints for Phase II trials. Our preliminary data based on direct DNA staining suggest that nuclear morphometric features that characterize 5ARI response may also define a field effect that predicts PCa in untreated men with negative biopsies. REDUCE, which was completed in 2009, provides a unique opportunity to address these questions because intermediate, on-study biopsy samples (mandatory at Years 2 and 4) were collected. Previous research indicated that 5ARIs (at higher doses for short periods) produce changes in benign prostate that resemble incomplete atrophy. Our overall goal is to apply cutting- edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5ARI chemoprevention as well as the risk of PCa among men with negative biopsies. We will obtain Year 2 slides and tissue blocks from a random sample of REDUCE participants with various outcomes. Aim 1: To determine the effects of dutasteride (vs. placebo) on both nuclear and architectural features in benign tissue. Aim 2: To determine whether a multivariable treatment-response score differs between subjects who develop PCa while on dutasteride and those who do not, and, Aim 3: To determine the magnitude of association between nuclear phenotype in benign biopsies, and subsequent risk of PCa in untreated men at elevated risk. Altogether, we will use 3 techniques to assess cytomorphology: a) a morphometric score based on nuclear size, shape and texture, b) expression -via quantum dot imaging - of p300 and nucleolin (two proteins with major effects on chromatin pattern and nuclear morphology) and c) mapping of architectural features (e.g., epithelial area and height) via trainable software. This will be the first work to relate the cytomorphological effects of a 5ARI, given at a chemopreventive dose level for a lengthy period, to subsequent cancer occurrence. The results will have implications for chemoprevention research and clinical practice, including the large number of U.S. men who remain at risk following a negative prostate biopsy.        Prostate cancer is the most commonly diagnosed form of cancer in men and strategies to prevent or inhibit its development are critically needed. The goal of the proposed research is to validate new tissue imaging methods for determining risk of prostate cancer among men who have a negative prostate biopsy and for identifying those who are most likely to benefit from life-long chemopreventive drugs.                  ",Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies,8540146,R01CA155301,"['Therapeutic Androgen ', ' Androgenic Compounds ', ' Androgenic Agents ', ' Androgens ', ' inhibitor ', ' inhibitor/antagonist ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Chromatin ', ' Diagnosis ', ' Deoxyribonucleic Acid ', ' DNA ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Expression ', ' Goals ', ' indexing ', ' Maps ', "" men's "", ' men ', ' Microscopy ', ' Morbidity ', ' Morbidity - disease rate ', ' Nuclear Proteins ', ' Reductases ', ' Dehydrogenases ', ' Oxidoreductase ', ' Phenotype ', ' sham therapy ', ' Sham Treatment ', ' Placebos ', ' Play ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' gene product ', ' Proteins ', ' Research ', ' Risk ', ' social role ', ' Role ', ' computer program/software ', ' Software ', ' Computer software ', ' Stains ', ' Body Tissues ', ' Tissues ', ' Work ', ' 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- ', ' Finasteride ', ' nucleolin ', ' Measures ', ' Intention ', ' Surrogate End Points ', ' Surrogate Endpoint ', ' base ', ' dosage ', ' morphometry ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Area ', ' Benign ', ' Phase ', ' Variation ', ' Variant ', ' Epithelial ', ' Blood Serum ', ' Serum ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' phase II trial ', ' phase II protocol ', ' phase 2 trial ', ' Phase 2 Clinical Trials ', ' Phase II Clinical Trials ', ' Chemoprevention ', ' Morphology ', ' Shapes ', ' Atrophy ', ' Atrophic ', ' Malignant Cell ', ' cancer cell ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Slide ', ' Texture ', ' Pattern ', ' Techniques ', ' Stainings ', ' Staining method ', ' Height ', ' Nuclear ', ' cancer risk ', ' drug efficacy ', ' Biopsy Sample ', ' Biopsy Specimen ', ' Participant ', ' member ', ' Metric ', ' 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one ', ' Dutasteride ', ' Sampling ', ' response ', ' deprivation ', ' protein expression ', ' Q-Dot ', ' Quantum Dots ', ' Normal Cell ', ' imaging method ', ' imaging modality ', ' Gland ', ' preventing ', ' prevent ', ' p300 ', ' EP300 ', ' EP300 gene ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Randomized ', ' anticarcinogenic ', ' Chemopreventive ', ' Chemopreventive Agent ', ' Nuclear Structure ', ' Pattern Recognition ', ' Validation ', ' developmental ', ' Development ', ' active treatment ', ' active technique ', ' active method ', ' imaging ', ' Image ', ' Placebo Control ', ' cost ', ' digital ', ' Outcome ', ' Population ', ' resistant ', ' Resistance ', ' treatment response ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' clinical practice ', ' Phase III study ', ' phase 3 study ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT CHICAGO,R01,2013,324739,IL-07,0.25455700287436306
"Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies    DESCRIPTION (provided by applicant): In the PCPT and REDUCE trials, finasteride and dutasteride significantly reduced the detection of prostate cancer (PCa) by 23 and 25% respectively, and thus established that 51-reductase inhibitors (5ARI) are the first class of drugs proven as chemopreventive agents for PCa. The actual efficacy of these drugs varies among individuals, even after considering compliance with the prescribed dosage. Better understanding of the basis for sensitivity to 5ARI chemoprevention will: 1) pave the way for development of better-tolerated and more effective agents that exploit this established mechanism, 2) allow clinicians to target responsive men, thus reducing the cost and morbidity of life-long dosage, and 3) validate specific tissue biomarkers as surrogate endpoints for Phase II trials. Our preliminary data based on direct DNA staining suggest that nuclear morphometric features that characterize 5ARI response may also define a field effect that predicts PCa in untreated men with negative biopsies. REDUCE, which was completed in 2009, provides a unique opportunity to address these questions because intermediate, on-study biopsy samples (mandatory at Years 2 and 4) were collected. Previous research indicated that 5ARIs (at higher doses for short periods) produce changes in benign prostate that resemble incomplete atrophy. Our overall goal is to apply cutting- edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5ARI chemoprevention as well as the risk of PCa among men with negative biopsies. We will obtain Year 2 slides and tissue blocks from a random sample of REDUCE participants with various outcomes. Aim 1: To determine the effects of dutasteride (vs. placebo) on both nuclear and architectural features in benign tissue. Aim 2: To determine whether a multivariable treatment-response score differs between subjects who develop PCa while on dutasteride and those who do not, and, Aim 3: To determine the magnitude of association between nuclear phenotype in benign biopsies, and subsequent risk of PCa in untreated men at elevated risk. Altogether, we will use 3 techniques to assess cytomorphology: a) a morphometric score based on nuclear size, shape and texture, b) expression -via quantum dot imaging - of p300 and nucleolin (two proteins with major effects on chromatin pattern and nuclear morphology) and c) mapping of architectural features (e.g., epithelial area and height) via trainable software. This will be the first work to relate the cytomorphological effects of a 5ARI, given at a chemopreventive dose level for a lengthy period, to subsequent cancer occurrence. The results will have implications for chemoprevention research and clinical practice, including the large number of U.S. men who remain at risk following a negative prostate biopsy.        Prostate cancer is the most commonly diagnosed form of cancer in men and strategies to prevent or inhibit its development are critically needed. The goal of the proposed research is to validate new tissue imaging methods for determining risk of prostate cancer among men who have a negative prostate biopsy and for identifying those who are most likely to benefit from life-long chemopreventive drugs.                  ",Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies,8723100,R01CA155301,"['Therapeutic Androgen ', ' Androgenic Compounds ', ' Androgenic Agents ', ' Androgens ', ' inhibitor ', ' inhibitor/antagonist ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Chromatin ', ' Diagnosis ', ' Deoxyribonucleic Acid ', ' DNA ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Expression ', ' Goals ', ' indexing ', ' Maps ', "" men's "", ' men ', ' Microscopy ', ' Morbidity ', ' Morbidity - disease rate ', ' Nuclear Proteins ', ' Reductases ', ' Dehydrogenases ', ' Oxidoreductase ', ' Phenotype ', ' sham therapy ', ' Sham Treatment ', ' Placebos ', ' Play ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' gene product ', ' Proteins ', ' Research ', ' Risk ', ' social role ', ' Role ', ' computer program/software ', ' Software ', ' Computer software ', ' Stains ', ' Body Tissues ', ' Tissues ', ' Work ', ' 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- ', ' Finasteride ', ' nucleolin ', ' Measures ', ' Intention ', ' Surrogate End Points ', ' Surrogate Endpoint ', ' base ', ' dosage ', ' morphometry ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Area ', ' Benign ', ' Phase ', ' Variation ', ' Variant ', ' Epithelial ', ' Blood Serum ', ' Serum ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' phase II trial ', ' phase II protocol ', ' phase 2 trial ', ' Phase 2 Clinical Trials ', ' Phase II Clinical Trials ', ' Chemoprevention ', ' Morphology ', ' Shapes ', ' Atrophy ', ' Atrophic ', ' Malignant Cell ', ' cancer cell ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Slide ', ' Texture ', ' Pattern ', ' Techniques ', ' Stainings ', ' Staining method ', ' Height ', ' Nuclear ', ' cancer risk ', ' drug efficacy ', ' Biopsy Sample ', ' Biopsy Specimen ', ' Participant ', ' member ', ' Metric ', ' 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one ', ' Dutasteride ', ' Sampling ', ' response ', ' deprivation ', ' protein expression ', ' Q-Dot ', ' Quantum Dots ', ' Normal Cell ', ' imaging method ', ' imaging modality ', ' Gland ', ' preventing ', ' prevent ', ' p300 ', ' EP300 ', ' EP300 gene ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Randomized ', ' anticarcinogenic ', ' Chemopreventive ', ' Chemopreventive Agent ', ' Nuclear Structure ', ' Pattern Recognition ', ' Validation ', ' developmental ', ' Development ', ' active treatment ', ' active technique ', ' active method ', ' imaging ', ' Image ', ' Placebo Control ', ' cost ', ' digital ', ' Outcome ', ' Population ', ' resistant ', ' Resistance ', ' treatment response ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' clinical practice ', ' Phase III study ', ' phase 3 study ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT CHICAGO,R01,2014,335385,IL-07,0.25455700287436306
"(PQC4) Habitats in Prostate Cancer     DESCRIPTION (provided by applicant): This proposal will address PQC-4: ""What in vivo imaging methods can be developed to portray the ""cytotype"" of a tumor defined as the identity, quantity, and location of each of the different cell types that make up a tumor and its microenvironment? An ideal system to address this question will have the following characteristics: 1) images and data should be obtained from human patients; 2) the relationship between imaging and cytotypes should have clinical relevance; 3) there should be a large amount and a balance in data obtained from within cancerous and non-cancerous volumes; 4) the image data should be of high quality and ideally multiparametric; and 5) registration of histology to radiographic images must be feasible. Such criteria are met in prostate cancer patients who are being monitored by active surveillance (AS). The University of Miami (UM) has a large AS population, and patients with prostate cancer are regularly and routinely imaged with multiparametric MRI (MP- MRI) that includes diffusion (DWI), dynamic contrast enhancement (DCE) and T2 weighted (T2w) imaging sequences as standard of care (SOC). These images are fused to a transrectal ultrasound (TRUS) guidance instrument for biopsy localization. The singular goal of the current work is to develop predictive models that define this interrelationshi based on profound image analyses (""radiomics"") in combination with quantitative histology and immunohistochemistry from spatially co-registered volumes; thus defining the ""cytotypes"" giving rise to MR image data. Researchers at the Moffitt Cancer Center have pioneered the application of radiomics and predictive (classifier like) modeling to cancer. Thus, this work will proceed with two interrelated aims. In Aim 1, MR images, histology, gene expression and clinical data will be generated at UM via the MAST Trial: MRI- Guided Biopsy Selection for Active Surveillance versus Treatment. In Aim 2, informatics data analysis, databasing and classifier modeling will be undertaken at Moffitt. Analysis of MR images will use a ""radiomics"" approach, wherein 432 size, shape and texture features are extracted from image-identified habitats. These will be matched up to registered histology images analyzed with quantitative pathology wherein 32 features are extracted from each cell to form clusters of similar morphotypes, as well as IHC for known and putative progression markers. From these quantitative markers, training and test set classifier models will be developed to relate the MR-defined habitats to their underlying mixtures of cytotypes. Because this will be a large and invaluable data base, it is our explicit intention to share the complete dataset, with the research community through material transfer agreements, which will allow alternative data mining schema.         PUBLIC HEALTH RELEVANCE: Virtually every cancer patient is imaged with CT, PET or MRI. Importantly, such imaging reveals that tumors are complex and heterogeneous, often containing multiple ""habitats"" within them. It is the intention of this research to deeply analyze these image so we can infer what is the cellular and molecular structure in each of these habitats. This will be performed in a large cohort of men with prostate cancer who are under ""active surveillance"". In other words, they have cancer, but it is not known if the cancer is life-threatening or not. Men under active surveillance receive regular MRI scans and regular biopsies. The MRI and biopsy data will be quantitatively compared in order for us to understand the cellular and molecular basis for these different habitats in cancers.            ",(PQC4) Habitats in Prostate Cancer,8792110,R01CA190105,"['driving ', ' Automobile Driving ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cell Extracts ', ' Cells ', ' clinical investigation ', ' Clinical Trials ', ' Communities ', ' Data Analysis ', ' Data Analyses ', ' Diagnosis ', ' Diffusion ', ' balance function ', ' balance ', ' Equilibrium ', ' Gene Expression ', ' Goals ', ' Histology ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Immunohistochemistry Staining Method ', ' Immunohistochemistry Cell/Tissue ', ' Immunohistochemistry ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', "" men's "", ' men ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' Methods ', ' Mining ', ' Macromolecular Structure ', ' Molecular Structure ', ' Pathology ', ' Patients ', ' Public Health Surveillance ', ' Population Surveillance ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Positron-Emission Tomography ', ' gene product ', ' Proteins ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Stains ', ' statistics ', ' Testing ', ' Universities ', ' Weight ', ' Work ', ' Schedule ', ' Dataset ', ' Data Set ', ' Blinded ', ' Intention ', ' base ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Medical ', ' prognostic ', ' Training ', ' Lesion ', ' Individual ', ' Oxygen Deficiency ', ' Hypoxic ', ' Hypoxia ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Sample Size ', ' Cell Structure ', ' Cell Components ', ' Cellular Structures ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Shapes ', ' Deposit ', ' Deposition ', ' instrument ', ' Diagnostic ', ' Transrectal Ultrasound ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Area Under Curve ', ' Complex ', ' Scanning ', ' Slide ', ' Source ', ' cell type ', ' Texture ', ' Pattern ', ' LOINC Axis 4 System ', ' System ', ' Location ', ' Stainings ', ' Staining method ', ' Hematoxylin and Eosin ', ' H and E ', ' Hematoxylin and Eosin Staining Method ', ' Best Practice Analysis ', ' Benchmarking ', ' interest ', ' meetings ', ' molecular pathology ', ' cohort ', ' Informatics ', ' Histopathology ', ' Biopsy Sample ', ' Biopsy Specimen ', ' Pathology Report ', ' p53-Binding Protein Gene ', ' MDM2 ', ' MDM 2 ', ' MDM2 gene ', ' Modeling ', ' Sampling ', ' Decision Support Systems ', ' Habitats ', ' MAST ', ' Drosophila orbit protein ', ' Drosophila multiple asters  protein ', ' Drosophila mast protein ', ' Drosophila chromosome bows protein ', ' Drosophila MESR7 protein ', ' Drosophila chb protein ', ' MRI Scans ', ' imaging method ', ' imaging modality ', ' datamining ', ' data mining ', ' MCT-1 ', ' MCT-1 gene ', ' Address ', ' Data ', ' Predictive Value ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prognostic Marker ', ' Resolution ', ' Cancer Center ', ' Cancer Patient ', ' Clinical Data ', ' Conduct Clinical Trials ', ' Tissue Chip ', ' Tissue Arrays ', ' Tissue Microarray ', ' Validation ', ' Monitor ', ' Characteristics ', ' Molecular ', ' Process ', ' Receiver Operator Characteristics ', ' imaging ', ' Image ', ' digital ', ' computer based prediction ', ' predictive modeling ', ' prospective ', ' Cancerous ', ' data acquisition ', ' clinical relevance ', ' clinically relevant ', ' tumor ', ' public health relevance ', ' patient population ', ' standard of care ', ' progression marker ', ' material transfer agreement ', ' relational database ', ' arm ', ' data reduction ', ' in vivo imaging ', ' ']",NCI,H. LEE MOFFITT CANCER CTR & RES INST,R01,2014,730977,FL-14,0.20560290085297311
"An integrated approach to dissect the functional network of large non-coding RNA DESCRIPTION (provided by applicant): Recent studies revealed that the human genome encodes thousands of lncRNAs with little protein-coding capacity. LncRNAs were shown to play important roles in cancer and are potentially a new class of therapeutic targets for cancer. However, the function of the vast majority of lncRNAs in cancer remains unknown. LncRNA function often depends on its physical interactions with protein complexes. They can also influence the abundance of other mRNAs that are targeted by the same microRNAs by competing for microRNA binding, i.e., serving as competing endogenous RNA (ceRNA). Advances in genomic technologies, especially those based on next generation sequencing (NGS), provide unparalleled opportunities to characterize the functional networks of lncRNA in cancer. However, analysis and integration of different types of genomic datasets to generate testable hypotheses is challenging, and systematic approaches to characterize lncRNA function in cancer are lacking. This application describes the development of computational methods and integrative genomic strategies for systematically dissecting the functional network of lncRNA in cancer, and a combination of computational and experimental approaches to unravel several important functional networks of lncRNA in prostate cancer. Specifically, it will (1) develop a computational method for repurposing the publically available array-based data to interrogate lncRNA expression in tumor samples and utilize an integrative genomic strategy to predict lncRNAs that may be important for tumorigenesis/tumor suppression in prostate cancer via analysis of lncRNA expression profiles, clinical information and somatic genomic alteration profiles of tumor samples, (2) identify the lncRNAs that are associated with EZH2 or direct transcriptional targets of EZH2 repression that are important for prostate tumorigenesis or tumor suppression, and (3) identify the ceRNAs of AR and PTEN that mediate prostate tumorigenesis or tumor suppression. In addition to its scientific proposal, this application proposes a comprehensive training program for preparing an independent investigator in the fields of computational genomics, non-coding RNA and cancer, who develops cutting-edge computational methods, and uses a combination of computational and experimental approaches to understand structure- function relationship of non-coding RNA and the function of non-coding RNA and RNA-protein interaction in cancer. While the candidate of this application has received extensive training in biophysics, statistics, machine learning and computational genomics, this career development award will allow him to develop his experimental skills, especially those next-generation sequencing-based techniques and molecular biology experiments in human cell lines. Dr. Liu, Professor of Biostatistics and Computational Biology and Dr. Brown, Professor of Medicine will mentor the candidate in the excellent training environment of Dana-Farber Cancer Institute, a part of Harvard Medical School community. A committee of experienced computational and cancer biologists will also advise him on both scientific research and career development. PUBLIC HEALTH RELEVANCE: The proposed study is to decipher lncRNA function in cancer using a combination of novel computational methods and high-throughput experimental technologies. The proposed research will result in publically available bioinformatic resources for studying lncRNA function in cancer, a greater understanding of lncRNA function in prostate cancer, and will help to discover novel therapeutic target of lncRNA for treating prostate cancer.",An integrated approach to dissect the functional network of large non-coding RNA,8710112,K99CA175290,"['Algorithms ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Communities ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Data Analysis ', ' Data Analyses ', ' Environment ', ' Exons ', ' human whole genome ', ' Human Genome ', ' Health ', ' Immune Precipitation ', ' Immunoprecipitation ', ' Medicine ', ' Mentors ', ' Methods ', ' Play ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' gene product ', ' Proteins ', ' Androgen Receptor ', ' Repression ', ' Research ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleoproteins ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' school of medicine ', ' medical college ', ' medical schools ', ' statistics ', ' structure function relationship ', ' chemical structure function ', ' Structure-Activity Relationship ', ' Technology ', ' Training Programs ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Training ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Computational Biology ', ' experience ', ' professor ', ' Base Pairing ', ' skills ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Human Cell Line ', ' Categories ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN ', ' MMAC1 ', ' BZS ', ' PTEN gene ', ' Coding System ', ' Code ', ' Modeling ', ' Sampling ', ' career development ', ' Genomics ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' enhancer of zeste homolog 2 (Drosophila) protein, human ', ' Enhancer of Zeste Homolog 2 ', ' human EZH2 protein ', ' protein complex ', ' Oncogenesis ', ' tumorigenesis ', ' ChIP (chromatin immunoprecipitation) ', ' CHIP assay ', ' chromatin immunoprecipitation ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' DF/HCC ', ' Dana-Farber Cancer Institute ', ' Data ', ' Molecular Biology Techniques ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' RNA-Protein Interaction ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' mRNA Expression ', ' Molecular Tumor Suppression ', ' Tumor Suppression ', ' developmental ', ' Development ', ' therapeutic target ', ' tumor ', ' novel therapeutic target ', ' new therapeutic target ', ' prostate tumorigenesis ', ' prostate carcinogenesis ', ' RNA-seq ', ' transcriptome sequencing ', ' next generation sequencing ', ' ']",NCI,DANA-FARBER CANCER INST,K99,2014,112476,MA-07,0.20970179356598065
"An integrated approach to dissect the functional network of large non-coding RNA PROJECT SUMMARY Recent studies revealed that the human genome encodes thousands of lncRNAs with little proteincoding capacity. LncRNAs were shown to play important roles in cancer and are potentially a new class of therapeutic targets for cancer. However, the function of the vast majority of lncRNAs in cancer remains unknown. LncRNA function often depends on its physical interactions with protein complexes. They can also influence the abundance of other mRNAs that are targeted by the same microRNAs by competing for microRNA binding, i.e., serving as competing endogenous RNA (ceRNA). Advances in genomic technologies, especially those based on next generation sequencing (NGS), provide unparalleled opportunities to characterize the functional networks of lncRNA in cancer. However, analysis and integration of different types of genomic datasets to generate testable hypotheses is challenging, and systematic approaches to characterize lncRNA function in cancer are lacking. This application describes the development of computational methods and integrative genomic strategies for systematically dissecting the functional network of lncRNA in cancer, and a combination of computational and experimental approaches to unravel several important functional networks of lncRNA in prostate cancer. Specifically, it will (1) develop a computational method for repurposing the publically available array-based data to interrogate lncRNA expression in tumor samples and utilize an integrative genomic strategy to predict lncRNAs that may be important for tumorigenesis/tumor suppression in prostate cancer via analysis of lncRNA expression profiles, clinical information and somatic genomic alteration profiles of tumor samples, (2) identify the lncRNAs that are associated with EZH2 or direct transcriptional targets of EZH2 repression that are important for prostate tumorigenesis or tumor suppression, and (3) identify the ceRNAs of AR and PTEN that mediate prostate tumorigenesis or tumor suppression. In addition to its scientific proposal, this application proposes a comprehensive training program for preparing an independent investigator in the fields of computational genomics, noncoding RNA and cancer, who develops cutting-edge computational methods, and uses a combination of computational and experimental approaches to understand structure-function relationship of noncoding RNA and the function of noncoding RNA and RNA-protein interaction in cancer. While the candidate of this application has received extensive training in biophysics, statistics, machine learning and computational genomics, this career development award will allow him to develop his experimental skills, especially those next-generation sequencing-based techniques and molecular biology experiments in human cell lines. Dr. Liu, Professor of Biostatistics and Computational Biology and Dr. Brown, Professor of Medicine will mentor the candidate in the excellent training environment of Dana Farber Cancer Institute, a part of Harvard Medical School community. A committee of experienced computational and cancer biologists will also advise him on both scientific research and career development. The proposed study is to decipher lncRNA function in cancer using a combination of novel computational methods and high-throughput experimental technologies. The proposed research will result in publically available bioinformatic resources for studying lncRNA function in cancer, a greater understanding of IncRNA function in prostate cancer, and will help to discover novel therapeutic target of lncRNA for treating prostate cancer.",An integrated approach to dissect the functional network of large non-coding RNA,8994367,R00CA175290,"['Algorithms ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Communities ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Data Analysis ', ' Data Analyses ', ' Environment ', ' Exons ', ' Human Genome ', ' human whole genome ', ' Immune Precipitation ', ' Immunoprecipitation ', ' Medicine ', ' Mentors ', ' Methods ', ' Play ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' Androgen Receptor ', ' Repression ', ' Research ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleoproteins ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' school of medicine ', ' medical college ', ' medical schools ', ' statistics ', ' structure function relationship ', ' chemical structure function ', ' Structure-Activity Relationship ', ' Technology ', ' Training Programs ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Training ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Computational Biology ', ' experience ', ' professor ', ' Base Pairing ', ' skills ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Human Cell Line ', ' Categories ', ' phosphatase and tensin homolog deleted from chromosome 10, human ', ' phosphatase and tensin homolog (mutated in multiple advanced cancers 1), human ', ' mutated in multiple advanced cancers 1 protein, human ', ' human MMAC1 protein ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN Tyrosine Phosphatase ', ' PTEN ', ' Mutated in Multiple Advanced Cancers 1 ', ' MMAC1 ', ' BZS ', ' PTEN gene ', ' Modeling ', ' Sampling ', ' career development ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Untranslated RNA ', ' Genomics ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' enhancer of zeste homolog 2 (Drosophila) protein, human ', ' Enhancer of Zeste Homolog 2 ', ' human EZH2 protein ', ' protein complex ', ' Oncogenesis ', ' tumorigenesis ', ' ChIP assay ', ' ChIP (chromatin immunoprecipitation) ', ' chromatin immunoprecipitation ', ' DNA Sequence Alteration ', ' DF/HCC ', ' Dana-Farber Cancer Institute ', ' Data ', ' Molecular Biology Techniques ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' RNA-Protein Interaction ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' mRNA Expression ', ' Molecular Tumor Suppression ', ' Tumor Suppression ', ' developmental ', ' Development ', ' therapeutic target ', ' tumor ', ' novel therapeutic target ', ' new therapeutic target ', ' prostate tumorigenesis ', ' prostate carcinogenesis ', ' RNAseq ', ' RNA-seq ', ' transcriptome sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' ']",NCI,UNIVERSITY OF TX MD ANDERSON CAN CTR,R00,2015,249000,TX-09,0.20970179356598065
"(PQC4) Habitats in Prostate Cancer DESCRIPTION (provided by applicant): This proposal will address PQC-4: ""What in vivo imaging methods can be developed to portray the ""cytotype"" of a tumor defined as the identity, quantity, and location of each of the different cell types that make up a tumor and its microenvironment? An ideal system to address this question will have the following characteristics: 1) images and data should be obtained from human patients; 2) the relationship between imaging and cytotypes should have clinical relevance; 3) there should be a large amount and a balance in data obtained from within cancerous and non-cancerous volumes; 4) the image data should be of high quality and ideally multiparametric; and 5) registration of histology to radiographic images must be feasible. Such criteria are met in prostate cancer patients who are being monitored by active surveillance (AS). The University of Miami (UM) has a large AS population, and patients with prostate cancer are regularly and routinely imaged with multiparametric MRI (MP- MRI) that includes diffusion (DWI), dynamic contrast enhancement (DCE) and T2 weighted (T2w) imaging sequences as standard of care (SOC). These images are fused to a transrectal ultrasound (TRUS) guidance instrument for biopsy localization. The singular goal of the current work is to develop predictive models that define this interrelationshi based on profound image analyses (""radiomics"") in combination with quantitative histology and immunohistochemistry from spatially co-registered volumes; thus defining the ""cytotypes"" giving rise to MR image data. Researchers at the Moffitt Cancer Center have pioneered the application of radiomics and predictive (classifier like) modeling to cancer. Thus, this work will proceed with two interrelated aims. In Aim 1, MR images, histology, gene expression and clinical data will be generated at UM via the MAST Trial: MRI- Guided Biopsy Selection for Active Surveillance versus Treatment. In Aim 2, informatics data analysis, databasing and classifier modeling will be undertaken at Moffitt. Analysis of MR images will use a ""radiomics"" approach, wherein 432 size, shape and texture features are extracted from image-identified habitats. These will be matched up to registered histology images analyzed with quantitative pathology wherein 32 features are extracted from each cell to form clusters of similar morphotypes, as well as IHC for known and putative progression markers. From these quantitative markers, training and test set classifier models will be developed to relate the MR-defined habitats to their underlying mixtures of cytotypes. Because this will be a large and invaluable data base, it is our explicit intention to share the complete dataset, with the research community through material transfer agreements, which will allow alternative data mining schema. PUBLIC HEALTH RELEVANCE: Virtually every cancer patient is imaged with CT, PET or MRI. Importantly, such imaging reveals that tumors are complex and heterogeneous, often containing multiple ""habitats"" within them. It is the intention of this research to deeply analyze these image so we can infer what is the cellular and molecular structure in each of these habitats. This will be performed in a large cohort of men with prostate cancer who are under ""active surveillance"". In other words, they have cancer, but it is not known if the cancer is life-threatening or not. Men under active surveillance receive regular MRI scans and regular biopsies. The MRI and biopsy data will be quantitatively compared in order for us to understand the cellular and molecular basis for these different habitats in cancers.",(PQC4) Habitats in Prostate Cancer,8930109,R01CA190105,"['driving ', ' Automobile Driving ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cell Extracts ', ' Cells ', ' clinical investigation ', ' Clinical Trials ', ' Communities ', ' Data Analysis ', ' Data Analyses ', ' Diagnosis ', ' Diffusion ', ' balance function ', ' balance ', ' Equilibrium ', ' Gene Expression ', ' Goals ', ' Health ', ' Histology ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Immunohistochemistry Staining Method ', ' Immunohistochemistry Cell/Tissue ', ' Immunohistochemistry ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', "" men's "", ' men ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' Methods ', ' Mining ', ' Macromolecular Structure ', ' Molecular Structure ', ' Pathology ', ' Patients ', ' Public Health Surveillance ', ' Population Surveillance ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Positron-Emission Tomography ', ' gene product ', ' Proteins ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Receiver Operating Characteristics ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Stains ', ' statistics ', ' Testing ', ' Universities ', ' Weight ', ' Work ', ' Schedule ', ' Dataset ', ' Data Set ', ' Blinded ', ' Intention ', ' base ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Medical ', ' prognostic ', ' Training ', ' Lesion ', ' Individual ', ' Oxygen Deficiency ', ' Hypoxic ', ' Hypoxia ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Sample Size ', ' Cell Structure ', ' Cell Components ', ' Cellular Structures ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Shapes ', ' Deposit ', ' Deposition ', ' instrument ', ' Diagnostic ', ' Transrectal Ultrasound ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Area Under Curve ', ' Complex ', ' Scanning ', ' Slide ', ' Source ', ' cell type ', ' Texture ', ' Pattern ', ' LOINC Axis 4 System ', ' System ', ' Location ', ' Stainings ', ' Staining method ', ' Hematoxylin and Eosin ', ' H and E ', ' Hematoxylin and Eosin Staining Method ', ' Best Practice Analysis ', ' Benchmarking ', ' interest ', ' meetings ', ' molecular pathology ', ' cohort ', ' Informatics ', ' Histopathology ', ' Biopsy Sample ', ' Biopsy Specimen ', ' Pathology Report ', ' Modeling ', ' Sampling ', ' Decision Support Systems ', ' Habitats ', ' MAST ', ' Drosophila orbit protein ', ' Drosophila multiple asters  protein ', ' Drosophila mast protein ', ' Drosophila chromosome bows protein ', ' Drosophila MESR7 protein ', ' Drosophila chb protein ', ' MRI Scans ', ' p53-Binding Protein MDM2 ', ' p53-Binding Protein Gene ', ' p53 Binding Protein ', ' Ubiquitin-Protein Ligase E3 MDM2 ', ' MDM2 gene ', ' MDM2 ', ' MDM 2 Protein ', ' MDM 2 ', ' HDM2 protein ', ' HDM2 ', ' human MDM2 protein ', ' imaging method ', ' imaging modality ', ' datamining ', ' data mining ', ' MCT-1 ', ' MCT-1 gene ', ' Address ', ' Data ', ' Predictive Value ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prognostic Marker ', ' Resolution ', ' Cancer Center ', ' Cancer Patient ', ' Clinical Data ', ' Conduct Clinical Trials ', ' Tissue Chip ', ' Tissue Arrays ', ' Tissue Microarray ', ' Validation ', ' Monitor ', ' Characteristics ', ' Molecular ', ' Process ', ' imaging ', ' Image ', ' digital ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' prospective ', ' Cancerous ', ' data acquisition ', ' clinical relevance ', ' clinically relevant ', ' tumor ', ' patient population ', ' standard of care ', ' progression marker ', ' material transfer agreement ', ' relational database ', ' arm ', ' data reduction ', ' in vivo imaging ', ' ']",NCI,H. LEE MOFFITT CANCER CTR & RES INST,R01,2015,692000,FL-14,0.20560290085297311
"Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies DESCRIPTION (provided by applicant): In the PCPT and REDUCE trials, finasteride and dutasteride significantly reduced the detection of prostate cancer (PCa) by 23 and 25% respectively, and thus established that 51-reductase inhibitors (5ARI) are the first class of drugs proven as chemopreventive agents for PCa. The actual efficacy of these drugs varies among individuals, even after considering compliance with the prescribed dosage. Better understanding of the basis for sensitivity to 5ARI chemoprevention will: 1) pave the way for development of better-tolerated and more effective agents that exploit this established mechanism, 2) allow clinicians to target responsive men, thus reducing the cost and morbidity of life-long dosage, and 3) validate specific tissue biomarkers as surrogate endpoints for Phase II trials. Our preliminary data based on direct DNA staining suggest that nuclear morphometric features that characterize 5ARI response may also define a field effect that predicts PCa in untreated men with negative biopsies. REDUCE, which was completed in 2009, provides a unique opportunity to address these questions because intermediate, on-study biopsy samples (mandatory at Years 2 and 4) were collected. Previous research indicated that 5ARIs (at higher doses for short periods) produce changes in benign prostate that resemble incomplete atrophy. Our overall goal is to apply cutting- edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5ARI chemoprevention as well as the risk of PCa among men with negative biopsies. We will obtain Year 2 slides and tissue blocks from a random sample of REDUCE participants with various outcomes. Aim 1: To determine the effects of dutasteride (vs. placebo) on both nuclear and architectural features in benign tissue. Aim 2: To determine whether a multivariable treatment-response score differs between subjects who develop PCa while on dutasteride and those who do not, and, Aim 3: To determine the magnitude of association between nuclear phenotype in benign biopsies, and subsequent risk of PCa in untreated men at elevated risk. Altogether, we will use 3 techniques to assess cytomorphology: a) a morphometric score based on nuclear size, shape and texture, b) expression -via quantum dot imaging - of p300 and nucleolin (two proteins with major effects on chromatin pattern and nuclear morphology) and c) mapping of architectural features (e.g., epithelial area and height) via trainable software. This will be the first work to relate the cytomorphological effects of a 5ARI, given at a chemopreventive dose level for a lengthy period, to subsequent cancer occurrence. The results will have implications for chemoprevention research and clinical practice, including the large number of U.S. men who remain at risk following a negative prostate biopsy. Prostate cancer is the most commonly diagnosed form of cancer in men and strategies to prevent or inhibit its development are critically needed. The goal of the proposed research is to validate new tissue imaging methods for determining risk of prostate cancer among men who have a negative prostate biopsy and for identifying those who are most likely to benefit from life-long chemopreventive drugs.",Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies,8902761,R01CA155301,"['Therapeutic Androgen ', ' Androgenic Compounds ', ' Androgenic Agents ', ' Androgens ', ' inhibitor ', ' inhibitor/antagonist ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Chromatin ', ' Diagnosis ', ' Deoxyribonucleic Acid ', ' DNA ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Expression ', ' Goals ', ' indexing ', ' Maps ', "" men's "", ' men ', ' Microscopy ', ' Morbidity ', ' Morbidity - disease rate ', ' Nuclear Proteins ', ' Reductases ', ' Dehydrogenases ', ' Oxidoreductase ', ' Phenotype ', ' sham therapy ', ' Sham Treatment ', ' Placebos ', ' Play ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' gene product ', ' Proteins ', ' Research ', ' Risk ', ' social role ', ' Role ', ' computer program/software ', ' Software ', ' Computer software ', ' Stains ', ' Body Tissues ', ' Tissues ', ' Work ', ' 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- ', ' Finasteride ', ' nucleolin ', ' Measures ', ' Intention ', ' Surrogate End Points ', ' Surrogate Endpoint ', ' base ', ' dosage ', ' morphometry ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Area ', ' Benign ', ' Phase ', ' Variation ', ' Variant ', ' Epithelial ', ' Blood Serum ', ' Serum ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Chemoprevention ', ' Morphology ', ' Shapes ', ' Atrophy ', ' Atrophic ', ' Malignant Cell ', ' cancer cell ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Slide ', ' Texture ', ' Pattern ', ' Techniques ', ' Stainings ', ' Staining method ', ' Height ', ' Nuclear ', ' cancer risk ', ' drug efficacy ', ' Biopsy Sample ', ' Biopsy Specimen ', ' Participant ', ' member ', ' 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one ', ' Dutasteride ', ' Sampling ', ' response ', ' deprivation ', ' protein expression ', ' Q-Dot ', ' Quantum Dots ', ' Normal Cell ', ' imaging method ', ' imaging modality ', ' Gland ', ' preventing ', ' prevent ', ' p300 ', ' EP300 ', ' EP300 gene ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Randomized ', ' anticarcinogenic ', ' Chemopreventive ', ' Chemopreventive Agent ', ' Nuclear Structure ', ' Pattern Recognition ', ' Validation ', ' developmental ', ' Development ', ' active treatment ', ' active technique ', ' active method ', ' imaging ', ' Image ', ' Placebo Control ', ' cost ', ' digital ', ' Outcome ', ' Population ', ' resistant ', ' Resistance ', ' treatment response ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' clinical practice ', ' Phase III study ', ' phase 3 study ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT CHICAGO,R01,2015,346053,IL-07,0.25455700287436306
"Big data convergence of pathology and omics for disease prognosis     DESCRIPTION (provided by applicant)    There is a pressing need for improved means of interrogating cancer biology in order to identify markers associated with disease aggressiveness and patient outcome. While for a number of cancers, pathologic grade (morphologic appearance of cancerous tissue as assessed by a pathologist) has been found to be highly correlated with disease outcome, pathologic grade tends to suffer from significant inter-observer variability. Additionally pathologic grade alone is not useful in scenarios where two tumors may have subtle differences in their morphologic phenotype but significantly different behavior and outcome. Additionally while a number of molecular, gene expression based assays have been proposed for predicting outcome in cancers, the relatively poor to at best moderate success for these assays suggests that a solely ""omics"" driven approach for prognosis is not an optimal strategy. For most cancers, no single biomarker to date has been identified that is able to accurately and consistently stratify disease risk. This suggests a strong need for analytic and computational tools for quantitatively mining and integrating histologic image and molecular biomarkers to create fused predictors of disease risk and outcome. Such a unified approach is especially needed in cases where molecularly or morphologically similar tumors might have significantly different outcomes. This project will focus on the development of novel big data tools for processing of two key large scale data streams: 1) the high resolution (gigabyte-sized) digital images which capture pathology architecture and tissue morphology, and 2) a large set (up to tens of thousands) of molecular markers (e.g. NF-kB/p65/RelA, p-Akt (Ser473), periostin, cacna1d, ezh2, her2neu, ki67, propsa, and propsa2) found within the disease site. The ability to mine this information via innovative big data tools will allow for the creation of fused predictors of outcome and disease aggressiveness. A central hypothesis of this project is that the combination of quantitative histomorphometric and molecular features will yield a more predictive assay for evaluating disease aggressiveness compared to any single biomarker. This project will develop and evaluate the big data analysis and fusion tools in the context of evaluating disease aggressiveness for prostate cancer. Our over-arching goal is to translate big data tools to process and integrate imaging and molecular markers extracted from diseased tissue outlined by the following aims, Aim 1: Computer vision and machine learning tools for mining sub- visual image features associated with disease aggressiveness, Aim 2: Creating a fused predictor of disease aggressiveness by combining quantitative histomorphometric and molecular measurements, Aim 3: Evaluating the tools developed in Aims 1 and 2 for distinguishing between indolent and aggressive prostate cancer on data acquired from patients from across the leading urology institutions in the US including Johns Hopkins, The Cleveland Clinic, University Hospitals at CWRU, and University of Pennsylvania.         PUBLIC HEALTH RELEVANCE    Each year, 15,000 prostate cancer patients fail curative radical prostatectomy treatment within 5 years. In this proposal, we will develop an integrated diagnostic tool using both computational analysis of high resolution prostate tissue images and the molecular profile of the tumor in order to identify patients most at risk for disease recurrence. This research will provide innovation for the development of novel image analysis tools, data integration algorithms, and fused imaging-molecular predictors which may significantly reduce cancer morbidity and mortalities via improved accuracy of diagnosis.                ",Big data convergence of pathology and omics for disease prognosis,9044354,K01ES026841,"['Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Nucleus ', ' Cell Nucleus ', ' Concurrent Studies ', ' Cohort Studies ', ' Complement Proteins ', ' Complement ', ' computer vision ', ' Computer Vision Systems ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Epithelial Cells ', ' Gene Expression ', ' Goals ', ' Heterogeneity ', ' University Hospitals ', ' Interobserver Variations ', ' Inter-Observer Variation ', ' Inter-Observer Variability ', ' Interobserver Variability ', "" men's "", ' men ', ' Mentors ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Mining ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' Pathology ', ' Patients ', ' Pennsylvania ', ' Phenotype ', ' Play ', ' Prognosis ', ' outcome forecast ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Scientific Publication ', ' Publications ', ' Recurrent ', ' Recurrence ', ' Research ', ' social role ', ' Role ', ' school of medicine ', ' medical college ', ' medical schools ', ' Stains ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Translating ', ' Universities ', ' Urology ', ' Work ', ' nuclear factor kappa beta ', ' kappa B Enhancer Binding Protein ', ' Transcription Factor NF-kB ', ' Nuclear Transcription Factor NF-kB ', ' Nuclear Factor kappa B ', ' NFKB ', ' NF-kappaB ', ' NF-kB ', ' Immunoglobulin Enhancer-Binding Protein ', ' NF-kappa B ', ' Treatment outcome ', ' health care ', ' Healthcare ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Histologically ', ' Histologic ', ' Biochemical ', ' Medical ', ' prognostic ', ' Training ', ' Indolent ', ' Visual ', ' Measurement ', ' Disease Progression ', ' Collaborations ', ' Morphology ', ' Shapes ', ' Pathologist ', ' tool ', ' Diagnostic ', ' Research Specimen ', ' Specimen ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Stream ', ' Clinic ', ' Texture ', ' Stainings ', ' Staining method ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Cellular Proliferation ', ' Cell Multiplication ', ' Cell Growth in Number ', ' Cell Proliferation ', ' computer imaging ', ' digital imaging ', ' molecular pathology ', ' Performance ', ' success ', ' Accuracy of Diagnosis ', ' diagnostic accuracy ', ' p65 ', ' Histopathology ', ' Disease Outcome ', ' novel ', ' validation studies ', ' Categories ', ' disease risk ', ' disorder risk ', ' Modality ', ' Appearance ', ' Early identification ', ' repository ', ' periostin ', ' Cell-Cell Adhesion ', ' Institution ', ' Gland ', ' Address ', ' Nomograms ', ' Data ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' Resolution ', ' Cancer Biology ', ' Cancer Patient ', ' computational analysis ', ' Computer Analysis ', ' Tissue Chip ', ' Tissue Arrays ', ' Tissue Microarray ', ' Validation ', ' Pathologic ', ' Molecular ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' molecular imaging ', ' imaging ', ' Image ', ' digital ', ' computational tools ', ' computerized tools ', ' data integration ', ' Outcome ', ' innovative ', ' innovate ', ' innovation ', ' Cancerous ', ' tumor ', ' public health relevance ', ' molecular phenotype ', ' molecular marker ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' Big Data ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIEHS,CASE WESTERN RESERVE UNIVERSITY,K01,2015,80841,OH-11,0.0885587914114652
"Prostate Cancer Assessment Via Integrated 3D ARFI Elasticity Imaging and Multi-Parametric MRI     DESCRIPTION (provided by applicant): Prostate cancer (PCA) is the most common non-skin cancer and the second leading cause of cancer death in American men, with over 186,000 new cases diagnosed and over 28,000 PCA deaths annually in the United States. Ultrasound-guided biopsy is the standard of care for confirming cancer, typically following elevated PSA levels; however, it has been estimated that up to 20% of men require three or more biopsy sessions for diagnosis, and biopsies have a high risk of hemorrhage and infection. Furthermore, biopsies are not sufficient for tumor delineation or characterization because they sparsely sample the entire organ. Regretfully, the deficiencies of biopsy have lead to over-treatment of indolent disease with radical prostatectomies, a drastic treatment that has significant risks of infection, hemorrhage, urinary incontinence, and impotence.  We are the inventors of Acoustic Radiation Force Impulse (ARFI) imaging and the inventors of Shear Wave Elasticity Imaging (SWEI) methods. We have now combined those methods into ARFI-SWEI imaging sequences that define a new and novel multi-parametric ultrasonic elasticity imaging system. This multi-parametric elasticity imaging approach provides an absolute, quantitative measure of tissue stiffness, at high resolution, in 3D, using ultrasound.  We hypothesize that synergistic diagnostic information from B-mode, ARFI-SWEI and multi-parametric MRI (mpMRI, e.g., diffusion weighted imaging and MR spectroscopy imaging) enable (a) the sensitive and specific diagnosis of PCA and (b) the accurate delineation of PCA margins. We propose retrospective studies on existing 3D B-mode, ARFI-SWEI and mpMRI imaging datasets to test this hypothesis. 1         PUBLIC HEALTH RELEVANCE: Prostate cancer is the second leading cause of cancer death in American men, with over 186,000 new cases and over 28,000 deaths annually. We have developed a novel ultrasonic elasticity imaging technique, called Acoustic Radiation Force Impulse-Shear Wave Elasticity Imaging (ARFI-SWEI), that is an enhanced, multi-parametric version of ultrasound imaging. We propose to test ARFI-SWEI's ability to replace invasive and risky biopsies for PCA diagnosis and focal treatment planning. 1            ",Prostate Cancer Assessment Via Integrated 3D ARFI Elasticity Imaging and Multi-Parametric MRI,8905274,R41CA196565,"['Acoustic ', ' Acoustics ', ' Award ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Data Analysis ', ' Data Analyses ', ' Data Collection ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Elasticity ', ' Goals ', ' blood loss ', ' Bleeding ', ' Hemorrhage ', ' Heterogeneity ', ' Histology ', ' impotent ', ' Impotence ', ' Incontinence ', ' Infection ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' Magnetic Resonance Imaging Scan ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' MRSI ', ' MR Spectroscopy ', ' Magnetic Resonance Spectroscopy ', "" men's "", ' men ', ' Methods ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Probability ', ' Retrospective Studies ', ' Risk ', ' computer program/software ', ' Software ', ' Computer software ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' United States ', ' Universities ', ' Urinary Incontinence ', ' Work ', ' Imaging Technics ', ' Imaging Procedures ', ' Imaging Techniques ', ' Measures ', ' Businesses ', ' Dataset ', ' Data Set ', ' Organ ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' Phase ', ' Indolent ', ' Measurement ', ' Funding ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' PSA level ', ' LOINC Axis 4 System ', ' System ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Consult ', ' American ', ' success ', ' treatment planning ', ' Biopsy Sample ', ' Biopsy Specimen ', ' novel ', ' secondary cancer ', ' Secondary Malignant Neoplasm ', ' Secondary Malignancy (After Treatment of Primary Cancer) ', ' Secondary Malignancy ', ' Second Cancer ', ' Second Primary Cancers ', ' ray (radiation) ', ' Radiation ', ' Modeling ', ' Sampling ', ' cancer diagnosis ', ' diffusion tensor imaging ', ' Diffusion Weighted MRI ', ' Diffusion MRI ', ' Diffusion Magnetic Resonance Imaging ', ' imaging method ', ' imaging modality ', ' Ultrasonic ', ' Ultrasonics ', ' Data ', ' Detection ', ' Resolution ', ' Cancer Cause ', ' Cancer Etiology ', ' Collection ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' image registration ', ' designing ', ' design ', ' spectroscopic imaging ', ' innovative ', ' innovate ', ' innovation ', ' open source ', ' commercialization ', ' tumor ', ' high risk ', ' public health relevance ', ' standard of care ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' phase II study ', ' phase 2 study ', ' Systems Development ', ' ']",NCI,"KITWARE, INC.",R41,2015,150002,NY-20,0.20344643679564253
"Gene-Gene Interactions and Their Functional Roles in Prostate Cancer Aggressiveness Project Summary/Abstract Prostate cancer with substantial clinical heterogeneity is the most common cancer and the second leading cause of cancer-related death in American men. It remains unclear why some prostate tumors are more aggressive than others. Existing clinical features (such as prostate specific antigen (PSA), clinical stage and Gleason score) are not sufficient for classifying high- and low-risk prostate cancer patients. It has been shown that approximately 20% of low-risk prostate cancer patients died due to conservative treatment. Thus, there is an urgent need for identifying additional biomarkers in order to improve prediction accuracy of prostate cancer aggressiveness. The majority of current studies focus on evaluating individual genetic variants, which may not be sufficient to explain the complexity of disease causality. The objective of this study is to identify gene-gene interactions within the four candidate pathways (angiogenesis, mitochondria, miRNA, and androgen metabolism) associated with prostate cancer aggressiveness and their impact on gene expression. The genetic variants (both individual effects and interactions) associated with prostate cancer aggressiveness will be performed using the existing genetic data from the large scale prostate cancer consortium, a collection of approximately 22,000 prostate cancer patients. The associations between genetic variants and gene expressions will be identified using public domain genetic data and will be validated using a cohort data set with 1065 prostate cancer patients. Evaluating genetic variants with gene expression levels helps to identify downstream genes which can guide further study and may lead to discovery of novel therapeutic targets. Our study findings can provide valuable information toward understanding pathogenesis of prostate cancer and identifying genotype combinations for predicting prostate cancer aggressiveness. As for the long-term impact, the study results may be applied in developing effective screening tools to predict prostate cancer aggressiveness. Project Narrative For prostate cancer patients, physicians often have difficulty at the time of a prostate cancer diagnosis distinguishing between patients who will develop indolent tumors and those who will develop aggressive tumors. This study aims to identify genetic markers (genetic variants and gene expressions) involved with multiple genes associated with prostate cancer aggressiveness. Our study findings can provide valuable information toward understanding pathogenesis of prostate cancer and identifying genotype combinations for predicting prostate cancer aggressiveness.",Gene-Gene Interactions and Their Functional Roles in Prostate Cancer Aggressiveness,9177847,R21CA202417,"['abstracting ', ' Affect ', ' Allelomorphs ', ' Alleles ', ' Death ', ' Cessation of life ', ' Disorder ', ' Disease ', ' Fibroblast Growth Regulatory Factor ', ' Fibroblast Growth Factor Gene Family ', ' FGF ', ' Endothelial Cell Growth Factor ', ' DNA Synthesis Factor ', ' Fibroblast Growth Factor ', ' Gene Expression ', ' Genes ', ' genetic biomarker ', ' Genetic Markers ', ' Genotype ', ' Goals ', ' Heterogeneity ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', "" men's "", ' men ', ' mitochondrial ', ' Mitochondria ', ' Risk Ratio ', ' Relative Odds ', ' Cross-Product Ratio ', ' Odds Ratio ', ' Patients ', ' Phenotype ', ' Physicians ', ' Play ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' Proteins ', ' Androgen Receptor ', ' proto-oncogene protein c-erbB-1 ', ' erbBl ', ' erbB-1 Proto-Oncogene Protein ', ' erbB-1 ', ' c-erbB-1 Protein ', ' c-erbB-1 ', ' Urogastrone Receptor ', ' Transforming Growth Factor alpha Receptor ', ' TGF-alpha Receptor ', ' HER1 ', ' Epidermal Growth Factor-Urogastrone Receptors ', ' Epidermal Growth Factor Receptor Protein-Tyrosine Kinase ', ' Epidermal Growth Factor Receptor Kinase ', ' ERBB Protein ', ' EGFR ', ' EGF Receptor ', ' Epidermal Growth Factor Receptor ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Risk ', ' social role ', ' Role ', ' Time ', ' Body Tissues ', ' Tissues ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Data Set ', ' Dataset ', ' Public Domains ', ' Apoptosis ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' base ', ' improved ', ' Solid ', ' Clinical ', ' Biological ', ' Indolent ', ' Individual ', ' Macrophage-2 Antigen ', ' Mac-2 Antigen ', ' LGALS3 ', ' L30 Lectin ', ' L-34 ', ' L-31 ', ' L-29 Lectin ', ' IgEBP ', ' IgE Binding Protein ', ' HL-29 ', ' Epsilon-Binding Protein ', ' Carbohydrate-Binding Protein 35 ', ' CBP35 ', ' CBP-35 ', ' CBP-30 ', ' Galectin 3 ', ' angiogenesis ', ' Genetic ', ' Staging ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Gleason Grade for Prostate Cancer ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Complex ', ' American ', ' cancer risk ', ' gene interaction ', ' QTL ', ' Quantitative Trait Loci ', ' Receptor Protein ', ' receptor ', ' cohort ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Pathogenesis ', ' Reporting ', ' secondary cancer ', ' Secondary Malignant Neoplasm ', ' Secondary Malignancy ', ' Second Cancer ', ' Second Primary Cancers ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' Regulation ', ' cancer diagnosis ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Androgen Metabolism ', ' VEGFs ', ' Vascular Endothelial Growth Factors ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' MGC31930 ', ' MCSF ', ' CSF1 ', ' CSF1 gene ', ' EGF ', ' EGF gene ', ' VEGF, Hypoxia, and Angiogenesis ', ' Angiogenesis Pathway ', ' Data ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Collection ', ' Validation ', ' pathway ', ' Pathway interactions ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' innovation ', ' innovative ', ' innovate ', ' Oncogenic ', ' tumor ', ' high risk ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new drug target ', ' evidence base ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' The Cancer Genome Atlas ', ' TCGA ', ' screening ', ' precision medicine ', ' ']",NCI,LSU HEALTH SCIENCES CENTER,R21,2016,147791,LA-02,0.3244345513417088
"Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Abstract: Fast, reliable and accurate delineation of pelvic organs in the planning and treatment images is a long- standing, important and technically challenging problem. Its solution is highly required for state-of-the-art image-guided radiation therapy planning and treatment, as better treatment decisions rely on timely interpretation of anatomical information in the images. However, automatic segmentation in male pelvic regions is always difficult due to 1) low contrast between prostate and surrounding organs, and 2) possibly disparate shapes/appearances of bladder and rectum caused by tissue deformations. The goal of this project is to create a set of novel machine learning tools to achieve accurate, reliable and efficient delineation of important pelvic organs (e.g., prostate, bladder, and rectum) in different modalities (e.g., planning CT, treatment CT/CBCT, and MRI) for radiotherapy of prostate cancer.  Planning CT. For automatic segmentation, landmark detection is often the first step in rapidly locating the target organs. Thus, in Aim 1, we will create a novel joint landmark detection approach, based on both random forests and auto-context model, to iteratively detect all landmarks and further coordinate their detection results for achieving more accurate and consistent landmark detection results. After roughly locating organs with the aid of those detected landmarks, the second step is to accurately segment boundaries of target organs in the planning CT. Accordingly, in Aim 2, we will create a set of learning methods to a) first simultaneously predict all pelvic organ boundaries in the planning CT with the regression forests trained by labeled training data, and b) then segment all pelvic organs jointly by deforming their respective shape models. In particular, to address the limitations of conventional deformable models in assuming simple Gaussian distributions for organ shapes, a novel hierarchical sparse shape composition approach will be developed to constrain shape models during deformable segmentation.  Treatment CT/CBCT. During the course of serial radiation treatments, to quantitatively record and monitor the accumulated dose delivered to the patient, organs in the treatment image also need to be segmented. Although methods proposed in Aims 1-2 can be simply applied, as done by many conventional methods, this will lead to a) inconsistent landmark detection and b) inconsistent segmentations across different treatment days because of possible large shape/appearance changes. Accordingly, in Aim 3, we will create a novel self- learning mechanism to gradually learn and incorporate patient-specific information into both joint landmark detection and deformable segmentation steps from the increasingly acquired treatment images of patient. Thus, population data will gradually be replaced by the patient's own data to train personalized models.  MRI. To guide pelvic organ segmentation in the planning CT, MRI is now often acquired for selected patients. To this end, in Aim 4, we will develop a) a prostate MRI segmentation method by using deep learning to learn MRI-specific features for guiding landmark detection and deformable segmentation as proposed in Aims 1-2; b) a novel collaborative MRI and CT segmentation algorithm for more accurate segmentation of planning CT.  All our developed algorithms will be evaluated for their performance in clinical (treatment planning and delivery) workflow for 130 patients in UNC Cancer Hospital and also hospitals of our consultants.  Benefit for Patient Care. Development of these segmentation tools will 1) dramatically accelerate the clinical workflow, 2) reduce workload (i.e., manual interaction time) for physicians, and 3) lead to better patient outcomes with reliable and accurate segmentations of target area and critical organs. Although these tools cannot replace the expertise of physicians, they can be of great assistance to physicians.  Narrative Description of Project This project aims to create a set of novel machine learning tools for accurate, reliable and efficient delineation of important pelvic organs (such as prostate, bladder, and rectum) in various imaging modalities to help radiotherapy of prostate cancer. To achieve this goal, we will create 1) a novel joint landmark detection and boundary prediction framework for accurate segmentation of the planning CT images, 2) an innovative updating mechanism for incorporating patient-specific information from previous treatment images of same patient to progressively improve treatment CT/CBCT segmentation, and 3) a deep-learning based framework for learning MRI-specific features for prostate MRI segmentation, as well as a novel method for collaborative MRI & planning CT segmentation. We will validate these methods on real patients in our clinical workflow. Besides, although these machine-learning tools are designed for radiotherapy of prostate cancer, they can also be easily extended to other new organs and new modalities after appropriate updating and training.",Automatic Pelvic Organ Delineation in Prostate Cancer Treatment,9186673,R01CA206100,"['abstracting ', ' Algorithms ', ' urinary bladder ', ' Bladder Urinary System ', ' Bladder ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Hospitals ', ' Cancer Hospital ', ' Articulation ', ' Joints ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' male ', ' Manuals ', ' Methods ', ' Normal Distribution ', ' Gaussian Distribution ', ' Normal Statistical Distribution ', ' Patient Monitoring ', ' Patients ', ' Pelvic Region ', ' Pelvic ', ' Pelvis ', ' Physicians ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' treatment with radiation ', ' radio-therapy ', ' radiation treatment ', ' Radiotherapy ', ' Radiotherapeutics ', ' Radiation therapy ', ' Rectum ', ' Time ', ' Body Tissues ', ' Tissues ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Workload ', ' Work Load ', ' forest ', ' base ', ' dosage ', ' Organ ', ' Label ', ' improved ', ' Area ', ' Clinical ', ' Training ', ' soft tissue ', ' Sample Size ', ' Shapes ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Clinic ', ' treatment days ', ' Treatment Period ', ' treatment duration ', ' Performance ', ' success ', ' treatment planning ', ' novel ', ' General Public ', ' General Population ', ' Modality ', ' Appearance ', ' Modeling ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' imaging method ', ' imaging modality ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' trial treatment ', ' trial regimen ', ' Clinical Treatment ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' Update ', ' Monitor ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' designing ', ' design ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' imaging Segmentation ', ' therapy design ', ' treatment design ', ' intervention design ', ' image guided radiation therapy ', ' image-guided radiotherapy ', ' image guided radiation treatment ', ' IGRT ', ' learning strategy ', ' learning method ', ' learning activity ', ' ']",NCI,UNIV OF NORTH CAROLINA CHAPEL HILL,R01,2016,347254,NC-04,0.1601918496567657
"Development of a Multimodal Deep Learning Model for the Generation of Cancer Probability Maps and Imaging Biomarkers for Prostate Cancer using Multiparametric MRI Project Summary/Abstract Background: Prostatic adenocarcinoma is the most common newly diagnosed cancer and second deadliest cancer in American men. There is a large discrepancy between the incidence of the disease and its mortality rate. Thus, the development of screening tools to identify prostate cancer and determine if it is aggressive or indolent is an area of considerable interest. Current methods rely on the use of serum biomarkers and follow-up biopsies for screening. However, there is substantial debate as to the appropriate methodology for screening. The goal of this proposal is the development of: 1) new imaging biomarkers (i.e., features) for prostate cancer; and 2) a novel predictive model for the presence of aggressive prostatic adenocarcinoma. These tools will enable more effective use of mp-MRI in prostate cancer screening in the future and thus enable a future improvement in the sensitivity and specificity of screening, reducing the rates of overdiagnosis and underdiagnosis. Aim 1: To implement a deep learning algorithm for clinical prostate mp-MRI sequences, creating a cancer prob- ability map that is predictive of biopsy results. Aim 2: To create a multimodal framework that will combine discovered imaging features with clinical data points from the medical record (e.g., age, risk factors, medical history, biomarkers) to predict the presence and aggressiveness of prostatic adenocarcinoma. Methods: In Aim 1, a deep convolutional neural network (CNN) will be trained on a clinical dataset comprised of patches extracted from pre-prostatectomy mp-MRI sequences from patients with prostate cancer, using his- topathology analysis of whole-mount radical prostatectomy specimens as ground truth. The innovations in this aim will be the development of a CNN that can simultaneously learn from three different imaging sequence types, the use of patches for data augmentation, and the proper alignment of mp-MRI sequences and prostatectomy specimens for machine learning. The result of the work of this aim will be the creation of an algorithm for gen- erating imaging biomarkers (features) and cancer probability maps from mp-MRI data. In Aim 2, a multimodal learning framework that will integrate mp-MRI sequence data with clinical parameters in order to predict the presence of aggressive prostatic adenocarcinoma will be developed. The innovation in this aim will be the devel- opment of a framework that can integrate information from multiple modalities (imaging, serum, history, etc.) in order to generate a high confidence prediction of the presence of aggressive prostate cancer without the use of invasive testing. Long-term Objective: The development of a novel predictive model for the presence of aggressive prostatic adenocarcinoma in prostate mp-MRI data that will enable better future use of this data for the early detection of prostate cancer. Project Narrative / Public Health Relevance Prostatic adenocarcinoma is the most common newly diagnosed cancer and second deadliest cancer in American men. This research aims to develop imaging features and a predictive model that will enable better use of mul- tiparametric MRI for noninvasive prostate cancer screening, which could reduce over- and underdiagnosis in order to provide better care at lower cost.",Development of a Multimodal Deep Learning Model for the Generation of Cancer Probability Maps and Imaging Biomarkers for Prostate Cancer using Multiparametric MRI,9190137,F30CA210329,"['abstracting ', ' Age ', ' Algorithms ', ' Belief ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Prostate Adenocarcinoma ', ' Systematics ', ' Classification ', ' Computer aided diagnosis ', ' Computer-Assisted Diagnosis ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Goals ', ' History ', ' Recording of previous events ', ' Hospitals ', ' Modern Man ', ' Human ', ' Incidence ', ' Learning ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', ' Medical Records ', "" men's "", ' men ', ' Methods ', ' Methodology ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' Pathology ', ' Patients ', ' Probability ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Prostatectomy ', ' Research ', ' Risk ', ' Risk Factors ', ' Sensitivity and Specificity ', ' Specificity ', ' Testing ', ' Body Tissues ', ' Tissues ', ' United States ', ' Work ', ' Generations ', ' Outcome Measure ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Data Set ', ' Dataset ', ' Caring ', ' Guidelines ', ' base ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' rectal ', ' Site ', ' Area ', ' Clinical ', ' Medical ', ' Evaluation ', ' Training ', ' Lesion ', ' Blood Serum ', ' Serum ', ' insight ', ' Indolent ', ' Visual ', ' Individual ', ' RDST ', ' radiologist ', ' Personal Medical History Epidemiology ', ' Personal Medical History ', ' Medical History ', ' prostate cancer early detection ', ' Screening for Prostate Cancer ', ' tool ', ' Research Specimen ', ' Specimen ', ' Transrectal Ultrasound ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Pulse ', ' Physiologic pulse ', ' Complex ', ' Techniques ', ' System ', ' interest ', ' American ', ' neural network ', ' Biological Neural Networks ', ' Histopathology ', ' novel ', ' secondary cancer ', ' Secondary Malignant Neoplasm ', ' Secondary Malignancy ', ' Second Cancer ', ' Second Primary Cancers ', ' Modeling ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' imaging method ', ' imaging modality ', ' Address ', ' Data ', ' Detection ', ' NCCN ', ' National Comprehensive Cancer Network ', ' Stratification ', ' Clinical Data ', ' Newly Diagnosed ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' cost ', ' digital ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' imaging Segmentation ', ' spatiotemporal ', ' high risk ', ' public health relevance ', ' primary outcome ', ' secondary outcome ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' imaging biomarker ', ' imaging marker ', ' non-linear transformation ', ' nonlinear transformation ', ' ']",NCI,UNIVERSITY OF CALIFORNIA LOS ANGELES,F30,2016,37074,CA-33,0.2775359125317824
"Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning DESCRIPTION (provided by applicant): Few biomarkers derived from genome scale data have translated into improved clinical classification of cancer subtypes, in spite of the wealth of available genome-wide studies and of the corresponding application of numerous statistical algorithms. This widespread shortcoming derives from the pervasive use of ""off the shelf"" algorithms and machine learning techniques developed for image classification and language processing, which are nave of the underlying biology of the system. Furthermore, for genome-wide data, the number of samples is often small relative to the number of potential candidate biomarkers, resulting in variable accuracy on independent test data despite high accuracy in the samples used for discovery, which contributes to the failure of clinical biomarkers. This problem - so called ""curse of dimensionality"" - is further exacerbated by the prohibitive cost of dramatically increasing sample size and by patient stratification into smaller subgroups for personalized and precision medicine. Disease phenotypes arise from distinct and specific perturbations in selected networks and pathways defined by the interactions of their molecular constituents. In cancer, these perturbations may reside in gene regulatory networks topology and state, in cell signaling activity, or in metabolic conditions. We hypothesize that by leveragin such prior biological information on cancer biology we will be able to reduce model complexity and build mechanistically justified predictive models. To pursue this hypothesis, we will develop an analytical framework to embed mechanistic constraints derived from network biology into the statistical learning process itself. Hence, this application will develop a novel suite of statistial learning algorithms that embed (Aim 1) gene expression regulatory networks, (Aim 2) cell signaling activity, and (Aim 3) metabolism to classify breast and prostate cancer. Throughout the study we will work closely with clinical collaborators to ensure that our method improve over and above current predictive and prognostic models. Finally, since in our study we will also generate mechanistic classifiers based on gene expression measurements obtained from clinical assays that are already commercially available (i.e., MammaPrint, and Decipher), our innovative models and predictors will be also readily available for clinical translation. Our mechanism-driven classifiers will simultaneously have greater accuracy and interpretability than classifiers developed without regard for the underlying biology of the disease. Furthermore, embedding biological mechanisms in the classifiers will also facilitate the identification of alternative therapeutic targets specific to each cancer subtype, potentially improving patient prognosis and health outcomes. Finally, the substantial curation of molecular pathways and biological networks we will carry on in the project will also provide a powerful resource for futur studies, and the methodologies we will develop will be also applicable to other cancer and other human diseases, like neurodegenerative disorders, hearth disease, and diabetes. PUBLIC HEALTH RELEVANCE    Project Narrative This study will use mechanistic biological knowledge to implement a suite of statistical algorithms for cancer patient classification, which will also reveal the biological reasoning behind the classification decision rules. In the study we will also apply our novel methods to develop improved biomarkers for breast and prostate cancer patient clinical stratification, with the ultimate goal of facilitating the selection of appropriate treatment. To achieve this goal we will directly improve the existing commercial tests offered to the patients, with an immediate clinical impact, since our biomarkers will be directly implementable into these assays, with the potential to quickly reach the bedside.",Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning,9003242,R01CA200859,"['genome wide analysis ', ' candidate marker ', ' candidate biomarker ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' genome-wide ', ' genomewide ', ' genome scale ', ' biological systems ', ' Knowledge Discovery ', ' Statistical Algorithm ', ' Statistics Algorithm ', ' precision medicine ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' biomarker development ', ' patient stratification ', ' stratified patient ', ' clinical biomarkers ', ' clinically useful biomarkers ', ' personalized health care ', ' precision health care ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' cancer subtypes ', ' cancer sub-types ', ' predict clinical outcome ', ' predictor of clinical outcome ', ' clinical outcome prediction ', ' Algorithms ', ' Dorsum ', ' Back ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biology ', ' malignant breast tumor ', ' Breast Cancer ', ' malignant breast neoplasm ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cell Body ', ' Cells ', ' Systematics ', ' Classification ', ' Complement Proteins ', ' Complement ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Energy Expenditure ', ' Energy Metabolism ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Goals ', ' Health ', ' Learning ', ' detoxification ', ' Metabolism of Toxic Agents ', ' Metabolic Drug Detoxications ', ' Drug Metabolic Detoxification ', ' Drug Metabolic Detoxication ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' Methods ', ' Methodology ', ' Patients ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' study design ', ' Study Type ', ' Research Design ', ' Research Resources ', ' Resources ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' statistics ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Translating ', ' Translations ', ' Work ', ' base ', ' improved ', ' Clinical ', ' Biological ', ' Ensure ', ' Failure ', ' Data Quality ', ' Measurement ', ' Sample Size ', ' Metabolic Networks ', ' Biochemical Pathway ', ' Space Models ', ' Metabolic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Knowledge ', ' Complex ', ' Side ', ' Techniques ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neuro-degenerative Disorders ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' Neurodegenerative Disorders ', ' cohort ', ' novel ', ' Modeling ', ' Sampling ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Address ', ' Systems Biology ', ' Data ', ' Detection ', ' Measurable ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Molecular Profiling ', ' Stratification ', ' Subgroup ', ' Cancer Biology ', ' Cancer Patient ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' cost ', ' feeding ', ' cancer research ', ' anticancer research ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' Resistance ', ' resistant ', ' clinically relevant ', ' clinical relevance ', ' open source ', ' human disease ', ' language processing ', ' chemotherapy ', ' therapeutic target ', ' therapy design ', ' treatment design ', ' intervention design ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2016,400481,MD-07,0.10256685329278825
"An integrated approach to dissect the functional network of large non-coding RNA PROJECT SUMMARY Recent studies revealed that the human genome encodes thousands of lncRNAs with little proteincoding capacity. LncRNAs were shown to play important roles in cancer and are potentially a new class of therapeutic targets for cancer. However, the function of the vast majority of lncRNAs in cancer remains unknown. LncRNA function often depends on its physical interactions with protein complexes. They can also influence the abundance of other mRNAs that are targeted by the same microRNAs by competing for microRNA binding, i.e., serving as competing endogenous RNA (ceRNA). Advances in genomic technologies, especially those based on next generation sequencing (NGS), provide unparalleled opportunities to characterize the functional networks of lncRNA in cancer. However, analysis and integration of different types of genomic datasets to generate testable hypotheses is challenging, and systematic approaches to characterize lncRNA function in cancer are lacking. This application describes the development of computational methods and integrative genomic strategies for systematically dissecting the functional network of lncRNA in cancer, and a combination of computational and experimental approaches to unravel several important functional networks of lncRNA in prostate cancer. Specifically, it will (1) develop a computational method for repurposing the publically available array-based data to interrogate lncRNA expression in tumor samples and utilize an integrative genomic strategy to predict lncRNAs that may be important for tumorigenesis/tumor suppression in prostate cancer via analysis of lncRNA expression profiles, clinical information and somatic genomic alteration profiles of tumor samples, (2) identify the lncRNAs that are associated with EZH2 or direct transcriptional targets of EZH2 repression that are important for prostate tumorigenesis or tumor suppression, and (3) identify the ceRNAs of AR and PTEN that mediate prostate tumorigenesis or tumor suppression. In addition to its scientific proposal, this application proposes a comprehensive training program for preparing an independent investigator in the fields of computational genomics, noncoding RNA and cancer, who develops cutting-edge computational methods, and uses a combination of computational and experimental approaches to understand structure-function relationship of noncoding RNA and the function of noncoding RNA and RNA-protein interaction in cancer. While the candidate of this application has received extensive training in biophysics, statistics, machine learning and computational genomics, this career development award will allow him to develop his experimental skills, especially those next-generation sequencing-based techniques and molecular biology experiments in human cell lines. Dr. Liu, Professor of Biostatistics and Computational Biology and Dr. Brown, Professor of Medicine will mentor the candidate in the excellent training environment of Dana Farber Cancer Institute, a part of Harvard Medical School community. A committee of experienced computational and cancer biologists will also advise him on both scientific research and career development. The proposed study is to decipher lncRNA function in cancer using a combination of novel computational methods and high-throughput experimental technologies. The proposed research will result in publically available bioinformatic resources for studying lncRNA function in cancer, a greater understanding of IncRNA function in prostate cancer, and will help to discover novel therapeutic target of lncRNA for treating prostate cancer.",An integrated approach to dissect the functional network of large non-coding RNA,9001952,R00CA175290,"['Algorithms ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Environment ', ' Exons ', ' human whole genome ', ' Human Genome ', ' Immune Precipitation ', ' Immunoprecipitation ', ' Medicine ', ' Mentors ', ' Methods ', ' Play ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' Androgen Receptor ', ' Repression ', ' Research ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleoproteins ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' school of medicine ', ' medical college ', ' medical schools ', ' statistics ', ' structure function relationship ', ' chemical structure function ', ' Structure-Activity Relationship ', ' Technology ', ' Training Programs ', ' Enhancers ', ' Mediating ', ' Data Set ', ' Dataset ', ' base ', ' Clinical ', ' Training ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' computer biology ', ' Computational Biology ', ' experience ', ' professor ', ' Base Pairing ', ' skills ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Human Cell Line ', ' Categories ', ' Phosphatase and Tensin Homolog Deleted on Chromosome 10 ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN Hamartoma Tumor Syndrome With Granular Cell Tumor ', ' PTEN Hamartoma Tumor Syndrome ', ' PTEN ', ' PHTS protein ', ' PHTS gene ', ' Mutated in Multiple Advanced Cancers 1 ', ' MMAC1 ', ' PTEN gene ', ' Modeling ', ' Sampling ', ' career development ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Genomics ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' protein complex ', ' Oncogenesis ', ' tumorigenesis ', ' ChIP assay ', ' chromatin immunoprecipitation ', ' Homologue ', ' Homolog ', ' GeneHomolog ', ' Homologous Gene ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' DNA Sequence Alteration ', ' DF/HCC ', ' Dana-Farber Cancer Institute ', ' Data ', ' Molecular Biology Techniques ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Molecular Profiling ', ' RNA-Protein Interaction ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' mRNA Expression ', ' Molecular Tumor Suppression ', ' Tumor Suppression ', ' developmental ', ' Development ', ' therapeutic target ', ' tumor ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new drug target ', ' prostate carcinogenesis ', ' prostate tumorigenesis ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' Genomic approach ', ' genomic strategy ', ' genomic effort ', ' RNA immunoprecipitation sequencing ', ' RIPseq ', ' RIP seq ', ' ']",NCI,UNIVERSITY OF TX MD ANDERSON CAN CTR,R00,2016,201953,TX-09,0.20970179356598065
"(PQC4) Habitats in Prostate Cancer DESCRIPTION (provided by applicant): This proposal will address PQC-4: ""What in vivo imaging methods can be developed to portray the ""cytotype"" of a tumor defined as the identity, quantity, and location of each of the different cell types that make up a tumor and its microenvironment? An ideal system to address this question will have the following characteristics: 1) images and data should be obtained from human patients; 2) the relationship between imaging and cytotypes should have clinical relevance; 3) there should be a large amount and a balance in data obtained from within cancerous and non-cancerous volumes; 4) the image data should be of high quality and ideally multiparametric; and 5) registration of histology to radiographic images must be feasible. Such criteria are met in prostate cancer patients who are being monitored by active surveillance (AS). The University of Miami (UM) has a large AS population, and patients with prostate cancer are regularly and routinely imaged with multiparametric MRI (MP- MRI) that includes diffusion (DWI), dynamic contrast enhancement (DCE) and T2 weighted (T2w) imaging sequences as standard of care (SOC). These images are fused to a transrectal ultrasound (TRUS) guidance instrument for biopsy localization. The singular goal of the current work is to develop predictive models that define this interrelationshi based on profound image analyses (""radiomics"") in combination with quantitative histology and immunohistochemistry from spatially co-registered volumes; thus defining the ""cytotypes"" giving rise to MR image data. Researchers at the Moffitt Cancer Center have pioneered the application of radiomics and predictive (classifier like) modeling to cancer. Thus, this work will proceed with two interrelated aims. In Aim 1, MR images, histology, gene expression and clinical data will be generated at UM via the MAST Trial: MRI- Guided Biopsy Selection for Active Surveillance versus Treatment. In Aim 2, informatics data analysis, databasing and classifier modeling will be undertaken at Moffitt. Analysis of MR images will use a ""radiomics"" approach, wherein 432 size, shape and texture features are extracted from image-identified habitats. These will be matched up to registered histology images analyzed with quantitative pathology wherein 32 features are extracted from each cell to form clusters of similar morphotypes, as well as IHC for known and putative progression markers. From these quantitative markers, training and test set classifier models will be developed to relate the MR-defined habitats to their underlying mixtures of cytotypes. Because this will be a large and invaluable data base, it is our explicit intention to share the complete dataset, with the research community through material transfer agreements, which will allow alternative data mining schema. PUBLIC HEALTH RELEVANCE: Virtually every cancer patient is imaged with CT, PET or MRI. Importantly, such imaging reveals that tumors are complex and heterogeneous, often containing multiple ""habitats"" within them. It is the intention of this research to deeply analyze these image so we can infer what is the cellular and molecular structure in each of these habitats. This will be performed in a large cohort of men with prostate cancer who are under ""active surveillance"". In other words, they have cancer, but it is not known if the cancer is life-threatening or not. Men under active surveillance receive regular MRI scans and regular biopsies. The MRI and biopsy data will be quantitatively compared in order for us to understand the cellular and molecular basis for these different habitats in cancers.",(PQC4) Habitats in Prostate Cancer,9118120,R01CA190105,"['driving ', ' Automobile Driving ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cell Extracts ', ' Cell Body ', ' Cells ', ' Clinical Trials ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Diagnosis ', ' Diffusion ', ' balance function ', ' balance ', ' Equilibrium ', ' Gene Expression ', ' Goals ', ' Health ', ' Histology ', ' Modern Man ', ' Human ', ' Immunohistochemistry Staining Method ', ' Immunohistochemistry Cell/Tissue ', ' Immunohistochemistry ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', "" men's "", ' men ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' Methods ', ' Mining ', ' Macromolecular Structure ', ' Molecular Structure ', ' Pathology ', ' Patients ', ' Public Health Surveillance ', ' Population Surveillance ', ' positron emitting tomography ', ' positron emission tomographic imaging ', ' positron emission tomographic (PET) imaging ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Positron-Emission Tomography ', ' Proteins ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Receiver Operator Characteristics ', ' Receiver Operating Characteristics ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Stains ', ' statistics ', ' Testing ', ' Universities ', ' Weight ', ' Work ', ' Schedule ', ' Data Set ', ' Dataset ', ' Blinded ', ' Intention ', ' base ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Medical ', ' prognostic ', ' Training ', ' Lesion ', ' Individual ', ' Oxygen Deficiency ', ' Hypoxic ', ' Hypoxia ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Sample Size ', ' Cell Structure ', ' Cell Components ', ' Cellular Structures ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Shapes ', ' Deposit ', ' Deposition ', ' instrument ', ' Diagnostic ', ' Transrectal Ultrasound ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Malignant neoplasm of prostate ', ' Life ', ' Area Under Curve ', ' Complex ', ' Scanning ', ' Slide ', ' Source ', ' cell type ', ' Texture ', ' Pattern ', ' System ', ' Location ', ' Stainings ', ' Staining method ', ' Hematoxylin and Eosin ', ' H and E ', ' Hematoxylin and Eosin Staining Method ', ' Best Practice Analysis ', ' Benchmarking ', ' interest ', ' meetings ', ' molecular pathology ', ' cohort ', ' Informatics ', ' Histopathology ', ' Biopsy Sample ', ' Biopsy Specimen ', ' Pathology Report ', ' Modeling ', ' Sampling ', ' Decision Support Systems ', ' Habitats ', ' gene expression microarray ', ' expression array ', ' GeneChip ', ' Gene Expression Chip ', ' Gene Chips ', ' MAST ', ' Drosophila orbit protein ', ' Drosophila multiple asters  protein ', ' Drosophila mast protein ', ' Drosophila chromosome bows protein ', ' Drosophila MESR7 protein ', ' Drosophila chb protein ', ' Magnetic Resonance Imaging Scan ', ' MRI Scans ', ' p53-Binding Protein MDM2 ', ' mdm2 protein ', ' mdm-2 oncogene protein ', ' Oncoprotein MDM2 ', ' Mdm-2 protein ', ' MDMX protein ', ' MDM2 ', ' HDM2 ', ' MDM2 gene ', ' imaging method ', ' imaging modality ', ' datamining ', ' data mining ', ' MCT-1 ', ' MCT-1 gene ', ' Address ', ' Data ', ' Predictive Value ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prognostic Marker ', ' Resolution ', ' Cancer Center ', ' Cancer Patient ', ' Clinical Data ', ' Conduct Clinical Trials ', ' Tissue Chip ', ' Tissue Arrays ', ' Tissue Microarray ', ' Validation ', ' Monitor ', ' Characteristics ', ' Molecular ', ' Process ', ' imaging ', ' Image ', ' digital ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Cancerous ', ' data acquisition ', ' clinically relevant ', ' clinical relevance ', ' tumor ', ' patient population ', ' standard of care ', ' progression marker ', ' material transfer agreement ', ' relational database ', ' arm ', ' data reduction ', ' in vivo imaging ', ' quantitative imaging ', ' model building ', ' T2 weighted imaging ', ' T2 weighted image ', ' prospective test ', ' radiomics ', ' ']",NCI,H. LEE MOFFITT CANCER CTR & RES INST,R01,2016,682812,FL-14,0.20560290085297311
"(PQC4) Habitats in Prostate Cancer DESCRIPTION (provided by applicant): This proposal will address PQC-4: ""What in vivo imaging methods can be developed to portray the ""cytotype"" of a tumor defined as the identity, quantity, and location of each of the different cell types that make up a tumor and its microenvironment? An ideal system to address this question will have the following characteristics: 1) images and data should be obtained from human patients; 2) the relationship between imaging and cytotypes should have clinical relevance; 3) there should be a large amount and a balance in data obtained from within cancerous and non-cancerous volumes; 4) the image data should be of high quality and ideally multiparametric; and 5) registration of histology to radiographic images must be feasible. Such criteria are met in prostate cancer patients who are being monitored by active surveillance (AS). The University of Miami (UM) has a large AS population, and patients with prostate cancer are regularly and routinely imaged with multiparametric MRI (MP- MRI) that includes diffusion (DWI), dynamic contrast enhancement (DCE) and T2 weighted (T2w) imaging sequences as standard of care (SOC). These images are fused to a transrectal ultrasound (TRUS) guidance instrument for biopsy localization. The singular goal of the current work is to develop predictive models that define this interrelationshi based on profound image analyses (""radiomics"") in combination with quantitative histology and immunohistochemistry from spatially co-registered volumes; thus defining the ""cytotypes"" giving rise to MR image data. Researchers at the Moffitt Cancer Center have pioneered the application of radiomics and predictive (classifier like) modeling to cancer. Thus, this work will proceed with two interrelated aims. In Aim 1, MR images, histology, gene expression and clinical data will be generated at UM via the MAST Trial: MRI- Guided Biopsy Selection for Active Surveillance versus Treatment. In Aim 2, informatics data analysis, databasing and classifier modeling will be undertaken at Moffitt. Analysis of MR images will use a ""radiomics"" approach, wherein 432 size, shape and texture features are extracted from image-identified habitats. These will be matched up to registered histology images analyzed with quantitative pathology wherein 32 features are extracted from each cell to form clusters of similar morphotypes, as well as IHC for known and putative progression markers. From these quantitative markers, training and test set classifier models will be developed to relate the MR-defined habitats to their underlying mixtures of cytotypes. Because this will be a large and invaluable data base, it is our explicit intention to share the complete dataset, with the research community through material transfer agreements, which will allow alternative data mining schema. PUBLIC HEALTH RELEVANCE: Virtually every cancer patient is imaged with CT, PET or MRI. Importantly, such imaging reveals that tumors are complex and heterogeneous, often containing multiple ""habitats"" within them. It is the intention of this research to deeply analyze these image so we can infer what is the cellular and molecular structure in each of these habitats. This will be performed in a large cohort of men with prostate cancer who are under ""active surveillance"". In other words, they have cancer, but it is not known if the cancer is life-threatening or not. Men under active surveillance receive regular MRI scans and regular biopsies. The MRI and biopsy data will be quantitatively compared in order for us to understand the cellular and molecular basis for these different habitats in cancers.",(PQC4) Habitats in Prostate Cancer,9333954,R01CA190105,"['driving ', ' Automobile Driving ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cell Extracts ', ' Cell Body ', ' Cells ', ' Clinical Trials ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Diagnosis ', ' Diffusion ', ' balance function ', ' balance ', ' Equilibrium ', ' Fermentation ', ' Gene Expression ', ' Goals ', ' Histology ', ' Modern Man ', ' Human ', ' Immunohistochemistry ', ' Immunohistochemistry Staining Method ', ' Immunohistochemistry Cell/Tissue ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Manuals ', ' Maps ', ' men ', "" men's "", ' Metabolism ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Methods ', ' Mining ', ' Molecular Structure ', ' Macromolecular Structure ', ' Pathology ', ' Patients ', ' Population Surveillance ', ' Public Health Surveillance ', ' Positron-Emission Tomography ', ' positron emitting tomography ', ' positron emission tomographic imaging ', ' positron emission tomographic (PET) imaging ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Proteins ', ' Radiology Specialty ', ' Radiology ', ' General Radiology ', ' Receiver Operating Characteristics ', ' Receiver Operator Characteristics ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Stains ', ' statistics ', ' Testing ', ' Universities ', ' Work ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Schedule ', ' Dataset ', ' Data Set ', ' Blinded ', ' Intention ', ' base ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Histologically ', ' Histologic ', ' Medical ', ' prognostic ', ' Training ', ' Lesion ', ' Individual ', ' Oxygen Deficiency ', ' Hypoxic ', ' Hypoxia ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Sample Size ', ' Cell Structure ', ' Cell Components ', ' Cellular Structures ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Shapes ', ' Deposition ', ' Deposit ', ' instrument ', ' Diagnostic ', ' Transrectal Ultrasound ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Life ', ' Area Under Curve ', ' Complex ', ' Scanning ', ' Slide ', ' Source ', ' cell type ', ' Texture ', ' Pattern ', ' System ', ' Location ', ' Staining method ', ' Stainings ', ' Hematoxylin and Eosin Staining Method ', ' Hematoxylin and Eosin ', ' H and E ', ' Benchmarking ', ' Best Practice Analysis ', ' interest ', ' molecular pathology ', ' cohort ', ' Informatics ', ' Histopathology ', ' Biopsy Specimen ', ' Biopsy Sample ', ' Pathology Report ', ' Modeling ', ' Sampling ', ' Decision Support Systems ', ' Habitats ', ' Gene Chips ', ' gene expression microarray ', ' expression array ', ' GeneChip ', ' Gene Expression Chip ', ' Drosophila chb protein ', ' MAST ', ' Drosophila orbit protein ', ' Drosophila multiple asters  protein ', ' Drosophila mast protein ', ' Drosophila chromosome bows protein ', ' Drosophila MESR7 protein ', ' MRI Scans ', ' Magnetic Resonance Imaging Scan ', ' MDM2 gene ', ' p53-Binding Protein MDM2 ', ' mdm2 protein ', ' mdm-2 oncogene protein ', ' Oncoprotein MDM2 ', ' Mdm-2 protein ', ' MDMX protein ', ' MDM2 ', ' HDM2 ', ' imaging modality ', ' imaging method ', ' image-based method ', ' data mining ', ' datamining ', ' MCT-1 gene ', ' MCT-1 ', ' Address ', ' Data ', ' Predictive Value ', ' Prognostic Marker ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Reproducibility ', ' Resolution ', ' Cancer Center ', ' Cancer Patient ', ' Clinical Data ', ' Conduct Clinical Trials ', ' Tissue Chip ', ' Tissue Arrays ', ' Tissue Microarray ', ' Validation ', ' Monitor ', ' Characteristics ', ' Molecular ', ' Process ', ' imaging ', ' Image ', ' virtual ', ' digital ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Cancerous ', ' data acquisition ', ' clinically relevant ', ' clinical relevance ', ' tumor ', ' public health relevance ', ' standard of care ', ' progression marker ', ' material transfer agreement ', ' relational database ', ' arm ', ' data reduction ', ' in vivo imaging ', ' quantitative imaging ', ' contrast enhanced ', ' model building ', ' prospective test ', ' radiomics ', ' routine imaging ', ' ']",NCI,H. LEE MOFFITT CANCER CTR & RES INST,R01,2017,681586,FL-14,0.20560290085297311
"Development of a Multimodal Deep Learning Model for the Generation of Cancer Probability Maps and Imaging Biomarkers for Prostate Cancer using Multiparametric MRI Project Summary/Abstract Background: Prostatic adenocarcinoma is the most common newly diagnosed cancer and second deadliest cancer in American men. There is a large discrepancy between the incidence of the disease and its mortality rate. Thus, the development of screening tools to identify prostate cancer and determine if it is aggressive or indolent is an area of considerable interest. Current methods rely on the use of serum biomarkers and follow-up biopsies for screening. However, there is substantial debate as to the appropriate methodology for screening. The goal of this proposal is the development of: 1) new imaging biomarkers (i.e., features) for prostate cancer; and 2) a novel predictive model for the presence of aggressive prostatic adenocarcinoma. These tools will enable more effective use of mp-MRI in prostate cancer screening in the future and thus enable a future improvement in the sensitivity and specificity of screening, reducing the rates of overdiagnosis and underdiagnosis. Aim 1: To implement a deep learning algorithm for clinical prostate mp-MRI sequences, creating a cancer prob- ability map that is predictive of biopsy results. Aim 2: To create a multimodal framework that will combine discovered imaging features with clinical data points from the medical record (e.g., age, risk factors, medical history, biomarkers) to predict the presence and aggressiveness of prostatic adenocarcinoma. Methods: In Aim 1, a deep convolutional neural network (CNN) will be trained on a clinical dataset comprised of patches extracted from pre-prostatectomy mp-MRI sequences from patients with prostate cancer, using his- topathology analysis of whole-mount radical prostatectomy specimens as ground truth. The innovations in this aim will be the development of a CNN that can simultaneously learn from three different imaging sequence types, the use of patches for data augmentation, and the proper alignment of mp-MRI sequences and prostatectomy specimens for machine learning. The result of the work of this aim will be the creation of an algorithm for gen- erating imaging biomarkers (features) and cancer probability maps from mp-MRI data. In Aim 2, a multimodal learning framework that will integrate mp-MRI sequence data with clinical parameters in order to predict the presence of aggressive prostatic adenocarcinoma will be developed. The innovation in this aim will be the devel- opment of a framework that can integrate information from multiple modalities (imaging, serum, history, etc.) in order to generate a high confidence prediction of the presence of aggressive prostate cancer without the use of invasive testing. Long-term Objective: The development of a novel predictive model for the presence of aggressive prostatic adenocarcinoma in prostate mp-MRI data that will enable better future use of this data for the early detection of prostate cancer. Project Narrative / Public Health Relevance Prostatic adenocarcinoma is the most common newly diagnosed cancer and second deadliest cancer in American men. This research aims to develop imaging features and a predictive model that will enable better use of mul- tiparametric MRI for noninvasive prostate cancer screening, which could reduce over- and underdiagnosis in order to provide better care at lower cost.",Development of a Multimodal Deep Learning Model for the Generation of Cancer Probability Maps and Imaging Biomarkers for Prostate Cancer using Multiparametric MRI,9313127,F30CA210329,"['ages ', ' Age ', ' Algorithms ', ' Belief ', ' Biopsy ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Prostate Adenocarcinoma ', ' Systematics ', ' Classification ', ' Computer aided diagnosis ', ' Computer-Assisted Diagnosis ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Goals ', ' History ', ' Recording of previous events ', ' Hospitals ', ' Modern Man ', ' Human ', ' Incidence ', ' Learning ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Manuals ', ' Maps ', ' Medical Records ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Pathology ', ' Patients ', ' Probability ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostatectomy ', ' Research ', ' Risk ', ' Risk Factors ', ' Sensitivity and Specificity ', ' Specificity ', ' Testing ', ' Tissues ', ' Body Tissues ', ' United States ', ' Work ', ' Generations ', ' Outcome Measure ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' Dataset ', ' Data Set ', ' Caring ', ' Guidelines ', ' base ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' rectal ', ' Site ', ' Area ', ' Clinical ', ' Medical ', ' Evaluation ', ' Training ', ' Lesion ', ' Blood Serum ', ' Serum ', ' insight ', ' Indolent ', ' Visual ', ' Individual ', ' RDST ', ' radiologist ', ' Personal Medical History Epidemiology ', ' Personal Medical History ', ' Medical History ', ' prostate cancer early detection ', ' Screening for Prostate Cancer ', ' tool ', ' Specimen ', ' Research Specimen ', ' Transrectal Ultrasound ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Physiologic pulse ', ' Pulse ', ' Complex ', ' Techniques ', ' System ', ' interest ', ' American ', ' Biological Neural Networks ', ' neural network ', ' Histopathology ', ' novel ', ' Modality ', ' Modeling ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer diagnosis ', ' Address ', ' Data ', ' Detection ', ' National Comprehensive Cancer Network ', ' NCCN ', ' Clinical Data ', ' Newly Diagnosed ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' cost ', ' digital ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' imaging Segmentation ', ' spatiotemporal ', ' high risk ', ' public health relevance ', ' multimodality ', ' primary outcome ', ' secondary outcome ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' imaging biomarker ', ' imaging marker ', ' non-linear transformation ', ' nonlinear transformation ', ' Risk stratification ', ' ']",NCI,UNIVERSITY OF CALIFORNIA LOS ANGELES,F30,2017,37542,CA-33,0.2775359125317824
"Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning DESCRIPTION (provided by applicant): Few biomarkers derived from genome scale data have translated into improved clinical classification of cancer subtypes, in spite of the wealth of available genome-wide studies and of the corresponding application of numerous statistical algorithms. This widespread shortcoming derives from the pervasive use of ""off the shelf"" algorithms and machine learning techniques developed for image classification and language processing, which are nave of the underlying biology of the system. Furthermore, for genome-wide data, the number of samples is often small relative to the number of potential candidate biomarkers, resulting in variable accuracy on independent test data despite high accuracy in the samples used for discovery, which contributes to the failure of clinical biomarkers. This problem - so called ""curse of dimensionality"" - is further exacerbated by the prohibitive cost of dramatically increasing sample size and by patient stratification into smaller subgroups for personalized and precision medicine. Disease phenotypes arise from distinct and specific perturbations in selected networks and pathways defined by the interactions of their molecular constituents. In cancer, these perturbations may reside in gene regulatory networks topology and state, in cell signaling activity, or in metabolic conditions. We hypothesize that by leveragin such prior biological information on cancer biology we will be able to reduce model complexity and build mechanistically justified predictive models. To pursue this hypothesis, we will develop an analytical framework to embed mechanistic constraints derived from network biology into the statistical learning process itself. Hence, this application will develop a novel suite of statistial learning algorithms that embed (Aim 1) gene expression regulatory networks, (Aim 2) cell signaling activity, and (Aim 3) metabolism to classify breast and prostate cancer. Throughout the study we will work closely with clinical collaborators to ensure that our method improve over and above current predictive and prognostic models. Finally, since in our study we will also generate mechanistic classifiers based on gene expression measurements obtained from clinical assays that are already commercially available (i.e., MammaPrint, and Decipher), our innovative models and predictors will be also readily available for clinical translation. Our mechanism-driven classifiers will simultaneously have greater accuracy and interpretability than classifiers developed without regard for the underlying biology of the disease. Furthermore, embedding biological mechanisms in the classifiers will also facilitate the identification of alternative therapeutic targets specific to each cancer subtype, potentially improving patient prognosis and health outcomes. Finally, the substantial curation of molecular pathways and biological networks we will carry on in the project will also provide a powerful resource for futur studies, and the methodologies we will develop will be also applicable to other cancer and other human diseases, like neurodegenerative disorders, hearth disease, and diabetes. PUBLIC HEALTH RELEVANCE    Project Narrative This study will use mechanistic biological knowledge to implement a suite of statistical algorithms for cancer patient classification, which will also reveal the biological reasoning behind the classification decision rules. In the study we will also apply our novel methods to develop improved biomarkers for breast and prostate cancer patient clinical stratification, with the ultimate goal of facilitating the selection of appropriate treatment. To achieve this goal we will directly improve the existing commercial tests offered to the patients, with an immediate clinical impact, since our biomarkers will be directly implementable into these assays, with the potential to quickly reach the bedside.",Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning,9253361,R01CA200859,"['Algorithms ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biology ', ' malignant breast tumor ', ' Breast Cancer ', ' malignant breast neoplasm ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cell Body ', ' Cells ', ' Systematics ', ' Classification ', ' Complement Proteins ', ' Complement ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Energy Expenditure ', ' Energy Metabolism ', ' Feedback ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Goals ', ' Health ', ' Learning ', ' Drug Metabolic Detoxication ', ' detoxification ', ' Metabolism of Toxic Agents ', ' Metabolic Drug Detoxications ', ' Drug Metabolic Detoxification ', ' Metabolism ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Methods ', ' Methodology ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' research and development ', ' R&D ', ' R & D ', ' Development and Research ', ' Research Design ', ' study design ', ' Study Type ', ' Resources ', ' Research Resources ', ' Signal Pathway ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' statistics ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Translating ', ' Work ', ' base ', ' improved ', ' Clinical ', ' Biological ', ' Biochemical ', ' Ensure ', ' Failure ', ' Data Quality ', ' Measurement ', ' Sample Size ', ' Metabolic Networks ', ' Biochemical Pathway ', ' Space Models ', ' Metabolic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' Dimensions ', ' Complex ', ' Side ', ' Techniques ', ' Neurodegenerative Disorders ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neuro-degenerative Disorders ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' functional group ', ' cohort ', ' novel ', ' Modeling ', ' Sampling ', ' cancer classification ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Address ', ' Systems Biology ', ' Data ', ' Detection ', ' Measurable ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Subgroup ', ' Cancer Biology ', ' Cancer Patient ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' cost ', ' feeding ', ' cancer research ', ' anticancer research ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' Resistance ', ' resistant ', ' clinically relevant ', ' clinical relevance ', ' open source ', ' human disease ', ' language processing ', ' chemotherapy ', ' therapeutic target ', ' therapy design ', ' treatment design ', ' intervention design ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide analysis ', ' public health relevance ', ' candidate marker ', ' candidate biomarker ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' genome-wide ', ' genomewide ', ' genome scale ', ' biological systems ', ' Knowledge Discovery ', ' Statistical Algorithm ', ' Statistics Algorithm ', ' precision medicine ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' biomarker development ', ' patient stratification ', ' stratified patient ', ' clinical biomarkers ', ' clinically useful biomarkers ', ' personalized health care ', ' precision health care ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' cancer subtypes ', ' cancer sub-types ', ' predict clinical outcome ', ' predictor of clinical outcome ', ' clinical outcome prediction ', ' predictive signature ', ' Clinical stratification ', ' clinical translation ', ' high dimensionality ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2017,384981,MD-07,0.10256685329278825
"Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Abstract: Fast, reliable and accurate delineation of pelvic organs in the planning and treatment images is a long- standing, important and technically challenging problem. Its solution is highly required for state-of-the-art image-guided radiation therapy planning and treatment, as better treatment decisions rely on timely interpretation of anatomical information in the images. However, automatic segmentation in male pelvic regions is always difficult due to 1) low contrast between prostate and surrounding organs, and 2) possibly disparate shapes/appearances of bladder and rectum caused by tissue deformations. The goal of this project is to create a set of novel machine learning tools to achieve accurate, reliable and efficient delineation of important pelvic organs (e.g., prostate, bladder, and rectum) in different modalities (e.g., planning CT, treatment CT/CBCT, and MRI) for radiotherapy of prostate cancer.  Planning CT. For automatic segmentation, landmark detection is often the first step in rapidly locating the target organs. Thus, in Aim 1, we will create a novel joint landmark detection approach, based on both random forests and auto-context model, to iteratively detect all landmarks and further coordinate their detection results for achieving more accurate and consistent landmark detection results. After roughly locating organs with the aid of those detected landmarks, the second step is to accurately segment boundaries of target organs in the planning CT. Accordingly, in Aim 2, we will create a set of learning methods to a) first simultaneously predict all pelvic organ boundaries in the planning CT with the regression forests trained by labeled training data, and b) then segment all pelvic organs jointly by deforming their respective shape models. In particular, to address the limitations of conventional deformable models in assuming simple Gaussian distributions for organ shapes, a novel hierarchical sparse shape composition approach will be developed to constrain shape models during deformable segmentation.  Treatment CT/CBCT. During the course of serial radiation treatments, to quantitatively record and monitor the accumulated dose delivered to the patient, organs in the treatment image also need to be segmented. Although methods proposed in Aims 1-2 can be simply applied, as done by many conventional methods, this will lead to a) inconsistent landmark detection and b) inconsistent segmentations across different treatment days because of possible large shape/appearance changes. Accordingly, in Aim 3, we will create a novel self- learning mechanism to gradually learn and incorporate patient-specific information into both joint landmark detection and deformable segmentation steps from the increasingly acquired treatment images of patient. Thus, population data will gradually be replaced by the patient's own data to train personalized models.  MRI. To guide pelvic organ segmentation in the planning CT, MRI is now often acquired for selected patients. To this end, in Aim 4, we will develop a) a prostate MRI segmentation method by using deep learning to learn MRI-specific features for guiding landmark detection and deformable segmentation as proposed in Aims 1-2; b) a novel collaborative MRI and CT segmentation algorithm for more accurate segmentation of planning CT.  All our developed algorithms will be evaluated for their performance in clinical (treatment planning and delivery) workflow for 130 patients in UNC Cancer Hospital and also hospitals of our consultants.  Benefit for Patient Care. Development of these segmentation tools will 1) dramatically accelerate the clinical workflow, 2) reduce workload (i.e., manual interaction time) for physicians, and 3) lead to better patient outcomes with reliable and accurate segmentations of target area and critical organs. Although these tools cannot replace the expertise of physicians, they can be of great assistance to physicians. Narrative Description of Project This project aims to create a set of novel machine learning tools for accurate, reliable and efficient delineation of important pelvic organs (such as prostate, bladder, and rectum) in various imaging modalities to help radiotherapy of prostate cancer. To achieve this goal, we will create 1) a novel joint landmark detection and boundary prediction framework for accurate segmentation of the planning CT images, 2) an innovative updating mechanism for incorporating patient-specific information from previous treatment images of same patient to progressively improve treatment CT/CBCT segmentation, and 3) a deep-learning based framework for learning MRI-specific features for prostate MRI segmentation, as well as a novel method for collaborative MRI & planning CT segmentation. We will validate these methods on real patients in our clinical workflow. Besides, although these machine-learning tools are designed for radiotherapy of prostate cancer, they can also be easily extended to other new organs and new modalities after appropriate updating and training.",Automatic Pelvic Organ Delineation in Prostate Cancer Treatment,9336855,R01CA206100,"['Algorithms ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Anatomy ', ' urinary bladder ', ' Bladder Urinary System ', ' Bladder ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Hospitals ', ' Cancer Hospital ', ' Joints ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' male ', ' Manuals ', ' Methods ', ' Normal Statistical Distribution ', ' Normal Distribution ', ' Gaussian Distribution ', ' Patient Monitoring ', ' Patients ', ' Pelvis ', ' Pelvic Region ', ' Pelvic ', ' Physicians ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Radiation therapy ', ' treatment with radiation ', ' radio-therapy ', ' radiation treatment ', ' Radiotherapy ', ' Radiotherapeutics ', ' Rectum ', ' Time ', ' Tissues ', ' Body Tissues ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Work Load ', ' Workload ', ' forest ', ' base ', ' dosage ', ' Organ ', ' Label ', ' improved ', ' Area ', ' Clinical ', ' Training ', ' soft tissue ', ' Sample Size ', ' Shapes ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Clinic ', ' treatment duration ', ' treatment days ', ' Treatment Period ', ' Performance ', ' success ', ' treatment planning ', ' novel ', ' General Population ', ' General Public ', ' Modality ', ' Appearance ', ' Modeling ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' imaging modality ', ' imaging method ', ' image-based method ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' Multimodal Imaging ', ' multimodality imaging ', ' multi-modality imaging ', ' trial treatment ', ' trial regimen ', ' Clinical Treatment ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' Update ', ' Monitor ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' designing ', ' design ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' imaging Segmentation ', ' therapy design ', ' treatment design ', ' intervention design ', ' image guided radiation therapy ', ' image-guided radiotherapy ', ' image guided radiation treatment ', ' IGRT ', ' learning strategy ', ' learning method ', ' learning activity ', ' ']",NCI,UNIV OF NORTH CAROLINA CHAPEL HILL,R01,2017,347700,NC-04,0.1601918496567657
"Gene-Gene Interactions and Their Functional Roles in Prostate Cancer Aggressiveness Project Summary/Abstract Prostate cancer with substantial clinical heterogeneity is the most common cancer and the second leading cause of cancer-related death in American men. It remains unclear why some prostate tumors are more aggressive than others. Existing clinical features (such as prostate specific antigen (PSA), clinical stage and Gleason score) are not sufficient for classifying high- and low-risk prostate cancer patients. It has been shown that approximately 20% of low-risk prostate cancer patients died due to conservative treatment. Thus, there is an urgent need for identifying additional biomarkers in order to improve prediction accuracy of prostate cancer aggressiveness. The majority of current studies focus on evaluating individual genetic variants, which may not be sufficient to explain the complexity of disease causality. The objective of this study is to identify gene-gene interactions within the four candidate pathways (angiogenesis, mitochondria, miRNA, and androgen metabolism) associated with prostate cancer aggressiveness and their impact on gene expression. The genetic variants (both individual effects and interactions) associated with prostate cancer aggressiveness will be performed using the existing genetic data from the large scale prostate cancer consortium, a collection of approximately 22,000 prostate cancer patients. The associations between genetic variants and gene expressions will be identified using public domain genetic data and will be validated using a cohort data set with 1065 prostate cancer patients. Evaluating genetic variants with gene expression levels helps to identify downstream genes which can guide further study and may lead to discovery of novel therapeutic targets. Our study findings can provide valuable information toward understanding pathogenesis of prostate cancer and identifying genotype combinations for predicting prostate cancer aggressiveness. As for the long-term impact, the study results may be applied in developing effective screening tools to predict prostate cancer aggressiveness. Project Narrative For prostate cancer patients, physicians often have difficulty at the time of a prostate cancer diagnosis distinguishing between patients who will develop indolent tumors and those who will develop aggressive tumors. This study aims to identify genetic markers (genetic variants and gene expressions) involved with multiple genes associated with prostate cancer aggressiveness. Our study findings can provide valuable information toward understanding pathogenesis of prostate cancer and identifying genotype combinations for predicting prostate cancer aggressiveness.",Gene-Gene Interactions and Their Functional Roles in Prostate Cancer Aggressiveness,9312780,R21CA202417,"['Affect ', ' Allelomorphs ', ' Alleles ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Death ', ' Cessation of life ', ' Disorder ', ' Disease ', ' Family ', ' Fibroblast Growth Regulatory Factor ', ' Fibroblast Growth Factor Gene Family ', ' FGF ', ' Endothelial Cell Growth Factor ', ' DNA Synthesis Factor ', ' Fibroblast Growth Factor ', ' Gene Expression ', ' Genes ', ' genetic biomarker ', ' Genetic Markers ', ' Genotype ', ' Goals ', ' Heterogeneity ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' men ', "" men's "", ' Mitochondria ', ' mitochondrial ', ' Odds Ratio ', ' Risk Ratio ', ' Relative Odds ', ' Cross-Product Ratio ', ' Patients ', ' Phenotype ', ' Physicians ', ' Play ', ' Prostatic Neoplasms ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Proteins ', ' Androgen Receptor ', ' Epidermal Growth Factor Receptor ', ' proto-oncogene protein c-erbB-1 ', ' erbBl ', ' erbB-1 Proto-Oncogene Protein ', ' erbB-1 ', ' c-erbB-1 Protein ', ' c-erbB-1 ', ' Urogastrone Receptor ', ' Transforming Growth Factor alpha Receptor ', ' TGF-alpha Receptor ', ' HER1 ', ' Epidermal Growth Factor-Urogastrone Receptors ', ' Epidermal Growth Factor Receptor Protein-Tyrosine Kinase ', ' Epidermal Growth Factor Receptor Kinase ', ' ERBB Protein ', ' EGFR ', ' EGF Receptor ', ' Research ', ' Research Design ', ' study design ', ' Study Type ', ' Risk ', ' Role ', ' social role ', ' Time ', ' Tissues ', ' Body Tissues ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' Dataset ', ' Data Set ', ' Public Domains ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Apoptosis ', ' base ', ' improved ', ' Solid ', ' Clinical ', ' Biological ', ' Indolent ', ' Individual ', ' Macrophage-2 Antigen ', ' Mac-2 Antigen ', ' LGALS3 ', ' L30 Lectin ', ' L-34 ', ' L-31 ', ' L-29 Lectin ', ' IgEBP ', ' IgE Binding Protein ', ' HL-29 ', ' Epsilon-Binding Protein ', ' Carbohydrate-Binding Protein 35 ', ' CBP35 ', ' CBP-35 ', ' CBP-30 ', ' Galectin 3 ', ' angiogenesis ', ' Genetic ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' BCL2 gene ', ' ced9 homolog ', ' bcl-2 Genes ', ' Bcl-2 ', ' BCL2 ', ' B-cell lymphoma/leukemia-2 ', ' B-Cell CLL/Lymphoma 2 Gene ', ' B cell lymphoma 2 ', ' Complex ', ' American ', ' cancer risk ', ' gene interaction ', ' Quantitative Trait Loci ', ' QTL ', ' receptor ', ' Receptor Protein ', ' cohort ', ' Pathogenesis ', ' Reporting ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Regulation ', ' cancer diagnosis ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Androgen Metabolism ', ' Vascular Endothelial Growth Factors ', ' VEGFs ', ' VEGF ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' CSF1 gene ', ' MGC31930 ', ' MCSF ', ' CSF1 ', ' EGF gene ', ' EGF ', ' Data ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Collection ', ' Validation ', ' pathway ', ' Pathway interactions ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' Oncogenic ', ' tumor ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' evidence base ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' The Cancer Genome Atlas ', ' TCGA ', ' screening ', ' precision medicine ', ' high risk population ', ' high risk group ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NCI,LSU HEALTH SCIENCES CENTER,R21,2017,135829,LA-02,0.3244345513417088
"An integrated approach to dissect the functional network of large non-coding RNA PROJECT SUMMARY Recent studies revealed that the human genome encodes thousands of lncRNAs with little proteincoding capacity. LncRNAs were shown to play important roles in cancer and are potentially a new class of therapeutic targets for cancer. However, the function of the vast majority of lncRNAs in cancer remains unknown. LncRNA function often depends on its physical interactions with protein complexes. They can also influence the abundance of other mRNAs that are targeted by the same microRNAs by competing for microRNA binding, i.e., serving as competing endogenous RNA (ceRNA). Advances in genomic technologies, especially those based on next generation sequencing (NGS), provide unparalleled opportunities to characterize the functional networks of lncRNA in cancer. However, analysis and integration of different types of genomic datasets to generate testable hypotheses is challenging, and systematic approaches to characterize lncRNA function in cancer are lacking. This application describes the development of computational methods and integrative genomic strategies for systematically dissecting the functional network of lncRNA in cancer, and a combination of computational and experimental approaches to unravel several important functional networks of lncRNA in prostate cancer. Specifically, it will (1) develop a computational method for repurposing the publically available array-based data to interrogate lncRNA expression in tumor samples and utilize an integrative genomic strategy to predict lncRNAs that may be important for tumorigenesis/tumor suppression in prostate cancer via analysis of lncRNA expression profiles, clinical information and somatic genomic alteration profiles of tumor samples, (2) identify the lncRNAs that are associated with EZH2 or direct transcriptional targets of EZH2 repression that are important for prostate tumorigenesis or tumor suppression, and (3) identify the ceRNAs of AR and PTEN that mediate prostate tumorigenesis or tumor suppression. In addition to its scientific proposal, this application proposes a comprehensive training program for preparing an independent investigator in the fields of computational genomics, noncoding RNA and cancer, who develops cutting-edge computational methods, and uses a combination of computational and experimental approaches to understand structure-function relationship of noncoding RNA and the function of noncoding RNA and RNA-protein interaction in cancer. While the candidate of this application has received extensive training in biophysics, statistics, machine learning and computational genomics, this career development award will allow him to develop his experimental skills, especially those next-generation sequencing-based techniques and molecular biology experiments in human cell lines. Dr. Liu, Professor of Biostatistics and Computational Biology and Dr. Brown, Professor of Medicine will mentor the candidate in the excellent training environment of Dana Farber Cancer Institute, a part of Harvard Medical School community. A committee of experienced computational and cancer biologists will also advise him on both scientific research and career development. The proposed study is to decipher lncRNA function in cancer using a combination of novel computational methods and high-throughput experimental technologies. The proposed research will result in publically available bioinformatic resources for studying lncRNA function in cancer, a greater understanding of IncRNA function in prostate cancer, and will help to discover novel therapeutic target of lncRNA for treating prostate cancer.",An integrated approach to dissect the functional network of large non-coding RNA,9207429,R00CA175290,"['Biostatistics ', ' Biometrics ', ' Biometry ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Environment ', ' Exons ', ' human whole genome ', ' Human Genome ', ' Immunoprecipitation ', ' Immune Precipitation ', ' Medicine ', ' Mentors ', ' Methods ', ' Molecular Biology ', ' DNA Molecular Biology ', ' Play ', ' Prostatic Neoplasms ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Androgen Receptor ', ' Repression ', ' Research ', ' research and development ', ' R&D ', ' R & D ', ' Development and Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Ribonucleoproteins ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Messenger RNA ', ' mRNA ', ' Role ', ' social role ', ' medical schools ', ' school of medicine ', ' medical college ', ' statistics ', ' Structure-Activity Relationship ', ' structure function relationship ', ' chemical structure function ', ' Technology ', ' Training Programs ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Enhancers ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Training ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Computational Biology ', ' computer biology ', ' Techniques ', ' experience ', ' professor ', ' Base Pairing ', ' skills ', ' novel ', ' Human Cell Line ', ' Categories ', ' PTEN gene ', ' Phosphatase and Tensin Homolog Deleted on Chromosome 10 ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN Hamartoma Tumor Syndrome With Granular Cell Tumor ', ' PTEN Hamartoma Tumor Syndrome ', ' PTEN ', ' PHTS protein ', ' PHTS gene ', ' Mutated in Multiple Advanced Cancers 1 ', ' MMAC1 ', ' Modeling ', ' Sampling ', ' career development ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' Binding ', ' Molecular Interaction ', ' protein complex ', ' tumorigenesis ', ' Oncogenesis ', ' chromatin immunoprecipitation ', ' ChIP assay ', ' Homologous Gene ', ' Homologue ', ' Homolog ', ' GeneHomolog ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Dana-Farber Cancer Institute ', ' DF/HCC ', ' Data ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' RNA-Protein Interaction ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' mRNA Expression ', ' Molecular Tumor Suppression ', ' Tumor Suppression ', ' developmental ', ' Development ', ' therapeutic target ', ' tumor ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' prostate carcinogenesis ', ' prostate tumorigenesis ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' Algorithmic Analysis ', ' Analysis of Algorithms ', ' Analyses of Algorithms ', ' Algorithmic Analyses ', ' Genomic approach ', ' genomic strategy ', ' genomic effort ', ' RNA immunoprecipitation sequencing ', ' RIPseq ', ' RIP seq ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NCI,UNIVERSITY OF TX MD ANDERSON CAN CTR,R00,2017,221939,TX-09,0.20970179356598065
"Imaging of prostate cancer by combined quantitative ultrasound and acoustic-radiation-force-impulse imaging Project Summary/Abstract Prostate cancer (PCa) is the most-common cancer of men in the United States. The goal of the project is to develop a reliable, imaging tool for characterizing prostate tissue. This tool will improve detection, grading, treatment, and monitoring of PCa. It can be implemented in existing clinical scanners for effective needle-biopsy guidance and for planning and targeting focal therapy. Such a tool would significantly reduce the amount of unnecessary biopsies of noncancerous tissue and the current high rate of false negative diagnoses. It also would allow monitoring diagnosed PCa during watchful waiting or after non-surgical therapies. We propose to investigate the feasibility of fusing acoustic radiation-force impulse (ARFI) imaging and quantitative ultrasound (QUS) for typing prostate tissue. Studies to date have demonstrated encouraging performance of each ultrasonic modality when used alone. However, the ability of the combined modalities has not yet been investigated. The proposed project seeks to extract features from a retrospective data set containing radio-frequency (RF) ultrasound data acquired while performing in vivo prostate ARFI imaging. Images generated from both technologies are intrinsically perfectly registered. We will employ our well-established QUS-processing procedures to extract QUS-parameter maps from the RF-data and will develop and test new algorithms to extend the feature set from our established QUS-processing to incorporate ARFI image features. We will use standard and new features from QUS and ARFI for training linear and non-linear classifiers (e.g. support vector machines) to identify and image PCa. We will compare the performance of classifiers trained with QUS alone, ARFI alone, and MRI alone. Furthermore, we will assess performance improvement if classifiers are trained based on QUS- ARFI, QUS-MRI, ARFI-MRI, and QUS-ARFI-MRI parameter combinations and will determine the best classifier to detect prostate cancerous tissue using cross-validation and receiver-operating-characteristic (ROC) statistics. If this project is successful, subsequent projects will focus on integrating the newly developed tools into clinical scanners. Project Narrative We propose to assess the feasibility of a novel tool for imaging and detection of prostate cancer (PCa) that combines quantitative ultrasound and acoustic radiation-force imaging. If our proposed method proves to be feasible and ultimately is successful, it will have a major impact on clinical practice by reducing the current high rates of false-negative diagnoses of PCa and by enabling non-invasive, low-risk, low-cost monitoring of PCa.",Imaging of prostate cancer by combined quantitative ultrasound and acoustic-radiation-force-impulse imaging,9510757,R03EB026233,"['Acoustics ', ' Acoustic ', ' Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Biopsy ', ' Needle biopsy procedure ', ' needle biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Classification ', ' Systematics ', ' Diagnosis ', ' Foundations ', ' Goals ', ' Gold ', ' Histocompatibility Testing ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histology ', ' Laboratories ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' male ', ' Maps ', ' men ', "" men's "", ' Methods ', ' Patients ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Publishing ', ' Receiver Operating Characteristics ', ' Receiver Operator Characteristics ', ' Relaxation ', ' Retrospective Studies ', ' Risk ', ' ROC Curve ', ' ROC Analyses ', ' statistics ', ' Technology ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Ultrasonography ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' United States ', ' Universities ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Data Set ', ' Dataset ', ' base ', ' image processing ', ' improved ', ' Procedures ', ' Area ', ' Clinical ', ' Histologically ', ' Histologic ', ' Training ', ' Lesion ', ' Measurement ', ' prostate cancer early detection ', ' prostate cancer detection ', ' detect prostate cancer ', ' Screening for Prostate Cancer ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' Texture ', ' Performance ', ' Intercept ', ' novel ', ' Modality ', ' Devices ', ' Patient observation ', ' Watchful Waiting ', ' Radiation ', ' Modeling ', ' Property ', ' cancer classification ', ' Core Biopsy ', ' Core Needle Biopsy ', ' Ultrasonics ', ' Ultrasonic ', ' Data ', ' Detection ', ' Imaging Device ', ' Imaging Tool ', ' Imaging Instrument ', ' in vivo ', ' Cancer Maps ', ' Atlas of Cancer Mortality in the United States ', ' Cancer Patient ', ' Validation ', ' Monitor ', ' imaging ', ' Image ', ' cost ', ' cost efficient ', ' Cancerous ', ' clinical significance ', ' clinically significant ', ' patient population ', ' quantitative ultrasound ', ' clinical practice ', ' signal processing ', ' imaging in vivo ', ' in vivo imaging ', ' radio frequency ', ' routine imaging ', ' ']",NIBIB,RIVERSIDE RESEARCH INSTITUTE,R03,2018,77402,NY-10,0.24254508033820826
"Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Abstract: Fast, reliable and accurate delineation of pelvic organs in the planning and treatment images is a long- standing, important and technically challenging problem. Its solution is highly required for state-of-the-art image-guided radiation therapy planning and treatment, as better treatment decisions rely on timely interpretation of anatomical information in the images. However, automatic segmentation in male pelvic regions is always difficult due to 1) low contrast between prostate and surrounding organs, and 2) possibly disparate shapes/appearances of bladder and rectum caused by tissue deformations. The goal of this project is to create a set of novel machine learning tools to achieve accurate, reliable and efficient delineation of important pelvic organs (e.g., prostate, bladder, and rectum) in different modalities (e.g., planning CT, treatment CT/CBCT, and MRI) for radiotherapy of prostate cancer.  Planning CT. For automatic segmentation, landmark detection is often the first step in rapidly locating the target organs. Thus, in Aim 1, we will create a novel joint landmark detection approach, based on both random forests and auto-context model, to iteratively detect all landmarks and further coordinate their detection results for achieving more accurate and consistent landmark detection results. After roughly locating organs with the aid of those detected landmarks, the second step is to accurately segment boundaries of target organs in the planning CT. Accordingly, in Aim 2, we will create a set of learning methods to a) first simultaneously predict all pelvic organ boundaries in the planning CT with the regression forests trained by labeled training data, and b) then segment all pelvic organs jointly by deforming their respective shape models. In particular, to address the limitations of conventional deformable models in assuming simple Gaussian distributions for organ shapes, a novel hierarchical sparse shape composition approach will be developed to constrain shape models during deformable segmentation.  Treatment CT/CBCT. During the course of serial radiation treatments, to quantitatively record and monitor the accumulated dose delivered to the patient, organs in the treatment image also need to be segmented. Although methods proposed in Aims 1-2 can be simply applied, as done by many conventional methods, this will lead to a) inconsistent landmark detection and b) inconsistent segmentations across different treatment days because of possible large shape/appearance changes. Accordingly, in Aim 3, we will create a novel self- learning mechanism to gradually learn and incorporate patient-specific information into both joint landmark detection and deformable segmentation steps from the increasingly acquired treatment images of patient. Thus, population data will gradually be replaced by the patient's own data to train personalized models.  MRI. To guide pelvic organ segmentation in the planning CT, MRI is now often acquired for selected patients. To this end, in Aim 4, we will develop a) a prostate MRI segmentation method by using deep learning to learn MRI-specific features for guiding landmark detection and deformable segmentation as proposed in Aims 1-2; b) a novel collaborative MRI and CT segmentation algorithm for more accurate segmentation of planning CT.  All our developed algorithms will be evaluated for their performance in clinical (treatment planning and delivery) workflow for 130 patients in UNC Cancer Hospital and also hospitals of our consultants.  Benefit for Patient Care. Development of these segmentation tools will 1) dramatically accelerate the clinical workflow, 2) reduce workload (i.e., manual interaction time) for physicians, and 3) lead to better patient outcomes with reliable and accurate segmentations of target area and critical organs. Although these tools cannot replace the expertise of physicians, they can be of great assistance to physicians. Narrative Description of Project This project aims to create a set of novel machine learning tools for accurate, reliable and efficient delineation of important pelvic organs (such as prostate, bladder, and rectum) in various imaging modalities to help radiotherapy of prostate cancer. To achieve this goal, we will create 1) a novel joint landmark detection and boundary prediction framework for accurate segmentation of the planning CT images, 2) an innovative updating mechanism for incorporating patient-specific information from previous treatment images of same patient to progressively improve treatment CT/CBCT segmentation, and 3) a deep-learning based framework for learning MRI-specific features for prostate MRI segmentation, as well as a novel method for collaborative MRI & planning CT segmentation. We will validate these methods on real patients in our clinical workflow. Besides, although these machine-learning tools are designed for radiotherapy of prostate cancer, they can also be easily extended to other new organs and new modalities after appropriate updating and training.",Automatic Pelvic Organ Delineation in Prostate Cancer Treatment,9527787,R01CA206100,"['Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Bladder ', ' urinary bladder ', ' Bladder Urinary System ', ' Patient Care ', ' Patient Care Delivery ', ' Goals ', ' Hospitals ', ' Cancer Hospital ', ' Joints ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' male ', ' Manuals ', ' Methods ', ' Normal Statistical Distribution ', ' Normal Distribution ', ' Gaussian Distribution ', ' Patient Monitoring ', ' Patients ', ' Pelvis ', ' Pelvic Region ', ' Pelvic ', ' Physicians ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Radiation therapy ', ' treatment with radiation ', ' radio-therapy ', ' radiation treatment ', ' Radiotherapy ', ' Radiotherapeutics ', ' Rectum ', ' Time ', ' Tissues ', ' Body Tissues ', ' X-Ray Computed Tomography ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' Workload ', ' Work Load ', ' forest ', ' base ', ' dosage ', ' Organ ', ' Label ', ' improved ', ' Area ', ' Clinical ', ' Training ', ' soft tissue ', ' Sample Size ', ' Shapes ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Clinic ', ' treatment duration ', ' treatment days ', ' Treatment Period ', ' Performance ', ' success ', ' treatment planning ', ' novel ', ' General Population ', ' General Public ', ' Modality ', ' Appearance ', ' Modeling ', ' imaging modality ', ' imaging method ', ' image-based method ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' Multimodal Imaging ', ' multimodality imaging ', ' multi-modality imaging ', ' trial treatment ', ' trial regimen ', ' Clinical Treatment ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' Update ', ' Monitor ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' designing ', ' design ', ' Population ', ' prostate cancer treatment ', ' Prostate CA therapy ', ' Prostate Cancer therapy ', ' innovative ', ' innovate ', ' innovation ', ' imaging Segmentation ', ' treatment design ', ' intervention design ', ' therapy design ', ' image-guided radiotherapy ', ' image guided radiation treatment ', ' IGRT ', ' image guided radiation therapy ', ' learning method ', ' learning activity ', ' learning strategy ', ' deep learning ', ' ']",NCI,UNIV OF NORTH CAROLINA CHAPEL HILL,R01,2018,347700,NC-04,0.1601918496567657
"Development of a Multimodal Deep Learning Model for the Generation of Cancer Probability Maps and Imaging Biomarkers for Prostate Cancer using Multiparametric MRI Project Summary/Abstract Background: Prostatic adenocarcinoma is the most common newly diagnosed cancer and second deadliest cancer in American men. There is a large discrepancy between the incidence of the disease and its mortality rate. Thus, the development of screening tools to identify prostate cancer and determine if it is aggressive or indolent is an area of considerable interest. Current methods rely on the use of serum biomarkers and follow-up biopsies for screening. However, there is substantial debate as to the appropriate methodology for screening. The goal of this proposal is the development of: 1) new imaging biomarkers (i.e., features) for prostate cancer; and 2) a novel predictive model for the presence of aggressive prostatic adenocarcinoma. These tools will enable more effective use of mp-MRI in prostate cancer screening in the future and thus enable a future improvement in the sensitivity and specificity of screening, reducing the rates of overdiagnosis and underdiagnosis. Aim 1: To implement a deep learning algorithm for clinical prostate mp-MRI sequences, creating a cancer prob- ability map that is predictive of biopsy results. Aim 2: To create a multimodal framework that will combine discovered imaging features with clinical data points from the medical record (e.g., age, risk factors, medical history, biomarkers) to predict the presence and aggressiveness of prostatic adenocarcinoma. Methods: In Aim 1, a deep convolutional neural network (CNN) will be trained on a clinical dataset comprised of patches extracted from pre-prostatectomy mp-MRI sequences from patients with prostate cancer, using his- topathology analysis of whole-mount radical prostatectomy specimens as ground truth. The innovations in this aim will be the development of a CNN that can simultaneously learn from three different imaging sequence types, the use of patches for data augmentation, and the proper alignment of mp-MRI sequences and prostatectomy specimens for machine learning. The result of the work of this aim will be the creation of an algorithm for gen- erating imaging biomarkers (features) and cancer probability maps from mp-MRI data. In Aim 2, a multimodal learning framework that will integrate mp-MRI sequence data with clinical parameters in order to predict the presence of aggressive prostatic adenocarcinoma will be developed. The innovation in this aim will be the devel- opment of a framework that can integrate information from multiple modalities (imaging, serum, history, etc.) in order to generate a high confidence prediction of the presence of aggressive prostate cancer without the use of invasive testing. Long-term Objective: The development of a novel predictive model for the presence of aggressive prostatic adenocarcinoma in prostate mp-MRI data that will enable better future use of this data for the early detection of prostate cancer. Project Narrative / Public Health Relevance Prostatic adenocarcinoma is the most common newly diagnosed cancer and second deadliest cancer in American men. This research aims to develop imaging features and a predictive model that will enable better use of mul- tiparametric MRI for noninvasive prostate cancer screening, which could reduce over- and underdiagnosis in order to provide better care at lower cost.",Development of a Multimodal Deep Learning Model for the Generation of Cancer Probability Maps and Imaging Biomarkers for Prostate Cancer using Multiparametric MRI,9516954,F30CA210329,"['Age ', ' ages ', ' Algorithms ', ' Belief ', ' Biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Prostate Adenocarcinoma ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Classification ', ' Systematics ', ' Computer-Assisted Diagnosis ', ' computer-assisted diagnostics ', ' Computer aided diagnosis ', ' Disease ', ' Disorder ', ' Engineering ', ' Future ', ' Goals ', ' Recording of previous events ', ' History ', ' Hospitals ', ' Human ', ' Modern Man ', ' Incidence ', ' Learning ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Manuals ', ' Maps ', ' Medical Records ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Pathology ', ' Patients ', ' Probability ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostatectomy ', ' Research ', ' Risk ', ' Risk Factors ', ' Sensitivity and Specificity ', ' Specificity ', ' Testing ', ' Tissues ', ' Body Tissues ', ' United States ', ' Work ', ' Generations ', ' Outcome Measure ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Data Set ', ' Dataset ', ' Caring ', ' Guidelines ', ' base ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' rectal ', ' Site ', ' Area ', ' Clinical ', ' Medical ', ' Evaluation ', ' screening tools ', ' Screening procedure ', ' Training ', ' Lesion ', ' Blood Serum ', ' Serum ', ' insight ', ' Indolent ', ' Visual ', ' Individual ', ' radiologist ', ' Personal Medical History Epidemiology ', ' Personal Medical History ', ' Medical History ', ' prostate cancer early detection ', ' prostate cancer detection ', ' detect prostate cancer ', ' Screening for Prostate Cancer ', ' tool ', ' Specimen ', ' Research Specimen ', ' Transrectal Ultrasound ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Physiologic pulse ', ' Pulse ', ' Complex ', ' Techniques ', ' System ', ' interest ', ' American ', ' Biological Neural Networks ', ' neural network ', ' Histopathology ', ' novel ', ' Modality ', ' Modeling ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer diagnosis ', ' Address ', ' Data ', ' Detection ', ' National Comprehensive Cancer Network ', ' NCCN ', ' Clinical Data ', ' Newly Diagnosed ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' cost ', ' digital ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' imaging Segmentation ', ' spatiotemporal ', ' high risk ', ' public health relevance ', ' multimodality ', ' primary outcome ', ' secondary outcome ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' screening ', ' imaging marker ', ' imaging biomarker ', ' nonlinear transformation ', ' non-linear transformation ', ' Risk stratification ', ' annual screening ', ' routine screening ', ' deep learning ', ' ']",NCI,UNIVERSITY OF CALIFORNIA LOS ANGELES,F30,2018,38022,CA-33,0.2775359125317824
"Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization Project Summary Prostate cancer (PCa) is the most diagnosed form of non-cutaneous cancer in US men. The selection of patients who require immediate treatment from those suitable for active surveillance currently relies on non- specific and inaccurate measurements. A method that allows clinicians to more confidently discriminate clinically relevant from non-life-threatening tumors is needed to improve patient management. Multiparametric magnetic resonance imaging (mpMRI) is the preferred non-invasive imaging modality for characterizing primary PCa. However, its accuracy for detecting clinically significant PCa is variable. We propose to address this limitation by combining mpMRI with positron emission tomography (PET) with a PCa-specific radiotracer and using advanced multimodal machine learning models (i.e. radiomics and deep learning) to characterize tumor aggressiveness based on the imaging data. Recently, scanners capable of simultaneous PET and MR data acquisition in human subjects have become commercially available. An integrated MR-PET scanner is the ideal tool for comparing MR and PET derived image features to identify those that provide complementary information and build a hybrid PET-mpMRI model that most accurately identifies clinically significant tumors. While this novel technology allows the acquisition of perfectly coregistered complementary anatomical, functional and metabolic data in a single imaging session, a new challenge needs to first be addressed to obtain quantitatively accurate PET data. In an integrated MR-PET scanner, the information needed for PET attenuation correction (AC) has to be derived from the MR data and the methods currently available for this task are inadequate for advanced quantitative studies. We have formed an academic-industrial partnership to accelerate the translation of multimodal MR-PET machine learning approaches into PCa research and clinical applications by addressing the AC challenge and validating machine learning models for detecting clinically significant disease against gold standard histopathology in patients undergoing radical prostatectomy. Specifically, we will: (1) Develop and validate an MR-based approach for obtaining quantitatively accurate PET data. We hypothesize that attenuation maps as accurate as those obtained using a 511 keV transmission source  the true gold standard for PET AC  will be obtained; (2) Identify the multimodal radiomics model that most accurately predicts PCa aggressiveness. We hypothesize that the diagnostic accuracy of this approach will be superior to that offered by the stand-alone modalities; (3) Evaluate radiomics and deep learning approaches for predicting pPCa aggressiveness. We hypothesize that machine learning approaches will achieve a higher predictive accuracy when applied to data acquired simultaneously than sequentially. Project narrative A better method to non-invasively characterize primary prostate cancer is needed to improve patient management. Extracting additional information from multimodality quantitative MR-PET data using machine learning approaches is expected to result in better diagnostic performance. In this work, we propose to accelerate the translation of quantitative MR-PET to prostate cancer research and clinical applications. In particular, we will develop and validate an MR-based attenuation correction approach to guarantee that quantitatively accurate PET data are obtained in an integrated MR-PET scanner and then use machine learning approaches to characterize the aggressiveness of the tumors in patients undergoing radical prostatectomy.",Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization,9524253,R01CA218187,"['Affect ', ' Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Classification ', ' Systematics ', ' Diagnosis ', ' Discrimination ', ' Cognitive Discrimination ', ' Disease ', ' Disorder ', ' Gold ', ' Hand ', ' Hybrids ', ' Interobserver Variability ', ' Interobserver Variations ', ' Inter-Observer Variation ', ' Inter-Observer Variability ', ' Kinetics ', ' Life Expectancy ', ' Ligands ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Maps ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Patients ', ' Pelvis ', ' Pelvic Region ', ' Pelvic ', ' Phenotype ', ' Positron-Emission Tomography ', ' positron emitting tomography ', ' positron emission tomographic imaging ', ' positron emission tomographic (PET) imaging ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Quality of life ', ' QOL ', ' Computer software ', ' Software ', ' Testing ', ' Time ', ' Translations ', ' Work ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Data Set ', ' Dataset ', ' Guidelines ', ' base ', ' human subject ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' skeletal imaging ', ' bone scanning ', ' bone imaging ', ' Biological ', ' Physiologic ', ' Physiological ', ' Lesion ', ' Individual ', ' Measurement ', ' Patient Selection ', ' radiologist ', ' Metabolic ', ' Morphology ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Scanning ', ' Source ', ' Early Diagnosis ', ' early detection ', ' Performance ', ' radiotracer ', ' radiolabel ', ' diagnostic accuracy ', ' Accuracy of Diagnosis ', ' attenuation ', ' Histopathology ', ' new technology ', ' novel technologies ', ' Modality ', ' Devices ', ' Modeling ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' cancer classification ', ' imaging modality ', ' imaging method ', ' image-based method ', ' FOLH1 gene ', ' Prostate-Specific Membrane Antigen ', ' PSMA ', ' PSM ', ' NAALADase I ', ' NAALAD1 ', ' N-Acetylated Alpha-Linked Acidic Dipeptidase 1 ', ' Glutamate Carboxypeptidase II ', ' GCP2 ', ' Folate Hydrolase 1 ', ' FOLH1 ', ' FOLH ', ' Address ', ' Data ', ' Reproducibility ', ' Cancer Death Rates ', ' Cancer Patient ', ' Transmission ', ' transmission process ', ' imaging ', ' Image ', ' cancer research ', ' anti-cancer research ', ' anticancer research ', ' tumor imaging ', ' oncology imaging ', ' oncologic imaging ', ' cancer imaging ', ' data acquisition ', ' clinical relevance ', ' clinically relevant ', ' clinical significance ', ' clinically significant ', ' clinical applicability ', ' clinical application ', ' early therapy ', ' Early treatment ', ' tumor ', ' multimodality ', ' industry partnership ', ' industrial partnership ', ' industry partner ', ' noninvasive imaging ', ' non-invasive imaging ', ' Patient risk ', ' radiomics ', ' deep learning ', ' ']",NCI,MASSACHUSETTS GENERAL HOSPITAL,R01,2018,684119,MA-08,0.1245754745824329
"Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning DESCRIPTION (provided by applicant): Few biomarkers derived from genome scale data have translated into improved clinical classification of cancer subtypes, in spite of the wealth of available genome-wide studies and of the corresponding application of numerous statistical algorithms. This widespread shortcoming derives from the pervasive use of ""off the shelf"" algorithms and machine learning techniques developed for image classification and language processing, which are nave of the underlying biology of the system. Furthermore, for genome-wide data, the number of samples is often small relative to the number of potential candidate biomarkers, resulting in variable accuracy on independent test data despite high accuracy in the samples used for discovery, which contributes to the failure of clinical biomarkers. This problem - so called ""curse of dimensionality"" - is further exacerbated by the prohibitive cost of dramatically increasing sample size and by patient stratification into smaller subgroups for personalized and precision medicine. Disease phenotypes arise from distinct and specific perturbations in selected networks and pathways defined by the interactions of their molecular constituents. In cancer, these perturbations may reside in gene regulatory networks topology and state, in cell signaling activity, or in metabolic conditions. We hypothesize that by leveragin such prior biological information on cancer biology we will be able to reduce model complexity and build mechanistically justified predictive models. To pursue this hypothesis, we will develop an analytical framework to embed mechanistic constraints derived from network biology into the statistical learning process itself. Hence, this application will develop a novel suite of statistial learning algorithms that embed (Aim 1) gene expression regulatory networks, (Aim 2) cell signaling activity, and (Aim 3) metabolism to classify breast and prostate cancer. Throughout the study we will work closely with clinical collaborators to ensure that our method improve over and above current predictive and prognostic models. Finally, since in our study we will also generate mechanistic classifiers based on gene expression measurements obtained from clinical assays that are already commercially available (i.e., MammaPrint, and Decipher), our innovative models and predictors will be also readily available for clinical translation. Our mechanism-driven classifiers will simultaneously have greater accuracy and interpretability than classifiers developed without regard for the underlying biology of the disease. Furthermore, embedding biological mechanisms in the classifiers will also facilitate the identification of alternative therapeutic targets specific to each cancer subtype, potentially improving patient prognosis and health outcomes. Finally, the substantial curation of molecular pathways and biological networks we will carry on in the project will also provide a powerful resource for futur studies, and the methodologies we will develop will be also applicable to other cancer and other human diseases, like neurodegenerative disorders, hearth disease, and diabetes. PUBLIC HEALTH RELEVANCE    Project Narrative This study will use mechanistic biological knowledge to implement a suite of statistical algorithms for cancer patient classification, which will also reveal the biological reasoning behind the classification decision rules. In the study we will also apply our novel methods to develop improved biomarkers for breast and prostate cancer patient clinical stratification, with the ultimate goal of facilitating the selection of appropriate treatment. To achieve this goal we will directly improve the existing commercial tests offered to the patients, with an immediate clinical impact, since our biomarkers will be directly implementable into these assays, with the potential to quickly reach the bedside.",Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning,9447142,R01CA200859,"['Cells ', ' Cell Body ', ' Classification ', ' Systematics ', ' Complement ', ' Complement Proteins ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Energy Metabolism ', ' Energy Expenditure ', ' Feedback ', ' Gene Expression ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Goals ', ' Health ', ' Learning ', ' Drug Metabolic Detoxication ', ' detoxification ', ' Metabolism of Toxic Agents ', ' Metabolic Drug Detoxications ', ' Drug Metabolic Detoxification ', ' Metabolism ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Methods ', ' Methodology ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' research and development ', ' R&D ', ' R & D ', ' Development and Research ', ' Research Design ', ' study design ', ' Study Type ', ' Resources ', ' Research Resources ', ' Signal Pathway ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' statistics ', ' Testing ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Translating ', ' Work ', ' base ', ' improved ', ' Clinical ', ' Biological ', ' Biochemical ', ' Ensure ', ' Failure ', ' Data Quality ', ' Measurement ', ' Sample Size ', ' Metabolic Networks ', ' Biochemical Pathway ', ' Space Models ', ' Metabolic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' Dimensions ', ' Complex ', ' Side ', ' Techniques ', ' Neurodegenerative Disorders ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' functional group ', ' cohort ', ' novel ', ' Modeling ', ' Sampling ', ' cancer classification ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Address ', ' Systems Biology ', ' Data ', ' Detection ', ' Measurable ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Subgroup ', ' Cancer Biology ', ' Cancer Patient ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' cost ', ' cancer research ', ' anti-cancer research ', ' anticancer research ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' Outcome ', ' innovative ', ' innovate ', ' innovation ', ' resistant ', ' Resistance ', ' clinical relevance ', ' clinically relevant ', ' open source ', ' human disease ', ' language processing ', ' chemotherapy ', ' therapeutic target ', ' treatment design ', ' intervention design ', ' therapy design ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' genome-wide analysis ', ' public health relevance ', ' candidate biomarker ', ' candidate marker ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' genomewide ', ' genome scale ', ' genome-wide ', ' biological systems ', ' Knowledge Discovery ', ' Statistics Algorithm ', ' Statistical Algorithm ', ' precision-based medicine ', ' precision medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' biomarker development ', ' stratified patient ', ' patient stratification ', ' clinically useful biomarkers ', ' clinical biomarkers ', ' precision health care ', ' personalized health care ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' cancer sub-types ', ' cancer subtypes ', ' predictor of clinical outcome ', ' clinical outcome prediction ', ' predict clinical outcome ', ' predictive signature ', ' Clinical stratification ', ' clinical translation ', ' high dimensionality ', ' clinical implementation ', ' Algorithms ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2018,384981,MD-07,0.10256685329278825
"Statistical Genetics and Genomics for Epidemiologic Research Project Summary/Abstract Genome-wide association studies have identi ed an unprecedented number of genetic variants associated with disease risk, yet molecular mechanisms and clinical implications of genetic risk alleles are largely unknown. Epidemiologic research is extending its reach to more translational and mechanistic studies, integrating genetic risk variants with environmental exposures, interventions, gene expression and epigenetics. Motivated by population-based studies for prostate cancer research, we will develop statistical methods for emerging translational topics: how to search for genotypes that predict individual and subgroup intervention e ects? how to identify epigenetic alterations that may be an interface of the environment and the genome? how to assess causal mediation e ect of a modi able risk factor or a molecular alteration in relation to disease outcomes? These topics present unmet statistical challenges because of high dimensionality and complex modeling. Speci c statistical methods to be developed include high-dimensional gene- treatment interaction, multi-locus regional association, mediation analyses, instrumental variable analyses, Mendelian randomization, and shrinkage and regularization.  The methodological research in this project is driven primarily by prostate cancer, the most common noncutaneous cancer and the second leading cause of cancer death in American men, a ecting one in six in his lifetime. This project nests in highly-accomplished consortium studies (PCPT/SELECT/PRACTICAL/PCPS), all of which have generated far-reaching impact on prostate cancer research. The unique feature of this project is that methodological development will be seamlessly integrated with ongoing analyses, ensuring immediate translation. Our transdisciplinary research team has been actively engaged in statistical genetics and genomics, and conducting molecular epidemiological studies. The PI brings a wealth of expertise in high-dimensional methods, molecular biomarkers, and genetic epidemiology. This project will have a far-reaching impact on methodologies in cancer etiology, prevention, and treatment outcomes. Project Narrative In this project we will develop a suite of statistical methodologies for dissecting the multi-faceted role of genetics and genomics in modern epidemiology, and perform innovative analyses in well-characterized extant populations for prostate cancer research. The methodological topics include precision prevention based on individual genetic susceptibility, epigenetic alterations as the interface of the environment and the genome, and causal inference and mediation.",Statistical Genetics and Genomics for Epidemiologic Research,9597142,R01CA222833,"['Alcohol consumption ', ' ethanol use ', ' ethanol product use ', ' ethanol intake ', ' ethanol ingestion ', ' ethanol drinking ', ' ethanol consumption ', ' alcoholic drink intake ', ' alcoholic beverage consumption ', ' alcohol use ', ' alcohol product use ', ' alcohol intake ', ' alcohol ingestion ', ' alcohol consumed ', ' EtOH use ', ' EtOH drinking ', ' Alcohol Drinking ', ' Beds ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cations ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Environment ', ' Environmental Exposure ', ' Epidemiology ', ' epidemiological ', ' epidemiologic ', ' Exercise ', ' Gene Expression ', ' Genes ', ' Genetic Markers ', ' genetic biomarker ', ' Genome ', ' Genotype ', ' Incidence ', ' Life Style ', ' Lifestyle ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Methylation ', ' Modernization ', ' mortality ', ' Neoplasm Metastasis ', ' tumor cell metastasis ', ' cancer metastasis ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastatic Mass ', ' Metastatic Lesion ', ' Metastasize ', ' Metastasis ', ' Public Health ', ' Research ', ' Risk Factors ', ' Role ', ' social role ', ' Smoking ', ' Translating ', ' Translations ', ' Insulin-Like Growth-Factor-Binding Proteins ', ' insulinlike growth factor binding protein ', ' Somatomedin-Binding Proteins ', ' IGFBP ', ' IGF-Binding Proteins ', ' Measures ', ' Treatment outcome ', ' Research Methodology ', ' Research Methods ', ' base ', ' Clinical ', ' Variation ', ' Variant ', ' Ensure ', ' Indolent ', ' Individual ', ' prevent prostate cancer ', ' Prostate CA Prevention ', ' prostate cancer prevention ', ' Chemoprevention ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetically predisposed ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' tool ', ' Diagnostic ', ' The Sun ', ' sun ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' DNA Methylation ', ' Complex ', ' Tumor Tissue ', ' American ', ' blood lipid ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' success ', ' cohort ', ' Primary Neoplasm ', ' Primary Tumor ', ' Disease Outcome ', ' novel ', ' Mediation ', ' Negotiation ', ' Negotiating ', ' Population Study ', ' study of the population ', ' studies of populations ', ' population-level study ', ' population-based study ', ' disorder risk ', ' disease risk ', ' drinking ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Prevention ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' International ', ' Prognostic Marker ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prostate Cancer Prevention Trial ', ' Randomized ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Subgroup ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Prognosis ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Genetic Risk ', ' lifestyle factors ', ' Selenium and Vitamin E Cancer Prevention Trial ', ' Selenium and Vitamin E Efficacy Trial ', ' SWOG ', ' Southwest Oncology Group ', ' Transcription Alteration ', ' Molecular ', ' developmental ', ' Development ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' neglect ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' cancer research ', ' anti-cancer research ', ' anticancer research ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' Outcome ', ' Guide prevention ', ' Population ', ' prostate cancer treatment ', ' Prostate CA therapy ', ' Prostate Cancer therapy ', ' innovative ', ' innovate ', ' innovation ', ' PSA test ', ' PSA screening ', ' tumor ', ' discover genes ', ' gene discovery ', ' high risk ', ' population based ', ' molecular biomarker ', ' molecular marker ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' genomewide ', ' genome scale ', ' genome-wide ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' epigenetic biomarker ', ' epigenetic marker ', ' precision treatment ', ' precision therapies ', ' Precision therapeutics ', ' precision prevention ', ' personalized prevention ', ' individualized prevention ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' predictive marker ', ' Patient risk ', ' methylation marker ', ' methylation biomarker ', ' Genetic study ', ' high dimensionality ', ' prostate cancer risk ', ' over-treatment ', ' overtreatment ', ' ']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,R01,2018,439543,WA-07,0.17367351812539844
"Methods and Tools for Integrating Pathomics Data into Cancer Registries ThegoalofthisprojectistoenrichSEERregistrydatawithhighqualitypopulationbased biospecimendataintheformofdigitalpathology,machinelearningbasedclassificationsand quantitativepathomicsfeaturesets.Wewillcreateawellcuratedrepositoryofhighquality digitizedpathologyimagesforsubjectswhosedataisbeingcollectedbytheregistries.These imageswillbeprocessedtoextractcomputationalfeaturesandestablishdeeplinkageswith registrydata,thusenablingthecreationofinformationrich,populationcohortscontaining objectiveimagingandclinicalattributes.SpecificexamplesofdigitalPathologyderivedfeature setsincludequantificationoftumorinfiltratinglymphocytesandsegmentationand characterizationofcancerorstromalnuclei.Featureswillalsoincludespectralandspatial signaturesoftheunderlyingpathology.Thescientificpremiseforthisapproachstemsfrom increasingevidencethatinformationextractedfromdigitizedpathologyimages (pathomicfeatures)areaquantitativesurrogateofwhatisdescribedinapathologyreport.The importantdistinctionbeingthatthesefeaturesarequantitativeandreproducible,unlikehuman observationsthatarehighlyqualitativeandsubjecttoahighdegreeofinterandintraobserver variability.Thisdatasetwillprovide,aunique,populationwidetissuebasedviewofcancer, anddramaticallyaccelerateourunderstandingofthestagesofdiseaseprogression,cancer outcomes,andpredictandassesstherapeuticeffectiveness. ThisworkwillbecarriedoutincollaborationwiththreeSEERregistries.Wewillpartner withTheNewJerseyStateCancerRegistryduringthedevelopmentphaseoftheproject(UG3). Duringthevalidationphaseoftheproject(UH3),theGeorgiaandKentuckyStateCancer Registrieswilljointheproject.Theinfrastructurewillbedevelopedinclosecollaborationwith SEERregistriestoensureconsistencywithregistryprocesses,scalabilityandabilitysupport creationofpopulationcohortsthatspanmultipleregistries.Wewilldeployvisualanalytictools tofacilitatethecreationofpopulationcohortsforepidemiologicalstudies,toolstosupport visualizationoffeatureclustersandrelatedwholeslideimageswhileprovidingadvanced algorithmsforconductingcontentbasedimageretrieval.Thescientificvalidationofthe proposedenvironmentwillbeundertakenthroughthreestudiesinProstateCancer,Lymphoma andNSCLC,ledbyinvestigatorsatthethreesites.   ThegoalofthisprojectistoenrichSEERcancerregistrydatawithhighqualitypopulationbased informationarisingfromdigitizedPathologyslides.Dataextracteddirectlyfromdigitized pathologyimages(Pathomicsdata)promisetoprovideinformationnotconsistentlyavailable fromPathologyreports.Thisdatasetwillprovide,aunique,populationwidetissuebasedview ofcancer,anddramaticallyaccelerateourunderstandingofthestagesofdiseaseprogression, canceroutcomes,andpredictandassesstherapeuticeffectiveness.Thescientificvalidationof theproposedenvironmentwillbeundertakenthroughthreestudiesinProstateCancer, LymphomaandNSCLC,ledbyinvestigatorsatthethreesites.  ",Methods and Tools for Integrating Pathomics Data into Cancer Registries,9472634,UG3CA225021,"['Kentucky ', ' Lymphoma ', ' Reticulolymphosarcoma ', ' Malignant Lymphoma ', ' Germinoblastoma ', ' Germinoblastic Sarcoma ', ' Maps ', ' Methods ', ' Methodology ', ' Modernization ', ' New Jersey ', ' Pathology ', ' Patients ', ' Perception ', ' Phenotype ', ' Registries ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Science ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Work ', ' Tumor-Infiltrating Lymphocytes ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Site ', ' Area ', ' Clinical ', ' Phase ', ' Link ', ' Ensure ', ' prognostic ', ' Visual ', ' Disease Progression ', ' Collaborations ', ' Morphology ', ' tool ', ' Diagnostic ', ' Specimen ', ' Research Specimen ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Investigation ', ' Slide ', ' Texture ', ' Nuclear ', ' Transcend ', ' interest ', ' data management ', ' cohort ', ' Informatics ', ' Histopathology ', ' validation studies ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' neoplasm registry ', ' cancer registry ', ' Pathology Report ', ' response ', ' repository ', ' Data ', ' Imaging Device ', ' Imaging Tool ', ' Imaging Instrument ', ' Reproducibility ', ' Research Infrastructure ', ' Infrastructure ', ' Resolution ', ' Retrieval ', ' Clinical Data ', ' Scientific Evaluation ', ' Tumor Subtype ', ' Validation ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' tumor registry ', ' image visualization ', ' Advanced Development ', ' Outcome ', ' scale up ', ' Population ', ' analytical tool ', ' computational resources ', ' computing resources ', ' therapeutic effectiveness ', ' picture archive ', ' image library ', ' image archive ', ' image archival system ', ' stem ', ' prototype ', ' tumor ', ' patient population ', ' population based ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' computational infrastructure ', ' computer infrastructure ', ' data registry ', ' Software Algorithm ', ' Algorithmic Tools ', ' Algorithmic Software ', ' precision-based medicine ', ' precision medicine ', ' stratified patient ', ' patient stratification ', ' informatics infrastructure ', ' whole slide imaging ', ' digital pathology ', ' pathology imaging ', ' Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Non-Small-Cell Lung Carcinoma ', ' nonsmall cell lung cancer ', ' Non-Small Cell Lung Cancer ', ' NSCLC - Non-Small Cell Lung Cancer ', ' NSCLC ', ' Cell Nucleus ', ' Nucleus ', ' Classification ', ' Systematics ', ' Cohort Studies ', ' Concurrent Studies ', ' Communities ', ' Cues ', ' Disease ', ' Disorder ', ' Environment ', ' Evaluation Studies ', ' Exhibits ', ' Eye ', ' Eyeball ', ' Goals ', ' Human ', ' Modern Man ', ' Intraobserver Variability ', ' Intraobserver Variations ', ' Intra-Observer Variation ', ' Intra-Observer Variability ', ' ']",NCI,STATE UNIVERSITY NEW YORK STONY BROOK,UG3,2018,430543,NY-01,0.1028834122112105
"High speed automated intraoperative microscopy of the prostate circumference to ensure tumor-free margins in radical prostatectomy Project Summary: In prostate cancer (PCa), the presence and amount of residual tumor at the surface of the excised prostate is the only prognostic factor that is affected by surgical technique, vs. other factors, which are fixed and non-modifiable. Yet, positive surgical margins (PSM), defined as the presence of tumor cells at the inked surface of the removed specimen, are common, especially in advanced stage cancers, and are a strong independent risk factor for clinical progression and secondary treatment. In addition, elevated post-operative PSA, which is understood to be related to tumor left behind in the patient, is also associated with high risk of progression and secondary treatment. Thus, complete tumor removal is important to achieve to improve pa- tient outcomes and reduce overtreatment, yet there is a delicate balance between resection radicality and min- imizing damage to the neurovascular bundles to preserve post-operative function. The NeuroSAFE trial demonstrated that real-time detection and correction of PSMs by comprehensive histology of the prostate cir- cumference results in improved patient outcomes, yet there are no widely adoptable methods to achieve this. In an effort to address this technical gap, we have developed video-rate structured illumination microscopy (VR-SIM) and demonstrated that it enables accurate diagnosis of PCa in the biopsy setting, and that it can rap- idly deliver gigapixel microscopic images of the entire prostate surface for detection of PSMs. VR-SIM delivers the surface area coverage and resolution needed to detect PSMs, yet it is also fast and relatively simple and inexpensive, opening the possibility for widespread adoption. In this project, our interdisciplinary team of engi- neers and clinicians with significant prostate expertise will further advance this technology towards clinical translation, by completing critical technology development steps and by prospectively validating it in a large patient series. Specifically, we will increase the mechanical automation speed of the device, and will develop a fully automated system for handling of the removed prostate, to enable gigapixel panoramas of the entire pros- tate circumferential surface to be delivered within 10 minutes of removal and with minimal tissue processing and user intervention. We will then leverage our recently developed dual-color fluorescent stain that replicates standard H&E with high specificity, to develop expert-validated clinical image atlases using biopsies and ca- daveric specimens to enhance image interpretation of VR-SIM prostate panoramas. These improvements will be combined to test the system in a prospective 250-patient clinical study, to determine the accuracy of the device for intra-operative detection of PSMs and prediction of post-operative PSA based on measurement of PSM extent. Finally, we will measure and model expert reviewer behavior using a novel web-enabled visual observer tracking method, which could be used in future computer-assisted search algorithms to expedite in- tra-operative image review. Successful completion will set the stage for multi-center clinical trials to validate the clinical utility of VR-SIM for real-time detection and correction of PSMs, and improvement of patient outcomes. Project Narrative: Achieving complete tumor removal in prostate cancer is an important goal to achieve because leaving tumor behind in the patient contributes to increased risk of cancer progression and need for additional harmful treatment. Yet, it is difficult to determine in real-time if surgery is successful due to the lack of available technologies for intra-operative guidance. This project will develop a rapid scanner that will automatically scan the entire prostate surface for residual tumor within 10 minutes of removal, providing images which are readily interpreted by trained pathologists and enabling real-time guidance of nerve-sparing prostate cancer surgery.",High speed automated intraoperative microscopy of the prostate circumference to ensure tumor-free margins in radical prostatectomy,9604121,R01CA222831,"['Adoption ', ' Affect ', ' Algorithms ', ' Atlases ', ' Automation ', ' Behavior ', ' Biopsy ', ' Cadaver ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' Color ', ' Equilibrium ', ' balance function ', ' balance ', ' Frozen Sections ', ' Freeze Sectioning ', ' Future ', ' Goals ', ' Gold ', ' Histology ', ' Human ', ' Modern Man ', ' Image Enhancement ', ' Ink ', ' Lighting ', ' Illumination ', ' Manuals ', ' men ', "" men's "", ' Methods ', ' Microscopy ', ' Nerve ', ' Online Systems ', ' web based ', ' online computer ', ' On-Line Systems ', ' Operating Rooms ', ' Optics ', ' optical ', ' Pathology ', ' Patients ', ' Postoperative Period ', ' Postoperative ', ' Post-Operative ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostatic Neoplasms ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Risk Factors ', ' Sensitivity and Specificity ', ' Specificity ', ' Stains ', ' Staining method ', ' Technology ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Translations ', ' Genitourinary system ', ' Urogenital System ', ' Urogenital ', ' Genitourinary ', ' Work ', ' Generations ', ' Measures ', ' Case Series ', ' Custom ', ' base ', ' Organ ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' improved ', ' prostate surgery ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' Left ', ' Site ', ' Area ', ' Surface ', ' Clinical ', ' Series ', ' Ensure ', ' Training ', ' Surgical margins ', ' Visual ', ' Measurement ', ' Progression-Free Survivals ', ' analog ', ' Pathologist ', ' tool ', ' Diagnostic ', ' Specimen ', ' Research Specimen ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Mechanics ', ' mechanical ', ' Adopted ', ' Surface of the Prostate ', ' Surface of Human Prostate ', ' Scanning ', ' Pattern ', ' Techniques ', ' System ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Residual Tumors ', ' residual disease ', ' cancer risk ', ' neoplastic cell ', ' Tumor Cell ', ' authority ', ' cohort ', ' technology development ', ' tech development ', ' Speed ', ' Structure ', ' novel ', ' Devices ', ' Excision ', ' resection ', ' Surgical Removal ', ' Removal ', ' Extirpation ', ' Abscission ', ' Modeling ', ' Sampling ', ' visual search ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' cancer surgery ', ' cancer diagnosis ', ' Image-Guided Surgery ', ' surgical imaging ', ' intraoperative imaging ', ' intra-operative imaging ', ' tissue processing ', ' Address ', ' Data ', ' Detection ', ' Multi-Institutional Clinical Trial ', ' multi site clinical trial ', ' multi site clinical study ', ' multi center clinical trial ', ' multi center clinical study ', ' Multi-site clinical trial ', ' Multi-site clinical study ', ' Multi-center clinical trial ', ' Multi-center clinical study ', ' Prognostic Factor ', ' Prognostic/Survival Factor ', ' General Prognostic Factor ', ' Resolution ', ' Clinical Management ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' Validation ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' computer aided ', ' Computer Assisted ', ' rapid detection ', ' Outcome ', ' tumor imaging ', ' oncology imaging ', ' oncologic imaging ', ' cancer imaging ', ' prospective ', ' web-enabled ', ' computer algorithm ', ' Computational algorithm ', ' tumor ', ' high risk ', ' clinical practice ', ' computer assisted detection ', ' computer aided detection ', ' accurate diagnosis ', ' imaging system ', ' contrast imaging ', ' neuro-vascular ', ' neurovascular ', ' microscopy imaging ', ' microscope imaging ', ' microscopic imaging ', ' histologic image ', ' histological image ', ' clinical imaging ', ' clinical translation ', ' recruit ', ' over-treatment ', ' overtreatment ', ' ']",NCI,TULANE UNIVERSITY OF LOUISIANA,R01,2018,456329,LA-01,0.19686915803704205
"Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy PROJECT SUMMARY/ABSTRACT Prostate cancer is the second leading cause of cancer death in American men, accounting for 26% of new cancer diagnoses and 9% of cancer deaths in men. Active surveillance, radical prostatectomy and radiotherapy are commonly used treatments for clinically localized prostate cancer. However, current risk stratification methods cannot be used effectively to avoid subjecting patients with clinically indolent cancers to unnecessary interventions, causing significant morbidity and cost. The primary components currently involved in screening are the digital rectal exam (DRE) and serum biomarkers, such as PSA, PCA3, PHI, and 4Kscore. Unfortunately, despite advances in these tests, overdiagnosis remains a major problem due to limited specificity. As a result, 90% of patients diagnosed with prostate cancer receive treatment, even though up to 60% of those patients could be candidates for active surveillance. Such treatment often results in long-term reductions in functional outcomes. The research objective of this R21 is to develop novel techniques using multiparametric magnetic resonance imaging (mp-MRI) and MRI-ultrasound (US) fusion guided biopsy data that provide discriminatory power in distinguishing indolent versus clinically significant prostatic adenocarcinoma based on non-invasive imaging. We propose to implement a multi-instance learning (MIL) based convolutional neural network (CNN) model for clinical prostate mp-MRI sequences to generate new quantitative imaging features representative of the underlying tissue. Our MIL-CNN model will accommodate ground truth labels from pathology whole mount specimens, as well as MRI-US fusion biopsy results. Hierarchical CNN features will be used to predict voxel- level cancer suspicion, thereby enabling a novel method for performing imaging biopsy. Finally, voxel-level suspicion maps will be aggregated into patient-level quantitative imaging biomarkers and combined with clinical data to create a multimodal nomogram for performing risk stratification. RELEVANCE TO PUBLIC HEALTH Prostate cancer is the second leading cause of cancer death in American men, accounting for 26% of new cancer diagnoses and 9% of cancer deaths in men. The focus of this research is to investigate new methods for distinguishing indolent from aggressive prostate cancer through the use of medical imaging and data min- ing, thus preventing patients from receiving unnecessary treatment and incurring associated negative function- al outcomes.",Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy,9604227,R21CA220352,"['Accounting ', ' Architecture ', ' Engineering / Architecture ', ' Biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Prostate Adenocarcinoma ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Classification ', ' Systematics ', ' Clinical Trials ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Goals ', ' Hospitals ', ' Learning ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Manuals ', ' Maps ', ' Medical Imaging ', ' men ', "" men's "", ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Pathology ', ' Patients ', ' Probability ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Public Health ', ' Radiology Specialty ', ' Radiology ', ' General Radiology ', ' Radiation therapy ', ' treatment with radiation ', ' radio-therapy ', ' radiation treatment ', ' Radiotherapy ', ' Radiotherapeutics ', ' Research ', ' Risk ', ' Risk Factors ', ' Savings ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Specificity ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Ultrasonography ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Work ', ' Prostate-Specific Antigen ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Data Set ', ' Dataset ', ' Guidelines ', ' base ', ' Label ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' rectal ', ' Clinical ', ' Evaluation ', ' Training ', ' Blood Serum ', ' Serum ', ' Indolent ', ' Individual ', ' radiologist ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' tool ', ' Specimen ', ' Research Specimen ', ' Transrectal Ultrasound ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Physiologic pulse ', ' Pulse ', ' Diagnostic Procedure ', ' Diagnostic Technique ', ' Diagnostic Method ', ' Severities ', ' Complex ', ' Slide ', ' Pattern ', ' Techniques ', ' Location ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' interest ', ' American ', ' digital imaging ', ' computer imaging ', ' Performance ', ' Biological Neural Networks ', ' neural network ', ' treatment planning ', ' novel ', ' Localized Malignant Neoplasm ', ' Localized Malignancy ', ' Localized Cancer ', ' Local Cancer ', ' Modeling ', ' Neural Network Simulation ', ' Perceptrons ', ' Neural Network Models ', ' Connectionist Models ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer diagnosis ', ' Institution ', ' prevent ', ' preventing ', ' Core Biopsy ', ' Core Needle Biopsy ', ' data mining ', ' datamining ', ' Nomograms ', ' Data ', ' Detection ', ' National Comprehensive Cancer Network ', ' NCCN ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Clinical Data ', ' trial treatment ', ' trial regimen ', ' Clinical Treatment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' Electronic Health Record ', ' imaging ', ' Image ', ' cost ', ' digital ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' image registration ', ' functional outcomes ', ' Outcome ', ' tumor imaging ', ' oncology imaging ', ' oncologic imaging ', ' cancer imaging ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' clinical significance ', ' clinically significant ', ' multimodality ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' screening ', ' noninvasive imaging ', ' non-invasive imaging ', ' clinical predictors ', ' Patient risk ', ' quantitative imaging ', ' imaging marker ', ' imaging biomarker ', ' stratified patient ', ' patient stratification ', ' unnecessary treatment ', ' Risk stratification ', ' prostate cancer risk ', ' digital pathology ', ' deep learning ', ' ']",NCI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R21,2018,195568,CA-33,0.32169892514983894
"Methods and Tools for Integrating Pathomics Data into Cancer Registries ThegoalofthisprojectistoenrichSEERregistrydatawithhighqualitypopulationbased biospecimendataintheformofdigitalpathology,machinelearningbasedclassificationsand quantitativepathomicsfeaturesets.Wewillcreateawellcuratedrepositoryofhighquality digitizedpathologyimagesforsubjectswhosedataisbeingcollectedbytheregistries.These imageswillbeprocessedtoextractcomputationalfeaturesandestablishdeeplinkageswith registrydata,thusenablingthecreationofinformationrich,populationcohortscontaining objectiveimagingandclinicalattributes.SpecificexamplesofdigitalPathologyderivedfeature setsincludequantificationoftumorinfiltratinglymphocytesandsegmentationand characterizationofcancerorstromalnuclei.Featureswillalsoincludespectralandspatial signaturesoftheunderlyingpathology.Thescientificpremiseforthisapproachstemsfrom increasingevidencethatinformationextractedfromdigitizedpathologyimages (pathomicfeatures)areaquantitativesurrogateofwhatisdescribedinapathologyreport.The importantdistinctionbeingthatthesefeaturesarequantitativeandreproducible,unlikehuman observationsthatarehighlyqualitativeandsubjecttoahighdegreeofinterandintraobserver variability.Thisdatasetwillprovide,aunique,populationwidetissuebasedviewofcancer, anddramaticallyaccelerateourunderstandingofthestagesofdiseaseprogression,cancer outcomes,andpredictandassesstherapeuticeffectiveness. ThisworkwillbecarriedoutincollaborationwiththreeSEERregistries.Wewillpartner withTheNewJerseyStateCancerRegistryduringthedevelopmentphaseoftheproject(UG3). Duringthevalidationphaseoftheproject(UH3),theGeorgiaandKentuckyStateCancer Registrieswilljointheproject.Theinfrastructurewillbedevelopedinclosecollaborationwith SEERregistriestoensureconsistencywithregistryprocesses,scalabilityandabilitysupport creationofpopulationcohortsthatspanmultipleregistries.Wewilldeployvisualanalytictools tofacilitatethecreationofpopulationcohortsforepidemiologicalstudies,toolstosupport visualizationoffeatureclustersandrelatedwholeslideimageswhileprovidingadvanced algorithmsforconductingcontentbasedimageretrieval.Thescientificvalidationofthe proposedenvironmentwillbeundertakenthroughthreestudiesinProstateCancer,Lymphoma andNSCLC,ledbyinvestigatorsatthethreesites.   ThegoalofthisprojectistoenrichSEERcancerregistrydatawithhighqualitypopulationbased informationarisingfromdigitizedPathologyslides.Dataextracteddirectlyfromdigitized pathologyimages(Pathomicsdata)promisetoprovideinformationnotconsistentlyavailable fromPathologyreports.Thisdatasetwillprovide,aunique,populationwidetissuebasedview ofcancer,anddramaticallyaccelerateourunderstandingofthestagesofdiseaseprogression, canceroutcomes,andpredictandassesstherapeuticeffectiveness.Thescientificvalidationof theproposedenvironmentwillbeundertakenthroughthreestudiesinProstateCancer, LymphomaandNSCLC,ledbyinvestigatorsatthethreesites.  ",Methods and Tools for Integrating Pathomics Data into Cancer Registries,9676988,UG3CA225021,"['Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Non-Small-Cell Lung Carcinoma ', ' nonsmall cell lung cancer ', ' Nonsmall Cell Lung Carcinoma ', ' Non-Small Cell Lung Cancer ', ' NSCLC - Non-Small Cell Lung Cancer ', ' NSCLC ', ' Nucleus ', ' Cell Nucleus ', ' Systematics ', ' Classification ', ' Concurrent Studies ', ' Cohort Studies ', ' Communities ', ' Cues ', ' Disorder ', ' Disease ', ' Environment ', ' Evaluation Studies ', ' Exhibits ', ' Eyeball ', ' Eye ', ' Goals ', ' Modern Man ', ' Human ', ' Intraobserver Variations ', ' Intra-Observer Variation ', ' Intra-Observer Variability ', ' Intraobserver Variability ', ' Kentucky ', ' Reticulolymphosarcoma ', ' Malignant Lymphoma ', ' Germinoblastoma ', ' Germinoblastic Sarcoma ', ' Lymphoma ', ' Maps ', ' Methods ', ' Methodology ', ' Modernization ', ' New Jersey ', ' Pathology ', ' Patients ', ' Perception ', ' Phenotype ', ' Registries ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Science ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Universities ', ' Work ', ' Tumor-Infiltrating Lymphocytes ', ' Dataset ', ' Data Set ', ' Imagery ', ' Visualization ', ' base ', ' improved ', ' Site ', ' Area ', ' Clinical ', ' Phase ', ' Link ', ' Ensure ', ' prognostic ', ' Visual ', ' Disease Progression ', ' Collaborations ', ' Morphology ', ' tool ', ' Diagnostic ', ' Specimen ', ' Research Specimen ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Investigation ', ' Slide ', ' Texture ', ' Nuclear ', ' Transcend ', ' interest ', ' data management ', ' cohort ', ' Informatics ', ' Histopathology ', ' validation studies ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' neoplasm registry ', ' cancer registry ', ' Pathology Report ', ' response ', ' repository ', ' Data ', ' Imaging Device ', ' Imaging Tool ', ' Imaging Instrument ', ' Reproducibility ', ' Resolution ', ' Retrieval ', ' Clinical Data ', ' Scientific Evaluation ', ' Tumor Subtype ', ' Validation ', ' Process ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' tumor registry ', ' image visualization ', ' Advanced Development ', ' Outcome ', ' scale up ', ' Population ', ' analytical tool ', ' computing resources ', ' computational resources ', ' therapeutic effectiveness ', ' image archival system ', ' picture archive ', ' image library ', ' image archive ', ' stem ', ' prototype ', ' tumor ', ' patient population ', ' population based ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' computer infrastructure ', ' computational infrastructure ', ' data registry ', ' Algorithmic Software ', ' Software Algorithm ', ' Algorithmic Tools ', ' precision medicine ', ' precision-based medicine ', ' patient stratification ', ' stratified patient ', ' informatics infrastructure ', ' whole slide imaging ', ' digital pathology ', ' pathology imaging ', ' Infrastructure ', ' ']",NCI,STATE UNIVERSITY NEW YORK STONY BROOK,UG3,2019,384048,NY-01,0.1028834122112105
"Statistical Genetics and Genomics for Epidemiologic Research Project Summary/Abstract Genome-wide association studies have identified an unprecedented number of genetic variants associated with disease risk, yet molecular mechanisms and clinical implications of genetic risk alleles are largely unknown. Epidemiologic research is extending its reach to more translational and mechanistic studies, integrating genetic risk variants with environmental exposures, interventions, gene expression and epigenetics. Motivated by population-based studies for prostate cancer research, we will develop statistical methods for emerging translational topics: how to search for genotypes that predict individual and subgroup intervention effects? how to identify epigenetic alterations that may be an interface of the environment and the genome? how to assess causal mediation effect of a modifiable risk factor or a molecular alteration in relation to disease outcomes? These topics present unmet statistical challenges because of high dimensionality and complex modeling. Specific statistical methods to be developed include high-dimensional gene- treatment interaction, multi-locus regional association, mediation analyses, instrumental variable analyses, Mendelian randomization, and shrinkage and regularization.  The methodological research in this project is driven primarily by prostate cancer, the most common noncutaneous cancer and the second leading cause of cancer death in American men, a ecting one in six in his lifetime. This project nests in highly-accomplished consortium studies (PCPT/SELECT/PRACTICAL/PCPS), all of which have generated far-reaching impact on prostate cancer research. The unique feature of this project is that methodological development will be seamlessly integrated with ongoing analyses, ensuring immediate translation. Our transdisciplinary research team has been actively engaged in statistical genetics and genomics, and conducting molecular epidemiological studies. The PI brings a wealth of expertise in high-dimensional methods, molecular biomarkers, and genetic epidemiology. This project will have a far-reaching impact on methodologies in cancer etiology, prevention, and treatment outcomes. Project Narrative In this project we will develop a suite of statistical methodologies for dissecting the multi-faceted role of genetics and genomics in modern epidemiology, and perform innovative analyses in well-characterized extant populations for prostate cancer research. The methodological topics include precision prevention based on individual genetic susceptibility, epigenetic alterations as the interface of the environment and the genome, and causal inference and mediation.",Statistical Genetics and Genomics for Epidemiologic Research,9746698,R01CA222833,"['Alcohol consumption ', ' ethanol use ', ' ethanol product use ', ' ethanol intake ', ' ethanol ingestion ', ' ethanol drinking ', ' ethanol consumption ', ' alcoholic drink intake ', ' alcoholic beverage consumption ', ' alcohol use ', ' alcohol product use ', ' alcohol intake ', ' alcohol ingestion ', ' EtOH use ', ' EtOH drinking ', ' Alcohol Drinking ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Coffee ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Environment ', ' Environmental Exposure ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Exercise ', ' Gene Expression ', ' Genes ', ' genetic biomarker ', ' Genetic Markers ', ' Genome ', ' Genotype ', ' Incidence ', ' Lifestyle ', ' Life Style ', "" men's "", ' men ', ' Methods ', ' Methodology ', ' Methylation ', ' Modernization ', ' mortality ', ' tumor cell metastasis ', ' cancer metastasis ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastatic Mass ', ' Metastatic Lesion ', ' Metastasize ', ' Metastasis ', ' Neoplasm Metastasis ', ' Patients ', ' Public Health ', ' Research ', ' Risk Factors ', ' social role ', ' Role ', ' Smoking ', ' Translating ', ' Translations ', ' insulinlike growth factor binding protein ', ' Somatomedin-Binding Proteins ', ' IGFBP ', ' IGF-Binding Proteins ', ' Insulin-Like Growth-Factor-Binding Proteins ', ' Measures ', ' Treatment outcome ', ' Research Methods ', ' Research Methodology ', ' base ', ' Clinical ', ' Variant ', ' Variation ', ' Ensure ', ' Indolent ', ' Individual ', ' prostate cancer prevention ', ' prevent prostate cancer ', ' Prostate CA Prevention ', ' Chemoprevention ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetically predisposed ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' tool ', ' Diagnostic ', ' The Sun ', ' sun ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' DNA Methylation ', ' Complex ', ' Tumor Tissue ', ' American ', ' blood lipid ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' success ', ' cohort ', ' Primary Neoplasm ', ' Primary Tumor ', ' alcohol effect ', ' ethanol effect ', ' Disease Outcome ', ' novel ', ' Mediation ', ' Negotiation ', ' Negotiating ', ' Population Study ', ' study of the population ', ' studies of populations ', ' population-level study ', ' population-based study ', ' disorder risk ', ' disease risk ', ' drinking ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Prevention ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' International ', ' Prognostic Marker ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prostate Cancer Prevention Trial ', ' Randomized ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Stratification ', ' Subgroup ', ' Cancer Etiology ', ' Cancer Cause ', ' Cancer Prognosis ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Genetic Risk ', ' lifestyle factors ', ' life-style factor ', ' Selenium and Vitamin E Efficacy Trial ', ' Selenium and Vitamin E Cancer Prevention Trial ', ' Southwest Oncology Group ', ' SWOG ', ' Transcription Alteration ', ' Molecular ', ' Development ', ' developmental ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' neglect ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' anticancer research ', ' cancer research ', ' anti-cancer research ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' Outcome ', ' Guide prevention ', ' Population ', ' Prostate Cancer therapy ', ' prostate cancer treatment ', ' Prostate CA therapy ', ' innovation ', ' innovative ', ' innovate ', ' modifiable risk ', ' treatment effect ', ' PSA screening ', ' PSA test ', ' tumor ', ' gene discovery ', ' discover genes ', ' high risk ', ' population based ', ' molecular marker ', ' molecular biomarker ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' genome-wide ', ' genomewide ', ' genome scale ', ' intervention effect ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' epigenetic marker ', ' epigenetic biomarker ', ' Precision therapeutics ', ' precision treatment ', ' precision therapies ', ' individualized prevention ', ' precision prevention ', ' personalized prevention ', ' predictive marker ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' methylation biomarker ', ' methylation marker ', ' Genetic study ', ' high dimensionality ', ' prostate cancer risk ', ' overtreatment ', ' over-treatment ', ' ']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,R01,2019,422105,WA-07,0.17547222096357562
"Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning DESCRIPTION (provided by applicant): Few biomarkers derived from genome scale data have translated into improved clinical classification of cancer subtypes, in spite of the wealth of available genome-wide studies and of the corresponding application of numerous statistical algorithms. This widespread shortcoming derives from the pervasive use of ""off the shelf"" algorithms and machine learning techniques developed for image classification and language processing, which are nave of the underlying biology of the system. Furthermore, for genome-wide data, the number of samples is often small relative to the number of potential candidate biomarkers, resulting in variable accuracy on independent test data despite high accuracy in the samples used for discovery, which contributes to the failure of clinical biomarkers. This problem - so called ""curse of dimensionality"" - is further exacerbated by the prohibitive cost of dramatically increasing sample size and by patient stratification into smaller subgroups for personalized and precision medicine. Disease phenotypes arise from distinct and specific perturbations in selected networks and pathways defined by the interactions of their molecular constituents. In cancer, these perturbations may reside in gene regulatory networks topology and state, in cell signaling activity, or in metabolic conditions. We hypothesize that by leveragin such prior biological information on cancer biology we will be able to reduce model complexity and build mechanistically justified predictive models. To pursue this hypothesis, we will develop an analytical framework to embed mechanistic constraints derived from network biology into the statistical learning process itself. Hence, this application will develop a novel suite of statistial learning algorithms that embed (Aim 1) gene expression regulatory networks, (Aim 2) cell signaling activity, and (Aim 3) metabolism to classify breast and prostate cancer. Throughout the study we will work closely with clinical collaborators to ensure that our method improve over and above current predictive and prognostic models. Finally, since in our study we will also generate mechanistic classifiers based on gene expression measurements obtained from clinical assays that are already commercially available (i.e., MammaPrint, and Decipher), our innovative models and predictors will be also readily available for clinical translation. Our mechanism-driven classifiers will simultaneously have greater accuracy and interpretability than classifiers developed without regard for the underlying biology of the disease. Furthermore, embedding biological mechanisms in the classifiers will also facilitate the identification of alternative therapeutic targets specific to each cancer subtype, potentially improving patient prognosis and health outcomes. Finally, the substantial curation of molecular pathways and biological networks we will carry on in the project will also provide a powerful resource for futur studies, and the methodologies we will develop will be also applicable to other cancer and other human diseases, like neurodegenerative disorders, hearth disease, and diabetes. PUBLIC HEALTH RELEVANCE    Project Narrative This study will use mechanistic biological knowledge to implement a suite of statistical algorithms for cancer patient classification, which will also reveal the biological reasoning behind the classification decision rules. In the study we will also apply our novel methods to develop improved biomarkers for breast and prostate cancer patient clinical stratification, with the ultimate goal of facilitating the selection of appropriate treatment. To achieve this goal we will directly improve the existing commercial tests offered to the patients, with an immediate clinical impact, since our biomarkers will be directly implementable into these assays, with the potential to quickly reach the bedside.",Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning,9653969,R01CA200859,"['Algorithms ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cell Body ', ' Cells ', ' Systematics ', ' Classification ', ' Complement Proteins ', ' Complement ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Energy Expenditure ', ' Energy Metabolism ', ' Feedback ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Goals ', ' Health ', ' Learning ', ' detoxification ', ' Metabolism of Toxic Agents ', ' Metabolic Drug Detoxications ', ' Drug Metabolic Detoxification ', ' Drug Metabolic Detoxication ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' Methods ', ' Methodology ', ' Patients ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' study design ', ' Study Type ', ' Research Design ', ' Research Resources ', ' Resources ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' statistics ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Translating ', ' Work ', ' base ', ' improved ', ' Clinical ', ' Biological ', ' Biochemical ', ' Ensure ', ' Failure ', ' Data Quality ', ' Measurement ', ' Sample Size ', ' Biochemical Pathway ', ' Metabolic Networks ', ' Space Models ', ' Metabolic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' Dimensions ', ' Complex ', ' Side ', ' Techniques ', ' Neurodegenerative Disorders ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' functional group ', ' cohort ', ' novel ', ' Modeling ', ' Sampling ', ' cancer classification ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Address ', ' Systems Biology ', ' Data ', ' Detection ', ' Measurable ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Subgroup ', ' Cancer Biology ', ' Cancer Patient ', ' Characteristics ', ' Molecular ', ' Process ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' Pathway interactions ', ' pathway ', ' disease phenotype ', ' cost ', ' anticancer research ', ' cancer research ', ' anti-cancer research ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' Resistance ', ' resistant ', ' clinically relevant ', ' clinical relevance ', ' open source ', ' human disease ', ' language processing ', ' chemotherapy ', ' therapeutic target ', ' therapy design ', ' treatment design ', ' intervention design ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' public health relevance ', ' candidate marker ', ' candidate biomarker ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' genome-wide ', ' genomewide ', ' genome scale ', ' biological systems ', ' Knowledge Discovery ', ' Statistical Algorithm ', ' Statistics Algorithm ', ' precision medicine ', ' precision-based medicine ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' biomarker development ', ' patient stratification ', ' stratified patient ', ' clinical biomarkers ', ' clinically useful biomarkers ', ' personalized health care ', ' precision healthcare ', ' precision health care ', ' personalized healthcare ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' cancer subtypes ', ' cancer sub-types ', ' predict clinical outcome ', ' predictor of clinical outcome ', ' clinical outcome prediction ', ' predictive signature ', ' Clinical stratification ', ' clinical translation ', ' high dimensionality ', ' clinical implementation ', ' learning algorithm ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2019,373431,MD-07,0.10256685329278825
"Real-time prostate lesion tracking during SBRT Multiple randomized clinical trials have shown that delivery of higher radiation doses to the prostate results in improved tumor control rates in prostate cancer radiation therapy (RT). As local recurrence mostly occurs at the primary tumor, particularly for high-risk patients, additional dose escalation is expected to improve the treatment outcome. However, the application of dose escalation for prostate RT is greatly limited by the tolerance of nearby healthy tissues that cannot adequately be excluded from the radiation field. This limitation can be overcome by dose painting, where a higher dose is applied to the prostate tumor only instead of the whole prostate gland. Stereotactic body radiation therapy (SBRT) offers reduced treatment time, convenience, and possibly increased treatment efficacy as compared to the conventionally fraction scheme. UTSW is currently conducting a dose escalation trial using SBRT for high-risk prostate cancer patients with an integrated dose boost on MRI-visualized prostate tumor. However, prostate can move and deform during the beam delivery. To ensure the escalated dose is actually delivered to tumor regions as planned, a reliable tumor tracking method is urgently needed. While intra-prostatic tumors can be identified by multi-parametric MRI (mpMRI) for treatment planning, intrafraction tumor tracking during the beam delivery is not achievable with mpMRI. In contrast, ultrasound offers a cost-effective and real-time imaging with high soft tissue contrast. However, conventional ultrasound techniques only provide anatomic structure of the prostate gland without the capability to differentiate tumor region from the rest of the prostate gland. Temporal enhanced ultrasound (TeUS) has emerged as a new paradigm for prostate tissue characterization by analyzing the time-series ultrasound images with advanced machine learning techniques. In this project, we aim to develop, optimize and evaluate an innovative TeUS based intra-prostatic tumor tracking method to guide SBRT with an integrated dose boost for high-risk prostate cancer patients. The specific aims are: 1) Develop TeUS-based intra-prostatic tumor delineation for guiding focused dose escalation; 2) Integrate and validate TeUS-based tumor tracking system during SBRT; and 3) Evaluate clinical gain of TeUS guided SBRT for high risk prostate cancer patients. Successful completion of the proposed project will lead to the development and validation of a low-cost yet highly accurate TeUS guided system for targeted prostate cancer RT. With enhanced real-time visualization of tumor, the use of TeUS for RT guidance will lead to better treatment efficacy and reduced toxicity. Delivery of higher radiation doses to the tumor region can improve outcome of radiation therapy for high-risk prostate cancer patients. As the prostate can move and deform during radiation beam delivery, there is an urgent need for a reliable method to ensure escalated dose is delivered to the tumor region as planned. We will develop, integrate and evaluate a novel prostate tumor tracking method based on temporal enhanced ultrasound (TeUS) to guide radiation therapy for high-risk patients, which will lead to higher local control with improved toxicity.",Real-time prostate lesion tracking during SBRT,9713860,R01EB027898,"['Aftercare ', ' post treatment ', ' After-Treatment ', ' After Care ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Biopsy ', ' Blood Vessels ', ' vascular ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' Motion ', ' Patients ', ' Probability ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' treatment with radiation ', ' radio-therapy ', ' radiation treatment ', ' Radiotherapy ', ' Radiotherapeutics ', ' Radiation therapy ', ' Rectum ', ' Recurrent ', ' Recurrence ', ' Rest ', ' Time ', ' Body Tissues ', ' Tissues ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' urethral ', ' Urethra ', ' Treatment outcome ', ' Imagery ', ' Visualization ', ' base ', ' Organ ', ' improved ', ' Benign ', ' Clinical ', ' Malignant - descriptor ', ' Malignant ', ' Phase ', ' Biochemical ', ' Series ', ' Randomized Clinical Trials ', ' Ensure ', ' Lesion ', ' soft tissue ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' Area Under Curve ', ' Physiologic pulse ', ' Pulse ', ' Techniques ', ' System ', ' vibration ', ' Radiation Dose Unit ', ' Radiation Dose ', ' cohort ', ' treatment planning ', ' Toxic effect ', ' Toxicities ', ' Biopsy Specimen ', ' Biopsy Sample ', ' Primary Neoplasm ', ' Primary Tumor ', ' novel ', ' Time Series Analysis ', ' Modality ', ' Radiation ', ' cancer radiation therapy ', ' Cancer Radiotherapy ', ' Dose ', ' Dose-Limiting ', ' Cancer Patient ', ' Enrollment ', ' enroll ', ' External Beam Radiation Therapy ', ' external-beam radiation ', ' External Radiation ', ' External Beam RT ', ' EBRT ', ' Definitive Radiation Therapy ', ' Scheme ', ' Validation ', ' Prostatic ', ' Development ', ' developmental ', ' cost ', ' Treatment Efficacy ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' cost effective ', ' Prostate Cancer therapy ', ' prostate cancer treatment ', ' Prostate CA therapy ', ' Consumption ', ' innovation ', ' innovative ', ' innovate ', ' tumor ', ' high risk ', ' standard care ', ' standard treatment ', ' Therapy trial ', ' prostate biopsy ', ' improved outcome ', ' prostate cancer risk ', ' early phase trial ', ' deep learning ', ' real-time images ', ' realtime image ', ' ']",NIBIB,UT SOUTHWESTERN MEDICAL CENTER,R01,2019,373971,TX-30,0.15279085103131052
"High speed automated intraoperative microscopy of the prostate circumference to ensure tumor-free margins in radical prostatectomy Project Summary: In prostate cancer (PCa), the presence and amount of residual tumor at the surface of the excised prostate is the only prognostic factor that is affected by surgical technique, vs. other factors, which are fixed and non-modifiable. Yet, positive surgical margins (PSM), defined as the presence of tumor cells at the inked surface of the removed specimen, are common, especially in advanced stage cancers, and are a strong independent risk factor for clinical progression and secondary treatment. In addition, elevated post-operative PSA, which is understood to be related to tumor left behind in the patient, is also associated with high risk of progression and secondary treatment. Thus, complete tumor removal is important to achieve to improve  patient outcomes and reduce overtreatment, yet there is a delicate balance between resection radicality and  minimizing damage to the neurovascular bundles to preserve post-operative function. The NeuroSAFE trial demonstrated that real-time detection and correction of PSMs by comprehensive histology of the prostate  circumference results in improved patient outcomes, yet there are no widely adoptable methods to achieve this. In an effort to address this technical gap, we have developed video-rate structured illumination microscopy (VR-SIM) and demonstrated that it enables accurate diagnosis of PCa in the biopsy setting, and that it can  rapidly deliver gigapixel microscopic images of the entire prostate surface for detection of PSMs. VR-SIM delivers the surface area coverage and resolution needed to detect PSMs, yet it is also fast and relatively simple and inexpensive, opening the possibility for widespread adoption. In this project, our interdisciplinary team of  engineers and clinicians with significant prostate expertise will further advance this technology towards clinical translation, by completing critical technology development steps and by prospectively validating it in a large patient series. Specifically, we will increase the mechanical automation speed of the device, and will develop a fully automated system for handling of the removed prostate, to enable gigapixel panoramas of the entire  prostate circumferential surface to be delivered within 10 minutes of removal and with minimal tissue processing and user intervention. We will then leverage our recently developed dual-color fluorescent stain that replicates standard H&E with high specificity, to develop expert-validated clinical image atlases using biopsies and  cadaveric specimens to enhance image interpretation of VR-SIM prostate panoramas. These improvements will be combined to test the system in a prospective 250-patient clinical study, to determine the accuracy of the device for intra-operative detection of PSMs and prediction of post-operative PSA based on measurement of PSM extent. Finally, we will measure and model expert reviewer behavior using a novel web-enabled visual observer tracking method, which could be used in future computer-assisted search algorithms to expedite  intra-operative image review. Successful completion will set the stage for multi-center clinical trials to validate the clinical utility of VR-SIM for real-time detection and correction of PSMs, and improvement of patient outcomes. Project Narrative: Achieving complete tumor removal in prostate cancer is an important goal to achieve because leaving tumor behind in the patient contributes to increased risk of cancer progression and need for additional harmful treatment. Yet, it is difficult to determine in real-time if surgery is successful due to the lack of available technologies for intra-operative guidance. This project will develop a rapid scanner that will automatically scan the entire prostate surface for residual tumor within 10 minutes of removal, providing images which are readily interpreted by trained pathologists and enabling real-time guidance of nerve-sparing prostate cancer surgery.",High speed automated intraoperative microscopy of the prostate circumference to ensure tumor-free margins in radical prostatectomy,9731447,R01CA222831,"['Adoption ', ' Affect ', ' Algorithms ', ' Atlases ', ' Automation ', ' Behavior ', ' Biopsy ', ' Cadaver ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Clinical Study ', ' Clinical Research ', ' Color ', ' Engineering ', ' balance function ', ' balance ', ' Equilibrium ', ' Freeze Sectioning ', ' Frozen Sections ', ' Future ', ' Goals ', ' Gold ', ' Histology ', ' Modern Man ', ' Human ', ' Image Enhancement ', ' Ink ', ' Illumination ', ' Lighting ', ' Manuals ', "" men's "", ' men ', ' Methods ', ' Microscopy ', ' Nerve ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Operating Rooms ', ' optical ', ' Optics ', ' Pathology ', ' Patients ', ' Postoperative ', ' Post-Operative ', ' Postoperative Period ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Prostatic Neoplasia ', ' Prostate Tumor ', ' Prostate Neoplasms ', ' Prostatic Neoplasms ', ' Risk Factors ', ' Sensitivity and Specificity ', ' Specificity ', ' Staining method ', ' Stains ', ' Technology ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Translations ', ' Urogenital System ', ' Urogenital ', ' Genitourinary ', ' Genitourinary system ', ' Work ', ' Generations ', ' Measures ', ' Case Series ', ' Custom ', ' base ', ' Organ ', ' tumor progression ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' improved ', ' prostate surgery ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' Left ', ' Site ', ' Area ', ' Surface ', ' Clinical ', ' Series ', ' Ensure ', ' Training ', ' Surgical margins ', ' Visual ', ' Measurement ', ' Progression-Free Survivals ', ' analog ', ' Pathologist ', ' tool ', ' Diagnostic ', ' Specimen ', ' Research Specimen ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Mechanics ', ' mechanical ', ' Adopted ', ' Surface of the Prostate ', ' Surface of Human Prostate ', ' Scanning ', ' Pattern ', ' Techniques ', ' System ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Residual Tumors ', ' residual disease ', ' cancer risk ', ' neoplastic cell ', ' Tumor Cell ', ' authority ', ' cohort ', ' technology development ', ' tech development ', ' Speed ', ' Structure ', ' novel ', ' Devices ', ' Excision ', ' resection ', ' Surgical Removal ', ' Removal ', ' Extirpation ', ' Abscission ', ' Modeling ', ' Sampling ', ' visual search ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' cancer surgery ', ' cancer diagnosis ', ' Image-Guided Surgery ', ' surgical imaging ', ' intraoperative imaging ', ' intra-operative imaging ', ' tissue processing ', ' Address ', ' Data ', ' Detection ', ' Multi-Institutional Clinical Trial ', ' Multisite clinical trial ', ' Multisite clinical study ', ' Multicenter clinical trial ', ' Multicenter clinical study ', ' Multi-site clinical trial ', ' Multi-site clinical study ', ' Multi-center clinical trial ', ' Multi-center clinical study ', ' Prognostic Factor ', ' Prognostic/Survival Factor ', ' General Prognostic Factor ', ' Resolution ', ' Clinical Management ', ' Patient-Focused Outcomes ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Validation ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' Computer Assisted ', ' computer aided ', ' rapid detection ', ' cancer imaging ', ' tumor imaging ', ' oncology imaging ', ' oncologic imaging ', ' prospective ', ' web-enabled ', ' tumor ', ' high risk ', ' clinical practice ', ' computer aided detection ', ' computer assisted detection ', ' accurate diagnosis ', ' prostate biopsy ', ' imaging system ', ' contrast imaging ', ' neurovascular ', ' neuro-vascular ', ' microscopic imaging ', ' microscopy imaging ', ' microscope imaging ', ' histological image ', ' histologic image ', ' clinical imaging ', ' clinical translation ', ' recruit ', ' preservation ', ' overtreatment ', ' over-treatment ', ' machine learning algorithm ', ' classification algorithm ', ' ']",NCI,TULANE UNIVERSITY OF LOUISIANA,R01,2019,384646,LA-01,0.20640543018843938
"Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy PROJECT SUMMARY/ABSTRACT Prostate cancer is the second leading cause of cancer death in American men, accounting for 26% of new cancer diagnoses and 9% of cancer deaths in men. Active surveillance, radical prostatectomy and radiotherapy are commonly used treatments for clinically localized prostate cancer. However, current risk stratification methods cannot be used effectively to avoid subjecting patients with clinically indolent cancers to unnecessary interventions, causing significant morbidity and cost. The primary components currently involved in screening are the digital rectal exam (DRE) and serum biomarkers, such as PSA, PCA3, PHI, and 4Kscore. Unfortunately, despite advances in these tests, overdiagnosis remains a major problem due to limited specificity. As a result, 90% of patients diagnosed with prostate cancer receive treatment, even though up to 60% of those patients could be candidates for active surveillance. Such treatment often results in long-term reductions in functional outcomes. The research objective of this R21 is to develop novel techniques using multiparametric magnetic resonance imaging (mp-MRI) and MRI-ultrasound (US) fusion guided biopsy data that provide discriminatory power in distinguishing indolent versus clinically significant prostatic adenocarcinoma based on non-invasive imaging. We propose to implement a multi-instance learning (MIL) based convolutional neural network (CNN) model for clinical prostate mp-MRI sequences to generate new quantitative imaging features representative of the underlying tissue. Our MIL-CNN model will accommodate ground truth labels from pathology whole mount specimens, as well as MRI-US fusion biopsy results. Hierarchical CNN features will be used to predict voxel- level cancer suspicion, thereby enabling a novel method for performing imaging biopsy. Finally, voxel-level suspicion maps will be aggregated into patient-level quantitative imaging biomarkers and combined with clinical data to create a multimodal nomogram for performing risk stratification. RELEVANCE TO PUBLIC HEALTH Prostate cancer is the second leading cause of cancer death in American men, accounting for 26% of new cancer diagnoses and 9% of cancer deaths in men. The focus of this research is to investigate new methods for distinguishing indolent from aggressive prostate cancer through the use of medical imaging and data min- ing, thus preventing patients from receiving unnecessary treatment and incurring associated negative function- al outcomes.",Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy,9699449,R21CA220352,"['Accounting ', ' Architecture ', ' Engineering / Architecture ', ' Biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Prostate Adenocarcinoma ', ' prostatic adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' Systematics ', ' Classification ', ' Clinical Trials ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Goals ', ' Hospitals ', ' Learning ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Manuals ', ' Maps ', ' Medical Imaging ', "" men's "", ' men ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' Pathology ', ' Patients ', ' Probability ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Public Health ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' treatment with radiation ', ' radio-therapy ', ' radiation treatment ', ' Radiotherapy ', ' Radiotherapeutics ', ' Radiation therapy ', ' Research ', ' Risk ', ' Risk Factors ', ' Savings ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Specificity ', ' Testing ', ' Body Tissues ', ' Tissues ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' Work ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' Dataset ', ' Data Set ', ' base ', ' Label ', ' improved ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' rectal ', ' Clinical ', ' Evaluation ', ' Training ', ' Serum ', ' Blood Serum ', ' Indolent ', ' Individual ', ' radiologist ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Gleason Grade for Prostate Cancer ', ' Gleason-SC ', ' Gleason Sum ', ' Gleason Score for Prostate Cancer ', ' Gleason Score ', ' Gleason Grade ', ' tool ', ' Specimen ', ' Research Specimen ', ' Transrectal Ultrasound ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Physiologic pulse ', ' Pulse ', ' Diagnostic Procedure ', ' Diagnostic Technique ', ' Diagnostic Method ', ' Severities ', ' Complex ', ' Slide ', ' Pattern ', ' Techniques ', ' Location ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' interest ', ' American ', ' digital imaging ', ' computer imaging ', ' Performance ', ' treatment planning ', ' novel ', ' Localized Malignant Neoplasm ', ' Localized Malignancy ', ' Localized Cancer ', ' Local Cancer ', ' Modeling ', ' Neural Network Simulation ', ' Perceptrons ', ' Neural Network Models ', ' Connectionist Models ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer diagnosis ', ' Institution ', ' preventing ', ' prevent ', ' Core Needle Biopsy ', ' Core Biopsy ', ' datamining ', ' data mining ', ' Nomograms ', ' Data ', ' Detection ', ' National Comprehensive Cancer Network ', ' NCCN ', ' Cancer Etiology ', ' Cancer Cause ', ' Cancer Patient ', ' Clinical Data ', ' Clinical Treatment ', ' trial treatment ', ' trial regimen ', ' Process ', ' follow-up ', ' followup ', ' followed up ', ' follow up ', ' active followup ', ' Active Follow-up ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' Image ', ' imaging ', ' cost ', ' digital ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' image registration ', ' functional outcomes ', ' Outcome ', ' cancer imaging ', ' tumor imaging ', ' oncology imaging ', ' oncologic imaging ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' clinically significant ', ' clinical significance ', ' multimodality ', ' multi-modality ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' non-invasive imaging ', ' noninvasive imaging ', ' clinical predictors ', ' Patient risk ', ' quantitative imaging ', ' imaging biomarker ', ' imaging-based marker ', ' imaging-based biomarker ', ' imaging-based biological marker ', ' imaging marker ', ' patient stratification ', ' stratified patient ', ' unnecessary treatment ', ' Risk stratification ', ' prostate cancer risk ', ' digital pathology ', ' deep learning ', ' convolutional neural network ', ' convolutional neural nets ', ' ConvNet ', ' screening guidelines ', ' screening recommendations ', ' recommended screening ', ' ']",NCI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R21,2019,156788,CA-33,0.32169892514983894
"Imaging of prostate cancer by combined quantitative ultrasound and acoustic-radiation-force-impulse imaging Project Summary/Abstract Prostate cancer (PCa) is the most-common cancer of men in the United States. The goal of the project is to develop a reliable, imaging tool for characterizing prostate tissue. This tool will improve detection, grading, treatment, and monitoring of PCa. It can be implemented in existing clinical scanners for effective needle-biopsy guidance and for planning and targeting focal therapy. Such a tool would significantly reduce the amount of unnecessary biopsies of noncancerous tissue and the current high rate of false negative diagnoses. It also would allow monitoring diagnosed PCa during watchful waiting or after non-surgical therapies. We propose to investigate the feasibility of fusing acoustic radiation-force impulse (ARFI) imaging and quantitative ultrasound (QUS) for typing prostate tissue. Studies to date have demonstrated encouraging performance of each ultrasonic modality when used alone. However, the ability of the combined modalities has not yet been investigated. The proposed project seeks to extract features from a retrospective data set containing radio-frequency (RF) ultrasound data acquired while performing in vivo prostate ARFI imaging. Images generated from both technologies are intrinsically perfectly registered. We will employ our well-established QUS-processing procedures to extract QUS-parameter maps from the RF-data and will develop and test new algorithms to extend the feature set from our established QUS-processing to incorporate ARFI image features. We will use standard and new features from QUS and ARFI for training linear and non-linear classifiers (e.g. support vector machines) to identify and image PCa. We will compare the performance of classifiers trained with QUS alone, ARFI alone, and MRI alone. Furthermore, we will assess performance improvement if classifiers are trained based on QUS- ARFI, QUS-MRI, ARFI-MRI, and QUS-ARFI-MRI parameter combinations and will determine the best classifier to detect prostate cancerous tissue using cross-validation and receiver-operating-characteristic (ROC) statistics. If this project is successful, subsequent projects will focus on integrating the newly developed tools into clinical scanners. Project Narrative We propose to assess the feasibility of a novel tool for imaging and detection of prostate cancer (PCa) that combines quantitative ultrasound and acoustic radiation-force imaging. If our proposed method proves to be feasible and ultimately is successful, it will have a major impact on clinical practice by reducing the current high rates of false-negative diagnoses of PCa and by enabling non-invasive, low-risk, low-cost monitoring of PCa.",Imaging of prostate cancer by combined quantitative ultrasound and acoustic-radiation-force-impulse imaging,9737939,R03EB026233,"['Acoustics ', ' Acoustic ', ' Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Biopsy ', ' Needle biopsy procedure ', ' needle biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Systematics ', ' Classification ', ' Diagnosis ', ' Foundations ', ' Goals ', ' Gold ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Histology ', ' Laboratories ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' male ', ' Maps ', "" men's "", ' men ', ' Methods ', ' Patients ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Publishing ', ' Receiver Operator Characteristics ', ' Receiver Operating Characteristics ', ' Relaxation ', ' Retrospective Studies ', ' Risk ', ' ROC Analyses ', ' ROC Curve ', ' statistics ', ' Technology ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' United States ', ' Universities ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' Dataset ', ' Data Set ', ' base ', ' image processing ', ' improved ', ' Procedures ', ' Area ', ' Clinical ', ' Histologic ', ' Histologically ', ' Training ', ' Lesion ', ' Measurement ', ' Screening for Prostate Cancer ', ' prostate cancer early detection ', ' prostate cancer detection ', ' detect prostate cancer ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' Texture ', ' Performance ', ' Intercept ', ' novel ', ' Modality ', ' Devices ', ' Patient observation ', ' Watchful Waiting ', ' Radiation ', ' Modeling ', ' Property ', ' cancer classification ', ' Core Needle Biopsy ', ' Core Biopsy ', ' Ultrasonics ', ' Ultrasonic ', ' Data ', ' Detection ', ' Imaging Device ', ' Imaging Tool ', ' Imaging Instrument ', ' in vivo ', ' Atlas of Cancer Mortality in the United States ', ' Cancer Maps ', ' Cancer Patient ', ' Validation ', ' Monitor ', ' Image ', ' imaging ', ' cost ', ' cost efficient ', ' Consumption ', ' Cancerous ', ' clinically significant ', ' clinical significance ', ' patient population ', ' quantitative ultrasound ', ' clinical practice ', ' signal processing ', ' in vivo imaging ', ' imaging in vivo ', ' radio frequency ', ' radiofrequency ', ' routine imaging ', ' ']",NIBIB,RIVERSIDE RESEARCH INSTITUTE,R03,2019,78801,NY-10,0.24254508033820826
"Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Abstract: Fast, reliable and accurate delineation of pelvic organs in the planning and treatment images is a long- standing, important and technically challenging problem. Its solution is highly required for state-of-the-art image-guided radiation therapy planning and treatment, as better treatment decisions rely on timely interpretation of anatomical information in the images. However, automatic segmentation in male pelvic regions is always difficult due to 1) low contrast between prostate and surrounding organs, and 2) possibly disparate shapes/appearances of bladder and rectum caused by tissue deformations. The goal of this project is to create a set of novel machine learning tools to achieve accurate, reliable and efficient delineation of important pelvic organs (e.g., prostate, bladder, and rectum) in different modalities (e.g., planning CT, treatment CT/CBCT, and MRI) for radiotherapy of prostate cancer.  Planning CT. For automatic segmentation, landmark detection is often the first step in rapidly locating the target organs. Thus, in Aim 1, we will create a novel joint landmark detection approach, based on both random forests and auto-context model, to iteratively detect all landmarks and further coordinate their detection results for achieving more accurate and consistent landmark detection results. After roughly locating organs with the aid of those detected landmarks, the second step is to accurately segment boundaries of target organs in the planning CT. Accordingly, in Aim 2, we will create a set of learning methods to a) first simultaneously predict all pelvic organ boundaries in the planning CT with the regression forests trained by labeled training data, and b) then segment all pelvic organs jointly by deforming their respective shape models. In particular, to address the limitations of conventional deformable models in assuming simple Gaussian distributions for organ shapes, a novel hierarchical sparse shape composition approach will be developed to constrain shape models during deformable segmentation.  Treatment CT/CBCT. During the course of serial radiation treatments, to quantitatively record and monitor the accumulated dose delivered to the patient, organs in the treatment image also need to be segmented. Although methods proposed in Aims 1-2 can be simply applied, as done by many conventional methods, this will lead to a) inconsistent landmark detection and b) inconsistent segmentations across different treatment days because of possible large shape/appearance changes. Accordingly, in Aim 3, we will create a novel self- learning mechanism to gradually learn and incorporate patient-specific information into both joint landmark detection and deformable segmentation steps from the increasingly acquired treatment images of patient. Thus, population data will gradually be replaced by the patient's own data to train personalized models.  MRI. To guide pelvic organ segmentation in the planning CT, MRI is now often acquired for selected patients. To this end, in Aim 4, we will develop a) a prostate MRI segmentation method by using deep learning to learn MRI-specific features for guiding landmark detection and deformable segmentation as proposed in Aims 1-2; b) a novel collaborative MRI and CT segmentation algorithm for more accurate segmentation of planning CT.  All our developed algorithms will be evaluated for their performance in clinical (treatment planning and delivery) workflow for 130 patients in UNC Cancer Hospital and also hospitals of our consultants.  Benefit for Patient Care. Development of these segmentation tools will 1) dramatically accelerate the clinical workflow, 2) reduce workload (i.e., manual interaction time) for physicians, and 3) lead to better patient outcomes with reliable and accurate segmentations of target area and critical organs. Although these tools cannot replace the expertise of physicians, they can be of great assistance to physicians. Narrative Description of Project This project aims to create a set of novel machine learning tools for accurate, reliable and efficient delineation of important pelvic organs (such as prostate, bladder, and rectum) in various imaging modalities to help radiotherapy of prostate cancer. To achieve this goal, we will create 1) a novel joint landmark detection and boundary prediction framework for accurate segmentation of the planning CT images, 2) an innovative updating mechanism for incorporating patient-specific information from previous treatment images of same patient to progressively improve treatment CT/CBCT segmentation, and 3) a deep-learning based framework for learning MRI-specific features for prostate MRI segmentation, as well as a novel method for collaborative MRI & planning CT segmentation. We will validate these methods on real patients in our clinical workflow. Besides, although these machine-learning tools are designed for radiotherapy of prostate cancer, they can also be easily extended to other new organs and new modalities after appropriate updating and training.",Automatic Pelvic Organ Delineation in Prostate Cancer Treatment,9745302,R01CA206100,"['Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Bladder ', ' urinary bladder ', ' Bladder Urinary System ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Hospitals ', ' Cancer Hospital ', ' Joints ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' male ', ' Manuals ', ' Methods ', ' Normal Distribution ', ' Gaussian Distribution ', ' Normal Statistical Distribution ', ' Patient Monitoring ', ' Patients ', ' Pelvic Region ', ' Pelvic ', ' Pelvis ', ' Physicians ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' treatment with radiation ', ' radio-therapy ', ' radiation treatment ', ' Radiotherapy ', ' Radiotherapeutics ', ' Radiation therapy ', ' Rectum ', ' Time ', ' Body Tissues ', ' Tissues ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Work Load ', ' Workload ', ' forest ', ' base ', ' dosage ', ' Organ ', ' Label ', ' improved ', ' Area ', ' Clinical ', ' Training ', ' soft tissue ', ' Sample Size ', ' Shapes ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Clinic ', ' treatment duration ', ' treatment days ', ' Treatment Period ', ' Performance ', ' success ', ' treatment planning ', ' novel ', ' General Population ', ' General Public ', ' Modality ', ' Appearance ', ' Modeling ', ' imaging method ', ' image-based method ', ' imaging modality ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' Multimodal Imaging ', ' multimodality imaging ', ' multi-modality imaging ', ' multi-modal imaging ', ' Clinical Treatment ', ' trial treatment ', ' trial regimen ', ' Patient-Focused Outcomes ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Update ', ' Monitor ', ' Process ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' design ', ' designing ', ' Population ', ' Prostate Cancer therapy ', ' prostate cancer treatment ', ' Prostate CA therapy ', ' innovation ', ' innovative ', ' innovate ', ' imaging Segmentation ', ' therapy design ', ' treatment design ', ' intervention design ', ' image guided radiation therapy ', ' image-guided radiotherapy ', ' image guided radiation treatment ', ' IGRT ', ' learning strategy ', ' learning method ', ' learning activity ', ' deep learning ', ' random forest ', ' Patient imaging ', ' ']",NCI,UNIV OF NORTH CAROLINA CHAPEL HILL,R01,2019,1,NC-04,0.1601918496567657
"Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization Project Summary Prostate cancer (PCa) is the most diagnosed form of non-cutaneous cancer in US men. The selection of patients who require immediate treatment from those suitable for active surveillance currently relies on non- specific and inaccurate measurements. A method that allows clinicians to more confidently discriminate clinically relevant from non-life-threatening tumors is needed to improve patient management. Multiparametric magnetic resonance imaging (mpMRI) is the preferred non-invasive imaging modality for characterizing primary PCa. However, its accuracy for detecting clinically significant PCa is variable. We propose to address this limitation by combining mpMRI with positron emission tomography (PET) with a PCa-specific radiotracer and using advanced multimodal machine learning models (i.e. radiomics and deep learning) to characterize tumor aggressiveness based on the imaging data. Recently, scanners capable of simultaneous PET and MR data acquisition in human subjects have become commercially available. An integrated MR-PET scanner is the ideal tool for comparing MR and PET derived image features to identify those that provide complementary information and build a hybrid PET-mpMRI model that most accurately identifies clinically significant tumors. While this novel technology allows the acquisition of perfectly coregistered complementary anatomical, functional and metabolic data in a single imaging session, a new challenge needs to first be addressed to obtain quantitatively accurate PET data. In an integrated MR-PET scanner, the information needed for PET attenuation correction (AC) has to be derived from the MR data and the methods currently available for this task are inadequate for advanced quantitative studies. We have formed an academic-industrial partnership to accelerate the translation of multimodal MR-PET machine learning approaches into PCa research and clinical applications by addressing the AC challenge and validating machine learning models for detecting clinically significant disease against gold standard histopathology in patients undergoing radical prostatectomy. Specifically, we will: (1) Develop and validate an MR-based approach for obtaining quantitatively accurate PET data. We hypothesize that attenuation maps as accurate as those obtained using a 511 keV transmission source  the true gold standard for PET AC  will be obtained; (2) Identify the multimodal radiomics model that most accurately predicts PCa aggressiveness. We hypothesize that the diagnostic accuracy of this approach will be superior to that offered by the stand-alone modalities; (3) Evaluate radiomics and deep learning approaches for predicting pPCa aggressiveness. We hypothesize that machine learning approaches will achieve a higher predictive accuracy when applied to data acquired simultaneously than sequentially. Project narrative A better method to non-invasively characterize primary prostate cancer is needed to improve patient management. Extracting additional information from multimodality quantitative MR-PET data using machine learning approaches is expected to result in better diagnostic performance. In this work, we propose to accelerate the translation of quantitative MR-PET to prostate cancer research and clinical applications. In particular, we will develop and validate an MR-based attenuation correction approach to guarantee that quantitatively accurate PET data are obtained in an integrated MR-PET scanner and then use machine learning approaches to characterize the aggressiveness of the tumors in patients undergoing radical prostatectomy.",Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization,9653979,R01CA218187,"['Affect ', ' Algorithms ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Systematics ', ' Classification ', ' Diagnosis ', ' Cognitive Discrimination ', ' Discrimination ', ' Disorder ', ' Disease ', ' Gold ', ' Hand ', ' Hybrids ', ' Interobserver Variations ', ' Inter-Observer Variation ', ' Inter-Observer Variability ', ' Interobserver Variability ', ' Kinetics ', ' Life Expectancy ', ' Ligands ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Maps ', "" men's "", ' men ', ' Methods ', ' Methodology ', ' Patients ', ' Pelvic Region ', ' Pelvic ', ' Pelvis ', ' Phenotype ', ' positron emitting tomography ', ' positron emission tomographic imaging ', ' positron emission tomographic (PET) imaging ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Positron-Emission Tomography ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' QOL ', ' Quality of life ', ' Risk ', ' Software ', ' Computer software ', ' Testing ', ' Time ', ' Translations ', ' Work ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' Dataset ', ' Data Set ', ' Guidelines ', ' base ', ' human subject ', ' improved ', ' Radical Prostatectomy ', ' Prostatovesiculectomy ', ' bone imaging ', ' skeletal imaging ', ' bone scanning ', ' Biological ', ' Physiological ', ' Physiologic ', ' Lesion ', ' Individual ', ' Measurement ', ' Patient Selection ', ' radiologist ', ' Metabolic ', ' Morphology ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Scanning ', ' Source ', ' 3-Dimensional ', ' 3D ', ' 3-D ', ' Early Diagnosis ', ' early detection ', ' Performance ', ' radiotracer ', ' radiolabel ', ' diagnostic accuracy ', ' Accuracy of Diagnosis ', ' attenuation ', ' Histopathology ', ' new technology ', ' novel technologies ', ' Modality ', ' Devices ', ' Modeling ', ' Meta-Analysis ', ' Data Pooling ', ' Clinical Trial Overviews ', ' cancer classification ', ' imaging method ', ' image-based method ', ' imaging modality ', ' FOLH1 gene ', ' Prostate-Specific Membrane Antigen ', ' PSMA ', ' PSM ', ' NAALADase I ', ' NAALAD1 ', ' N-Acetylated Alpha-Linked Acidic Dipeptidase 1 ', ' Glutamate Carboxypeptidase II ', ' GCP2 ', ' Folate Hydrolase 1 ', ' FOLH1 ', ' FOLH ', ' Address ', ' Data ', ' Reproducibility ', ' Cancer Death Rates ', ' Cancer Patient ', ' transmission process ', ' Transmission ', ' Image ', ' imaging ', ' anticancer research ', ' cancer research ', ' anti-cancer research ', ' cancer imaging ', ' tumor imaging ', ' oncology imaging ', ' oncologic imaging ', ' data acquisition ', ' clinically relevant ', ' clinical relevance ', ' clinically significant ', ' clinical significance ', ' clinical application ', ' clinical applicability ', ' Early treatment ', ' early therapy ', ' tumor ', ' multimodality ', ' multi-modality ', ' industry partner ', ' industry partnership ', ' industrial partnership ', ' non-invasive imaging ', ' noninvasive imaging ', ' radiomics ', ' deep learning ', ' ']",NCI,MASSACHUSETTS GENERAL HOSPITAL,R01,2019,663746,MA-08,0.1245754745824329
"Content-based MR-TRUS Fusion without Tracking There are about 3 million American men living with prostate cancer, the second leading cause of cancer death for men in the United States. If the prostate cancer is caught early before it spreads to other parts of the body, by active monitoring or treatment, most men will not die from it. Nevertheless, 22% to 47% of the patients with negative biopsies but elevated prostate-specific antigen levels may still harbor malignant tumors, which can be life threatening and could have been missed by the commonly used ultrasound guided random biopsy. By contrast, fusion of magnetic resonance (MR) imaging and transrectal ultrasound (TRUS) for guiding targeted biopsies has shown to significantly improve the cancer detection rate. However, MR-TRUS fusion itself is very challenging due to the difficulties in directly registering images of these two very different modalities in different dimensions. To bypass the difficult registration problems, the existing fusion techniques require the use of specialized expensive and cumbersome hardware tracking devices, which increases cost and elongates procedures. More importantly, due to a number of factors such as patient movement, respiratory motion and ultrasound transducer pressure change, prostate motion can happen during a procedure and cause the images to be misaligned. Timely noticing and correcting such motion require great skill and knowledge of radiological imaging, where studies show a steep learning curve for mastering fusion systems. Failing in image registration and motion compensation renders the fusion guided biopsy performing no differently than random biopsy. To address the fundamental cause of the problems, the goal of this project is to create enabling technology of MR- TRUS image fusion solely based on internal image content without using external tracking devices. The proposed research is foundational for developing next generation of MR-TRUS fusion guidance systems for prostate biopsy to achieve robust performance with lower costs. Recent advancement in machine learning, especially deep learning, has provided us new tools and new angles to tackle this challenging problem. This project aims for directly fusing 2D TRUS frames with 3D MR volume by developing novel deep learning methods for image reconstruction and registration. The proposed methods are designed to exploit both population and patient specific imaging information to accurately align images. As all learning-based image registration methods try to better use population knowledge to improve the registration performance, few of them have been able to efficiently use patient specific information, which can be essential to obtain robust and accurate performance. Upon successful completion, the innovation created from the project will disrupt the common perception that hardware tracking has to be used for multimodal image fusion-guided interventions and alleviate the demand on physicians experience and skill in image analysis and fusion to help obtain consistent results. This project will lead to the development of novel prostate biopsy systems and will also impact a range of other image fusion based interventional guidance technologies. Fusion of magnetic resonance (MR) imaging and transrectal ultrasound (TRUS) for guiding targeted prostate biopsies can significantly improve the detection of aggressive cancer. The goal of this project is to create enabling technology of MR-TRUS image fusion solely based on internal image content without using external tracking devices. The proposed research is foundational for developing next generation of MR-TRUS fusion guidance systems for prostate biopsy to achieve robust performance with lower costs.",Content-based MR-TRUS Fusion without Tracking,9726560,R21EB028001,"['Biopsy ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' web-based training ', ' web-based instruction ', ' virtual learning ', ' virtual education ', ' technology-enhanced learning ', ' online learning ', ' online education ', ' on-line learning ', ' on-line education ', ' multimedia learning ', ' internet-based training ', ' internet-assisted education ', ' electronic learning ', ' eLearning ', ' digital learning ', ' digital education ', ' computer-based training ', ' computer-based learning ', ' computer-based instruction ', ' computer-based education ', ' computer-assisted instruction ', ' E-learning ', ' Cyst ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Electromagnetic ', ' Electromagnetics ', ' Foundations ', ' Future ', ' Goals ', ' Heart ', ' image generation ', ' image construction ', ' image reconstruction ', ' Intelligence ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' Learning ', ' hepatic organ system ', ' hepatic body system ', ' Liver ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Manuals ', "" men's "", ' men ', ' Methods ', ' Methodology ', ' Motion ', ' body movement ', ' Movement ', ' Patients ', ' Perception ', ' Physicians ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Research ', ' Retrospective Studies ', ' Survival Rate ', ' Technology ', ' Leanness ', ' Thinness ', ' Time ', ' Pressure Transducers ', ' training transfer ', ' learning transfer ', ' Psychological Transfer ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' United States ', ' Risk Assessment ', ' hK3 Kallikrein ', ' gamma-Seminoprotein ', ' Seminin ', ' Semenogelase ', ' Prostate Specific Antigen Preproprotein ', ' Plasma Prekallikrein ', ' Plasma Kallikrein Precursor ', ' P-30 Antigen ', ' Kallikrein 3 ', ' EC 3.4.21.34 ', ' Prostate-Specific Antigen ', ' calcification ', ' Calcified ', ' base ', ' Ultrasonic Transducer ', ' Ultrasound transducer ', ' improved ', ' Procedures ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Area ', ' Financial compensation ', ' Compensation ', ' Training ', ' Body part ', ' tool ', ' Transrectal Ultrasound ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Knowledge ', ' Life ', ' Dimensions ', ' Techniques ', ' System ', ' 3-Dimensional ', ' 3D ', ' 3-D ', ' Location ', ' respiratory ', ' American ', ' Early Diagnosis ', ' early detection ', ' experience ', ' Performance ', ' skills ', ' novel ', ' Modality ', ' Devices ', ' Bypass ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Magnetic Resonance ', ' imaging method ', ' image-based method ', ' imaging modality ', ' Address ', ' Data ', ' Detection ', ' Multimodal Imaging ', ' multimodality imaging ', ' multi-modality imaging ', ' multi-modal imaging ', ' Cancer Detection ', ' Cancer Etiology ', ' Cancer Cause ', ' research clinical testing ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' Slice ', ' Monitor ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' cost ', ' reconstruction ', ' image registration ', ' design ', ' designing ', ' next generation ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' patient population ', ' population based ', ' prostate biopsy ', ' learning strategy ', ' learning method ', ' learning activity ', ' radiological imaging ', ' radiologic imaging ', ' imaging study ', ' deep neural network ', ' deep neural net ', ' deep learning neural network ', ' deep learning based neural network ', ' deep learning ', ' deep learning algorithm ', ' ']",NIBIB,RENSSELAER POLYTECHNIC INSTITUTE,R21,2019,217513,NY-20,0.19175726084040517
"Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Automatic Pelvic Organ Delineation in Prostate Cancer Treatment Abstract: Fast, reliable and accurate delineation of pelvic organs in the planning and treatment images is a long- standing, important and technically challenging problem. Its solution is highly required for state-of-the-art image-guided radiation therapy planning and treatment, as better treatment decisions rely on timely interpretation of anatomical information in the images. However, automatic segmentation in male pelvic regions is always difficult due to 1) low contrast between prostate and surrounding organs, and 2) possibly disparate shapes/appearances of bladder and rectum caused by tissue deformations. The goal of this project is to create a set of novel machine learning tools to achieve accurate, reliable and efficient delineation of important pelvic organs (e.g., prostate, bladder, and rectum) in different modalities (e.g., planning CT, treatment CT/CBCT, and MRI) for radiotherapy of prostate cancer.  Planning CT. For automatic segmentation, landmark detection is often the first step in rapidly locating the target organs. Thus, in Aim 1, we will create a novel joint landmark detection approach, based on both random forests and auto-context model, to iteratively detect all landmarks and further coordinate their detection results for achieving more accurate and consistent landmark detection results. After roughly locating organs with the aid of those detected landmarks, the second step is to accurately segment boundaries of target organs in the planning CT. Accordingly, in Aim 2, we will create a set of learning methods to a) first simultaneously predict all pelvic organ boundaries in the planning CT with the regression forests trained by labeled training data, and b) then segment all pelvic organs jointly by deforming their respective shape models. In particular, to address the limitations of conventional deformable models in assuming simple Gaussian distributions for organ shapes, a novel hierarchical sparse shape composition approach will be developed to constrain shape models during deformable segmentation.  Treatment CT/CBCT. During the course of serial radiation treatments, to quantitatively record and monitor the accumulated dose delivered to the patient, organs in the treatment image also need to be segmented. Although methods proposed in Aims 1-2 can be simply applied, as done by many conventional methods, this will lead to a) inconsistent landmark detection and b) inconsistent segmentations across different treatment days because of possible large shape/appearance changes. Accordingly, in Aim 3, we will create a novel self- learning mechanism to gradually learn and incorporate patient-specific information into both joint landmark detection and deformable segmentation steps from the increasingly acquired treatment images of patient. Thus, population data will gradually be replaced by the patient's own data to train personalized models.  MRI. To guide pelvic organ segmentation in the planning CT, MRI is now often acquired for selected patients. To this end, in Aim 4, we will develop a) a prostate MRI segmentation method by using deep learning to learn MRI-specific features for guiding landmark detection and deformable segmentation as proposed in Aims 1-2; b) a novel collaborative MRI and CT segmentation algorithm for more accurate segmentation of planning CT.  All our developed algorithms will be evaluated for their performance in clinical (treatment planning and delivery) workflow for 130 patients in UNC Cancer Hospital and also hospitals of our consultants.  Benefit for Patient Care. Development of these segmentation tools will 1) dramatically accelerate the clinical workflow, 2) reduce workload (i.e., manual interaction time) for physicians, and 3) lead to better patient outcomes with reliable and accurate segmentations of target area and critical organs. Although these tools cannot replace the expertise of physicians, they can be of great assistance to physicians. Narrative Description of Project This project aims to create a set of novel machine learning tools for accurate, reliable and efficient delineation of important pelvic organs (such as prostate, bladder, and rectum) in various imaging modalities to help radiotherapy of prostate cancer. To achieve this goal, we will create 1) a novel joint landmark detection and boundary prediction framework for accurate segmentation of the planning CT images, 2) an innovative updating mechanism for incorporating patient-specific information from previous treatment images of same patient to progressively improve treatment CT/CBCT segmentation, and 3) a deep-learning based framework for learning MRI-specific features for prostate MRI segmentation, as well as a novel method for collaborative MRI & planning CT segmentation. We will validate these methods on real patients in our clinical workflow. Besides, although these machine-learning tools are designed for radiotherapy of prostate cancer, they can also be easily extended to other new organs and new modalities after appropriate updating and training.",Automatic Pelvic Organ Delineation in Prostate Cancer Treatment,10003010,R01CA206100,"['Algorithms ', ' Anatomy ', ' Anatomic ', ' Anatomic Sites ', ' Anatomic structures ', ' Anatomical Sciences ', ' Bladder ', ' Bladder Urinary System ', ' urinary bladder ', ' Patient Care ', ' Patient Care Delivery ', ' Goals ', ' Hospitals ', ' Cancer Hospital ', ' Joints ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Learning ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' male ', ' Manuals ', ' Methods ', ' Normal Statistical Distribution ', ' Gaussian Distribution ', ' Normal Distribution ', ' Patient Monitoring ', ' Patients ', ' Pelvis ', ' Pelvic ', ' Pelvic Region ', ' Physicians ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Radiation therapy ', ' Radiotherapeutics ', ' Radiotherapy ', ' radiation treatment ', ' radio-therapy ', ' treatment with radiation ', ' Rectum ', ' Time ', ' Tissues ', ' Body Tissues ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Workload ', ' Work Load ', ' forest ', ' base ', ' dosage ', ' Organ ', ' Label ', ' improved ', ' Area ', ' Clinical ', ' Training ', ' soft tissue ', ' Sample Size ', ' Shapes ', ' tool ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Clinic ', ' Treatment Period ', ' treatment days ', ' treatment duration ', ' Performance ', ' success ', ' treatment planning ', ' novel ', ' General Public ', ' General Population ', ' Modality ', ' Appearance ', ' Modeling ', ' image-based method ', ' imaging method ', ' imaging modality ', ' Address ', ' Dose ', ' Data ', ' Detection ', ' multi-modal imaging ', ' multi-modality imaging ', ' multimodality imaging ', ' Multimodal Imaging ', ' trial regimen ', ' trial treatment ', ' Clinical Treatment ', ' Patient outcome ', ' Patient-Centered Outcomes ', ' Patient-Focused Outcomes ', ' Update ', ' Monitor ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' designing ', ' design ', ' Population ', ' Prostate CA therapy ', ' prostate cancer treatment ', ' Prostate Cancer therapy ', ' innovate ', ' innovative ', ' innovation ', ' imaging Segmentation ', ' intervention design ', ' treatment design ', ' therapy design ', ' IGRT ', ' image guided radiation treatment ', ' image-guided radiotherapy ', ' image guided radiation therapy ', ' learning activity ', ' learning method ', ' learning strategy ', ' deep learning ', ' random forest ', ' Patient imaging ', ' prostatectomy radiotherapy ', ' prostate radiotherapy ', ' auto-segmentation ', ' automatic segmentation ', ' autosegmentation ', ' automated segmentation ', ' segmentation algorithm ', ' ']",NCI,UNIV OF NORTH CAROLINA CHAPEL HILL,R01,2020,315338,NC-04,0.1601918496567657
"Pathomic Predictors of Prostate Cancer Progression Abstract  Recent studies suggest that in the U.S. prostate cancer is over-detected and over-treated resulting in significant morbidity and financial costs. These problems are the product of poor sensitivity and specificity serum Prostate Specific Antigen (PSA) as a screening tool, leading to unnecessary biopsies that find small and predominantly indolent prostate tumors. While many prostate cancers should be managed with active surveillance, uncertainties surrounding available clinical tools of aggressiveness (such as PSA, Gleason score and clinical stage) will often drive patients and physicians to treatment. Attempts to improve prognostication using candidate biomarkers, mostly discovered from genomic analyses of large pieces of cancers, have had few successes, and available molecular tools provide only modest prediction, at best. An alternative to the genomic driver focus is that a combination of molecular events, under the influence of the tumor microenvironment, drive tumors molecular evolution and progression. Consequently, analysis of tumor characteristics detectable in pathomic data, such as heterogeneity of expression subtypes, amount of stroma, extent of microenvironmental heterogeneity, extent of immune infiltration, or extent of hypoxia, may ultimately lead to better patient stratification. Our proposal fundamentally centers around the most critical clinical question in early prostate cancer that is the basis for clinical decision making: Can we identify proteomic, imaging, and/or microenvironment features that distinguish those aggressive cancers that will progress to cause harm from benign cancers that can be safely monitored by watchful waiting?  To examine the links between the heterogeneity of early, screen-detected prostate cancers and likelihood of progression, we will interrogate a retrospective set of 225 prostatectomy patients. In Aim 1, we will use GEs hyperplexed immune-pathology platform (Cell DIVE) to profile over 50 proteins at the cellular and subcellular level along with matrix components that define the microenvironments with the cells present in this matrix. In Aim 2, we will focus on single-cell level data and systematically extract the prevalence of the diverse cell subtypes found within these tumors. Cells will be typed along traditional axes (e.g. epithelial, CD4+ T-cells). In addition, we will use molecular and structural characteristics to define novel subtypes. Features associated with cell types (e.g. existence, prevalence, diversity) will be used alone and in combination with Gleason grading to distinguish patients with aggressive tumors that are likely to progress. Aim 3 will focus on neighborhood and regional analyses, particularly on developing approaches to extract tumor microenvironmental characteristics that have demonstrated linkages to progression (hypoxia, stromal reactivity, immune cell patterning). Using a diverse set of these features, alongside deep learning techniques on primary images, we will develop classifiers distinguishing aggressive and benign tumors. Finally, in Aim 4 we will validate classifiers in large cohorts. Project Narrative  Our proposal fundamentally centers around the most critical clinical question in early prostate cancer that is the basis for clinical decision making; namely, can we identify proteomic, imaging, and/or microenvironment features that distinguish those aggressive cancers that will progress to cause harm from benign cancers that can be safely monitored by watchful waiting?",Pathomic Predictors of Prostate Cancer Progression,9976347,R01CA249899,"['Biopsy ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell Cycle ', ' Cell Division Cycle ', ' Cells ', ' Cell Body ', ' Financial cost ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Environment ', ' Epithelium ', ' Epithelium Part ', ' Heterogeneity ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Molecular Structure ', ' Macromolecular Structure ', ' Morbidity - disease rate ', ' Morbidity ', ' Neighborhoods ', ' Neoplasm Metastasis ', ' Metastasis ', ' Metastasize ', ' Metastatic Lesion ', ' Metastatic Mass ', ' Metastatic Neoplasm ', ' Metastatic Tumor ', ' Secondary Neoplasm ', ' Secondary Tumor ', ' cancer metastasis ', ' tumor cell metastasis ', ' Pathology ', ' Patients ', ' Physicians ', ' Prostatectomy ', ' Prostatic Neoplasms ', ' Prostate Neoplasms ', ' Prostate Tumor ', ' Prostatic Neoplasia ', ' Proteins ', ' Risk ', ' Role ', ' social role ', ' Sensitivity and Specificity ', ' Signal Pathway ', ' Stains ', ' Staining method ', ' CD4 Positive T Lymphocytes ', ' CD4 Cells ', ' CD4 T cells ', ' CD4 helper T cell ', ' CD4 lymphocyte ', ' CD4+ T-Lymphocyte ', ' CD4-Positive Lymphocytes ', ' T4 Cells ', ' T4 Lymphocytes ', ' Immunofluorescence Immunologic ', ' Immunofluorescence ', ' Paraffin Embedding ', ' doubt ', ' Uncertainty ', ' EC 3.4.21.34 ', ' Kallikrein 3 ', ' P-30 Antigen ', ' Plasma Kallikrein Precursor ', ' Plasma Prekallikrein ', ' Prostate Specific Antigen Preproprotein ', ' Semenogelase ', ' Seminin ', ' gamma-Seminoprotein ', ' hK3 Kallikrein ', ' Prostate-Specific Antigen ', ' Apoptosis Pathway ', ' Programmed Cell Death ', ' Apoptosis ', ' base ', ' density ', ' cancer progression ', ' neoplasm progression ', ' neoplastic progression ', ' tumor progression ', ' improved ', ' Benign ', ' Clinical ', ' Biological ', ' Histologically ', ' Histologic ', ' Link ', ' prognostic ', ' screening tools ', ' Screening procedure ', ' Epithelial ', ' Indolent ', ' Hypoxic ', ' Oxygen Deficiency ', ' Hypoxia ', ' detect prostate cancer ', ' prostate cancer detection ', ' prostate cancer early detection ', ' Screening for Prostate Cancer ', ' Molecular Evolution ', ' Immunological response ', ' host response ', ' immunoresponse ', ' Immune response ', ' angiogenesis ', ' Gleason Grade ', ' Gleason Score ', ' Gleason Score for Prostate Cancer ', ' Gleason Sum ', ' Gleason-SC ', ' Gleason Grade for Prostate Cancer ', ' Morphology ', ' Infiltration ', ' tool ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Immunes ', ' Immune ', ' Event ', ' In Situ ', ' cell type ', ' Texture ', ' Pattern ', ' Techniques ', ' System ', ' molecular pathology ', ' success ', ' cohort ', ' novel ', ' Environmental Factor ', ' environmental risk ', ' Environmental Risk Factor ', ' Watchful Waiting ', ' Patient observation ', ' Proteomics ', ' Genomics ', ' cancer care ', ' Formalin ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Imaging Instrument ', ' Imaging Tool ', ' Imaging Device ', ' Molecular Analysis ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Carcinoma Cell ', ' Malignant Epithelial Cell ', ' Patient outcome ', ' Patient-Centered Outcomes ', ' Patient-Focused Outcomes ', ' Tissue Arrays ', ' Tissue Chip ', ' Tissue Microarray ', ' Monitor ', ' Characteristics ', ' Molecular ', ' Process ', ' Active Follow-up ', ' active followup ', ' follow up ', ' followed up ', ' followup ', ' follow-up ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' cancer microenvironment ', ' tumor microenvironment ', ' cost ', ' PI-3K/AKT ', ' PI3K/AKT ', ' Prevalence ', ' serum prostate specific antigen ', ' serum PSA ', ' PSA test ', ' prostate specific antigen screening ', ' prostate specific antigen test ', ' PSA screening ', ' tumor ', ' candidate biomarker ', ' candidate marker ', ' molecular phenotype ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' clinical decision-making ', ' adverse consequence ', ' adverse outcome ', ' cancer cell metabolism ', ' cancer metabolism ', ' tumor cell metabolism ', ' tumor metabolism ', ' stratified patient ', ' patient stratification ', ' expression subtypes ', ' molecular sub-types ', ' molecular subsets ', ' molecular subtypes ', ' ethnically diverse ', ' ethnic diversity ', ' early screening ', ' prostate cancer progression ', ' Immune infiltrates ', ' T cell infiltration ', ' T cell tumor trafficking ', ' immune cell infiltrate ', ' immune infiltration ', ' intratumoral immune cell ', ' tumor immune cell ', ' Tumor-infiltrating immune cells ', ' Hypoxic tumor ', ' tumor hypoxia ', ' deep learning ', ' ConvNet ', ' convolutional network ', ' convolutional neural nets ', ' convolutional neural network ', ' ']",NCI,STANFORD UNIVERSITY,R01,2020,910446,CA-18,0.16811311477344876
"Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification PROJECT SUMMARY Prostate cancer (PCa) develops in sixteen percent of males and is the second leading cause of cancer-related death in men in the United States. While incidence is high, PCa presents with a wide range of aggressiveness and in many cases does not develop into life-threatening aggressive cancer. Current diagnostic strategies may fail to detect all instances of clinically significant PCa and have limited ability to accurately distinguish clinically significant from indolent PCa due to incomplete and inconsistent information. This not only subjects patients to detrimental co-morbidities including overtreatment and undertreatment, but also exacerbates already significant healthcare costs. Consequently, there is an urgent clinical need to achieve accurate detection and classification of clinically significant PCa and determine the appropriate management strategy. Multi-parametric MRI (mp-MRI), consisting of T2-weighted, diffusion-weighted, and dynamic contrast-enhanced imaging, has emerged as the preferred imaging technique for non-invasive detection and grading of PCa. However, the current standardized scoring system for mp-MRI, Prostate Imaging Reporting and Data System (PI-RADS) v2, has limited ability to distinguish between indolent and clinically significant PCa, with sensitivity and specificity in the range of 60-85%. This suboptimal accuracy and considerable variation in performance is mainly due to the fact that current PI-RADS scoring is based on qualitative analysis and subjective interpretation of mp-MRI, confounded by scanner- and patient-specific variations, including B1+ inhomogeneity, arterial input function, and susceptibility and eddy current effects. This proposal aims to overcome these critical limitations of current mp-MRI by establishing a new MRI-based artificial intelligence based on two synergistic innovations: 1) new quantitative dynamic contrast-enhanced MRI analysis techniques and diffusion-weighted MRI acquisition methods that minimize scanner- and patient-specific variations, and 2) novel multi-class deep learning models that can fully integrate the multi-labeled quantitative mp- MRI information. By leveraging the synergy between existing mp-MRI data and to-be-acquired quantitative mp- MRI data with subsequent mapping of all lesions at whole-mount histopathology, the proposed MRI-based deep learning model will be evaluated for detection and classification of clinically significant PCa, compared with the current standard-of-care, PI-RADS v2. Completion of this project will lead to the creation, clinical deployment, and pivotal validation of a new MRI-based artificial intelligence that achieves unprecedented accuracy for detection and classification of clinically significant PCa, thereby increasing confidence in separating indolent PCa from significant PCa and reducing unnecessary biopsies, undertreatment, and overtreatment. PROJECT NARRATIVE Current diagnostic strategies can fail to accurately detect and classify clinically significant prostate cancer, leading to detrimental overtreatment and undertreatment. This research project aims to jointly develop and integrate innovative quantitative magnetic resonance imaging (MRI) techniques and artificial intelligence algorithms to achieve significantly improved accuracy for detection and classification of clinically significant prostate cancer. The new MRI- based artificial intelligence will be a transformative technology to reduce unnecessary prostate biopsies and enhance decision making for patient management to avoid overtreatment and undertreatment of prostate cancer.",Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification,9946182,R01CA248506,"['Radiology Specialty ', ' General Radiology ', ' Radiology ', ' ROC Curve ', ' ROC Analyses ', ' receiver operating characteristic analyses ', ' receiver operating characteristic curve ', ' Sensitivity and Specificity ', ' Standardization ', ' Technology ', ' United States ', ' Imaging Techniques ', ' Imaging Procedures ', ' Imaging Technics ', ' Health Care Costs ', ' Health Costs ', ' Healthcare Costs ', ' doubt ', ' Uncertainty ', ' prisma ', ' base ', ' Label ', ' improved ', ' Area ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Histologically ', ' Histologic ', ' Susceptibility ', ' Predisposition ', ' Lesion ', ' Indolent ', ' R-Series Research Projects ', ' R01 Mechanism ', ' R01 Program ', ' Research Grants ', ' Research Projects ', ' Research Project Grants ', ' Gleason Grade ', ' Gleason Score ', ' Gleason Score for Prostate Cancer ', ' Gleason Sum ', ' Gleason-SC ', ' Gleason Grade for Prostate Cancer ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Life ', ' Scanning ', ' Texture ', ' Techniques ', ' System ', ' Performance ', ' synergism ', ' Histopathology ', ' novel ', ' Reporting ', ' Modeling ', ' Ig Variable Region ', ' Immunoglobulin V ', ' Variable Region ', ' Immunoglobulin Variable Region ', ' cancer classification ', ' DWI (diffusion weighted imaging) ', ' DWI-MRI ', ' Diffusion MRI ', ' Diffusion Weighted MRI ', ' Diffusion weighted imaging ', ' Diffusion-weighted Magnetic Resonance Imaging ', ' dMRI ', ' diffusion tensor imaging ', ' Diffusion Magnetic Resonance Imaging ', ' image-based method ', ' imaging method ', ' imaging modality ', ' Data ', ' Detection ', ' Reproducibility ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Non-Invasive Detection ', ' Noninvasive Cancer Detection ', ' Noninvasive Detection ', ' Non-Invasive Cancer Detection ', ' Validation ', ' imaging ', ' Image ', ' designing ', ' design ', ' prospective ', ' innovate ', ' innovative ', ' innovation ', ' clinical significance ', ' clinically significant ', ' standard of care ', ' prostate biopsy ', ' diffusion weighted ', ' contrast enhanced ', ' over-treatment ', ' overtreatment ', ' deep learning ', ' ConvNet ', ' convolutional network ', ' convolutional neural nets ', ' convolutional neural network ', ' smart algorithm ', ' intelligent algorithm ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Biopsy ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Classification ', ' Systematics ', ' comorbidity ', ' co-morbid ', ' co-morbidity ', ' Cessation of life ', ' Death ', ' Decision Making ', ' Diffusion ', ' Goals ', ' Image Enhancement ', ' Incidence ', ' Information Systems ', ' Data Systems ', ' IT Systems ', ' Information Technology Systems ', ' Interobserver Variability ', ' Inter-Observer Variability ', ' Inter-Observer Variation ', ' Interobserver Variations ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' male ', ' men ', "" men's "", ' Methods ', ' Patients ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' ']",NCI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2020,567651,CA-33,0.22938246892956574
"Generalizable biomedical informatics strategies for predictive modeling of treatment response Identification of patients with poor and favorable treatment response prior to therapy administration is invaluable for improving patient survival and disease management. We propose to build an open-source scalable generalizable method that would assist experimentalists and clinicians on assessing patient's risk of developing therapy resistance and would establish a foundation for our long-term goal to build a platform for patient-centric clinical decision making, personalized therapeutic advice, and disease management.  We propose to develop a generalizable versatile bioinformatics paradigm that will use patient molecular profiles to PREDICT their Therapy Response, PREDICTTR, which combines network analysis, statistical modeling, and ensemble machine learning in a unique innovative way that allows accurate elucidation of complex multi-level relationships that govern treatment response. The objective of our proposed approach is two-fold: (i) uncover molecular markers and valuable candidates for therapeutic intervention, which can potentially be targeted to preclude or overcome resistance; and (ii) predict patient's response to therapy administration, which holds a long-term promise to improve disease outcome and reduce the cost of unnecessary and ineffective treatments.  Motivated by increasing cases of treatment resistance in oncology, we will apply our algorithm to elucidate (i) response to androgen targeting in prostate cancer and (ii) response to standard-of-care chemotherapy in acute myeloid leukemia. We will disseminate our approach through a web-based decision- making tool, which will be implemented through a Hadoop-oriented solution to (i) broaden its practical impact and (ii) establish clinical utility. Taken together, this multi-task resource is a unique innovative effort of its kind in the therapeutic resistance space with a direct broad impact on personalized therapeutic advice and disease management. Even though we will train our model in prostate cancer and acute myeloid leukemia, our approach can be easily and broadly applicable to other therapies and diseases.  This effort will be led by an Early Stage Investigator, Antonina Mitrofanova (PI) who has extensive training and expertise in biomedical informatics and big data analytics. Her collaborative team includes Dr. Shantenu Jha (Rutgers, co-I) who is an expert in distributed systems and will advise on Hadoop development and validation; Dr. Shridar Ganesan (Rutgers, co-I) who will provide clinical and sequencing patient data and incorporate the utilization of our method into the Rutgers CINJ Molecular Tumor Board; Dr. Isaac Kim (Rutgers, co-I) who will provide additional data for validation in prostate cancer; Dr. Christopher Hourigan (NHLBI , NIH, Significant Collaborator), who will provide data for clinical validation in acute myeloid leukemia and is committed to test our web-based portal; and Dr. Scott Parrott (Rutgers, co-I), who is an expert in statistical analysis and will consult on power calculations and multiple testing corrections. PROJECT NARRATIVE Identification of patients with poor and favorable treatment response prior to therapy administration is invaluable for improving patient survival and disease management. This proposal is dedicated to developing novel biomedical informatics paradigm to uncover genomic and transcriptomic mechanisms of therapeutic resistance and predict patients at risk of treatment failure, which will be shared with a wide scientific community through an open-source web-based portal. We utilize resistance to androgen-deprivation and second- generation anti-androgens in prostate cancer and resistance to standard-of-care chemotherapy in acute myeloid leukemia as our training examples, yet our paradigm can be broadly generalizable to study resistance to various therapeutic regimens and across different diseases.",Generalizable biomedical informatics strategies for predictive modeling of treatment response,10117702,R01LM013236,"['Affect ', ' Age ', ' ages ', ' Algorithms ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', ' Androgen Antagonists ', ' Anti-Androgen ', ' Anti-Androgen Agents ', ' Antiandrogen Agents ', ' Antiandrogens ', ' androgen inhibitor ', ' Androgens ', ' Androgenic Agents ', ' Androgenic Compounds ', ' Therapeutic Androgen ', ' Atlases ', ' Prostate Adenocarcinoma ', ' Prostate Gland Adenocarcinoma ', ' prostatic adenocarcinoma ', ' Clinical Trials ', ' Communities ', ' Computers ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Statistical Data Interpretation ', ' Statistical Data Analyses ', ' Statistical Data Analysis ', ' statistical analysis ', ' Decision Making ', ' Disease ', ' Disorder ', ' Distributed Systems ', ' Engineering ', ' Foundations ', ' Genes ', ' Goals ', ' Acute Myelocytic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Acute Myeloblastic Leukemia ', ' Acute Myelogenous Leukemia ', ' acute granulocytic leukemia ', ' acute myeloid leukemia ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Online Systems ', ' On-Line Systems ', ' online computer ', ' web based ', ' Patients ', ' Publishing ', ' Race ', ' Racial Group ', ' Racial Stocks ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Risk ', ' Testing ', ' Time ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Translations ', ' Work ', ' Generations ', ' case report ', ' Case Study ', ' therapy failure ', ' Treatment Failure ', ' base ', ' improved ', ' Clinical ', ' Ensure ', ' Training ', ' Sample Size ', ' Oncology Cancer ', ' Oncology ', ' Therapeutic ', ' Gleason Grade ', ' Gleason Score ', ' Gleason Score for Prostate Cancer ', ' Gleason Sum ', ' Gleason-SC ', ' Gleason Grade for Prostate Cancer ', ' tool ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Disorder Management ', ' Disease Management ', ' Investigation ', ' Complex ', ' Event ', ' Consult ', ' cohort ', ' Disease Outcome ', ' novel ', ' Position ', ' Positioning Attribute ', ' intervention therapy ', ' Therapeutic Intervention ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' response ', ' deprivation ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Transcription Regulation ', ' Transcriptional Control ', ' Transcriptional Regulation ', ' Institution ', ' T-Stage ', ' Tumor stage ', ' Data ', ' Molecular Analysis ', ' Molecular Fingerprinting ', ' molecular profile ', ' molecular signature ', ' Molecular Profiling ', ' predict therapeutic response ', ' predict therapy response ', ' predict treatment response ', ' therapy prediction ', ' treatment prediction ', ' treatment response prediction ', ' Prediction of Response to Therapy ', ' CINJ ', ' Cancer Institute of New Jersey ', ' Clinical Data ', ' Validation ', ' Molecular ', ' developmental ', ' Development ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' resistance to therapy ', ' resistant to therapy ', ' therapeutic resistance ', ' treatment resistance ', ' therapy resistant ', ' cost ', ' biomed informatics ', ' biomedical informatics ', ' cancer cell genome ', ' tumor genome ', ' cancer genome ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' designing ', ' design ', ' innovate ', ' innovative ', ' innovation ', ' resistant ', ' Resistance ', ' transcriptomics ', ' open source ', ' multi-task ', ' multitask ', ' chemotherapy ', ' develop therapy ', ' intervention development ', ' treatment development ', ' therapy development ', ' tumor ', ' standard of care ', ' response to treatment ', ' therapeutic response ', ' treatment response ', ' molecular biomarker ', ' molecular marker ', ' genome scale ', ' genomewide ', ' genome-wide ', ' Regimen ', ' clinical decision-making ', ' BigData ', ' Big Data ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' personalized therapeutic ', ' Patient risk ', ' clinical sequencing ', ' internet portal ', ' on-line portal ', ' online portal ', ' web-based portal ', ' web portal ', ' unnecessary treatment ', ' patient profile ', ' profiles in patients ', ' ineffective treatment ', ' ineffective therapies ', ' androgen ablation therapy ', ' androgen blockade therapy ', ' androgen deprivation treatment ', ' androgen deprivation therapy ', ' therapeutic candidate ', ' patient specific response ', ' responsive patient ', ' patient response ', ' Big Data Analytics ', ' Big Data Tools ', ' Big Data Methods ', ' treatment risk ', ' multiple omic data ', ' Multiomic Data ', ' statistical learning ', ' ']",NLM,RBHS-SCHOOL/ HEALTH RELATED PROFESSIONS,R01,2020,323986,NJ-10,0.11877453932408194
"High speed automated intraoperative microscopy of the prostate circumference to ensure tumor-free margins in radical prostatectomy Project Summary: In prostate cancer (PCa), the presence and amount of residual tumor at the surface of the excised prostate is the only prognostic factor that is affected by surgical technique, vs. other factors, which are fixed and non-modifiable. Yet, positive surgical margins (PSM), defined as the presence of tumor cells at the inked surface of the removed specimen, are common, especially in advanced stage cancers, and are a strong independent risk factor for clinical progression and secondary treatment. In addition, elevated post-operative PSA, which is understood to be related to tumor left behind in the patient, is also associated with high risk of progression and secondary treatment. Thus, complete tumor removal is important to achieve to improve  patient outcomes and reduce overtreatment, yet there is a delicate balance between resection radicality and  minimizing damage to the neurovascular bundles to preserve post-operative function. The NeuroSAFE trial demonstrated that real-time detection and correction of PSMs by comprehensive histology of the prostate  circumference results in improved patient outcomes, yet there are no widely adoptable methods to achieve this. In an effort to address this technical gap, we have developed video-rate structured illumination microscopy (VR-SIM) and demonstrated that it enables accurate diagnosis of PCa in the biopsy setting, and that it can  rapidly deliver gigapixel microscopic images of the entire prostate surface for detection of PSMs. VR-SIM delivers the surface area coverage and resolution needed to detect PSMs, yet it is also fast and relatively simple and inexpensive, opening the possibility for widespread adoption. In this project, our interdisciplinary team of  engineers and clinicians with significant prostate expertise will further advance this technology towards clinical translation, by completing critical technology development steps and by prospectively validating it in a large patient series. Specifically, we will increase the mechanical automation speed of the device, and will develop a fully automated system for handling of the removed prostate, to enable gigapixel panoramas of the entire  prostate circumferential surface to be delivered within 10 minutes of removal and with minimal tissue processing and user intervention. We will then leverage our recently developed dual-color fluorescent stain that replicates standard H&E with high specificity, to develop expert-validated clinical image atlases using biopsies and  cadaveric specimens to enhance image interpretation of VR-SIM prostate panoramas. These improvements will be combined to test the system in a prospective 250-patient clinical study, to determine the accuracy of the device for intra-operative detection of PSMs and prediction of post-operative PSA based on measurement of PSM extent. Finally, we will measure and model expert reviewer behavior using a novel web-enabled visual observer tracking method, which could be used in future computer-assisted search algorithms to expedite  intra-operative image review. Successful completion will set the stage for multi-center clinical trials to validate the clinical utility of VR-SIM for real-time detection and correction of PSMs, and improvement of patient outcomes. Project Narrative: Achieving complete tumor removal in prostate cancer is an important goal to achieve because leaving tumor behind in the patient contributes to increased risk of cancer progression and need for additional harmful treatment. Yet, it is difficult to determine in real-time if surgery is successful due to the lack of available technologies for intra-operative guidance. This project will develop a rapid scanner that will automatically scan the entire prostate surface for residual tumor within 10 minutes of removal, providing images which are readily interpreted by trained pathologists and enabling real-time guidance of nerve-sparing prostate cancer surgery.",High speed automated intraoperative microscopy of the prostate circumference to ensure tumor-free margins in radical prostatectomy,9932350,R01CA222831,"['Adoption ', ' Affect ', ' Algorithms ', ' Atlases ', ' Automation ', ' Behavior ', ' Biopsy ', ' Cadaver ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Clinical Research ', ' Clinical Study ', ' Color ', ' Engineering ', ' Equilibrium ', ' balance ', ' balance function ', ' Frozen Sections ', ' Freeze Sectioning ', ' Future ', ' Goals ', ' Gold ', ' Histology ', ' Human ', ' Modern Man ', ' Image Enhancement ', ' Ink ', ' Lighting ', ' Illumination ', ' Manuals ', ' men ', "" men's "", ' Methods ', ' Microscopy ', ' Nerve ', ' Online Systems ', ' On-Line Systems ', ' online computer ', ' web based ', ' Operating Rooms ', ' Optics ', ' optical ', ' Pathology ', ' Patients ', ' Postoperative Period ', ' Post-Operative ', ' Postoperative ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Prostatic Neoplasms ', ' Prostate Neoplasms ', ' Prostate Tumor ', ' Prostatic Neoplasia ', ' Risk Factors ', ' Sensitivity and Specificity ', ' Specificity ', ' Stains ', ' Staining method ', ' Technology ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Translations ', ' Genitourinary system ', ' Genitourinary ', ' Urogenital ', ' Urogenital System ', ' Work ', ' Generations ', ' Measures ', ' Case Series ', ' Custom ', ' base ', ' Organ ', ' cancer progression ', ' neoplasm progression ', ' neoplastic progression ', ' tumor progression ', ' improved ', ' prostate surgery ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Left ', ' Site ', ' Area ', ' Surface ', ' Clinical ', ' Series ', ' Ensure ', ' Training ', ' Surgical margins ', ' Visual ', ' Measurement ', ' Progression-Free Survivals ', ' analog ', ' Pathologist ', ' tool ', ' Diagnostic ', ' Research Specimen ', ' Specimen ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' mechanical ', ' Mechanics ', ' Adopted ', ' Surface of Human Prostate ', ' Surface of the Prostate ', ' Scanning ', ' Pattern ', ' Techniques ', ' System ', ' Operative Procedures ', ' Surgical ', ' Surgical Interventions ', ' Surgical Procedure ', ' surgery ', ' Operative Surgical Procedures ', ' residual disease ', ' Residual Tumors ', ' cancer risk ', ' Tumor Cell ', ' neoplastic cell ', ' authority ', ' cohort ', ' tech development ', ' technology development ', ' Speed ', ' Structure ', ' novel ', ' Devices ', ' Abscission ', ' Extirpation ', ' Removal ', ' Surgical Removal ', ' resection ', ' Excision ', ' Modeling ', ' Sampling ', ' visual search ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' cancer surgery ', ' cancer diagnosis ', ' intra-operative imaging ', ' intraoperative imaging ', ' surgical imaging ', ' Image-Guided Surgery ', ' tissue processing ', ' Address ', ' Data ', ' Detection ', ' Multi-center clinical trial ', ' Multi-site clinical trial ', ' Multicenter clinical trial ', ' Multisite clinical trial ', ' Multi-Institutional Clinical Trial ', ' General Prognostic Factor ', ' Prognostic/Survival Factor ', ' Prognostic Factor ', ' Resolution ', ' Clinical Management ', ' Patient outcome ', ' Patient-Centered Outcomes ', ' Patient-Focused Outcomes ', ' Validation ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' computer aided ', ' Computer Assisted ', ' rapid detection ', ' oncologic imaging ', ' oncology imaging ', ' tumor imaging ', ' cancer imaging ', ' prospective ', ' web-enabled ', ' tumor ', ' high risk ', ' clinical practice ', ' computer assisted detection ', ' computer aided detection ', ' accurate diagnosis ', ' prostate biopsy ', ' imaging system ', ' contrast imaging ', ' neuro-vascular ', ' neurovascular ', ' microscope imaging ', ' microscopy imaging ', ' microscopic imaging ', ' histologic image ', ' histological image ', ' clinical imaging ', ' clinical translation ', ' recruit ', ' preservation ', ' over-treatment ', ' overtreatment ', ' machine learned algorithm ', ' machine learning algorithm ', ' classification algorithm ', ' ']",NCI,TULANE UNIVERSITY OF LOUISIANA,R01,2020,355935,LA-01,0.20640543018843938
"Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization Project Summary Prostate cancer (PCa) is the most diagnosed form of non-cutaneous cancer in US men. The selection of patients who require immediate treatment from those suitable for active surveillance currently relies on non- specific and inaccurate measurements. A method that allows clinicians to more confidently discriminate clinically relevant from non-life-threatening tumors is needed to improve patient management. Multiparametric magnetic resonance imaging (mpMRI) is the preferred non-invasive imaging modality for characterizing primary PCa. However, its accuracy for detecting clinically significant PCa is variable. We propose to address this limitation by combining mpMRI with positron emission tomography (PET) with a PCa-specific radiotracer and using advanced multimodal machine learning models (i.e. radiomics and deep learning) to characterize tumor aggressiveness based on the imaging data. Recently, scanners capable of simultaneous PET and MR data acquisition in human subjects have become commercially available. An integrated MR-PET scanner is the ideal tool for comparing MR and PET derived image features to identify those that provide complementary information and build a hybrid PET-mpMRI model that most accurately identifies clinically significant tumors. While this novel technology allows the acquisition of perfectly coregistered complementary anatomical, functional and metabolic data in a single imaging session, a new challenge needs to first be addressed to obtain quantitatively accurate PET data. In an integrated MR-PET scanner, the information needed for PET attenuation correction (AC) has to be derived from the MR data and the methods currently available for this task are inadequate for advanced quantitative studies. We have formed an academic-industrial partnership to accelerate the translation of multimodal MR-PET machine learning approaches into PCa research and clinical applications by addressing the AC challenge and validating machine learning models for detecting clinically significant disease against gold standard histopathology in patients undergoing radical prostatectomy. Specifically, we will: (1) Develop and validate an MR-based approach for obtaining quantitatively accurate PET data. We hypothesize that attenuation maps as accurate as those obtained using a 511 keV transmission source  the true gold standard for PET AC  will be obtained; (2) Identify the multimodal radiomics model that most accurately predicts PCa aggressiveness. We hypothesize that the diagnostic accuracy of this approach will be superior to that offered by the stand-alone modalities; (3) Evaluate radiomics and deep learning approaches for predicting pPCa aggressiveness. We hypothesize that machine learning approaches will achieve a higher predictive accuracy when applied to data acquired simultaneously than sequentially. Project narrative A better method to non-invasively characterize primary prostate cancer is needed to improve patient management. Extracting additional information from multimodality quantitative MR-PET data using machine learning approaches is expected to result in better diagnostic performance. In this work, we propose to accelerate the translation of quantitative MR-PET to prostate cancer research and clinical applications. In particular, we will develop and validate an MR-based attenuation correction approach to guarantee that quantitatively accurate PET data are obtained in an integrated MR-PET scanner and then use machine learning approaches to characterize the aggressiveness of the tumors in patients undergoing radical prostatectomy.",Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization,9853761,R01CA218187,"['Affect ', ' Algorithms ', ' Anatomy ', ' Anatomic ', ' Anatomic Sites ', ' Anatomic structures ', ' Anatomical Sciences ', ' Biopsy ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Classification ', ' Systematics ', ' Diagnosis ', ' Discrimination ', ' Cognitive Discrimination ', ' Disease ', ' Disorder ', ' Gold ', ' Hand ', ' Hybrids ', ' Interobserver Variability ', ' Inter-Observer Variability ', ' Inter-Observer Variation ', ' Interobserver Variations ', ' Kinetics ', ' Life Expectancy ', ' Ligands ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Maps ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Patients ', ' Pelvis ', ' Pelvic ', ' Pelvic Region ', ' Phenotype ', ' Positron-Emission Tomography ', ' PET ', ' PET Scan ', ' PET imaging ', ' PETSCAN ', ' PETT ', ' Positron Emission Tomography Medical Imaging ', ' Positron Emission Tomography Scan ', ' Rad.-PET ', ' positron emission tomographic (PET) imaging ', ' positron emission tomographic imaging ', ' positron emitting tomography ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Quality of life ', ' QOL ', ' Risk ', ' Computer software ', ' Software ', ' Testing ', ' Time ', ' Translations ', ' Work ', ' Dataset ', ' Data Set ', ' Guidelines ', ' base ', ' human subject ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' bone scanning ', ' skeletal imaging ', ' bone imaging ', ' Biological ', ' Physiologic ', ' Physiological ', ' Lesion ', ' Individual ', ' Measurement ', ' Patient Selection ', ' radiologist ', ' Metabolic ', ' Morphology ', ' tool ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' prostate specific antigen level ', ' PSA level ', ' Scanning ', ' Source ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' early detection ', ' Early Diagnosis ', ' Performance ', ' radiolabel ', ' radiotracer ', ' Accuracy of Diagnosis ', ' diagnostic accuracy ', ' attenuation ', ' Histopathology ', ' novel technologies ', ' new technology ', ' Modality ', ' Devices ', ' Modeling ', ' Meta-Analysis ', ' cancer classification ', ' image-based method ', ' imaging method ', ' imaging modality ', ' FOLH ', ' FOLH1 ', ' Folate Hydrolase 1 ', ' GCP2 ', ' Glutamate Carboxypeptidase II ', ' N-Acetylated Alpha-Linked Acidic Dipeptidase 1 ', ' NAALAD1 ', ' NAALADase I ', ' PSM ', ' PSMA ', ' Prostate-Specific Membrane Antigen ', ' FOLH1 gene ', ' Address ', ' Data ', ' Reproducibility ', ' Cancer Death Rates ', ' Cancer Patient ', ' Transmission ', ' transmission process ', ' imaging ', ' Image ', ' anti-cancer research ', ' cancer research ', ' anticancer research ', ' oncologic imaging ', ' oncology imaging ', ' tumor imaging ', ' cancer imaging ', ' data acquisition ', ' clinical relevance ', ' clinically relevant ', ' clinical significance ', ' clinically significant ', ' clinical applicability ', ' clinical application ', ' early therapy ', ' Early treatment ', ' tumor ', ' multi-modality ', ' multimodality ', ' industrial partnership ', ' industry partnership ', ' industry partner ', ' noninvasive imaging ', ' non-invasive imaging ', ' radiomics ', ' deep learning ', ' multi-modal data ', ' multi-modal datasets ', ' multimodal datasets ', ' multimodal data ', ' ']",NCI,MASSACHUSETTS GENERAL HOSPITAL,R01,2020,671823,MA-08,0.1245754745824329
"Prostate Cancer Diagnosis by Multiparametric Ultrasound Prostate cancer (PCa) is the most frequently diagnosed cancer among American males, accounting for 20% of new cancer diagnoses, but PCa is directly responsible for only 9% of cancer related deaths. PSA screening facilitates the detection of PCa, but many of the cancers detected by PSA screening are low to intermediate grade, resulting in overtreatment of non-aggressive PCa. Recent studies suggest an urgent need to selectively identify clinically significant PCa that will result in cost-effective treatment of PCa. In the past few years, multiparametric MRI (mp-MRI) has become the standard of care for diagnosis of aggressive PCa. Although mp- MRI guided biopsy can selectively detect higher grade PCa lesions, several recent studies acknowledge that a considerable number of clinically important lesions are missed by mp-MRI. Furthermore, given the high cost of MRI, the geographic variability in the availability of MRI systems, the inexact methods used to register and fuse MRI with ultrasound for biopsy, and the dangers of Gadolinium in patients with renal insufficiency, there is a need for a more cost-effective, alternative to detect high-grade PCa. Recent studies have demonstrated that contrast-enhanced ultrasound (CEUS) can selectively detect patients with clinically significant PCa. New methods have been proposed to enhance conventional ultrasound detection of PCa, including subharmonic imaging (SHI), contrast-enhanced ultrasound dispersion imaging (CUDI) and viscoelastography. The objective of this project is to develop a system capable of a multiparametric combination of ultrasound techniques (mp- US) for detection of clinically significant PCa. We will compare 3D mp-US and mp-MRI to identify significant PCa (defined as: Gleason score  7, a single core with > 50% involvement, or > 25% of biopsy cores positive for PCa or as Gleason grade group  2, PSA > 10 or clinical stage of cT2b or worse). The first year of the study will be dedicated to implementation of our mp-US technique on a commercially available 3D transrectal probe, and to adapting a MRI-based fusion/registration system to mp-US. During the second year, we will optimize mp-US with a machine learning approach, based upon pathologic correlation with 50 radical prostatectomy patients. The final 3 years of the study will be dedicated to a clinical trial with 300 participants suspected of having PCa. Each participant will receive an experimental intervention in the form of biopsy of up to 3 suspicious areas identified by transrectal ultrasound evaluation of the prostate with mp-US. For comparison, a maximum of 3 targeted biopsy cores will also be obtained from each participant, based on mp-MRI (the clinical intervention). Following the targeted biopsy, each participant will also receive a systematic biopsy (standard of care) consisting of 6 laterally directed biopsy cores and 6 medially directed biopsy cores. The study is powered to demonstrate that targeted biopsy based upon mp-US is not inferior to targeted biopsy based upon mp-MRI. Project Narrative This project will develop a novel, cost-effective Intervention, 3D multi-parametric ultrasound imaging (mp-US), for selectively guiding biopsies to detect clinically significant PCa in patients, and demonstrate that 3D mp-US is comparable (i.e., non-inferior) to mp-MRI (the clinical intervention). Thus, at the end of this project our partnership will deliver an accurate, 3D mp-US system ready for clinical deployment. mp-US prostate rev3 narrative DRAFT October 2, 2019 11:56 AM 1",Prostate Cancer Diagnosis by Multiparametric Ultrasound,10032625,R01CA252311,"['Accounting ', ' Behavior ', ' Biopsy ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Clinical Trials ', ' Contrast Media ', ' Contrast Agent ', ' Contrast Drugs ', ' Radiopaque Media ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Elasticity ', ' Engineering ', ' Gadolinium ', ' Gd element ', ' Geography ', ' Industry ', ' Kinetics ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' male ', ' men ', "" men's "", ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Neighborhoods ', ' Patients ', ' Pilot Projects ', ' pilot study ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Kidney Failure ', ' Kidney Insufficiency ', ' Renal Failure ', ' Renal Insufficiency ', ' Resources ', ' Research Resources ', ' ROC Curve ', ' ROC Analyses ', ' receiver operating characteristic analyses ', ' receiver operating characteristic curve ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Specificity ', ' Time ', ' Tissues ', ' Body Tissues ', ' Ultrasonography ', ' Echography ', ' Echotomography ', ' Medical Ultrasound ', ' Ultrasonic Imaging ', ' Ultrasonogram ', ' Ultrasound Diagnosis ', ' Ultrasound Medical Imaging ', ' Ultrasound Test ', ' diagnostic ultrasound ', ' sonogram ', ' sonography ', ' sound measurement ', ' ultrasound ', ' ultrasound imaging ', ' ultrasound scanning ', ' Viscosity ', ' base ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' Ovarian ', ' Left ', ' Medial ', ' Area ', ' Clinical ', ' Evaluation ', ' Lesion ', ' Base of Human Prostate ', ' Base of the Prostate ', ' Structure of base of prostate ', ' European ', ' detect prostate cancer ', ' prostate cancer detection ', ' prostate cancer early detection ', ' Screening for Prostate Cancer ', ' editorial ', ' Gleason Grade ', ' Gleason Score ', ' Gleason Score for Prostate Cancer ', ' Gleason Sum ', ' Gleason-SC ', ' Gleason Grade for Prostate Cancer ', ' Transrectal Ultrasound ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Scientist ', ' Scanning ', ' Home ', ' Home environment ', ' Techniques ', ' System ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' Country ', ' Colon or Rectum ', ' colo-rectal ', ' colorectum ', ' Colorectal ', ' American ', ' early detection ', ' Early Diagnosis ', ' Accuracy of Diagnosis ', ' diagnostic accuracy ', ' viscoelasticity ', ' Histopathology ', ' novel ', ' Participant ', ' treatment program ', ' Local Cancer ', ' Localized Cancer ', ' Localized Malignancy ', ' Localized Malignant Neoplasm ', ' technology/technique ', ' portability ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' Meta-Analysis ', ' cancer diagnosis ', ' Microbubbles ', ' Core Needle Biopsy ', ' Core Biopsy ', ' Detection ', ' Predictive Value ', ' PLCO study ', ' PLCO trial ', ' Prostate, Lung, Colo-rectal and Ovarian (PLCO) Cancer Screening Trial ', ' Prostate, Lung, Colo-rectal and Ovarian Cancer (PLCO) screening trial ', ' Prostate, Lung, Colo-rectal, and Ovarian (PLCO) ', ' Prostate, Lung, Colo-rectal, and Ovarian Cancer Screening Trial ', ' Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial ', ' Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial ', ' Prostate, Lung, Colorectal, and Ovarian (PLCO) ', ' Prostate, Lung, Ovarian (PLCO) ', ' Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial ', ' randomisation ', ' randomization ', ' randomly assigned ', ' Randomized ', ' Pathologic ', ' socio-economic ', ' socio-economically ', ' socioeconomically ', ' socioeconomics ', ' imaging ', ' Image ', ' cost ', ' cost effective ', ' Imaging technology ', ' Prostate CA therapy ', ' prostate cancer treatment ', ' Prostate Cancer therapy ', ' clinical significance ', ' clinically significant ', ' early therapy ', ' Early treatment ', ' PSA test ', ' prostate specific antigen screening ', ' prostate specific antigen test ', ' PSA screening ', ' effective intervention ', ' standard of care ', ' new marker ', ' novel biomarker ', ' novel marker ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' industrial partnership ', ' industry partnership ', ' industry partner ', ' screening ', ' contrast enhanced ', ' screening program ', ' over-treatment ', ' overtreatment ', ' Visualization ', ' ']",NCI,THOMAS JEFFERSON UNIVERSITY,R01,2020,673228,PA-03,0.14158533138314677
"Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS Project Summary Prostate cancer is one of the most commonly occurring forms of cancer, accounting for 21% of all cancer in men. The Prostate Imaging Reporting and Data System (PI-RADS) aims to standardize reporting of prostate cancer using multi-parametric magnetic resonance imaging (mpMRI). However, the in-depth analysis, as demanded by PI-RADS, remains challenging due to the complexity and heterogeneity of the disease, and it is a clinically burdensome task subject to both signicant intra- and inter-reader variability. Auxiliary tools based on machine learning methods such as deep learning can reduce diagnostic variability and increase workload efciency by automatically performing tasks and presenting results to a radiologist for the purpose of decision support. In particular, automated identication and classication of lesion candidates using imaging data can be performed with respect to PI-RADS scoring. In Phase I of this project, we developed two automated methods to reduce the intra- and inter-observer variability while interpreting mpMRI images using the PI-RADS protocol: (i) a method to co-register mpMRI data, and (ii) a method to geometrically segment the prostate gland into the PI-RADS protocol sector map. The overarching goal of this Phase II project is to develop machine learning algorithms that incorporate both co-registered multi-modal imaging biomarkers and PI-RADS sector map information into an automated clinical diagnostic aid. The innovation in this project lies in the use of deep learning to automatically predict PI-RADS classication. This project is signicant in that it has the potential to improve clinical efciency and reduce diagnostic variation in prostate cancer diagnosis. In Aim 1 of this project, we will develop a deep learning approach to localize and classify lesions in mpMRI. In Aim 2, we will integrate this diagnostic tool into the ProFuseCAD system and perform rigorous multi-site validation to quantify PI-RADS classication performance. Both aims will utilize a database of over 1,000 existing mpMRI images from multiple clinical sites to develop and validate the algorithms. Ultimately, enhancements from this project will create a novel feature for Eigen's (the applicant company's) FDA 510(k)-cleared imaging product, ProFuseCAD, in order to improve the diagnosis and reporting of prostate cancer. Project Narrative Radiological interpretation of multimodal prostate imaging data is challenging and subject to high levels of vari- ability. To address this problem, auxiliary tools based on machine learning methods such as deep learning can increase workload efciency by automatically performing tasks and presenting results to a radiologist for the purpose of decision support. In particular, automated identication of lesion candidates and assessment of po- tentially benign or malignant lesions with respect to specic PI-RADS categories from clinical imaging data can improve prostate cancer reporting and reduce variation in radiological interpretation.",Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS,10155627,R42CA224888,"['Accounting ', ' Algorithms ', ' Atlases ', ' Biopsy ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Classification ', ' Systematics ', ' Communication ', ' Data Collection ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Diffusion ', ' Environment ', ' Goals ', ' Image Enhancement ', ' Information Systems ', ' Data Systems ', ' IT Systems ', ' Information Technology Systems ', ' Interobserver Variability ', ' Inter-Observer Variability ', ' Inter-Observer Variation ', ' Interobserver Variations ', ' Intraobserver Variability ', ' Intra-Observer Variability ', ' Intra-Observer Variation ', ' Intraobserver Variations ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Manuals ', ' Maps ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' mortality ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Radiology Specialty ', ' General Radiology ', ' Radiology ', ' Reading ', ' Research ', ' medical specialties ', ' Specialty ', ' Specificity ', ' Standardization ', ' Time ', ' Work ', ' Workload ', ' Work Load ', ' base ', ' Label ', ' improved ', ' Procedures ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Site ', ' Benign ', ' Clinical ', ' Malignant ', ' Malignant - descriptor ', ' Specified ', ' Specific qualifier value ', ' Phase ', ' Variation ', ' Variant ', ' Training ', ' Lesion ', ' mental ', ' Psyche structure ', ' Data Bases ', ' data base ', ' Databases ', ' radiologist ', ' Collaborations ', ' Letters ', ' Staging ', ' tool ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Protocol ', ' Protocols documentation ', ' Source ', ' System ', ' Performance ', ' novel ', ' Agreement ', ' Categories ', ' Reporting ', ' Modeling ', ' Meta-Analysis ', ' cancer diagnosis ', ' DWI (diffusion weighted imaging) ', ' DWI-MRI ', ' Diffusion MRI ', ' Diffusion Weighted MRI ', ' Diffusion weighted imaging ', ' Diffusion-weighted Magnetic Resonance Imaging ', ' dMRI ', ' diffusion tensor imaging ', ' Diffusion Magnetic Resonance Imaging ', ' Radiologic Finding ', ' Address ', ' Data ', ' Cancer Diagnostics ', ' multi-modal imaging ', ' multi-modality imaging ', ' multimodality imaging ', ' Multimodal Imaging ', ' Reader ', ' Reproducibility ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Evaluation ', ' Clinical Testing ', ' clinical test ', ' research clinical testing ', ' Localized Lesion ', ' Validation ', ' Monitor ', ' Process ', ' imaging ', ' Image ', ' image registration ', ' computer aided ', ' Computer Assisted ', ' designing ', ' design ', ' clinical site ', ' clinical research site ', ' Consumption ', ' innovate ', ' innovative ', ' innovation ', ' commercialization ', ' multi-modality ', ' multimodality ', ' clinical practice ', ' prostate biopsy ', ' contrast enhanced ', ' image guidance ', ' image guided ', ' T2 imaging ', ' T2 weighted image ', ' T2 weighted imaging ', ' imaging marker ', ' imaging-based biological marker ', ' imaging-based biomarker ', ' imaging-based marker ', ' imaging biomarker ', ' support tools ', ' disease heterogeneity ', ' clinical diagnostics ', ' clinical imaging ', ' radiologic imaging ', ' radiological imaging ', ' clinical decision support ', ' deep learning ', ' machine learned algorithm ', ' machine learning algorithm ', ' machine learning method ', ' ']",NCI,EIGEN HEALTH SERVICES LLC,R42,2020,700836,CA-01,0.26748299222350386
"Methods and Tools for Integrating Pathomics Data into Cancer Registries ThegoalofthisprojectistoenrichSEERregistrydatawithhigh-qualitypopulation-based biospecimendataintheformofdigitalpathology,machinelearningbasedclassificationsand quantitativepathomicsfeaturesets.Wewillcreateawell-curatedrepositoryofhigh-quality digitizedpathologyimagesforsubjectswhosedataisbeingcollectedbytheregistries.These imageswillbeprocessedtoextractcomputationalfeaturesandestablishdeeplinkageswith registrydata,thusenablingthecreationofinformation-rich,populationcohortscontaining objectiveimagingandclinicalattributes.SpecificexamplesofdigitalPathologyderivedfeature setsincludequantificationoftumorinfiltratinglymphocytesandsegmentationand characterizationofcancerorstromalnuclei.Featureswillalsoincludespectralandspatial signaturesoftheunderlyingpathology.Thescientificpremiseforthisapproachstemsfrom increasingevidencethatinformationextractedfromdigitizedpathologyimages (pathomicfeatures)areaquantitativesurrogateofwhatisdescribedinapathologyreport.The importantdistinctionbeingthatthesefeaturesarequantitativeandreproducible,unlikehuman observationsthatarehighlyqualitativeandsubjecttoahighdegreeofinter-andintra-observer variability.Thisdatasetwillprovide,aunique,population-widetissuebasedviewofcancer, anddramaticallyaccelerateourunderstandingofthestagesofdiseaseprogression,cancer outcomes,andpredictandassesstherapeuticeffectiveness. ThisworkwillbecarriedoutincollaborationwiththreeSEERregistries.Wewillpartner withTheNewJerseyStateCancerRegistryduringthedevelopmentphaseoftheproject(UG3). Duringthevalidationphaseoftheproject(UH3),theGeorgiaandKentuckyStateCancer Registrieswilljointheproject.Theinfrastructurewillbedevelopedinclosecollaborationwith SEERregistriestoensureconsistencywithregistryprocesses,scalabilityandabilitysupport creationofpopulationcohortsthatspanmultipleregistries.Wewilldeployvisualanalytictools tofacilitatethecreationofpopulationcohortsforepidemiologicalstudies,toolstosupport visualizationoffeatureclustersandrelatedwhole-slideimageswhileprovidingadvanced algorithmsforconductingcontentbasedimageretrieval.Thescientificvalidationofthe proposedenvironmentwillbeundertakenthroughthreestudiesinProstateCancer,Lymphoma andNSCLC,ledbyinvestigatorsatthethreesites. ThegoalofthisprojectistoenrichSEERcancerregistrydatawithhigh-qualitypopulation-based informationarisingfromdigitizedPathologyslides.Dataextracteddirectlyfromdigitized pathologyimages(Pathomicsdata)promisetoprovideinformationnotconsistentlyavailable fromPathologyreports.Thisdatasetwillprovide,aunique,population-widetissuebasedview ofcancer,anddramaticallyaccelerateourunderstandingofthestagesofdiseaseprogression, canceroutcomes,andpredictandassesstherapeuticeffectiveness.Thescientificvalidationof theproposedenvironmentwillbeundertakenthroughthreestudiesinProstateCancer, LymphomaandNSCLC,ledbyinvestigatorsatthethreesites.",Methods and Tools for Integrating Pathomics Data into Cancer Registries,10216066,UH3CA225021,"['Algorithms ', ' Anatomy ', ' Anatomic ', ' Anatomic Sites ', ' Anatomic structures ', ' Anatomical Sciences ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Non-Small-Cell Lung Carcinoma ', ' NSCLC ', ' NSCLC - Non-Small Cell Lung Cancer ', ' Non-Small Cell Lung Cancer ', ' Nonsmall Cell Lung Carcinoma ', ' nonsmall cell lung cancer ', ' Cell Nucleus ', ' Nucleus ', ' Classification ', ' Systematics ', ' Cohort Studies ', ' Concurrent Studies ', ' Communities ', ' Cues ', ' Disease ', ' Disorder ', ' Environment ', ' Evaluation Studies ', ' Exhibits ', ' Eye ', ' Eyeball ', ' Goals ', ' Human ', ' Modern Man ', ' Intraobserver Variability ', ' Intra-Observer Variability ', ' Intra-Observer Variation ', ' Intraobserver Variations ', ' Kentucky ', ' Lymphoma ', ' Germinoblastic Sarcoma ', ' Germinoblastoma ', ' Malignant Lymphoma ', ' Reticulolymphosarcoma ', ' Maps ', ' Methods ', ' Methodology ', ' Modernization ', ' New Jersey ', ' Pathology ', ' Patients ', ' Perception ', ' Phenotype ', ' Registries ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Science ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Work ', ' Tumor-Infiltrating Lymphocytes ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Area ', ' Clinical ', ' Phase ', ' Link ', ' Ensure ', ' prognostic ', ' Visual ', ' Disease Progression ', ' Collaborations ', ' Morphology ', ' tool ', ' Diagnostic ', ' Research Specimen ', ' Specimen ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Investigation ', ' Slide ', ' Texture ', ' Nuclear ', ' Transcend ', ' interest ', ' data management ', ' cohort ', ' Informatics ', ' Histopathology ', ' validation studies ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Epidemiological Studies ', ' Epidemiology Research ', ' epidemiologic investigation ', ' epidemiology study ', ' cancer registry ', ' neoplasm registry ', ' Pathology Report ', ' response ', ' depository ', ' repository ', ' Data ', ' Imaging Instrument ', ' Imaging Tool ', ' Imaging Device ', ' Reproducibility ', ' Resolution ', ' Retrieval ', ' Clinical Data ', ' Scientific Evaluation ', ' Tumor Subtype ', ' Validation ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' tumor registry ', ' image visualization ', ' Advanced Development ', ' Outcome ', ' scale up ', ' Population ', ' analytical tool ', ' computational resources ', ' computing resources ', ' therapeutic effectiveness ', ' Image data archive ', ' image archive ', ' image library ', ' picture archive ', ' image archival system ', ' stem ', ' prototype ', ' tumor ', ' patient population ', ' population based ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' computational infrastructure ', ' computer infrastructure ', ' data registry ', ' Algorithmic Tools ', ' Software Algorithm ', ' Algorithmic Software ', ' precision-based medicine ', ' precision medicine ', ' stratified patient ', ' patient stratification ', ' informatics infrastructure ', ' whole slide imaging ', ' digital pathology ', ' pathology imaging ', ' Infrastructure ', ' Visualization ', ' feature extraction ', ' ']",NCI,STATE UNIVERSITY NEW YORK STONY BROOK,UH3,2020,643291,NY-01,0.1028834122112105
"Content-based MR-TRUS Fusion without Tracking There are about 3 million American men living with prostate cancer, the second leading cause of cancer death for men in the United States. If the prostate cancer is caught early before it spreads to other parts of the body, by active monitoring or treatment, most men will not die from it. Nevertheless, 22% to 47% of the patients with negative biopsies but elevated prostate-specific antigen levels may still harbor malignant tumors, which can be life threatening and could have been missed by the commonly used ultrasound guided random biopsy. By contrast, fusion of magnetic resonance (MR) imaging and transrectal ultrasound (TRUS) for guiding targeted biopsies has shown to significantly improve the cancer detection rate. However, MR-TRUS fusion itself is very challenging due to the difficulties in directly registering images of these two very different modalities in different dimensions. To bypass the difficult registration problems, the existing fusion techniques require the use of specialized expensive and cumbersome hardware tracking devices, which increases cost and elongates procedures. More importantly, due to a number of factors such as patient movement, respiratory motion and ultrasound transducer pressure change, prostate motion can happen during a procedure and cause the images to be misaligned. Timely noticing and correcting such motion require great skill and knowledge of radiological imaging, where studies show a steep learning curve for mastering fusion systems. Failing in image registration and motion compensation renders the fusion guided biopsy performing no differently than random biopsy. To address the fundamental cause of the problems, the goal of this project is to create enabling technology of MR- TRUS image fusion solely based on internal image content without using external tracking devices. The proposed research is foundational for developing next generation of MR-TRUS fusion guidance systems for prostate biopsy to achieve robust performance with lower costs. Recent advancement in machine learning, especially deep learning, has provided us new tools and new angles to tackle this challenging problem. This project aims for directly fusing 2D TRUS frames with 3D MR volume by developing novel deep learning methods for image reconstruction and registration. The proposed methods are designed to exploit both population and patient specific imaging information to accurately align images. As all learning-based image registration methods try to better use population knowledge to improve the registration performance, few of them have been able to efficiently use patient specific information, which can be essential to obtain robust and accurate performance. Upon successful completion, the innovation created from the project will disrupt the common perception that hardware tracking has to be used for multimodal image fusion-guided interventions and alleviate the demand on physicians experience and skill in image analysis and fusion to help obtain consistent results. This project will lead to the development of novel prostate biopsy systems and will also impact a range of other image fusion based interventional guidance technologies. Fusion of magnetic resonance (MR) imaging and transrectal ultrasound (TRUS) for guiding targeted prostate biopsies can significantly improve the detection of aggressive cancer. The goal of this project is to create enabling technology of MR-TRUS image fusion solely based on internal image content without using external tracking devices. The proposed research is foundational for developing next generation of MR-TRUS fusion guidance systems for prostate biopsy to achieve robust performance with lower costs.",Content-based MR-TRUS Fusion without Tracking,10204244,R21EB028001,"['Biopsy ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' E-learning ', ' computer-assisted instruction ', ' computer-based education ', ' computer-based instruction ', ' computer-based learning ', ' computer-based training ', ' digital education ', ' digital learning ', ' eLearning ', ' electronic learning ', ' internet-assisted education ', ' internet-based training ', ' multimedia learning ', ' on-line education ', ' on-line learning ', ' online education ', ' online learning ', ' technology-enhanced learning ', ' virtual learning ', ' web-based instruction ', ' web-based training ', ' Cyst ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Electromagnetics ', ' Foundations ', ' Future ', ' Goals ', ' Heart ', ' image reconstruction ', ' image construction ', ' image generation ', ' Intelligence ', ' Kidney ', ' Kidney Urinary System ', ' renal ', ' Learning ', ' Liver ', ' hepatic body system ', ' hepatic organ system ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Manuals ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Motion ', ' Movement ', ' body movement ', ' Patients ', ' Perception ', ' Physicians ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Research ', ' Retrospective Studies ', ' Survival Rate ', ' Technology ', ' Thinness ', ' Leanness ', ' Time ', ' Pressure Transducers ', ' Psychological Transfer ', ' learning transfer ', ' training transfer ', ' Ultrasonography ', ' Echography ', ' Echotomography ', ' Medical Ultrasound ', ' Ultrasonic Imaging ', ' Ultrasonogram ', ' Ultrasound Diagnosis ', ' Ultrasound Medical Imaging ', ' Ultrasound Test ', ' diagnostic ultrasound ', ' sonogram ', ' sonography ', ' sound measurement ', ' ultrasound ', ' ultrasound imaging ', ' ultrasound scanning ', ' United States ', ' Risk Assessment ', ' Calcified ', ' calcification ', ' base ', ' Ultrasound transducer ', ' Ultrasonic Transducer ', ' improved ', ' Procedures ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Area ', ' Compensation ', ' Financial compensation ', ' Training ', ' Body part ', ' tool ', ' Transrectal Ultrasound ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Knowledge ', ' Life ', ' prostate specific antigen level ', ' PSA level ', ' Dimensions ', ' Techniques ', ' System ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' Location ', ' respiratory ', ' American ', ' early detection ', ' Early Diagnosis ', ' experience ', ' Performance ', ' skills ', ' novel ', ' Modality ', ' Devices ', ' Bypass ', ' Modeling ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' Magnetic Resonance ', ' image-based method ', ' imaging method ', ' imaging modality ', ' Address ', ' Data ', ' Detection ', ' multi-modal imaging ', ' multi-modality imaging ', ' multimodality imaging ', ' Multimodal Imaging ', ' Cancer Detection ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Evaluation ', ' Clinical Testing ', ' clinical test ', ' research clinical testing ', ' Slice ', ' Monitor ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' cost ', ' reconstruction ', ' image registration ', ' designing ', ' design ', ' next generation ', ' Population ', ' innovate ', ' innovative ', ' innovation ', ' patient population ', ' population based ', ' prostate biopsy ', ' learning activity ', ' learning method ', ' learning strategy ', ' radiologic imaging ', ' radiological imaging ', ' imaging study ', ' deep learning based neural network ', ' deep learning neural network ', ' deep neural net ', ' deep neural network ', ' deep learning ', ' deep learning algorithm ', ' ']",NIBIB,RENSSELAER POLYTECHNIC INSTITUTE,R21,2020,194351,NY-20,0.19175726084040517
"AACR Special Conference on Advances in Prostate Cancer Research PROJECT SUMMARY The proposed conference, titled Advances in Prostate Cancer, will be held from March 12-15, 2020 at the Grand Hyatt Denver in Denver, CO. This conference covers the current findings on the basic biology underlying prostate cancer, emerging technologies and approaches, and how these may be translated to the clinic. The goal of this conference is to provide a unique opportunity for interactions and exchanges between basic scientists, translational researchers, and clinicians to discuss how basic research findings can be translated effectively to the clinic to combat prostate cancer. Thematic sessions will consist of three to four 20-25-minute presentations from expert researchers and will incorporate ample time for discussion. Sessions will include presentations on the most up-to-date findings in biologic drivers of prostate cancer risk, advances in detection and diagnosis, tumor evolution and plasticity, DNA repair, hormone receptor signaling and crosstalk, metabolism, tumor and immune microenvironment, and novel targets. Strategies for translating basic science findings and emerging technologies into clinical impact will be highlighted throughout the conference. In addition, a number of highly-rated proffered abstracts will be selected for presentation in the plenary sessions. Poster sessions will be held to allow investigators to present and discuss their latest research in an informal setting. This conference will appeal to investigators focused on the basic, translational, and clinical aspects of prostate cancer and will foster collaborative interdisciplinary interactions and partnerships to stimulate the development of new basic research and clinical practices. It is expected that this conference will provide a unique forum for discussions that will further the scientific and translational goals of the field. PROJECT NARRATIVE Prostate cancer is the second most common cancer in American men. To combat prostate cancer, there is a need to bring together experts across different fields to discuss the role of the various factors involved in the development of prostate cancer and how basic research findings and emerging technologies, such as artificial intelligence, can be translated effectively to the clinic to develop new preventative and therapeutic approaches. At this conference, a wide range of basic researchers, translational researchers, physicians, and health professionals will assemble to present the latest findings in their fields, to foster collaborative interdisciplinary interactions and partnerships, and to stimulate the development of new research and clinical practices.",AACR Special Conference on Advances in Prostate Cancer Research,9994621,R13CA250290,"['Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Communities ', ' Diagnosis ', ' DNA Repair ', ' DNA Damage Repair ', ' Unscheduled DNA Synthesis ', ' Evolution ', ' Goals ', ' Hormone Receptor ', ' Industry ', ' Learning ', ' men ', "" men's "", ' Metabolism ', ' Intermediary Metabolism ', ' Metabolic Processes ', ' Physicians ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Role ', ' social role ', ' Students ', ' Time ', ' Translating ', ' Work ', ' conference ', ' convention ', ' summit ', ' symposia ', ' symposium ', ' career ', ' Clinical ', ' Biological ', ' Fostering ', ' Therapeutic ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Knowledge ', ' posters ', ' Scientist ', ' Clinic ', ' American ', ' novel ', ' Basic Research ', ' Basic Science ', ' Academia ', ' Detection ', ' Receptor Signaling ', ' AACR ', ' American Association of Cancer Research ', ' Emergent Technologies ', ' Emerging Technologies ', ' developmental ', ' Development ', ' Health Care Professional ', ' Healthcare professional ', ' Health Professional ', ' anti-cancer research ', ' cancer research ', ' anticancer research ', ' tumor ', ' combat ', ' new therapeutic approach ', ' new therapeutic intervention ', ' new therapeutic strategies ', ' new therapy approaches ', ' novel therapeutic approach ', ' novel therapy approach ', ' novel therapeutic intervention ', ' clinical practice ', ' translational investigator ', ' translational researcher ', ' translational scientist ', ' prostate cancer risk ', ' immune microenvironment ', ' immunosuppressive microenvironment ', ' immunosuppressive tumor microenvironment ', ' tumor immune microenvironment ', ' tumor-immune system interactions ', ' ']",NCI,AMERICAN ASSOCIATION FOR CANCER RESEARCH,R13,2020,1,PA-03,0.2620835614732876
"Development of Methods for a Simplified and Reliable Prostate Cancer MRI Exam Abstract Non-invasive, multi-parametric characterization of prostate cancer (PC), with magnetic resonance imaging (MRI) methods, is an active area of research with great potential for providing improved diagnosis and treatment monitoring. The PI-RADSv2 assessment system that was established by an international team of experts recognizes the value of quantitative images in PC diagnosis, but relies largely on qualitative evaluation of weighted images. Although this grading approach achieves reasonably good separation be- tween normal and abnormal prostate tissue, it does not achieve adequate separation between indolent and aggressive disease, with the risk that more unnecessary and costly surgery is performed with poten- tially dire consequences on patient quality of life. High-value protocols, without need for an invasive and costly endo-rectal radio-frequency coil are being investigated. This comes at the cost of extended scan time and reduced image quality in terms of spatial resolution, signal-to-noise ratio and signal bias, which negatively impacts sensitivity and specicity of multi-parametric MRI. With the pronounced increase of multi-parametric MRI exams, there is also the desire to integrate the support by the most recent revolution in diagnostic imaging, i.e., machine learning. It becomes increasingly clear, that in order to avoid having to train neural networks for each specic system and protocol, reproducible and thus preferably quantitative imaging protocols are essential. To overcome these limitations, we propose both pulse sequence develop- ment, investigation of ADC validity and reproducibility and novel post-processing strategies. The overall objective is to demonstrate the added value of lesion characterization with quantitative values and at the same time understand and minimize the inuence of protocol choices and scan hardware, hence improve overall reproducibility. Specic Aim 1 will focus on the development of a low distortion MR imaging sequence for rapid concurrent quantication of T2 and diusion signal decay. Specic Aim 2 will examine ADC variations that result from changes in diusion time over a range that is typical with present day clinical MR systems. Specic Aim 3 introduces advanced handling of low noise diusion data, which will be indispensable for achieving high accuracy and precision with non-invasive and economic external coils. Specic Aim 4 introduces a novel ADC computation approach that fully captures the complex diusion signal decays in tissues and at the same time is largely protocol and system independent. Moreover, re- sulting images and quantitative maps processed according this approach, exhibit considerably lower noise, which can be traded for higher spatial resolution or shorter scan duration. In combination, the consis- tently quantitative nature of the data and its ubiquitous validity and comparability will greatly facilitate the establishment of recommendations for disease-related thresholds. Ultimately this may permit much more reliable dierentiation of aggressive from indolent disease. Project Narrative Magnetic resonance imaging plays an important role for staging of prostate cancer. We propose advances that permit quantitative and a more reliable assessment of prostate cancer. Potentially this will permit better dierentiation of disease that is aggressive from disease that poses low risk of spreading.",Development of Methods for a Simplified and Reliable Prostate Cancer MRI Exam,9973564,R01CA241817,"['Architecture ', ' Engineering / Architecture ', ' Biopsy ', ' Diagnosis ', ' Diagnostic Imaging ', ' Diffusion ', ' Disease ', ' Disorder ', ' Economics ', ' Exhibits ', ' Fingerprint ', ' Joints ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Maps ', ' Noise ', ' Patients ', ' Play ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Qualitative Evaluations ', ' Quality of life ', ' QOL ', ' Recommendation ', ' Relaxation ', ' Research ', ' Risk ', ' Role ', ' social role ', ' Sensitivity and Specificity ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Translating ', ' Tweens ', ' Weight ', ' Measures ', ' method development ', ' improved ', ' Prostatovesiculectomy ', ' Radical Prostatectomy ', ' rectal ', ' Area ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Link ', ' Training ', ' Lesion ', ' Indolent ', ' Measurement ', ' Staging ', ' Nature ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Pulse ', ' Physiologic pulse ', ' Investigation ', ' Complex ', ' Scanning ', ' Protocol ', ' Protocols documentation ', ' Techniques ', ' System ', ' Operative Procedures ', ' Surgical ', ' Surgical Interventions ', ' Surgical Procedure ', ' surgery ', ' Operative Surgical Procedures ', ' magnetic field ', ' Performance ', ' novel ', ' Sampling ', ' cancer diagnosis ', ' Consequentialism ', ' DWI (diffusion weighted imaging) ', ' DWI-MRI ', ' Diffusion MRI ', ' Diffusion Weighted MRI ', ' Diffusion weighted imaging ', ' Diffusion-weighted Magnetic Resonance Imaging ', ' dMRI ', ' diffusion tensor imaging ', ' Diffusion Magnetic Resonance Imaging ', ' image-based method ', ' imaging method ', ' imaging modality ', ' Data ', ' International ', ' Reproducibility ', ' Resolution ', ' enroll ', ' Enrollment ', ' Monitor ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' cost ', ' new approaches ', ' novel approaches ', ' novel strategy ', ' novel strategies ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' quantitative imaging ', ' radiofrequency ', ' radio frequency ', ' contrast imaging ', ' neural network ', ' ']",NCI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2020,454234,MA-07,0.16384881186818415
"Identifying optimal dynamic strategies for prostate cancer control PROJECT SUMMARY/ABSTRACT Big Data has the potential to revolutionize cancer research and care, but extracting the information it holds on the optimal strategies for cancer control will require cutting-edge tools in data science. The optimal strategies for cancer control will be dynamic strategies that adapt clinical decisions over time to a patients evolving clinical history. Unfortunately, conventional statistical methods cannot appropriately compare dynamic strategies, so we need methods specifically designed for this task: g-methods. G-methods have helped to shape clinical care in many areas, but they have not been systematically applied to cancer research. Further, while g-methods let us validly estimate the effect of pre-specified strategies, these may not be the optimal strategies. My overarching goal is to apply and further develop analytic methods to learn the optimal strategies for cancer control from complex longitudinal data and generate user-friendly, publicly-available software to make these methods available to the cancer research community. I will apply these methods to answer key clinical questions across the prostate cancer control continuum: 1) the optimal dietary and lifestyle strategies to prevent aggressive prostate cancer, 2) the optimal screening strategy following a baseline PSA test to maximize detection of aggressive disease while minimizing detection of indolent tumors, and 3) the optimal statin therapy strategy to maximize survival among men with nonmetastatic prostate cancer. This project will leverage data from a large prospective cohort study and a novel platform of electronic health records linked with genetic data. I will first apply g-methods to estimate the effects of recommended strategies for cancer control that a randomized trial would have limited feasibility to evaluate. I will then investigate whether novel methods that learn the optimal strategies from the data may lead to improved, targeted recommendations that get the right interventions to the right people at the right time. This innovative project will advance comparative effectiveness research for cancer care at the cutting edge of data science. I am optimally positioned to undertake this research based on my 1) expertise in cancer, epidemiology, and causal inference; 2) exceptional multidisciplinary mentoring team comprised of global leaders in their respective fields; and 3) unparalleled research environment to support my career development. Through this work, I will expand my expertise in new areas, including machine learning. The proposed research and training will help me achieve my long-term career goal to become an independent investigator and lead a transdisciplinary research program that integrates causal inference and machine learning to identify optimal strategies for cancer control. Leveraging rich, existing data, this proposal represents a significant opportunity to develop, apply, and disseminate powerful methods for big clinical data to accelerate progress in cancer research and care. PROJECT NARRATIVE We will answer key clinical questions about the optimal strategies for prostate cancer prevention, detection, and treatment by applying innovative analytic methods to complex longitudinal data. This research will result in the development, application, and dissemination of powerful methods for big clinical data that accelerate progress in cancer research and care.",Identifying optimal dynamic strategies for prostate cancer control,9944221,K99CA248335,"['Award ', ' Classification ', ' Systematics ', ' Communities ', ' comorbidity ', ' co-morbid ', ' co-morbidity ', ' Diet ', ' dietary ', ' Disease ', ' Disorder ', ' Environment ', ' Future ', ' Goals ', ' Health ', ' Recording of previous events ', ' History ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Learning ', ' Life Style ', ' Lifestyle ', ' men ', "" men's "", ' Mentors ', ' Methods ', ' Patients ', ' Recommendation ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Computer software ', ' Software ', ' Time ', ' Work ', ' analytical method ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Specified ', ' Specific qualifier value ', ' Phase ', ' Link ', ' Training ', ' Indolent ', ' Data Bases ', ' data base ', ' Databases ', ' cancer prevention ', ' Prostate CA Prevention ', ' prevent prostate cancer ', ' prostate cancer prevention ', ' Genetic ', ' Genetic Predisposition ', ' Genetic Susceptibility ', ' Inherited Predisposition ', ' Inherited Susceptibility ', ' genetic etiology ', ' genetic mechanism of disease ', ' genetic vulnerability ', ' genetically predisposed ', ' Genetic Predisposition to Disease ', ' Shapes ', ' tool ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' programs ', ' Hereditary ', ' Inherited ', ' Complex ', ' interest ', ' Toxicities ', ' Toxic effect ', ' novel ', ' Prevention ', ' Position ', ' Positioning Attribute ', ' Statistical Methods ', ' career development ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' Documentation ', ' cancer care ', ' cancer epidemiology ', ' preventing ', ' prevent ', ' Data ', ' Detection ', ' Research Training ', ' Cancer Control Science ', ' Cancer Control ', ' Clinical Data ', ' Non-metastatic ', ' Nonmetastatic ', ' Screening Result ', ' developmental ', ' Development ', ' electronic health care record ', ' electronic healthcare record ', ' Electronic Health Record ', ' anti-cancer research ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' cost effective ', ' innovate ', ' innovative ', ' innovation ', ' analytical tool ', ' multidisciplinary ', ' user-friendly ', ' open source ', ' PSA test ', ' prostate specific antigen screening ', ' prostate specific antigen test ', ' PSA screening ', ' tumor ', ' clinical care ', ' longitudinal database ', ' Randomization trial ', ' randomized trial ', ' clinical decision-making ', ' screening ', ' BigData ', ' Big Data ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' trial design ', ' learning activity ', ' learning method ', ' learning strategy ', ' Data Science ', ' Prospective cohort study ', ' Comparative Effectiveness Research ', ' ']",NCI,HARVARD SCHOOL OF PUBLIC HEALTH,K99,2020,128088,MA-07,0.15469071860103395
"Content-based MR-TRUS Fusion without Tracking There are about 3 million American men living with prostate cancer, the second leading cause of cancer death for men in the United States. If the prostate cancer is caught early before it spreads to other parts of the body, by active monitoring or treatment, most men will not die from it. Nevertheless, 22% to 47% of the patients with negative biopsies but elevated prostate-specific antigen levels may still harbor malignant tumors, which can be life threatening and could have been missed by the commonly used ultrasound guided random biopsy. By contrast, fusion of magnetic resonance (MR) imaging and transrectal ultrasound (TRUS) for guiding targeted biopsies has shown to significantly improve the cancer detection rate. However, MR-TRUS fusion itself is very challenging due to the difficulties in directly registering images of these two very different modalities in different dimensions. To bypass the difficult registration problems, the existing fusion techniques require the use of specialized expensive and cumbersome hardware tracking devices, which increases cost and elongates procedures. More importantly, due to a number of factors such as patient movement, respiratory motion and ultrasound transducer pressure change, prostate motion can happen during a procedure and cause the images to be misaligned. Timely noticing and correcting such motion require great skill and knowledge of radiological imaging, where studies show a steep learning curve for mastering fusion systems. Failing in image registration and motion compensation renders the fusion guided biopsy performing no differently than random biopsy. To address the fundamental cause of the problems, the goal of this project is to create enabling technology of MR- TRUS image fusion solely based on internal image content without using external tracking devices. The proposed research is foundational for developing next generation of MR-TRUS fusion guidance systems for prostate biopsy to achieve robust performance with lower costs. Recent advancement in machine learning, especially deep learning, has provided us new tools and new angles to tackle this challenging problem. This project aims for directly fusing 2D TRUS frames with 3D MR volume by developing novel deep learning methods for image reconstruction and registration. The proposed methods are designed to exploit both population and patient specific imaging information to accurately align images. As all learning-based image registration methods try to better use population knowledge to improve the registration performance, few of them have been able to efficiently use patient specific information, which can be essential to obtain robust and accurate performance. Upon successful completion, the innovation created from the project will disrupt the common perception that hardware tracking has to be used for multimodal image fusion-guided interventions and alleviate the demand on physicians experience and skill in image analysis and fusion to help obtain consistent results. This project will lead to the development of novel prostate biopsy systems and will also impact a range of other image fusion based interventional guidance technologies. Fusion of magnetic resonance (MR) imaging and transrectal ultrasound (TRUS) for guiding targeted prostate biopsies can significantly improve the detection of aggressive cancer. The goal of this project is to create enabling technology of MR-TRUS image fusion solely based on internal image content without using external tracking devices. The proposed research is foundational for developing next generation of MR-TRUS fusion guidance systems for prostate biopsy to achieve robust performance with lower costs.",Content-based MR-TRUS Fusion without Tracking,9968409,R21EB028001,"['Biopsy ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' E-learning ', ' computer-assisted instruction ', ' computer-based education ', ' computer-based instruction ', ' computer-based learning ', ' computer-based training ', ' digital education ', ' digital learning ', ' eLearning ', ' electronic learning ', ' internet-assisted education ', ' internet-based training ', ' multimedia learning ', ' on-line education ', ' on-line learning ', ' online education ', ' online learning ', ' technology-enhanced learning ', ' virtual learning ', ' web-based instruction ', ' web-based training ', ' Cyst ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Electromagnetics ', ' Foundations ', ' Future ', ' Goals ', ' Heart ', ' image reconstruction ', ' image construction ', ' image generation ', ' Intelligence ', ' Kidney ', ' Kidney Urinary System ', ' renal ', ' Learning ', ' Liver ', ' hepatic body system ', ' hepatic organ system ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Manuals ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Motion ', ' Movement ', ' body movement ', ' Patients ', ' Perception ', ' Physicians ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Research ', ' Retrospective Studies ', ' Survival Rate ', ' Technology ', ' Thinness ', ' Leanness ', ' Time ', ' Pressure Transducers ', ' Psychological Transfer ', ' learning transfer ', ' training transfer ', ' Ultrasonography ', ' Echography ', ' Echotomography ', ' Medical Ultrasound ', ' Ultrasonic Imaging ', ' Ultrasonogram ', ' Ultrasound Diagnosis ', ' Ultrasound Medical Imaging ', ' Ultrasound Test ', ' diagnostic ultrasound ', ' sonogram ', ' sonography ', ' sound measurement ', ' ultrasound ', ' ultrasound imaging ', ' ultrasound scanning ', ' United States ', ' Risk Assessment ', ' Calcified ', ' calcification ', ' base ', ' Ultrasound transducer ', ' Ultrasonic Transducer ', ' improved ', ' Procedures ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Area ', ' Compensation ', ' Financial compensation ', ' Training ', ' Body part ', ' tool ', ' Transrectal Ultrasound ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Knowledge ', ' Life ', ' prostate specific antigen level ', ' PSA level ', ' Dimensions ', ' Techniques ', ' System ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' Location ', ' respiratory ', ' American ', ' early detection ', ' Early Diagnosis ', ' experience ', ' Performance ', ' skills ', ' novel ', ' Modality ', ' Devices ', ' Bypass ', ' Modeling ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' Magnetic Resonance ', ' image-based method ', ' imaging method ', ' imaging modality ', ' Address ', ' Data ', ' Detection ', ' multi-modal imaging ', ' multi-modality imaging ', ' multimodality imaging ', ' Multimodal Imaging ', ' Cancer Detection ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Evaluation ', ' Clinical Testing ', ' clinical test ', ' research clinical testing ', ' Slice ', ' Monitor ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' cost ', ' reconstruction ', ' image registration ', ' designing ', ' design ', ' next generation ', ' Population ', ' innovate ', ' innovative ', ' innovation ', ' patient population ', ' population based ', ' prostate biopsy ', ' learning activity ', ' learning method ', ' learning strategy ', ' radiologic imaging ', ' radiological imaging ', ' imaging study ', ' deep learning based neural network ', ' deep learning neural network ', ' deep neural net ', ' deep neural network ', ' deep learning ', ' deep learning algorithm ', ' ']",NIBIB,RENSSELAER POLYTECHNIC INSTITUTE,R21,2020,192513,NY-20,0.19175726084040517
"Enhanced imaging and treatment of aggressive subtypes of prostate cancer Targeting the prostate-specific membrane antigen (PSMA) with small molecules for imaging and therapy of prostate cancer (PC) has revitalized the field of nuclear medicine. Few targets have its combination of salutary attributes, namely, high concentration in malignant with restricted expression in normal tissues, easy access with recycling to and from the plasma membrane, an enzymatic active site toward which small molecules of high affinity and specificity can be designed, and biological relevance  an inverse relationship with androgen signaling while being directly related to degree of malignancy. The ureas that we initially described for imaging PSMA in 2002 have inspired a wide variety of cancer targeting species from radiotherapeutics to synthetic antibody mimics. Our goal is to use what we have learned from PSMA-targeted detection, imaging and treatment of PC to focus on highly aggressive disease, including that which does not express PSMA. We will deploy this prolific cancer target here by beginning with a project that leverages the considerable clinical data obtained during the last funding period to refine and simplify PSMA-targeted imaging with positron emission tomography (PET)  in a way agnostic to imaging agent employed. Complementing PET we will explore sensitive new PSMA- targeted agents and methods for photoacoustic (PA) imaging, which can characterize primary disease in new ways in an effort to uncover signatures that could separate aggressive from indolent cancer to prevent unnecessary surgery and its attendant morbidity. Because PC is a heterogeneous disease, in the second half of the project we will move from detection and characterization of PSMA-expressing PC to address highly aggressive, PSMA-negative adenocarcinoma and especially neuroendocrine PC (NEPC), a lethal and increasingly prevalent subtype with the proliferation of modern anti-androgen therapies. First, we will use a PSMA reporter gene strategy to track NEPC-targeted chimeric antigen receptor (CAR) T cells in order to gauge their spatial relationship to tumor, measure their expansion in vivo, and sense their microenvironment, with a view to improving this case of solid tumor CAR T cell therapy. Finally, we will use cancer cell specific promoter (CCSP) technology, which we developed for imaging and treating metastases, to enhance PSMA expression specifically within NEPC tissue so that it may become susceptible to the detection and treatment of its PSMA- expressing adenocarcinoma counterpart. In addition to using existing PSMA-targeted radiotherapy we will show how a new urea-drug conjugate we have developed can kill NEPC once it is re-programmed to express PSMA. To achieve these goals, we take the approach of beginning with a more sophisticated analysis of our clinical PSMA PET data then work toward more laboratory-based imaging and therapeutic studies also designed for translation. The team we have assembled is comprised of clinicians and scientists with a track record of high productivity and impact working together. We present a graded approach  beginning with imaging and ending with therapy  to management of advanced, aggressive prostate cancer (PC) by leveraging what we have learned over the past two decades about the prostate-specific membrane antigen (PSMA). We propose machine learning methodology to enhance clinical interpretation of PSMA PET scans for patient management, and development of sensitive, new detection methods using photoacoustic imaging ultimately to avoid unnecessary surgery. We also propose ways to improve immunotherapy for the lethal neuroendocrine subtype of PC and to re-program it to render it more susceptible to emerging PC therapies.",Enhanced imaging and treatment of aggressive subtypes of prostate cancer,9886337,R01CA134675,"['Adenocarcinoma ', ' Malignant Adenoma ', ' Androgens ', ' Androgenic Agents ', ' Androgenic Compounds ', ' Therapeutic Androgen ', ' Attention ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell membrane ', ' Cytoplasmic Membrane ', ' Plasma Membrane ', ' plasmalemma ', ' Complement ', ' Complement Proteins ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Engineering ', ' Genes ', ' Goals ', ' Human ', ' Modern Man ', ' Image Enhancement ', ' Immunotherapy ', ' Immune mediated therapy ', ' Immunologically Directed Therapy ', ' immune therapeutic approach ', ' immune therapeutic interventions ', ' immune therapeutic regimens ', ' immune therapeutic strategy ', ' immune therapy ', ' immune-based therapies ', ' immune-based treatments ', ' immuno therapy ', ' Laboratories ', ' Methods ', ' Methodology ', ' Modernization ', ' Morbidity - disease rate ', ' Morbidity ', ' Neoplasm Metastasis ', ' Metastasis ', ' Metastasize ', ' Metastatic Lesion ', ' Metastatic Mass ', ' Metastatic Neoplasm ', ' Metastatic Tumor ', ' Secondary Neoplasm ', ' Secondary Tumor ', ' cancer metastasis ', ' tumor cell metastasis ', ' Neurosecretory Systems ', ' Neuroendocrine ', ' Neuroendocrine System ', ' Discipline of Nuclear Medicine ', ' Atomic Medicine ', ' Nuclear Medicine ', ' Radiology / Radiation Biology / Nuclear Medicine ', ' Patients ', ' Positron-Emission Tomography ', ' PET ', ' PET Scan ', ' PET imaging ', ' PETSCAN ', ' PETT ', ' Positron Emission Tomography Medical Imaging ', ' Positron Emission Tomography Scan ', ' Rad.-PET ', ' positron emission tomographic (PET) imaging ', ' positron emission tomographic imaging ', ' positron emitting tomography ', ' Productivity ', ' Prostate ', ' Prostate Gland ', ' Prostatic Gland ', ' Radiation therapy ', ' Radiotherapeutics ', ' Radiotherapy ', ' radiation treatment ', ' radio-therapy ', ' treatment with radiation ', ' Reagent ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Specificity ', ' T-Lymphocyte ', ' T-Cells ', ' thymus derived lymphocyte ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Translations ', ' Urea ', ' Carbamide ', ' Elaqua XX ', ' Urea Carbamide ', ' Ureaphil ', ' Work ', ' Measures ', ' promotor ', ' promoter ', ' Edodekin Alfa ', ' IL-12 ', ' IL12 ', ' NKSF ', ' Natural Killer Cell Stimulatory Factor ', ' Interleukin-12 ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Clinical ', ' Malignant ', ' Malignant - descriptor ', ' Biological ', ' Active Sites ', ' Targeted Radiotherapy ', ' Reporter Genes ', ' Training ', ' Lesion ', ' Indolent ', ' Funding ', ' Anti-androgen Therapy ', ' Anti-androgen Treatment ', ' Antiandrogen Treatment ', ' Antiandrogen Therapy ', ' Solid Tumor ', ' Solid Neoplasm ', ' Recycling ', ' Gleason Grade ', ' Gleason Score ', ' Gleason Score for Prostate Cancer ', ' Gleason Sum ', ' Gleason-SC ', ' Gleason Grade for Prostate Cancer ', ' Normal Tissue ', ' Normal tissue morphology ', ' Malignant Cell ', ' cancer cell ', ' scaffolding ', ' scaffold ', ' Research Specimen ', ' Specimen ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' programs ', ' Unnecessary Surgery ', ' Scientist ', ' Techniques ', ' System ', ' Categories ', ' Position ', ' Positioning Attribute ', ' nano tech ', ' nano technology ', ' nano-technological ', ' nanotech ', ' nanotechnological ', ' Nanotechnology ', ' preventing ', ' prevent ', ' small molecule ', ' CD66e ', ' CEACAM5 ', ' CEACAM5 gene ', ' FOLH ', ' FOLH1 ', ' Folate Hydrolase 1 ', ' GCP2 ', ' Glutamate Carboxypeptidase II ', ' N-Acetylated Alpha-Linked Acidic Dipeptidase 1 ', ' NAALAD1 ', ' NAALADase I ', ' PSM ', ' PSMA ', ' Prostate-Specific Membrane Antigen ', ' FOLH1 gene ', ' Address ', ' Affinity ', ' Data ', ' Detection ', ' Therapy Research ', ' Therapeutic Studies ', ' in vivo ', ' Antigen Targeting ', ' Clinical Data ', ' Clinical Management ', ' Monitor ', ' developmental ', ' Development ', ' molecule imaging ', ' molecular imaging ', ' imaging ', ' Image ', ' Output ', ' cancer microenvironment ', ' tumor microenvironment ', ' designing ', ' design ', ' Prostate CA therapy ', ' prostate cancer treatment ', ' Prostate Cancer therapy ', ' optical sensor ', ' spatial relationship ', ' tumor ', ' multi-modality ', ' multimodality ', ' theranostics ', ' optoacoustic imaging ', ' photoacoustic imaging ', ' imaging agent ', ' targeted imaging ', ' targeted agent ', ' cancer markers ', ' cancer biomarkers ', ' prognostic significance ', ' synthetic antibodies ', ' imaging study ', ' CAR T cells ', ' T cells for CAR ', ' chimeric antigen receptor (CAR) T cells ', ' chimeric antigen receptor T cells ', ' CAR T therapy ', ' chimeric antigen receptor (CAR) T cell therapy ', ' chimeric antigen receptor T cell therapy ', ' CAR T cell therapy ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2020,473165,MD-07,0.12319993123081593
"Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning DESCRIPTION (provided by applicant): Few biomarkers derived from genome scale data have translated into improved clinical classification of cancer subtypes, in spite of the wealth of available genome-wide studies and of the corresponding application of numerous statistical algorithms. This widespread shortcoming derives from the pervasive use of ""off the shelf"" algorithms and machine learning techniques developed for image classification and language processing, which are nave of the underlying biology of the system. Furthermore, for genome-wide data, the number of samples is often small relative to the number of potential candidate biomarkers, resulting in variable accuracy on independent test data despite high accuracy in the samples used for discovery, which contributes to the failure of clinical biomarkers. This problem - so called ""curse of dimensionality"" - is further exacerbated by the prohibitive cost of dramatically increasing sample size and by patient stratification into smaller subgroups for personalized and precision medicine. Disease phenotypes arise from distinct and specific perturbations in selected networks and pathways defined by the interactions of their molecular constituents. In cancer, these perturbations may reside in gene regulatory networks topology and state, in cell signaling activity, or in metabolic conditions. We hypothesize that by leveragin such prior biological information on cancer biology we will be able to reduce model complexity and build mechanistically justified predictive models. To pursue this hypothesis, we will develop an analytical framework to embed mechanistic constraints derived from network biology into the statistical learning process itself. Hence, this application will develop a novel suite of statistial learning algorithms that embed (Aim 1) gene expression regulatory networks, (Aim 2) cell signaling activity, and (Aim 3) metabolism to classify breast and prostate cancer. Throughout the study we will work closely with clinical collaborators to ensure that our method improve over and above current predictive and prognostic models. Finally, since in our study we will also generate mechanistic classifiers based on gene expression measurements obtained from clinical assays that are already commercially available (i.e., MammaPrint, and Decipher), our innovative models and predictors will be also readily available for clinical translation. Our mechanism-driven classifiers will simultaneously have greater accuracy and interpretability than classifiers developed without regard for the underlying biology of the disease. Furthermore, embedding biological mechanisms in the classifiers will also facilitate the identification of alternative therapeutic targets specific to each cancer subtype, potentially improving patient prognosis and health outcomes. Finally, the substantial curation of molecular pathways and biological networks we will carry on in the project will also provide a powerful resource for futur studies, and the methodologies we will develop will be also applicable to other cancer and other human diseases, like neurodegenerative disorders, hearth disease, and diabetes. PUBLIC HEALTH RELEVANCE    Project Narrative This study will use mechanistic biological knowledge to implement a suite of statistical algorithms for cancer patient classification, which will also reveal the biological reasoning behind the classification decision rules. In the study we will also apply our novel methods to develop improved biomarkers for breast and prostate cancer patient clinical stratification, with the ultimate goal of facilitating the selection of appropriate treatment. To achieve this goal we will directly improve the existing commercial tests offered to the patients, with an immediate clinical impact, since our biomarkers will be directly implementable into these assays, with the potential to quickly reach the bedside.",Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning,9881257,R01CA200859,"['Algorithms ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell physiology ', ' Cell Function ', ' Cell Process ', ' Cellular Function ', ' Cellular Physiology ', ' Cellular Process ', ' Subcellular Process ', ' Cells ', ' Cell Body ', ' Classification ', ' Systematics ', ' Complement ', ' Complement Proteins ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Energy Metabolism ', ' Energy Expenditure ', ' Feedback ', ' Gene Expression ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Goals ', ' Health ', ' Learning ', ' Drug Metabolic Detoxication ', ' Drug Metabolic Detoxification ', ' Metabolic Drug Detoxications ', ' Metabolism of Toxic Agents ', ' detoxification ', ' Metabolism ', ' Intermediary Metabolism ', ' Metabolic Processes ', ' Methods ', ' Methodology ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' research and development ', ' Development and Research ', ' R & D ', ' R&D ', ' Research Design ', ' Study Type ', ' study design ', ' Resources ', ' Research Resources ', ' Signal Pathway ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' statistics ', ' Testing ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Translating ', ' Work ', ' base ', ' improved ', ' Clinical ', ' Biological ', ' Biochemical ', ' Ensure ', ' Failure ', ' data quality ', ' Measurement ', ' Sample Size ', ' Metabolic Networks ', ' Biochemical Pathway ', ' Space Models ', ' Metabolic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' machine learned ', ' Machine Learning ', ' Malignant Tumor of the Prostate ', ' Malignant prostatic tumor ', ' Prostate CA ', ' Prostate Cancer ', ' Prostatic Cancer ', ' Malignant neoplasm of prostate ', ' Knowledge ', ' Dimensions ', ' Complex ', ' Side ', ' Techniques ', ' Degenerative Neurologic Diseases ', ' Degenerative Neurologic Disorders ', ' Nervous System Degenerative Diseases ', ' Neural Degenerative Diseases ', ' Neural degenerative Disorders ', ' Neurodegenerative Diseases ', ' Neurologic Degenerative Conditions ', ' degenerative diseases of motor and sensory neurons ', ' degenerative neurological diseases ', ' neurodegenerative illness ', ' Neurodegenerative Disorders ', ' functional group ', ' cohort ', ' novel ', ' Modeling ', ' Sampling ', ' cancer classification ', ' Micro RNA ', ' miRNA ', ' miRNAs ', ' MicroRNAs ', ' Address ', ' Systems Biology ', ' Data ', ' Detection ', ' Measurable ', ' Molecular Fingerprinting ', ' molecular profile ', ' molecular signature ', ' Molecular Profiling ', ' Subgroup ', ' Cancer Biology ', ' Cancer Patient ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' cost ', ' anti-cancer research ', ' cancer research ', ' anticancer research ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' Outcome ', ' innovate ', ' innovative ', ' innovation ', ' resistant ', ' Resistance ', ' clinical relevance ', ' clinically relevant ', ' open source ', ' human disease ', ' language processing ', ' chemotherapy ', ' therapeutic target ', ' intervention design ', ' treatment design ', ' therapy design ', ' genome wide analysis ', ' genome wide studies ', ' genome-wide identification ', ' genome-wide analysis ', ' public health relevance ', ' candidate biomarker ', ' candidate marker ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' genome scale ', ' genomewide ', ' genome-wide ', ' biological systems ', ' Knowledge Discovery ', ' Statistics Algorithm ', ' Statistical Algorithm ', ' precision-based medicine ', ' precision medicine ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' biomarker development ', ' stratified patient ', ' patient stratification ', ' clinically useful biomarkers ', ' clinical biomarkers ', ' personalized healthcare ', ' precision health care ', ' precision healthcare ', ' personalized health care ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' cancer sub-types ', ' cancer subtypes ', ' clinical outcome prediction ', ' predictor of clinical outcome ', ' predict clinical outcome ', ' predictive signature ', ' Clinical stratification ', ' clinical translation ', ' high dimensionality ', ' clinical implementation ', ' learning algorithm ', ' statistical learning ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,R01,2020,150129,MD-07,0.10256685329278825
